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Background: Women appear to experience worse outcomes after stroke than men but 
the causes of these differences have not been conclusively determined. There is also 
some evidence that women receive evidence-based stroke care less often than men but 
how this influences outcomes after stroke is unclear. There is a need for high-quality 
studies to explore these sex differences to inform interventions to address these 
differences. 
Aims: My aims were to 1) quantify the sex differences in management and outcomes 
of stroke; and 2) to identify factors that contribute to the worse outcomes in women. 
Methods: Two different data sources were used in the thesis. The first was individual 
participant data (IPD) on long-term outcomes after stroke from 13 population-based 
stroke incidence studies conducted in Europe, Australasia, South America, and the 
Caribbean between 1987 and 2014, forming the INternational STroke oUtCome 
sTtudy (INSTRUCT). Data on sociodemographics, stroke-related factors, pre-stroke 
health, stroke management, and post-stroke factors were obtained. Study outcomes 
were: (1) severity of acute stroke, (2) long-term all-cause mortality, (3) functional 
outcomes and participation restriction, and (4) HRQoL up to 5 years after stroke. I 
performed IPD meta-analyses of the sex differences in these outcomes (at 1 and 5 
years after stroke) and contributing factors, forming the first four studies of the thesis. 
The second dataset included first-ever strokes admitted to 39 hospitals between 2010 
and 2014 in the Australian Stroke Clinical Registry (AuSCR) - a national stroke 




important processes of stroke care in Australia and patient outcomes. Study factors 
included sociodemographics, stroke-related factors, evidence-based processes 
received in hospital (i.e. stroke unit care, thrombolysis, secondary prevention 
medications), and self-reported 3-month indicators (e.g. living arrangements). Study 
outcomes were (1) all-cause mortality, (2) causes of death (COD) up to 1 year after 
stroke, and (3) HRQoL at 3-6 months follow-up. The causes of the sex differences in 
stroke care and outcomes were investigated using the AuSCR, forming the other three 
studies as part of the thesis.   
Results: In the meta-analyses of 16,957 strokes included in the INSTRUCT, women 
were about 35% more likely to be deceased and 32% more likely to have a poor 
functional outcome by 1 year after stroke compared to men. Women also had greater 
participation restriction and poorer HRQoL than men.  
The sex differences in stroke outcomes were mostly explained by women’s greater 
age, greater pre-stroke functional limitations and more severe strokes than men. The 
presence of atrial fibrillation (AF) also accounted for the greater mortality in women 
and post-stroke depression contributed to the sex differences in HRQoL. There was 
limited evidence that stroke management, socioeconomic status, cardiovascular risk 
factors, or other comorbidities were responsible for the worse outcomes in women 
compared to men. Similar results were observed in 5-year analyses. Further 
examination of stroke severity at the acute stage showed that pre-stroke factors only 




In the analyses of the AuSCR on 14,118 strokes, women had a 40% greater all-cause 
mortality at 1 year following stroke. The COD differed between sexes with women 
having more deaths attributed to stroke or other cardiovascular diseases (CVD; e.g. 
AF and heart failure) than men. Women’s lower aspirin administration within 48 
hours of admission, advanced age and stroke severity explained the greater all- and 
specific-cause mortality. About 60% of the participants (n=6852) had HRQoL 
assessments at 3-6 months. Women had worse HRQoL than men, with the difference 
mostly explained by age, stroke severity, and 3-month place of residence (aged care). 
However, older women had poorer HRQoL than older men, independent of the 
measured covariates including evidence-based care and other factors.   
Conclusions: Women faced poorer outcomes after stroke than men. Worse outcomes 
in women were mostly because of pre-stroke factors including age but also stroke 
severity, pre-stroke functional limitations and, to a lesser extent, AF. Of all aspects of 
management examined, only lower aspirin administration in women contributed to 
their greater mortality. The findings highlight the importance of better management of 
vascular risk factors and comorbidity in the elderly, with more women prevalent in 
that age group than men. The findings suggest opportunities for interventions to 
reduce sex differences in stroke outcome may include better access to evidence-based 
care for cardiovascular and general health, and opportunities for post-stroke 
rehabilitation, especially targeting those with less capacity to recover (i.e. pre-stroke 
functional limitation, more severe strokes and mood disorders). Further research on 
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Thesis Aims, Hypothesis, and Guide to Chapters 
Aims 
The aims of the thesis were to:  
1) quantify the sex differences in stroke management and outcomes following stroke; 
2) to identify factors that contribute to the worse outcomes in women compared to 
men. 
Hypotheses  
1. Women with stroke receive evidence-based care less often than men. Age and pre-
stroke factors such as cardiovascular risk factors will mostly account for these 
differences. 
2. In unadjusted analyses, women, compared to men, will have higher mortality, 
worse functional outcomes, greater participation restriction, and poorer HRQoL in 
the long term after stroke.  
3. Age, stroke severity and co-morbid disease will account for most of the sex 
differences in these long-term outcomes after stroke. Others confounders such as 
clinical management and post-stroke mental health will partially account for the 
sex differences in long-term outcomes. 
Thesis organisation and guide to chapters 
The thesis provides a comprehensive examination of the differences between men and 
women in stroke outcomes including all-cause and specific-cause mortality, 
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functional outcome, participation restriction, health-related quality of life, in-hospital 
management, and stroke severity.  
Two different datasets were used in the thesis: one is a data pooling study including 
13 population-based stroke incidence studies worldwide that met the ‘gold standard’ 
criteria for such studies, and the other was from a national stroke registry including 
data collected from 39 hospitals around Australia with up-to-date information on 
quality of care and outcomes. Therefore, the methods for each dataset are presented in 
two separate chapters. The structure of the thesis is as follows:  
Chapter 1: Review of literature  
I summarise key topics related to thesis including what is known about sex 
differences in patient outcomes after first-ever stroke, limitations of current research, 
the measurement of outcomes following stroke, and factors that may contribute to sex 
difference in outcomes after stroke.  
Chapter 2: Methods for the International Stroke Outcome Study (INSTRUCT) 
using pooling data of population-based stroke incidence studies 
In this chapter, I provide a systematic search for eligible studies for the individual 
participant data (IPD) meta-analysis of high-quality stroke incidence studies forming 
the INSTRUCT. I also present general information on the methods used in the 
INSTRUCT (Chapter 3-6). More detailed information on covariates, outcomes and 
data analysis are included in the relevant results chapters.  
Chapter 3: Sex difference in long-term mortality after stroke in the INSTRUCT 
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I report estimates of sex differences in mortality at 1 and 5 years after stroke from the 
meta-analysis of IPD in INSTRUCT including examination of confounding factors of 
the sex difference are presented in this chapter.  
Chapter 4: Sex difference in long-term functional outcome and participation 
after stroke in the INSTRUCT 
I report estimates of sex difference in functional outcome and participation restriction 
up to 5 years after stroke from 11 out of 13 studies included in INSTRUCT.  
Chapter 5: Sex difference in long-term health-related quality of life (HRQoL) in 
the INSTRUCT 
I report estimates of sex difference in HRQoL at 1 and 5 years after stroke from 10 
out of 13 high quality stroke incidence studies included in INSTRUCT.  
Chapter 6: Sex difference in severity of stroke in the INSTRUCT 
In this chapter, I report sex difference in severity of stroke using National Institute 
Health Stroke Scale from a meta-analysis of individual participant data from 8 out of 
13 studies included in INSTRUCT.  
Chapter 7: Methods related to Australian Stroke Clinical Registry (AuSCR) 
data collection and application in my research 
The chapter describes the methods for the studies using the AuSCR – a national 
stroke registry (Chapters 8-10). More detailed information on covariates, outcomes 
and data analysis are included in the relevant results chapters.  
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Chapter 8: Sex difference in management and all-cause mortality after stroke in 
the AuSCR 
In this chapter, I report sex difference in management of acute stroke and mortality up 
to 1 year after stroke using AuSCR data between 2010 and 2014.  
Chapter 9: Sex difference in specific-cause mortality and excess death rates after 
stroke: the AuSCR 
I report sex difference in causes of death after stroke, including excess death rates 
after stroke compared to the general population, up to 1 year after stroke using a 
subset of AuSCR data between 2010 and 2013 in this chapter.   
Chapter 10: Sex difference in HRQoL after stroke in the AuSCR 
In this chapter, I report sex difference in HRQoL at 3-6 months after stroke using 
AuSCR data between 2010 and 2014.  
Chapter 11: Summary, implications and future directions 
This chapter draws together the major findings and conclusions, summaries the 
contributions of the thesis to the field, and provides recommendations for future 
research. 
Appendices: A-I 
This chapter provides supplementary information for the thesis. Some tables and 
figures that were published as peer-reviewed supplemental materials have been added 
to the Methods sections (Chapters 2 and 7) for easier interpretation.  
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Chapter 1: Review of literature 
1.1 Impact of stroke  
Stroke affects 33 million people, including 16.9 million first-ever strokes, each year 
worldwide.1 In 2013, stroke was responsible for 6.5 million of deaths, accounting for 
11.8% of total deaths worldwide.2 It was also a leading cause of long-term disability.3 
Despite a substantial decline in stroke mortality rates over the last few decades,2 the 
absolute number of stroke deaths and disability-adjusted life-years (DALYs) lost are 
rising.1,4 One-third of 5-year survivors remain dependent on others,5 and up to a half 
experience psychosocial comorbidity (mainly depression) after stroke.6 There is a 
considerable proportion of stroke survivors with poor health-related quality of life up 
to 5 years after stroke.7  
In Australia, stroke was the third leading cause of death in 2013.2 It was estimated 
that approximately 440,000 Australians were living with the effects of stroke in 
2014,8 and this number is anticipated to surge to over 700,000 by 2032.9 Stroke was 
responsible for 4.5% of the overall of burden of disease in Australia10 with the total 
financial costs estimated to be $5 billion in 2012.8 Approximately two-thirds of those 
living with stroke suffered a disability that meant they required assistance to do 
activities of daily living.8 
The global burden of stroke is predicted to continue to grow in association with an 
ageing population.2 Therefore, stroke remains a serious public health concern with 
devastating physical, psychological (emotional and mental), and economic impacts on 
Chapter 1: Review of literature 
2 
 
not only patients but also their families,11 communities, and the health-care system.12-
14 
1.2 Sex differences in the epidemiology of stroke 
It is not often recognised that stroke has placed a higher burden on women than men. 
Globally, women have a higher crude incidence of stroke than men but this is 
reversed once age is taken into account.7,15 Although stroke mortality has decreased 
over the past two decades,16,17 the annual crude death rate from stroke in women (94.8 
per 100,000 people) has outweighed that of men (80.3 per 100,000 people).18 The 
global burden of stroke in women is predicted to continue to grow19 associated with 
an increase in life expectancy for both sexes.15 (Figure 1-1). Because women live 
longer than men,20 women that suffer stroke may be exposed to more physical 
disabilities, psychological and social problems, and have fewer years of healthy life 
compared to men.21  
In Australia, stroke was ranked as the third leading contributor of death for women in 
comparison with being ranked fifth for men, accounting for 6.1% and 3.9% of the 
total burden of disease, respectively.10 The crude death rate of stroke was 
approximately 50% greater in women than in men (45.6 vs 26.6 per 100,000)22 and 
disabilities appeared to be disproportionately higher amongst women survivors.8  
Among studies of outcomes after stroke, women appeared to have poorer functional 
outcomes, greater handicap, and worse health-related quality of life than men both in 
the short23 and long term.24  




Figure 1-1. Global life expectancy by sex. The table was created using data from 
the Global Burden of Disease Study 2015.25 (Online data: 
http://ghdx.healthdata.org/gbd-results-tool) 
1.3 Limitations of existing studies of sex differences in outcomes  
There is an increased interest related to investigating the differences between men and 
women in outcomes after stroke. However, uncertainty exists over the sex differences 
due to several limitations of the existing research into the long term following stroke 
(≥1 year), identified in a review led by Gall et al (2012).24 More recently, our focused 
update of sex differences in patient outcomes ≤ 1 year after stroke less than one year 
(Gall et al. 2018) has again identified similar problems to the aforementioned issues 
of the long-term studies.23  
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Overall, the studies of the sex differences in stroke outcome have mainly been 
reported in the short-term up to 6 months. Many studies have been based on hospital 
cohorts or convenience samples. This is a potential problem because the selection bias 
from the hospital-based studies may adversely affect the conclusion of the sex 
differences in outcomes.26 On the one hand, those with more severe strokes may be 
more likely to be admitted to hospital and have poorer survival and disability than 
those not admitted to hospital with less severe stroke.27 Therefore, selection bias from 
the hospital-based studies may inflate the sex differences in outcomes after stroke.28 
On the other hand, women are less often admitted to hospital potentially due to more 
often residing in an institution when they experience their stroke,29 which may bias 
hospital-based outcome studies of sex differences in outcomes in an unpredictable 
way.26  
Population-based stroke incidence studies, therefore, provide better external and 
internal validity and are ideally designed to explore sex differences in outcomes after 
stroke.30 The highest quality are those that have adhered to standardised guidelines for 
‘ideal’ stroke incidence studies (Table 1-1) as proposed by Sudlow and Warlow,31 
and by Malmgren et al.32 These guidelines are discussed in detail below. 
Although there are many good quality studies of stroke outcome, very few studies 
have been specifically designed to examine the aetiology of sex differences in 
outcomes. Most of the existing studies either failed to undertake detailed analyses of 
sex differences5,33-52 or potential confounding factors were not well examined.53,54 
The associations between sex and outcomes after stroke have usually been reported as 
incidental findings in multivariable models (e.g. using step-wise regression) with 
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considerable variation in outcome measurement and adjustment for covariates.24 The 
role of potential confounding or mediating variables for sex disparities are still 
inconclusive. This is because very few investigators have examined the relative 
effects of individual covariates and provided both unadjusted and adjusted results to 
see the influence on effect estimates. Additionally, in some studies the focus on the 
sex difference has only included ischaemic stroke, which accounts for 75-80% of 
events, instead of all stroke types.55 In other studies, only one aspect of outcomes in 
the long term after stroke, such as survival, has been examined.41,56  
 
Table 1-1. Core criteria for a comparable study of stroke incidence proposed by  
Sudlow and Warlow31 and by Malmgren et al.32 
Standard definitions 
World Health Organization definition 
First-ever-in-a-lifetime stroke 
Standard methods 
Complete, community-based case ascertainment, based on multiple overlapping 
sources 
Prospective study design, ideally with “hot pursuit” of cases 
Large, well-defined, stable population 
Reliable method for estimating denominator 
Standard data presentation 
Whole years of data 
Not >5 years of data averaged together 
Men and women presented separately 
Include ages up to ≥85 years if possible 
Standard mid-decade age bands (e.g., 55 to 64 years) used in publications 
Unpublished 5-year age bands available for comparison with other studies 
Presentation of 95% confidence intervals around incidence rates 
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1.4 Study designs to examine the sex differences in outcomes 
Population-based stroke incidence studies offer better external and internal validity 
than other studies undertaken within hospital settings or where a convenience sample 
has been used.30 These high-quality studies provide the best way to document the 
processes of care, stroke outcomes (e.g. case fatality, functional outcome, and 
HRQoL), and costs of stroke on representative cohorts of people that have had a 
stroke.31 As these studies are conducted prospectively, important stroke-related 
factors can be collected such as pathological subtypes, socio-demographics, stroke 
severity, and comorbidities that are often unavailable in routinely gathered data from 
other sources.  
‘Gold standard’ population-based stroke incidence studies are ideal to examine the 
sex differences in outcomes after stroke. However, it is cumbersome and labour-
intensive to conduct these high-quality studies, which can partly explain why a large 
number of them were conducted a long time ago (i.e. 1970s-1990s).57 These studies, 
therefore, may be less able to provide information on contemporary stroke care. In 
addition, there are some countries where population-based stroke incidence studies 
cannot be conducted nor repeated due to costs and labour intensity.58 Further, 
examination of longer term outcomes means that by the time follow-up assessments 
are completed, the care provided at baseline some years later may be outdated. 
National stroke registries allow us to capture aspects of the quality of care through 
measuring current processes of in-hospital care as well as associated outcomes after 
stroke.25 These clinical registries, therefore, could be served as a proxy for 
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population-based incidence studies in locations where the majority of incidence cases 
are treated in hospital.58 There are several national quality registries for stroke (e.g. 
the Get-with-the-Guidelines-Stroke program in the United States,59 the Australian 
Stroke Clinical Registry in Australia,60 or the Riks-Stroke register in Sweden),61 
which provide up-to-date data on stroke performance indicators aligned with 
evidence-based practice recommendations. The national registries include 
standardised data collection to ensure data quality and often have adequate power to 
test research hypotheses among different subgroups of patients. Nevertheless, detailed 
information on pre-existing comorbidities and some patient outcomes (e.g. post-
stroke depression) may not be captured in these registries.  
1.5 Measurement of outcomes after stroke 
Patient outcomes after stroke can be gathered from the studies of stroke, either based 
on community-based or hospital samples. Outcomes that are commonly assessed in 
research include survival, functional outcomes, participation restriction, and health-
related quality of life. An overview of these outcomes is described below.  
1.5.1.1 Survival  
Mortality rate (or death rate) is calculated by diving number of deaths occurring in 
the population during the stated period of time by the number of persons at risk of 
dying during the period often expressed as a rate per year.  
Mortality can be collected nationally for comparison across countries such as through 
national data linkage of death registers among the whole population. However, the 
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accuracy of official stroke-mortality statistics depends not only on the coding 
methodology but also on the quality of the data itself which may misclassify 
stroke.62,63  
Mortality after stroke can also be gathered. In these studies, survival can be expressed 
as a case fatality rate (CFR). The CFR represents a measure of risk of deaths due to 
stroke within a designated population of stroke "cases" and usually expressed as a 
percentage.  
Survival is also reported in stroke studies, indicating the percentage of people who are 
alive after a stroke event in a specific time of follow-up after diagnosis.  
1.5.1.2 Functional outcome and participation restriction (or handicap) 
The World Health Organization (WHO) first introduced a detailed concept of 
impairment, disability, and handicap in manual of International Classification of 
Impairments, Disabilities and Handicap (ICIDH)64 in 1980. Impairment refers to any 
loss or abnormality of psychological, physiological or anatomical structure or 
function. Disability is a functional limitation with regard to a particular activity or 
task in the range considered normal for an individual. Handicap is defined as a 
disadvantage in filling a role in life for a given individual. 
Changes in health care during the 20th century called for a shift from the treatment 
focus of acute disease to the management of chronic disease and/or disability, in other 
words, “from disease to health”. To avoid the negative connotations of certain terms 
used previously by the original ICIDH, the development of the ICIDH-265 by the 
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WHO (1998) provided the terms "activities" instead of disability and "participation" 
instead of handicap. The ICIDH-2 covers the same three dimensions: (1) body 
structures or functions; (2) personal activities; and (3) participation in society with 
adding contextual factors (environmental and personal). The WHO (2001) provided 
the new model, namely International Classification of Functioning, Disability and 
Health (ICF),66 comprising components of functioning and disability “in the context 
of health”.  
The terminology ‘functional outcome’ (or activity limitation, or disability) used in 
this thesis is based on the ICF classification.66 Having worse functional outcomes 
after stroke means the patients are restricted in the activities of daily living (ADL),66 
and may require supported care.67  
Participation restriction (or handicap) reflects the influence of functional loss on a 
person’s social, economic and recreational activities after stroke.24 Participation 
restriction is rarely measured in stroke outcomes research, although it is a person-
centred outcome that is important to survivors of stroke68 and can greatly affect stroke 
survivor’s health-related quality of life.69 In the thesis, the official terminology 
‘participation restriction’ based on the ICF66 definition was used instead of the term 
‘handicap’. Handicap is defined as a disadvantage in filling a role in life for a given 
individual.65 To avoid the negative connotations of the traditional term, ‘participation 
restriction’ is widely accepted by both medical and non-medical clinicians and 
increasingly used in stroke research.68,70  
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1.5.1.3 Health-related quality of life  
Health-related quality of life (HRQOL) is a multi-dimensional concept that has 
evolved since the 1980s that encompasses domains related to functional ability, 
psychological state, social function, and an individual's perception of his or her 
health.71,72 HRQoL is defined as an assessment of how the individual's well-being 
may be affected over time by a health condition such as disease, disability, or 
disorder.73 HRQOL has become an important component of health surveillance and is 
generally considered a valid indicator of service needs and intervention outcomes. It 
goes beyond direct measures of population health, life expectancy and causes of 
death, and focuses on the impact of health status on quality of life. There are a 
number of HRQoL measurements74 including generic HRQL and condition-specific 
HRQoL instruments. Generic instruments are designed to be able to compare HRQOL 
across populations or different diseases while condition-specific instruments are 
designed to assess HRQOL with questions and scales that are specific to a disease or 
condition. Given the rising burden of stroke worldwide, HRQoL is an important 
outcome to measure as it reflects the person’s experience. Generic and stroke specific 
measurements of HRQoL are widely used in stroke research with acknowledged 
strengths and limitations.75 
Changes in scores of patient-reported outcomes including HRQoL should be assessed 
in the context of clinically or minimally meaningful differences. These can also be 
used to evaluate the effectiveness of an intervention as well as improve healthcare 
decisions and policies.76 The minimal important difference or minimal clinically 
important difference (MCID) is considered as a standard approach in the 
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interpretation of clinical relevance of changes in patient-reported outcomes.76 The 
MCID represents the smallest change in a treatment outcome that an individual 
patient would identify as important and which would warrant a change in the patient’s 
management.77 There are various computational techniques to assess the meaningful 
threshold for HRQoL utility scores such as distribution-based and anchor-based (e.g. 
regression, average change approach, minimum detectable change approach, change 
difference approach and ROC curves) methods.78 However, interpreting the results of 
studies reporting HRQoL is not straightforward. The MCID has not been commonly 
reported in the studies designed to examine the sex difference in HRQoL after stroke.  
1.6 Magnitude of the sex differences in outcomes in existing 
research  
Current reviews have been undertaken to explore the sex differences in stroke 
worldwide, which generally have shown less favourable outcomes in physical, 
psychological and HRQoL after stroke in women when compared to men.23,79-84 In the 
following sections, I present some selected findings of the sex differences in 
outcomes following stroke identified in the current literature. Women are frequently 
under-represented in stroke randomised controlled trials (RCTs), potentially leading 
to selection bias that may affect analyses of differences between men and women in 
the receipt of stroke care and outcomes after stroke.85 I have, therefore, included 
population-based or hospital-based studies in the chapter. 
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1.6.1 Survival outcome 
As explained earlier, at the population level, women appear to have greater mortality 
than men based on the data from the Global Burden of Disease Study 2015 (Figure 1-
2).25 However, the quality and completeness of the global mortality data may be 
sometimes questionable because of potential data coding problems of underlying 
causes of death from the national death registrations.86  
 
Figure 1-2. Global stroke mortality by sex. The table was created using data 
from the Global Burden of Disease Study 201525 (Online data: 
http://ghdx.healthdata.org/gbd-results-tool) 
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Table 1-2 presented my general overview of selected studies with survival outcome 
data following stroke. Women generally have lower survival after stroke both in the 
short and long term although the magnitude of the differences varied between studies 
varies (Table 1-2). In a meta-analysis of 31 high-quality population-based stroke 
incidence studies conducted between 1970 and 2004 it was found that women had 
about 25% greater 28-day CFR of stroke than men.56 There are some other studies 
whereby the CFRs for women and men have been discordant (e.g. at 1 month,87,88 or 
up to 6 years after stroke; Table 1-2).39,89 There is some evidence that women and 
men differ in respect to important risk factors of stroke,82 which may contribute to the 
sex differences in survival after stroke. However, current research is limited by the 
lack of detail on potential contributing factors to explain the sex differences.  
Among the few studies with multivariable adjustment (Table 1-2), women appeared 
to have greater mortality compared to men in unadjusted analyses (e.g. relative risk: 
1.34-1.38 up to 3 months, or hazard ratio: 1.18 up to 5 years after stroke).90 However, 
these sex differences in survival were mostly explained by contributing factors 
including age, stroke severity, stroke type, and co-morbid disease. After accounting 
for the covariates, the mortality was lower for women compared to men in four 
studies (1 month,91 1 year,92 5 years,90 and 10 years93) while no evidence of the sex 
differences was observed in the remaining studies (1 month,92,94,95 1 year,96 and 5 
years97).   
There have been a myriad of discrepancies in study design (i.e. hospital-based or 
population-based), setting and analysis method (i.e. using Cox model, Poisson 
regression), and adjustment for covariates between studies. Few studies examined 
Chapter 1: Review of literature 
14 
 
whether differences in management after stroke influenced the sex difference in 
survival. This suggests a need for studies designed to comprehensively examine 
factors contributing to the sex differences in mortality, particularly in the long term 
after stroke.  
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Table 1-2. Summary of selected studies with survival outcome data by sex up to 10 years after stroke 
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2009 Chausson39 SC 
PB 
Prosp 








2009 Palnum91* MC 
PB 
Prosp 
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       Poor outcome in adjusted results  
















2009 Oh90* MC 
HB 
Prosp 

















































tPA, time delays 
from onset to 
hospital arrival 
2005 Anderson93* SC 
PB 
Prosp 
10 yrs Survival M: F 
survival  
1-yr 70.3% 
vs 66.7%, ns 
 
5-yr 40.0% 
vs 38.9%, ns 
F:M 
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       Poor outcome in adjusted results  























2003 Appelros96 SC 
PB 
Prosp 








 x  
Age, co-morbid 
CVD, severity, 













Mortality  F:M  











*denotes studies designed to examine the sex differences in outcome 
SC: single centre, MC: multi-centre, HB: hospital-based, PB: population-based, prosp: prospective study, Hx: history, tPA: Tissue plasminogen activator, 
mths: months, yr: year, M: men; W: women; CVD: cardiovascular disease; RR: relative risk; HR: hazard ratio; ns: non-significant 
 
Chapter 1: Review of literature 
19 
 
1.6.2 Functional outcome  
Women generally have worse functional outcomes than men in both short and long 
term studies after stroke.23,24 However, there are variations in outcome measures (e.g. 
modified Rankin Scale − mRS, Barthel Index − BI, and disability on Katz ADL 
items), study settings (population-based or hospital-based), definition of poorer 
outcome (e.g. BI< 95, BI≤60, or mRS≥3) between these studies that hamper 
comparisons.  
The existing reviews highlight the fact that very few studies were population-based 
and specifically designed to examine the aetiology of sex differences in functional 
outcomes.23,24 Only four out of 21 long-term studies (≥ 1 year after stroke) were 
aimed to investigate the sex differences and none of these four studies were 
population-based.24 Similarly, of the 22 studies with functional outcome up to 1 year 
after stroke, only 3 were population-based studies that were designed to examine sex 
differences.  
According to the most recent review, among studies that designed to examine the sex 
differences up to 1 year after stroke,23 women had 44-61% lower odds of good 
functional outcome or 29-62% greater odds of poor functional outcome in unadjusted 
analyses (Table 1-3). Adjustment of covariates, most commonly age, stroke severity, 
comorbidities, and pre-stroke function reduced the association by 9-20% but did not 
fully explain the sex differences among 6/8 studies (female:male adjusted odds ratios 
[OR] of good outcome: 0.37-0.75; OR of poor outcome: 1.17-1.74). The list of 
covariates in study-specific multivariable models and magnitude of the sex 
differences substantially differed between studies. Few studies examined whether 
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differences in management after stroke influenced the sex difference in functional 
outcome. More comprehensive research designed to quantify the sex differences in 
functional outcomes in the long term after stroke and identify the contributing factors 
is needed.  
1.6.3 Participation restriction 
Women generally faced a higher crude risk of having participation restriction in both 
the short and the long term after stroke.23,24 In adjusted analyses, the sex differences 
were mostly explained by age, post-stroke disability and depression. It is noticeable 
that participation restriction is rarely measured in stroke outcomes research.24 Also 
very few investigators have provided unadjusted and adjusted effect estimates of the 
sex differences (Table 1-4).23 Participation was assessed by different instruments (i.e. 
London Handicap Scale, the Work and Social Adjustment Scale and the participation 
of the Stroke Impact Scale) that are not comparable between studies. Uncertainty also 
exists over the contributing factors to the sex differences in participation restriction. 
Few studies examined whether differences in management after stroke influenced the 
sex difference in participation restriction. There is a need for further research 
designed to examine the differences between men and women in participation 
restriction following stroke and identify the contributing factors to the differences.  
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Table 1-3. Summary of sex differences in functional outcome up to 1 year after stroke in studies designed to examine sex difference with 
multivariable adjustment (source: Gall et al., 2018)23 
       Worse outcome in adjusted 
results 
 
Year  Author  Desig
n 















2014 Wu98 SC 
HB 
Prosp 








  x 
Age, race, stroke type, 
co-morbidities, severity 










OR 1.41  
(95% CI 
0.99, 2.01) 
 x  
Age, marital status, pre-
stroke modified Rankin 
scale (mRS), severity, 


























  x 
Age, stroke severity, 
small vessel occlusion, 
stroke Hx, co-morbidities 
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       Worse outcome in adjusted 
results 
 
Year  Author  Desig
n 



















  x 
Age, stroke severity, 
small vessel occlusion, 
stroke Hx, co-morbidities 
2009 Petrea67 PB 3-6 
mths 
Disability on Katz 
ADL items 











 x  
Age, systolic blood 
pressure, hypertension 
treatment, AF, smoking, 
co-morbid cardiovascular 
disease, diabetes 















  x 
Age, pre-stroke 
ambulatory status 
2008 Reid103 SC 
HB 
Prosp 








  x 
Age, pre-stroke 
functional status, stroke 
type, stroke severity, AF 
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       Worse outcome in adjusted 
results 
 
Year  Author  Desig
n 





























  x 
Age, race, pre-stroke 
ambulatory status, pre-
stroke, discharge mRS, 
proxy, stroke Hx 
ADL: activities of daily living; AF: atrial fibrillation; SC: single centre, MC: multi-centre, HB: hospital-based, PB: population-based, prosp: prospective 
study, BI: Barthel Index, mths: months, yr: year; M: men; W: women 
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Table 1-4. Summary of sex differences in participation restriction up to 1 year after stroke in studies with multivariable adjustment 
(source: Gall et al., 2018)23 
       Worse outcome in adjusted results  














2014 Vincent105* SC 
HB 
Prosp 
1, 3, 6, 
9 and 
12 mths 
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       Worse outcome in adjusted results  
































2008 Lo109 HB 
Prosp 
12 mths LHS NR W:M 










*denotes studies designed to examine the sex differences in outcome 
BMI: Body mass index; SC: single centre, MC: multi-centre, HB: hospital-based, PB: population-based, prosp: prospective study, retro: retrospective 
study, mths: months, yrs: years, RNLI: Reintegration to Normal Living Scale, SIS: Stroke Impact Scale, LHS: London Handicap Scale, FIM: Functional 
Independence Measure, MMSE: Mini Mental State Examination, PSD: post-stroke depression, mRS: modified Rankin Scale, NR: not reported 
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1.6.4 Health-related quality of life 
Existing reviews of studies of HRQoL after stroke reported worse HRQoL after 
stroke in women compared to men in unadjusted analyses.23,24 Despite the increased 
interest in sex differences, existing research has not adequately investigated the 
reasons for worse HRQoL in women, either in short or long-term studies. Age, 
sociodemographic factors, stroke severity, functional outcome and depressive 
symptoms were the most common contributing factors of the sex difference in 
HRQoL. Few studies examined whether differences in management after stroke 
influenced the sex difference in HRQoL. Some authors reported that difference in 
HRQoL between women and men still exists even after adjusting for some potential 
confounding factors.24,98,110-115 while others show contrary findings or no significant 
difference between men and women in post-stroke HRQoL.24,116  
The inconsistent findings on the sex difference may due to study design (e.g. only 2 
out of 13 short-term studies were population-based; Table 1-5) to examine underlying 
reasons for the association between sex and HRQoL. Uncertainty exists over the 
causes of sex difference in HRQoL given variations in the outcome measurements, 
adjustment for different covariates, and methods of analysis.23 As can be shown in 
Table 1-5, HRQoL up to 1 year after stroke has been assessed by several generic (i.e. 
European Quality of Life – 5 dimensions, 36-item Short Form Health Survey, 12-item 
Short Form Health Survey) and stroke-specific instruments (i.e. Stroke-Specific 
Quality Of Life; Stroke Impact Scale) while the unadjusted and adjusted results were 
reported in different scales such as mean difference or odds ratio. This calls for a 
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more comprehensive investigation of contributing factors to the sex differences in 
HRQoL following stroke.
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Table 1-5. Summary of sex differences in health-related quality of life up to 1 year after stroke from studies with multivariable 
adjustment (source: Gall et al., 2018)23 
       Good outcome in adjusted 
results 
 














2016 Chang117 MC 
HB 
Prosp 
6 mths  EQ5D   






2016 Chuluunbaatar118 MC 
HB 
Prosp 













2015 Guajardo119 SC 
HB 
Prosp 
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       Good outcome in adjusted 
results 
 




































2014 Bushnell110* MC 
HB 
Prosp 
3 mths, 1 yr  EQ5D W:M mean 
difference 
(95% CI) 



























outcome, place of 
residence 
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       Good outcome in adjusted 
results 
 














2012 Abubakar121 SC 
HB 
Prosp 




















2011 Delcourt122 MC 
HB 
Prosp 




















2010 Almborg123 SC 
HB 
Prosp 











2009 Shyu124 SC 
HB 
Prosp 
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       Good outcome in adjusted 
results 
 



















2007 Gargano104* MC 
HB 
Prosp 















2007 Lindgren125 MC 
HB 
Prosp 
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Age, severity, 
stroke type, 
stroke Hx, time of 
stroke 
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       Good outcome in adjusted 
results 
 


































*denotes studies designed to examine the sex differences in outcome 
EQ5D: European Quality of Life – 5 dimensions; BP: blood pressure; SC: single centre, MC: multi-centre, HB: hospital-based, PB: population-based, 
prosp: prospective study, retro: retrospective study, DC: discharge, mths: months, Hx: history, BP: blood pressure, tPA: Tissue plasminogen activator, 
mths: months, yr: year, SF36: Short Form 36, SSQOL: Stroke-Specific Quality of Life Scale, WHOQOL-BREF: The Brief World Health Organization 
Quality of Life Assessment Instrument, SIS-16: Stroke Impact Scale-16, SE: standard error; QOL-35: 35-item quality-of-life questionnaire, yr: year; 
MHSS: mental health; PHSS: physical health; M: men; W: women; OR: odds ratio 
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1.7 Potential factors associated with sex differences in outcomes 
after stroke   
1.7.1 Socio-demographics 
One of the major reasons why women may have worse outcomes than men after 
stroke is that they are more likely to be older than men55,83 by up to 5 years.61,94,126-128 
For example, women had a mean age of 72.9 years at stroke onset while among 
men the average age at first-ever stroke was 68.6 years.129 Other evidence reveals that 
socioeconomic position may be important as it is associated with stroke risk profile130 
and severity of stroke131 and is, therefore, an important contributor to poor outcomes 
after stroke.130-133 Several studies reported lower socioeconomic position among 
women compared to men134,135 including socioeconomic position,134 educational 
level,135 occupation,135,136 and income.132 This may, therefore, partly explain the sex 
differences in long-term outcomes of stroke. Given their advanced age at the time of 
stroke onset, women tend to more often be living alone137 before stroke, even 3-6 
months following stroke.67 They are thus more likely to reside in an institution or 
have less social support after stroke81,138 which are associated with poorer 
outcomes.139,140  The effects of loneliness, social isolation, social support, and living 
alone on health outcomes have received increasing attention recently. Living alone is 
particularly important in older women because they are more than twice as likely to 
live alone than men (46% of women 75 years of age and older live alone compared to 
only 23% of men).141 
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1.7.2 Pre-stroke function, comorbidity, risk factors, stroke type and stroke 
severity 
Women may have poorer physical function prior to stroke onset,94,140,142,143 and more 
post-stroke depression than men.143 In addition, sex differences in stroke risk factor 
profiles99,144-148 and pathology149 may partly explain why women often experience 
more severe stroke.127,129 Women tend to more often have pre-existing hypertension 
and atrial fibrillation while smoking, alcohol overuse, peripheral disease prior to 
stroke are more often found in men.81,140 The differences in risk factor profile have 
been suggested to account for the differences of stroke lesion patterns in genders. 
Evidence also shows that women were more likely to suffer from haemorrhage84,145 
and cardio-embolic infarction83,144,150 whilst men develop large and small vessel 
diseases more often.151  
1.7.3 Treatment and management 
Current reviews articles on stroke indicated that it is under debate whether there are 
sex-related differences in stroke management.80,84,149 When it comes to the time of 
arrival to emergency department from onset, a majority of studies showed no 
difference between men and women.152-155 However, others reported greater pre-
hospital delay among women than in men with stroke.84,156,157 Also, women with 
acute stroke have been reported to experience greater emergency department delays 
than men, which were not attributable to differences in presenting symptoms, time of 
arrival, age, or other confounders.158  
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Some investigators from the United States of America and Europe have reported that 
women receive evidence-based care less often compared to men.80,84 Studies indicated 
that there were sex differences in receipt of diagnostic and treatment-related 
procedures such as brain imaging and echocardiograms after accounting for age and 
stroke severity.142,159 Others found that women were less likely to receive 
thrombolytic therapy,160-162 and the difference remained significant even after 
adjustment for age, comorbidities like heart diseases, smoking and pre-stroke 
ambulatory status (e.g. walking ability).102 This disparity may be due to the delayed 
time to hospital presentation in women,163 which can limit the ability to receive this 
treatment. Although the evidence shows no sex difference in access to rehabilitation 
hospitals,12 women may experience more difficulties in stroke recovery.80,101 Risk of 
death or recurrence after stroke is substantial and profoundly influenced by sex and 
comorbidities164 which may influence the differences in outcomes between two sexes. 
Therefore, how treatment and management contribute to sex differences in stroke 
outcome should be explored carefully. 
1.7.4 Post-stroke factors 
There is a relationship between psychological issues such as depression and cognitive 
impairment and outcomes of stroke. For example, emerging data reveal that post-
stroke depression was associated with mortality,165 worse functional outcomes166 as 
well as reduced HRQoL.166,167 A systematic review showed that prevalence of post-
stroke depression was higher in women than in men168 which may influence the sex 
differences in long-term outcomes of stroke. 




Women appear to experience worse outcomes after stroke than men but the causes of 
these differences have not been conclusively determined in either short- or long-term 
studies. Potential factors associated with poorer outcomes in women included older 
age, lower socioeconomic position, living alone more often, having more pre-stroke 
functional limitation, comorbidities, severe strokes, and the presence of depression 
after stroke more often than men. There is also some evidence that women receive 
evidence-based care less often than men after stroke but how this influences outcomes 
after stroke is unclear. There is a need for high-quality studies to explore the sex 
differences in outcomes following stroke and contributing factors to inform 
interventions to address these differences. 
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Chapter 2: Methods for studies using data from 
population based stroke incidence studies: the INternational 
STRoke oUtComes sTudy (INSTRUCT) 
2.1 Preface 
The first four studies in this thesis use individual participant data (IPD) from 13 
population-based stroke incidence studies worldwide. I used these data to examine the 
differences between men and women in various outcomes of stroke. This study — the 
INSTRUCT (INternational STRoke oUtComes sTudy) was an IPD meta-analysis on 
over 16,900 first-ever stroke cases. This chapter describes the methods for this study 
including settings, participants, outcome variables, covariates and statistical analyses 
techniques. More specific details of the statistical methods for each outcome after 
stroke are described in subsequent chapters (Chapter 3: mortality; Chapter 4: 
functional outcome and participation restriction; Chapter 5: HRQoL; Chapter 6: 
severity of stroke). 
2.2 Ethics 
The INSTRUCT was approved by the Tasmanian Health and Medical Human 
Research Ethics Committee (H0014861). All of the participating studies had signed 
informed consent from participants and approval from their respective local ethics 
committees. 
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2.3 Study population and design 
The INSTRUCT is a collaboration between 13 ‘gold standard’ stroke incidence 
studies conducted around the world between 1987 and 2014 (Table 2-1). The 
included studies represented 59% of the 22 potentially eligible studies identified by 
systematic search (see below for details of the search strategy, search term, data 
collection and data management). Investigators for these studies provided de-
identified datasets containing the relevant variables to undertake our analyses. I 
created a pooled dataset and undertook statistical analyses to examine sex differences 
in long-term outcomes after stroke. 
Table 2-1. Details of included cohorts 
Study ID Study year Baseline (n) 
Oxford, United Kingdom  A 2002-2013 1374 
Joinville, Brazil* B 2011-2013 980 
Melbourne, Australia C 1996-1999 1316 
Arcadia, Greece† D 1993-1995 555 
Perth, Australia  E 2000-2001 183 
Orebro, Sweden  F 1999-2000 377 
Dijon, France  G 1987-2012 4621 
Martinique, West Indies H 1998-1999 580 
Porto, Portugal I 1998-2000 688 
Auckland, New Zealand K 2002-2003 1423 
L’Aquila, Italia L 1994-1998 4353 
Matão, Brazil M 2001-2002 81 
Tartu, Estonia† N 2002-2003 433 
Total cases   16,964 
* Additional data from the Joinville study have been provided in mid-2017 when all 
the results of the first study of long-term mortality (Chapter 3) were finalised and 
published. The follow-up data up to 5 years of 2,448 first-ever strokes between 
2009 and 2014 at baseline were, therefore, included in the following analyses on 
the long-term functional outcome and participation restriction, health-related 
quality of life and stroke severity at the time of stroke. 
† only have 1-year follow-up data 
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Search strategy, search term, data collection and management 
Our study was a collaboration between investigators for 13 population-based 
incidence studies identified through a previous systematic review (2008),57 and our 
research networks. To understand how representative these studies were of all 
possible studies, the investigator team undertook a systematic literature search in 
2015 of the literature published after the aforementioned systematic review, as 
detailed below. 
2.3.1 Search strategy  
We identified potential studies using previous systematic reviews of these ‘ideal’ 
stroke incidence studies31,169 supplemented with an updated search for new studies 
published since May 2008, the end date for the systematic review by Feigin et al.57 
The Feigin’s review aimed to identify worldwide population-based studies that 
reported stroke incidence and early case fatality. We systematically searched 
population-based studies from academic databases (PubMed, Scopus, Embase and 
ScienceDirect) aiming to identify all ‘ideal’ incidence studies conducted between 
May 2008 and May 2014 with terms “stroke”, “isch(a)emic stroke”, “intracerebral”, 
“intraparenchymal”, “subarachnoid”, “h(a)emorrhage”, “population-based”, 
“community-based”, “community”, “epidemiology”, “epidemiological”, “incidence”, 
“attack rates”, “survey”, “surveillance”, “mortality”, “morbidity”, “fatality”, “case 
fatality”, or “trends”.  
The inclusion criteria were any stroke incidence study which met criteria of ‘gold 
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standard’,31,169 restricted to human studies only and published in the English 
language. These studies have standardised methods to ensure high quality data, 
including standard definitions for first-ever-in-a-lifetime stroke; a prospective design, 
population-based case ascertainment from multiple overlapping sources from inside 
and outside hospital systems; subtyping of a large proportion of events using imaging; 
a large and preferably stable population base; and surveillance over at least one year 
to control for seasonal variation in stroke occurrence. The exclusion criteria were any 
population-based study which was not an adequate design (e.g. age limitations, 
ischaemic stroke only).  
We then established whether investigators of all eligible studies identified by reviews 
and updated search had published on outcomes at 1 or more years after stroke. We 
then approached those who had published these outcomes to participate. Where repeat 
incidence studies with assessments were conducted over time, we requested access to 
the follow-up data from the most recent incidence study.  
Two reviewers (Hoang Phan and Seana Gall) performed an online database search 
separately to identify eligible studies based on title or abstract and, where necessary, 
review the full-text articles. References list of studies were also searched for 
additional eligible articles and unpublished data from contact with authors. Each 
reviewer also performed an assessment to determine which studies met our inclusion 
criteria and all these activities were undertaken with each reviewer blinded to the 
results. Disagreements were resolved via consensus.  
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Our search strategy identified 28 new ‘ideal’ studies in addition to 56 population-
based studies identified by the previous systematic review (Figure 2-1). Of these, 22 
‘ideal’ population-based stroke incidence studies had published on follow-up of 
participants at 1 year or more after stroke. In 2014, the chief investigator approached 
investigators of 17 eligible studies with long term follow-up to participate, with 13 
agreeing (Figure 2-1). The 13 studies were conducted in Australasia, Europe, South 
America, and the Caribbean (Figure 2-2). The main reasons for exclusion of 9 studies 
(Table 2-2) occurred due to refusal to participate (4 studies) and late identification of 
the study (5 studies). 
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Table 2-2. Eligible ‘ideal’ population-based studies of stroke for which long-term 









1 year 725 Mortality No sex-specific 
findings 
Warsaw, Poland42,171 ‘05 1 year 127 Mortality 1-year crude CFR 
24.1% for men vs 
41.5% for women  












up to 3 
years 




3 years 2290 Mortality 1-year crude CFR 
45.9% for men vs 
54.1% for women 
Aeolian Islands, Italia173 ’99-
‘00 
1 year 62 Mortality No sex-specific 
findings 
Vibo Valentia, Italia174* ‘96 1 year 321 Mortality No sex-specific 
findings 







1-year crude CFR 
46.5% for men vs 
44.3% for women 
Valley of Aosta, Italy175 ‘04-
‘08 





Total n   9,985   
CFR, case fatality rate 
*declined to participate 
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Figure 2-1. Flow diagram of potential stroke incidence studies 
Of note, the studies without a proper design were those based on hospitals or other 
designs (e.g. randomised controlled trials, retrospective study, and case-control).   
 




Figure 2-2. World map showing 13 population-based studies with data on long-term mortality of stroke included in the INternational 
STRoke OUtComes STudy 
Chapter 2. Methods for studies using data from population based stroke incidence 
studies: the INternational STRoke oUtComes sTudy (INSTRUCT) 
45 
 
2.3.2 Search term 
Pubmed (n=1851) 
Search ((“stroke”[Title] OR “isch(a)emic stroke”[Title] OR “intracerebral”[Title] OR 
“intraparenchymal”[Title] OR “subarachnoid”[Title] OR “h(a)emorrhage”[Title])) 
AND (“population-based”[Title] OR “community-based”[Title] OR 
“community”[Title] OR “epidemiology”[Title] OR “epidemiological”[Title] OR 
“incidence”[Title] OR “attack rates”[Title] OR “survey”[Title] OR 
“surveillance”[Title] OR “mortality”[Title] OR “morbidity”[Title] OR 
“fatality”[Title] OR “case fatality”[Title] OR “trends”[Title]) Filters: Publication date 
from 2008/05/01 to 2014/05/01; English 
Embase (n=721) 
(1) 'population-based' OR 'community-based' OR 'community' OR 'epidemiology' 
OR 'epidemiological' OR 'incidence' OR 'attack rates' OR 'survey' OR 'surveillance' 
OR 'ideal study' OR 'mortality' OR 'morbidity' OR 'fatality' OR 'case fatality' OR 
'trends' OR 'population-based' OR 'community-based' OR 'community' OR 
'epidemiology' OR 'epidemiological' OR 'incidence' OR 'attack rates' OR 'survey' OR 
'surveillance'  
(2) 'stroke' OR 'ischaemic stroke' OR 'ischemic stroke' OR 'intracerebral' OR 
'intraparenchymal' OR 'subarachnoid' OR 'haemorrhage' OR 'hemorrhage' AND .tw  
(3) #1 AND #2 AND (2008:py OR 2009:py OR 2010:py OR 2011:py OR 
2012:py OR 2013:py OR 2014:py OR 2015:py), human, English  
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Search (TITLE ("population-based" OR "community-based"  OR  "community"  OR  
"epidemiology" OR "epidemiological"  OR "incidence"  OR  "attack rates"  OR  
"survey" OR "surveillance" OR "mortality"  OR "morbidity"  OR  "fatality"  OR  
"case fatality" OR "trends"))  AND (TITLE ("stroke" OR  "ischaemic stroke"  OR  
"ischemic stroke" OR "intracerebral" OR "intraparenchymal" OR "subarachnoid" OR 
"haemorrhage" OR hemorrhage)) AND ( LIMIT-TO ( PUBYEAR, 2014 ) OR  
LIMIT-TO ( PUBYEAR, 2013) OR LIMIT-TO ( PUBYEAR, 2012) OR LIMIT-TO ( 
PUBYEAR, 2011) OR LIMIT-TO (PUBYEAR, 2010) OR LIMIT-TO ( PUBYEAR, 
2009) OR LIMIT-TO (PUBYEAR, 2008)) AND (LIMIT-TO (DOCTYPE, "ar") OR 
LIMIT-TO (DOCTYPE, "ip")) AND ( LIMIT-TO (LANGUAGE, "English")) 
ScienceDirect (n=811) 
Limitation: pub-date > 2007 and pub-date < 2015 and TITLE ( "stroke" OR 
"ischaemic stroke" OR "ischemic stroke" OR "intracerebral" OR "intraparenchymal" 
OR "subarachnoid" OR "haemorrhage" OR “hemorrhage" ) AND TITLE ( 
"mortality" OR "morbidity" OR "fatality" OR "case fatality" OR "trends" OR 
"population-based" OR "community-based" OR "community" OR "epidemiology" 
OR "epidemiological" OR "incidence" OR "attack rates" OR "survey" OR 
"surveillance") 
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2.3.3 Data collection 
Authors of each eligible study (n=13 studies; Table 2-1) were contacted with a 
request for de-identified individual participant data (IPD) on stroke outcomes up to 5 
years after stroke. Outcomes included mortality (date, time of stroke, date of death), 
functional outcomes and health-related quality of life. Data on participant 
characteristics were requested, if available, including (1) socio-demographics (age, 
sex, marital status, education, occupation, socioeconomic position), (2) pre-stroke 
health including body mass index, health behaviours (smoking, alcohol use), pre-
stroke function (dependency, institutional residence), pre-stroke medication, history 
of comorbidities (atrial fibrillation, hypertension, ischaemic heart disease, peripheral 
vascular disease, transient ischaemic attack, diabetes, dementia), (3) stroke-related 
factors (stroke severity, stroke type, year of stroke occurrence), (4) treatment and 
management (hospital admission, time to hospital, admission and discharge 
medication, neuroimaging, carotid investigation, echocardiography and surgical 
intervention) and (5) post-stroke factors (depression and stroke recurrence).  
Data provided were checked against published data, where possible, and if 
discrepancies were identified, clarification was sought from authors. When there was 
no response from authors, we checked whether results of sex differences were 
reported in published papers.  
Available study factors for each study included in the INSTRUCT are provided in the 
Table 2-3. 
Chapter 2. Methods for studies using data from population based stroke incidence 
studies: the INternational STRoke oUtComes sTudy (INSTRUCT) 
48 
 
Table 2-3. Study factors that are available in included cohorts 
Study factors 
Study ID* Baseline 
n A B C D E F G H I K L M N 
Socio-demographics 
Age              16,645 
Race/Ethnicity              3,450 







     
 
 5,595 
Marital status  
 
     
 








   
 
     14,799 
Atrial 
fibrillation 
             16,645 
Hypertension              16,645 
IHD              16,645 
PVD              13,945 
TIA              15,222 
Diabetes              3,836 




     3,197 
Smoking              16,212 
Alcohol use      
 
       11,482 




       4,329 
Pre-stroke 
medication 
             4016 
Stroke-related factor 
Stroke severity              16,645 
Stroke type              16,564 
Treatment and management 
Time to 
admission 
             5,284 
Admission 
medication 
             7,336 
Hospital 
admission 
             16,645 
Investigations 
 
            15,271 
Surgical 
intervention 






    
 




1-yr depression  
 
            1,316 
5-yr depression         
 
    3,319 
1-yr stroke 
recurrence  
             13,568 
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             7,999 
* Study ID was described in Table 2-1 
IHD=Ischaemic heart disease; PVD=peripheral vascular disease; TIA= Transient 
ischaemic attack; Body mass index=BMI; SEP=Socioeconomic position; yr:year 
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2.3.4 Data management 
Study-specific outcomes and variable definitions (i.e. covariates) were recorded and, 
where necessary, recoded to create common variables with consistent definitions (e.g. 
stroke severity). Data collection methods of study factors across study are presented 
in Table 2.4. Following recoding, 13 datasets were then merged into one common 
database using study identification numbers.   
2.4 Research questions 
The research questions addressed in the part of thesis using the INSTRUCT data are 
highlighted below. 
1) Are there differences between women and men in mortality up to 5 years after 
stroke? Which factors contribute to the sex differences? 
2) Are there differences between women and men in functional outcome and 
participation restriction up to 5 years after stroke? Which factors contribute to the 
sex differences? 
3) Are there differences between women and men in HRQoL up to 5 years after 
stroke? Which factors contribute to the sex differences? 
4) Are there differences between women and men in severity of stroke at acute 
stage? Which factors contribute to the sex differences? 
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2.5 Measurement of potential confounding factors of sex difference 
in mortality in the long term after stroke 
2.5.1 Socio-demographics 
Data on age at the index stroke were available in all studies without age restriction. 
Race from studies from Joinville, Melbourne and Matão was categorised as 
Caucasian/Non-Caucasian. Educational level (6 studies: Oxford, Joinville, 
Melbourne, Porto, Auckland and Matão) was divided into two groups with the cut-off 
point of completing secondary education (grade 12). Classification of socioeconomic 
position (SEP) includes three groups: professional/non-manual (skilled + 
unskilled)/manual (skilled + unskilled) in 4 studies (Oxford, Melbourne, Perth and 
Auckland) whereas SEP was categorised as occupational/retired/unemployed & other 
in the Martinique and Porto studies. Data on marital status (5 studies: Oxford, Perth, 
Orebro, Auckland and Matão) were categorised into 2 groups: married/unmarried 
(single/divorced/widowed).




Table 2-4. Data collection methods of study factors across 13 studies 
Study Source of data 
Oxford176 Pre-morbid medication and vascular risk factors were obtained from the patients or relative, hospital records, and general practice 
records. Blood pressure (BP) was recorded from the general practice records.  
Premorbid mRS was recorded from self-report questionnaire. Recurrent strokes were assessed during regular follow ups by a 
research nurse or therapist. If a recurrent vascular event was suspected the patient was assessed by a study doctor. 
Joinville177 A self-reported history or current treatment for cardiovascular diseases and risk factors, smoking and alcohol was obtained from 
patients or their relatives by research nurses. 
Melbourne178 Risk factors and management of risk factors were recorded by trained data collectors using a standardised questionnaire. 
Supporting data were collected from patients, relative, medical records and treating doctor.  
Dementia, hypertension, peripheral vascular disease (PVD), prior transient ischaemic attack (TIA), and prior myocardial infarction 
were defined as a known history. Diabetes was defined as either a known history or current presentation with fasting blood glucose 
≥7.0 mmol/L. Atrial fibrillation (AF) was defined as either a known history or current presentation confirmed on ECG.  
Smoking status was classified from self-report as current smoker, ex-smoker, or never smoked. 
Prestroke disability was recorded from self-report questionnaire using Barthel Index.  
Recurrent stroke events were recorded by initial case finding methods or at annual follow-up interviews conducted by research 
nurses with possible recurrent event form. A panel of experts verified recurrent strokes using information from medical or nursing 
home records and from treating doctors. 
Arcadia179 A history of hypertension was defined as systolic BP >160 mm Hg and/or diastolic BP >90 mm Hg ≥ 2 occasions before the stroke 
or documented treatment of hypertension. Diabetes was defined as use of a blood sugar lowering drug before stroke or a 
documented fasting blood glucose >120 mg/dl. AF was diagnosed by ECG for patients in hospital; for those not in hospital, at least 
one an ECG with documentation of AF in the year before the event was required. A history of TIA was defined when a patient had 
an attack diagnosed by a neurologist as a temporary, focal neurological deficit presumably related to ischaemia and lasting <24 
hours. History of coronary heart disease (CHD) including myocardial infarction, angina pectoris and congestive heart failure was 
assessed by questionnaire without medical confirmation if it was diagnosed by a cardiologist and the patient had been given a 
relevant treatment.  




Study Source of data 
Smoking was considered present when a patient smoked daily prior to the stroke and was considered absent when the patient had 
never smoked or stopped smoking for ≥1 year before stroke. High alcohol consumption was defined as 60 g/day for men and 40 
g/day for women.  
Premorbid mRS was recorded from self-report questionnaire. 
Recurrent stroke event was recorded during the follow-up. 
Perth180 The presence of heart failure was based on clinical criteria that included one of the following: raised venous pressure, gallop 
cardiac rhythm (abnormal rhythm of the heart on auscultation), and crepitations at the base of the lungs. The presence of AF 
needed to be confirmed by an ECG within 1 month of the onset of stroke.  
Premorbid levels of physical disability were based on self-report or proxy sources (caregivers or medical records for those patients 
who were deceased or disabled) with the modified Barthel Index and mRS. 
Recurrence was recorded during the follow-up and confirmed by medical records. 
Orebro181 A record of medical history was taken and logistic data regarding hospital treatment period, investigations were noted from 
medical records.  
Premorbid mRS was recorded from self-report questionnaire. 
Dijon52 History of hypertension was defined as known hypertension in a patient’s medical history (either self-reported or from medical 
notes) or if a patient was under anti-hypertensive treatment. History of AF, previous myocardial infarction, or TIA was recoded. 
Pre-stroke treatments by anticoagulants, antiplatelet agents and antihypertensive treatments were noted. 
Recurrent stroke was recorded during the follow-up and confirmed by medical records. It was classified as ischaemic or 
haemorrhagic, on the basis of a CT scan. 
Martinique182 Hypertension was defined as known hypertension with antihypertensive therapy (the number of drugs was recorded) or systolic 
BP> 160 mm Hg and/or diastolic BP>90 mm Hg on ≥2 different occasions, the second one 1 week after stroke. AF was diagnosed 
when present on a standard 12-lead ECG. PVD was recorded on the basis of a history of intermittent claudication or previous 
arterial intervention or Doppler ultrasonography documentation. CHD was defined as history of acute myocardial infarction or 
angina pectoris.  




Study Source of data 
Smoking was defined as a cumulative consumption 10 pack-years. Alcohol abuse was diagnosed when the patient had a daily 
consumption 120 g.  
Recurrence was recorded during the follow-up. Survivors were interviewed by investigators with a questionnaire designed to detect 
recurrent cerebrovascular and cardiovascular events. 
Porto183 Vascular risk factors were obtained from medical records from hospitals and/or general practitioners (GP). 
A history of hypertension was defined as systolic BP >160 mm Hg and/or diastolic BP >95 mm Hg ≥ 2 occasions before the stroke 
or documented treatment of hypertension. History of cardiac disease was defined as any previous diagnosis of angina, myocardial 
infarction or AF (confirmed by ECG). A history of TIA was recoded. 
Smoking was categorised as never smoked, former smoker for ≥1 year and current smoker.  
Pre-stroke disability was recorded from self-report questionnaire using Barthel Index.  
Recurrence was recorded during the follow-up. Medical records were used for follow-up purposes whenever the patient could not 
be contacted. The principal investigator reviewed the information collected for each patient. Throughout the study period, GPs 
received a report on their patients registered in the study, and every 2 months a periodic newsletter with the updated results was 
sent to all collaborators. 
Auckland184 A self-reported history or current treatment for cardiovascular diseases and risk factors was obtained from patients or their relatives 
and then confirmed by medical records. 
History of hypertension was defined by self-report history of high BP or by the use of antihypertensive drugs. History of cardiac 
disease (AF, heart attack, angina, or other forms of heart disease).  
Smoking status (current smoker, former smoker for more than 1 year, never smoked) was defined by patients’ self-report.  
L’Aquila36 
Hypertension was defined as known hypertension treated with antihypertensive therapy or systolic BP >160 mm Hg and/or 
diastolic BP >90 mm Hg on 2 different occasions. AF was confirmed by a standard 12-lead ECG. Coronary heart disease was 
defined as a history of acute myocardial infarction or angina pectoris. PVD was diagnosed in the presence of a history of 
intermittent claudication or previous arterial intervention or Doppler ultrasonography documentation. 




Study Source of data 
Smoking status was defined as never, current, and ex-smoker. Alcohol abuse was diagnosed in the presence of a daily consumption 
>120 g.  
Recurrent stroke was recorded during the follow-up with quarterly planned visits or with a structured telephone interview. It was 
defined as any new fatal and nonfatal event subsequent to the initial one, with an increased handicap at the time of the event, 
persisting beyond 24 hours. 
Matão40 Risk factors and management of risk factors were recorded by trained data collectors using standardised questionnaire. 
Recurrence was recorded during the follow-up if there are any new episode of focal cerebral dysfunction persistence >24 hours. 
Tartu185 Stroke risk factors were recorded based on case history and clinical evaluations. History of disease was obtained from outpatients 
and hospital records, family and patients. BP was measured at admission. AF was confirmed by ECG. Myocardial infarction was 
confirmed by ECG or autopsy.  
Premorbid mRS was recorded from self-report questionnaire. 
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2.5.2 Pre-stroke health 
2.5.2.1 Co-morbidities 
Co-morbidities included self-reported history of diabetes (4 studies: Oxford, 
Melbourne, Arcadia, Perth and Orebro), dementia (studies Melbourne, Orebro, 
Auckland and Matão), and cardiovascular diseases including ischaemic heart disease 
(all studies), atrial fibrillation (all studies), hypertension (all studies), transient 
ischaemic attack (all studies except the Auckland study), and peripheral vascular 
disease (studies Oxford, Melbourne, Arcadia, Orebro, Dijon, Martinique,  Porto, 
L’Aquila and Matão) were performed (Table 2-4).  
2.5.2.2 Body mass index 
Body mass index was recorded in five studies: Oxford, Joinville, Perth, Martinique, 
and Porto. 
2.5.2.3 Pre-stroke medication 
Data on pre-stroke use of antihypertensive and antiplatelet agents were available in 
five studies (Joinville, Melbourne, Perth, Auckland, and Tartu) and information on 
use of anticoagulants before stroke was only available in the Melbourne and 
Auckland studies. 
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2.5.2.4 Health behaviours:  
Smoking status, which was recorded in 12 studies (except the Tartu study), was 
categorised into 3 levels: never/former/current. Data on alcohol consumption were 
available in 11 studies. Alcohol use was classified as 3 groups – no/current 
drinkers/ex-drinkers (9 studies: Joinville, Arcadia, Perth, Dijon, Martinique, Porto, 
Auckland, Matão, and Tartu) or 4 groups – no/not heavy drinkers/heavy drinkers/ex-
drinkers (3 studies: Oxford, Melbourne and Auckland).  
2.5.2.5 Pre-stroke dependency 
Pre-stroke functional status was assessed according to whether or not the patient was 
living independently before stroke in study Auckland, residing in an institution before 
stroke among 4 studies (Melbourne, Perth, Orebro and Dijon), the pre-stroke Barthel 
Index (BI) in 3 studies (Melbourne, Perth and Orebro) or pre-stroke modified Rankin 
Score (mRS) in 4 studies (Oxford, Perth, Porto and Tartu). Pre-stroke dependency or 
pre-stroke functional limitation was defined as pre-stroke BI<20 or pre-stroke 
mRS>2. 
2.5.3 Stroke-related factors  
2.5.3.1 Stroke type 
Types of stroke, both ischaemic stroke and haemorrhagic stroke, were reported for all 
studies. We categorised stroke type into 4 groups: ischaemic stroke, intracerebral 
haemorrhage, subarachnoid haemorrhage (SAH) and undetermined stroke. Note that 
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these SAH cases were not followed up in Orebro (2.8%, 11/388 cases), Tartu (3.99%, 
18/451 cases), and Melbourne studies (68/1316 cases).  
2.5.3.2 Stroke severity 
Items on loss of consciousness (6 studies: Melbourne, Arcadia, Dijon, Porto, 
Auckland, L’Aquila), paresis (6 studies: Melbourne, Arcadia, Dijon, Porto, Auckland, 
L’Aquila) and incontinence at onset (2 studies: Melbourne and Arcadia) were yes/no 
items used as markers of stroke severity. In the Dijon study, Barthel Index score (0-
100) at admission, which was measured and categorised into 10 groups using a 10-
point interval, were analysed as stroke severity. Barthel Index scores were reversed, 
with higher scores indicating greater severity of stroke, for analyses. Other 
assessments of stroke severity were the Glasgow Coma Scale (GCS)186 with score 
ranging from 0 “coma” to 15 “alert” in studies from Arcadia, Auckland and Tartu and 
the Unified Neurological Stroke Scale (UNSS)187 in the Porto study ranging from 0 to 
33, with maximum score 33 for normal subjects. We analysed reversed scores for 
GCS and UNSS so that higher scores indicate more severe strokes for analyses. 
National Institutes of Health Stroke Scale (NIHSS)188 was recorded in 7 studies 
(Oxford, Joinville, Melbourne, Perth, Orebro, and Dijon) with score ranging from 0-
42, with larger scores indicating more severe stroke. Note that the NIHSS was 
measured in the Dijon study since 2008 only (n=1552). The Scandinavian 
Neurological Stroke Scale (SSS) was measured in the Matão study, with scores 
ranging from 0 (worst neurological deficit) to 58 (no neurological deficit). It was 
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mapped to the NIHSS (SSS = 50 – 2 x NIHSS)189 for the purpose of comparing 
between studies.  
2.5.3.3 Year of stroke occurrence 
Data on the year the stroke occurred were available in all studies with ranges from 
1987 to 2014. Additional data from the Joinville study were provided in the middle of 
2017 after the first study of long-term mortality (Chapter 2), including first-ever 
strokes between 1987 and 2013, was published. The additional follow-up data up to 5 
years of 2,448 first-ever strokes between 2009 and 2014 at baseline were included in 
the analyses on long-term functional outcome and participation restriction (Chapter 
4), health-related quality of life (Chapter 5) and stroke severity at the time of stroke 
(Chapter 6). 
2.5.4 Treatment and management  
2.5.4.1 Hospital admission 
All studies had data on whether or not people were admitted to hospital for their 
stroke.  
2.5.4.2 Delay to hospital 
Analyses of these data were based on the time from stroke onset to admission time in 
7 studies. Out of these, studies from Martinique and Auckland only recorded time to 
hospital as ≤1 day/>1 day. Among the other 5 studies (Joinville, Melbourne, Arcadia, 
Porto and Tartu), we calculated the time to hospital from time of stroke onset to time 
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of admission and then categorised them into three groups (≤4.5 hours/4.5 hours-24 
hours/>24 hours).  
2.5.4.3 Admission medication 
Three studies (Melbourne, Perth and Dijon) had data on treatment with 
antihypertensive agents at admission and four studies (Melbourne, Arcadia, Perth and 
Dijon) had data on antithrombotics, including antiplatelets and anticoagulants, at 
admission. Thrombolytic therapy (intravenous thrombolysis or rTPA) was also 
recorded in four studies (Joinville, Melbourne, Dijon and Auckland). 
2.5.4.4 Investigation 
Brain imaging (computed tomography― CT scan or magnetic resonance imaging 
―MRI) was recorded in all studies although we did not have the data for Oxford 
study. Carotid investigations during admission included carotid or transcranial 
Doppler (7 studies:  Joinville, Melbourne, Arcadia, Dijon, Porto, L’Aquila and Tartu), 
CT or magnetic resonance angiography (3 studies: Melbourne, Martinique and Porto), 
and cerebral angiography (in 7 studies: Melbourne, Arcadia, Perth, Porto, Auckland, 
L’Aquila and Tartu). Cardiac investigations during admission included 
electrocardiography - ECG (9 studies: Joinville, Melbourne, Arcadia, Perth, Dijon, 
Porto, Auckland, L’Aquila and Tartu), echocardiography (7 studies: Melbourne, 
Arcadia, Perth, Dijon, Porto, Auckland and L’Aquila) and holter monitoring (3 
studies: Melbourne, Porto and L’Aquila). In terms of surgical interventions, carotid 
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endarterectomy was recorded in studies from Oxford and Melbourne while 
coiling/clipping of SAH was recorded in studies from Oxford and Auckland. 
2.5.5 Post-stroke factors 
2.5.5.1 Depression  
Depression was measured after 1 year and 5 years stroke in the study from Melbourne 
using the Irritability, Depression and Anxiety (IDA) Scale.190 IDA was categorised 
with scores ≥ 8 defining depression.191 In the Auckland study, depression at 5 years 
after stroke was recorded by sub-score of depression from the 28-item General Health 
Questionnaire (GHQ-28).192 The Montgomery-Åsberg Depression Rating Scale 
(MADRS-S)193 was recorded at 5 years after stroke in the study from Martinique, 
with the score ranging from 0 to 60. In the original study conducted in Martinique, 
investigators used a simplified MADRS version with a maximum score of 30, rather 
than 60, with scores ≥ 8 defining depression and scores ≥ 18 of 30, severe 
depression.39 
2.5.5.2 Self-reported stroke recurrence 
Stroke recurrence was recorded in most studies by participants reporting any stroke-
like event since their last follow-up. In most studies, these events were verified 
against medical records, with a physician classifying the event as stroke or not. Data 
on recurrent stroke are available in 8 studies at 1 year follow-up (Oxford, Melbourne, 
Arcadia, Dijon, Martinique, Porto, L’Aquila and Matão) while 4 studies had data on 
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any recurrent stroke within 5 years after index event (Oxford, Melbourne, Dijon and 
Porto). 
2.6 Study outcomes 
2.6.1 Mortality outcome 
All 13 studies gathered data on mortality at 1 year (n=16645) and 8 studies (n=12839) 
measured this at 5 years post-stroke (see Table 2-5 for the source of mortality data). 
Nine studies also matched patients to national death registries (Table 2-6). 
2.6.2 Functional outcome and participation restriction 
Participants were followed up with face-to-face interviews conducted at 1 and 5 years 
after stroke in most studies. In two studies (Joinville and Tartu), mail or telephone 
interviews were used (Table 2-6).  
Functional outcomes or disability (Tables 2-6 and 2-7) were assessed by the 
modified Rankin scale (mRS) or Barthel Index (BI). Poor outcome was defined as 
mRS >2 (score 0-5) and BI<20 (score 0-20). Two studies (Melbourne and Auckland) 
had data on participation restriction assessed by the London Handicap Scale (LHS; 
score 0-100).  
2.6.3 Health-related quality of life (HRQoL) 
Analyses on HRQoL were based on assessments undertaken from 1 year and up to 5 
year after stroke among stroke survivors (Table 2-7). Three instruments were used to 
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assess the HRQoL in the long term after stroke. In the Oxford study, HRQoL was 
assessed using the European Quality of Life–5 Dimensions (EQ-5D-3L) 
instrument.194 For each of the five dimensions of the EQ-5D including mobility, self-
care, usual activities, depression/anxiety, and pain), there are three response 
categories: no problem, some/moderate, and extreme problem. In the Melbourne 
study, the Assessment of Quality of Life (AQoL)195 was used. The AQoL has five 
dimensions comprising illness, independent living, social relationships, physical 
senses, and psychological wellbeing with four response levels for each domain (from 
needing no help to requiring daily help). The Short Form–36 questions (SF36) was 
used to assess HRQoL among stroke survivors in the studies conducted in Perth and 
Auckland. The SF36 instrument covers both physical and mental health with eight 
sub-dimensions.  
The EQ5D utility score was measured in the Oxford study but also mapped from 
modified Rankin Scale (mRS)196 data among six studies with available data on the 
mRS at 1 and/or 5 years after stroke (Table 2-7). 
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Table 2-5. Source of mortality data across 13 population-based studies 
Study Source of data 
Oxford176 Death data were obtained from medical records in hospital. Deaths out of 
hospital were identified via the Coroner’s Office, by review of all death 
certificates in the study practices, and by ICD10 vascular death codes 
from the local Department of Public Health.  
Joinville197 Death data were obtained from follow-up assessment and Death 
certificates 
Melbourne94 Mortality was mostly recorded when contact was attempted for 1-year 
and 5-year assessments of functional outcomes. Matching of participants 
with the National Death Index provided mortality data for those lost to 
follow-up. 
Arcadia51  Medical records for patients in hospital; general practitioners and private 
family physicians; health centres and death certificates. 
Perth46  Vital status was initially ascertained by electronic linkage of Perth 
Community Stroke Study record to mortality data supplied by the 
Registrar General of Births, Marriages and Deaths for Western Australia.  
Orebro181 Hospital discharge records and death certificates. Population statistics 
were used to ascertain whether a patient was still alive 1 year after 
stroke. 
Dijon52 Death certificates obtained from the local Social Security Bureau that is 
responsible for registering all deaths in the community to identify fatal 
strokes occurring in non-hospitalised patients. 
Martinique39 Survival status was ascertained from hospital records and death 
certificates 
Porto198 Death data were obtained from follow-up assessment. Otherwise, a 
search was undertaken in the computer files held at the Northern 
Regional Health administration. In case of death, information about date 
and circumstances of death was confirmed by written monthly reports of 
death certificates at each health centre. 
Auckland53 Hospital and other medical records, death certificates, and autopsy 
reports, and by maintaining regular contact with all long-term residential 
care facilities such as rest homes and private hospitals. 
L’Aquila36 Death certificates were checked monthly, and clinical details of all 
deceased patients with a diagnosis of stroke, not otherwise included in 
the registry, were reviewed. The use of a case-finding method including 
multiple overlapping sources allowed an assessment of the completeness 
of case ascertainment by means of a capture-recapture technique. 
Matão40 Death certificates were checked monthly, follow-up was assessed by 
hospital visits or telephone contact when moving to another city.  
Tartu199 The survival was analysed using outcome data provided by the patients, 
by the National Population Registry and death certificates at Outpatient 
clinics. 
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Table 2-6. Source of functional outcome and participation restriction data across 
11 population-based studies 
Study Source of data 
Oxford176 All surviving cases were followed up by a research nurse or therapist at 
12 months from the time of the stroke and modified Rankin Scale (mRS) 
score was calculated. 
Joinville197 The functional outcomes were measured at 12 months and 5 years by 
telephone using the mRS. 
Melbourne94 Survivors were interviewed in person; however, some telephone 
interviews were conducted. For those with cognitive or communication 
difficulties, a reliable proxy was sought. Interpreters were used when 
required. The functional outcomes were measured at 12 months and 5 
years using Barthel Index, and the participation outcomes were measured 
at 5 years only using the London Handicap Scale. There was about 16% 
proxy response200 
Arcadia51  For each patient with stroke, the mRS was applied at discharge from 
hospital and at the final follow up 1 year after stroke onset. Functional 
outcome for patients not in hospital was obtained by questionnaire from 
attending physicians or by examination of the patient at home. 
Perth46  Patients not known to be deceased were sent a letter of invitation, which 
was followed by a telephone call or home visit. Those who agreed to 
participate were assessed at their usual place of residence by the study 
nurse. In addition to information regarding recurrent vascular events, 
major illnesses, and medications, this assessment included grading the 
current level of disability using the mRS. 
Orebro181  Consultation visit and telephone interview. The functional outcomes 
were measured at 12 months (the mRS and Barthel Index).  
Martinique39 Survivors were visited and underwent standardised interviews, conducted 
by visiting nurses, specially trained to apply different well-validated 
scales of evaluation. The functional outcomes were measured at 12 
months and 5 years (the mRS). 
Porto198 All patients were followed up by neurologists at 1 year and 7 years after 
the index event. Patients who collaborated but were not willing to 
complete the consultation were contacted by phone, and for those unable 
to come to the hospital, home visits were scheduled. Functional outcome 
was measured using the mRS. 
Auckland53 After gaining verbal informed consent, subjects were interviewed via 
telephone to update details and complete a questionnaire. Participants 
were then invited to complete self-administered questionnaires. They 
were then contacted to arrange face-to-face interviews. Face-to-face 
interviews occurred at participants’ usual places of residence and 
included neuropsychological tests and assessment of functional outcome 
at 1 year and 5 years (the mRS) and participation at 5 years (London 
Handicap Scale). 
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Matão40 All included cases were followed-up prospectively by the research team 
at 1 year after the stroke event with hospital visits. Patients unable to 
attend the scheduled visits or who had moved to another city were 
contacted by telephone. The functional outcome was measured at 12 
months (Barthel Index). 
Tartu199  The mRS assessments were made by the study physician by telephone at 
1 year and 4 years after stroke. Barthel Index was evaluated at 1 year 
through questionnaire by post. 




Table 2-7. Study outcomes in the included cohorts 
 Severity Mortality Functional outcome Participation restriction Health-related quality of life 
Study acute stage 1 year 5 year 1 year 5 year 5 year 1 year 5 year 
Oxford  NIHSS * 
* 




Joinville NIHSS   mRS mRS  mapped EQ5D mapped EQ5D 
Melbourne NIHSS * 
* 
BI BI LHS AQoL AQoL 
Arcadia    mRS   mapped EQ5D  
Perth  NIHSS *  mRS   SF36 
mapped EQ5D 
 
Orebro  NIHSS * 
* 
mRS   mapped EQ5D  
Dijon  NIHSS * 
* 
     
Martinique    mRS mRS  mapped EQ5D mapped EQ5D 
Porto    mRS mRS  mapped EQ5D mapped EQ5D 
Auckland     mRS LHS  SF36 
mapped EQ5D 
L’Aquila         
Matão NIHSS *  BI     
Tartu mapped NIHSS *  mRS mRS  mapped EQ5D mapped EQ5D 
*denotes death data being matched to the national death registries 
BI=Barthel Index; mRS=modified Rankin Scale; LHS=London Handicap Scale; NIHSS=National Institute of Health Stroke Scale; mapped 
EQ5D=EQ5D utility score was mapped from the mRS data; mapped NIHSS=NIHSS score was mapped from the Scandinavian Stroke Scale 
data. 
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Chapter 3: Sex differences in long-term mortality after 
stroke in the INternational STRoke oUtComes sTudy 
(INSTRUCT) 
3.1 Preface 
This thesis chapter has been published as a paper in the Circulation: Cardiovascular 
Quality and Outcomes (see Appendix H).  
Phan H, Blizzard L, Thrift A, Cadilhac D, Sturm J, Heeley E, Konstantinos V, 
Anderson C, Parmar P, Krishnamurthi R, Barker-Collo S, Feigin V, Para V, Bejot Y, 
Cabral N, Carolei A, Sacco S, Chausson N, Olindo S, Rothwell P, Silva C, Correia M, 
Magalhães R, Appelros P, Korv J, Vibo R, Minelli C, Reeves M, Otahal P, Gall S. 
Sex Differences in Long-Term Mortality After Stroke in the INSTRUCT 
(INternational STRoke oUtComes sTudy). Circ Cardiovasc Qual Outcomes. 2017; 
10. (Journal IF ~ 4.5; citation: 14). 
https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.116.003436.  
This article was highlighted in the special edition ‘Spotlight: Women and Heart 
Disease’ of the Circulation: Cardiovascular Quality and Outcomes aligned with Go 
Red for Women® campaign by American Heart Association, which recognises that 
the burden of cardiovascular diseases in women is a major concern worldwide. This 
paper is accompanied by an editorial noting its novelty, significance and implications 
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for improving long-term outcome after stroke (see Editorial by Lisabeth and Madsen: 
https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.117.003546) 
3.2 Abstract 
Background: Women are reported to have greater mortality after stroke than men, 
but the reasons are uncertain. We examined sex differences in mortality at 1 and 5 
years after stroke, and identified factors contributing to these differences.  
Methods: Individual participant data for incident strokes were obtained from 13 
population-based incidence studies conducted in Europe, Australasia, South America 
and the Caribbean between 1987 and 2013. Data on socio-demographics, stroke-
related factors, pre-stroke health, and 1- and 5-year survival were obtained. Poisson 
modelling was used to estimate the mortality rate ratio (MRR) for women compared 
to men at 1 year (13 studies) and 5 years (8 studies) after stroke. Study-specific 
adjusted MRRs were pooled to create a summary estimate using random-effects meta-
analysis. Overall, 16,957 participants with first-ever stroke followed up at 1 year, and 
13,216 followed up to 5 years, were included. Crude pooled mortality was greater for 
women than men at 1 year (MRR 1.35, 95% CI [1.24-1.47]) and 5 years (MRR 1.24, 
95% CI [1.12-1.38]). However, these pooled sex differences were reversed after 
adjustment for confounding factors (1 year MRR, 0.81, 95% CI [0.72-0.92]; 5-year 
MRR 0.76, 95% CI [0.65-0.89]). Confounding factors included age, pre-stroke 
functional limitations, stroke severity and history of atrial fibrillation (AF).  
Conclusions: Greater mortality in women is mostly due to age but also stroke 
severity, AF and pre-stroke functional limitations. Lower survival after stroke among 
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the elderly is inevitable but there may be opportunities for intervention, including 
better access to evidence-based care for cardiovascular and general health.  
3.3 Introduction 
Women are reported to have greater mortality in the short term after stroke than men. 
In a review of 31 population-based studies of short-term mortality after stroke, 
Appelros and colleagues129 reported that women had a 25% greater risk of 1-month 
crude mortality than men. It remains unclear what accounts for this disparity and 
whether these differences persist into the longer term. There have been no studies 
specifically designed to examine sex differences in long-term mortality after stroke. 
Identifying factors that explain the sex differences in mortality is important because 
better understanding could lead to interventions to reduce the differences.201 In an 
Australian study, the 36% greater risk of death at 28 days for women compared to 
men was explained by age, pre-stroke health, stroke severity and use of anticoagulants 
at discharge.94 After adjustment in that study, women had a 17% lower short-term 
mortality than men. It is unknown whether these same factors account for the relative 
sex differences in other geographical regions or in long-term mortality.  
Our aims were to quantify the relative sex difference in long-term mortality and to 
identify factors that contribute to the greater mortality of women after stroke using a 
meta-analysis of pooled individual participant data (IPD) from 13 ‘ideal’ incidence 
stroke studies conducted worldwide.  
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This study – the INternational STRoke oUtComes sTudy (INSTRUCT) – was 
registered in the international PROSPEective Register Of systematic reviews 
(PROSPERO; CRD42016036723)202 and adhered to the Preferred Reporting Items for 
a Systematic Review and Meta-analysis of Individual Participant Data (PRISMA-
IPD).203 
INSTRUCT is an IPD meta-analysis of long-term outcomes after first-ever stroke. It 
included 13 ‘ideal’31,169 population-based stroke incidence studies. These studies have 
greater internal validity and less selection bias than hospital-based studies.28 The 
INSTRUCT study was a collaboration between investigators for 13 population-based 
incidence studies identified through a previous systematic review by Feigin et al.,57 
and our research networks. We requested de-identified IPD on mortality (up to 5 
years after stroke) and participant characteristics from the investigators of 17 eligible 
studies with long term follow-up to participate, with 13 agreeing. To understand how 
representative these studies were of all possible studies, we undertook a systematic 
literature search in 2015 of the literature published since May 2008, the end date for 
the Feigin’s review. The 13 included studies in the INSTRUCT represented 59% of 
the 22 potentially eligible studies later identified by our systematic search. The main 
reasons for exclusion of 9 studies occurred due to refusal to participate (4 studies) and 
late identification of the study (5 studies; see Methods Chapter 2: section 2.1, 
Figures 2-1 and 2-2, and Table 2-1 for full details of study selection). 
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3.4.1 Outcome measurement 
The outcome was all-cause mortality at 1 year and 5 years after stroke. In 7 studies, 
mortality was obtained from national death registries (Table 2-5; Chapter 2). In the 
remaining 6 cohorts, a combination of hospital records, death certificates or direct 
participant follow-up was used. In four studies (Martinique, L’Aquila, Matão and 
Tartu) at 1 year and two studies at 5 years (Martinique and L’Aquila) vital status was 
recorded, but the exact date of death was not recorded (see ‘Statistical analysis’ for 
further details). 
3.4.2 Study factors 
The study factors assessed were those that might explain sex differences in mortality 
after stroke.94 They included (1) socio-demographics, (2) pre-stroke health 
(dependence, co-morbidities and health behaviours), (3) stroke-related factors (stroke 
type, severity of stroke and year of stroke occurrence), (4) treatment and 
management, and (5) post-stroke factors (depression and recurrence). Details 
regarding how these data were collected and the definitions used for each variable in 
each specific study are provided in brief below and in full in the Chapter 2 (Table 2-
5 and section 2.5). In general, the patient or a proxy was interviewed within a few 
days of their event with clinical information supplemented from medical records 
and/or physician consultation, where possible.  
Socio-demographic factors included age, sex, race/ethnicity, marital status, education, 
and socioeconomic status. Data on pre-stroke health status included dependence 
(retrospective modified Rankin scale, 4 studies; retrospective Barthel Index, 3 studies; 
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institutional residence, 4 studies and whether or not the patient was living 
independently before stroke, 1 study); co-morbidities (atrial fibrillation, hypertension, 
ischaemic heart disease, peripheral vascular disease, transient ischaemic attack, 
diabetes and dementia); medications before stroke (antihypertensives, antiplatelets, 
anticoagulants); body mass index; and health behaviours (smoking, alcohol use). 
Stroke-related factors included the type of stroke categorised into 4 groups: ischaemic 
stroke, intracerebral haemorrhage, subarachnoid haemorrhage and undetermined 
stroke. Measurement of stroke severity included the National Institutes of Health 
Stroke Scale (NIHSS, 7 studies), Glasgow Coma Scale (3 studies), Unified 
Neurological Stroke Scale (1 study), Scandinavian Stroke Scale (1 study), Barthel 
index at onset (1 study) or loss of consciousness (6 studies), hemiparesis (6 studies) 
and incontinence at onset (2 studies).  
Treatment and management included whether the patient was admitted to hospital; 
time delay to hospital presentation; thrombolytic therapy (rtPA); admission and 
discharge medications (antihypertensives, antiplatelets, anticoagulants); in-hospital 
investigations including neuroimaging (CT scan or MRI), carotid or transcranial 
Doppler, or echocardiography; and surgical interventions including carotid 
endarterectomy and aneurysm clipping or coiling.  
Post-stroke depression was measured in 3 studies: the Irritability, Depression and 
Anxiety (IDA) Scale 190 was used in Melbourne (scores ≥ 8 defining depression),191 
the General Health Questionnaire (sub-score of depression)192 in Auckland and the 
Montgomery-Åsberg Depression Rating Scale193 (scores ≥ 8 defining depression)39 in 
Martinique. Stroke recurrence was gathered by self-report of stroke-like events during 
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follow-up in 8 studies. In 6/8 studies (not including Arcadia and Matão), these events 
were verified by physician review of medical records. 
3.4.3 Statistical analysis 
Harmonising covariates across studies was not possible due to lack of uniform 
definitions. We, therefore, used the two-stage method of analysis proposed for IPD 
meta-analyses.204 The first stage involved building study-specific crude and adjusted 
models to estimate the relative mortality rate ratio (MRR) for women compared to 
men. We used Poisson regression at 1 year (13 studies) and 5 years (8 studies) after 
stroke with the logarithm of the number of person-years at risk of dying within that 
period entered as an offset.205 To undertake Poisson modelling in studies without 
exact date of death, multiple imputation by chained equations206 (m=50 imputations) 
was used to impute person-years for men and women separately (see Supplement 3, 
‘Missing data and multiple imputation’ for details). The role of covariates in the 
association between sex and mortality was determined using purposeful model 
building207 to identify the significant confounders of sex difference in mortality. The 
following rules were applied to determine the covariates in the study-specific 
multivariable models: 1) the covariate was missing in <20% of cases; 2) the covariate 
was associated with mortality (p<0.1); 3) the covariate was associated with sex (p 
<0.1); and 4) the inclusion of the covariate in a model with only sex changed the 
magnitude of the sex coefficient by ≥10%.207 Age and stroke severity were forced into 
the final multivariable models because they are well-established predictors of 
mortality and are associated with sex.208 Covariates were transformed, as necessary 
using fractional polynomials in multivariable modelling209, to get the best model fit. 
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We report fully adjusted models but also examine the effect of individual covariates 
on the sex difference in mortality. Within each study, statistical interactions were 
assessed by a test of statistical significance of a sex × covariate product term. 
The second stage of the analysis involved combining the crude and adjusted study-
specific effect estimates using random-effects meta-analysis. Statistical heterogeneity 
was evaluated using Q-statistics and I2 statistics. Potential sources of heterogeneity 
were assessed among variables of study-level characteristics (e.g. geographic region, 
income group and severity instrument; Supplemental Methods: section 3.7.2). 
Between-study interactions between sex and these study-level characteristics were 
assessed by meta-regression.  
To further examine the robustness of our findings we also tested interaction effects 
using the single pooled individual participant data dataset.210 In this data, we assessed 
the interaction between sex and participant-level covariates (stroke type, age at stroke 
onset and the year of stroke occurrence) by again testing the statistical significance of 
the sex × covariate product terms using multivariate random-effects meta-analysis.211  
To describe the sex differences in crude mortality, Kaplan Meier survival curves by 
sex, accounting for study-specific curves, were estimated among the pooled IPD of 
studies with exact date of death to 1 year (9 studies) and 5 years (5 studies) after 
stroke. 
Sensitivity analyses were used to examine the effect of the multiple imputation to 
account for unknown date of death or missing data, early deaths after stroke (e.g. 6 
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months) and, in a subset of studies, clinical treatment on the results (Supplemental 
Methods: section 3.7.2).  
Analyses were conducted in Stata 12.1. A two-tailed P-value ≤0.05 was considered 
statistically significant.  
3.5 Results 
There were 16,957 participants (13 studies; Chapter 2: Table 2-7) with data on 1-
year mortality and 13,216 with data on 5-year mortality (8 studies). Table 3-1 shows 
the baseline characteristics of each study population, further stratified by sex as 
shown in Appendix A: Supplemental Tables A-1a to A-1c. Women were older 
(statistically significant differences found in 10/13 studies) and more often unmarried 
(statistically significant difference 4/5 studies), living in institutions (statistically 
significant difference 3/4 studies) and functionally dependent before stroke 
(statistically significant difference 5/8 studies) than men (Supplemental Tables A-1a 
to A-1c). Women were more likely to be prescribed anti-hypertensive agents 
(statistically significant difference 3/5 studies) before stroke. In about half of the 
studies, women more often had an undetermined stroke type (statistically significant 
difference 6/12 studies) and had suffered more severe stroke than men (statistically 
significant difference 6/13 studies). In all studies, men were more often smokers 
(12/12 studies) or drinkers (10/10 studies) and more often had peripheral vascular 
disease (statistically significant difference 7/9 studies).  
The crude survival rate using pooled IPD was 79.6% (men) and 68.5% (women) at 1 
year (9 studies), and 58.7% (men) and 51.5% (women) at 5 years (6 studies; Figure 
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1). Data were available from 13 studies on 1-year mortality after stroke. The sample 
for complete-case analysis was n=14,972 cases (88% of available cases) due to 
missing data on some confounding factors. Women were 35% more likely than men 
to be deceased at 1 year in crude analyses (top panel, Figure 3-2) without evidence of 
heterogeneity (I2=26.5, Q=16.3, p=0.177). 
The direction of the pooled MRR was reversed in fully adjusted analyses, with 
women having lower 1-year mortality than men (adjusted MRR=0.81 [95% CI 0.72, 
0.92]), albeit with some evidence of statistical heterogeneity (I2=36.4, Q=18.9, 
p=0.092; bottom panel, Figure 3-2). The following covariates met our conditions for 
inclusion in the study-specific multivariable models (Table 3-2): age, stroke severity, 
stroke type, AF, pre-stroke dependency, smoking and history of peripheral vascular 
disease. There was limited evidence that other factors including socioeconomic status, 
cardiovascular risk factors and other comorbidities were responsible for the greater 1-
year mortality in women (Supplemental Table A-2). Partial adjustment by inclusion 
of individual covariates changed the coefficient for sex difference substantially with 
age alone reducing the effect by 77%. Adjustment separately for stroke severity, AF, 
and pre-stroke dependency reduced the MRR by 42%, 5% and 45%, respectively 
(Supplemental Table A-3). There was no evidence that any of these covariates 
modified the effect of sex on mortality. In study-level analyses using meta-regression, 
difference in 1-year mortality (Table 3-3, ‘study-level characteristics’). 
The sex difference in the adjusted MRR was less among studies with actual person-
years than in studies with estimated person-years (adjusted MRR=0.74 vs 0.97, 
P=0.023, heterogeneity explained R2=99.9%). Data were available from 8 studies on 
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5-year mortality after stroke. The sample for complete-case analysis was n=11,368 
(86% of available cases). In crude analyses of 5-year mortality, women were 24% 
more likely than men to have died after stroke (top panel, Figure 3-3), but 
heterogeneity was significant (I2=57.2, Q=16.4, p=0.022).  
The direction of the 5-year pooled MRR (bottom panel, Figure 3-3) was again 
reversed on adjustment for covariates (adjusted MRR=0.76 [95% CI 0.65, 0.89]). 
However, there was significant heterogeneity in the study-specific multivariable 
estimates (I2=69.1, Q=22.7, p=0.002). The factors most commonly adjusted for in the 
study-specific analyses were age, stroke severity, stroke type and AF (Table 3-2). 
There was limited evidence that other factors including socioeconomic status, 
cardiovascular risk factors and other comorbidities were responsible for the greater 5-
year mortality in women (Supplemental Table A-4). Partial adjustment by inclusion 
of individual covariates changed the coefficient for sex difference substantially, age 
alone reversed the relative sex difference in 5-year mortality (pooled age-adjusted 
MRR 0.96 [95% CI 0.86, 1.08]; I2=59.7, p=0.015). The effect was also reduced with 
separate adjustment for stroke severity (51%), AF (11%) and pre-stroke dependency 
(55%; Supplemental Table A-5). There was no evidence that any of these covariates 
modified the effect of sex on mortality. Meta-regression did not identify any sources 
of the heterogeneity observed in 5-year crude or adjusted models (Table 3-4, ‘study-
level characteristics’). 
In participant-level analyses of the single pooled IPD dataset using multivariate 
random-effects meta-analysis, estimations of the sex difference in unadjusted and 
adjusted mortality at either 1 or 5 years after stroke were independent of stroke type 
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and the year that the stroke occurred (Tables 3-3 and 3-4, 'participant-level 
characteristics’). As illustrated in Figure 3-4, the magnitude of the sex differences in 
mortality at 1 year or 5 years after stroke was not modified by age group. 
Sensitivity analysis to account for missing data in one study with ≥ 20% missing data 
(Melbourne) using multiple imputation showed no difference in the estimated pooled 
effects for 1-year and 5-year mortality analyses when compared to complete-case 
analyses (Supplemental Tables A-7a and A-7b).  
There was some evidence that the relative sex differences in 1-year and 5-year 
mortality were greatest in the first 6 months after stroke. The unadjusted female:male 
MRRs were reduced markedly by excluding deaths prior to 6 months with pooled 
MRR changing from 1.35 (95% CI 1.24, 1.47) to 1.14 (95% CI 0.92, 1.40) at 1 year 
and from 1.24 (95% CI 1.12, 1.38) to 1.07 (95% CI 0.92, 1.25) at 5 years 
(Supplemental Table A-8).  
There was a variety of measures of treatment and management of stroke and its risk 
factors across studies. Significant differences existed in the prevalence of some of 
these between men and women but results were inconsistent across studies 
(Supplemental Table A-9). For example, women received less carotid investigations 
than men in 4/9 studies and underwent fewer echocardiography procedures in 3/7 
studies but there were no sex differences in neuroimaging, thrombolysis, discharge 
medication and surgical intervention. However, there was very little evidence that 
these differences influenced the pooled female:male MRR at 1 or 5 years. With the 
exception of carotid investigations in Joinville, none of these factors confounded the 
Association between sex and mortality among hospitalised patients (Supplemental 
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A-10). In Joinville, adjustment for carotid investigations reduced the 1-year MRR by 
59% among hospitalised cases. Nevertheless, the pooled estimates of the MRR for 
women compared to men were virtually unchanged by the revised estimate for 
Joinville (Supplemental Table A-11). 
3.6 Discussion 
We found that the crude sex differences in long-term mortality after stroke were 
consistent across time periods and various regions of the world. Compared to men, 
women were 35% more likely to die by 1 year and 24% more likely to die by 5 years 
after stroke, consistent with the 25% greater case fatality for women at 1 month 
reported in a previous review.129 Our meta-analysis of this large individual participant 
dataset demonstrated that the greater mortality after stroke in women was mostly 
attributable to their advanced age but that greater stroke severity, greater pre-stroke 
functional limitations and the presence of AF also explained the difference. The 
substantial sex difference in crude mortality rates was reversed after accounting for 
these confounding factors. This finding suggests that the sex difference in mortality is 
largely due to biological and clinical differences between men and women present 
before or at the time of stroke while there was little evidence that differences in 
clinical management influenced the sex difference in mortality.  
Age was the most important contributor to the sex difference in long-term mortality 
after stroke but there was no statistical evidence of effect modification by age. This is 
potentially due to reduced functional capacity of brain cells to recover after 
neurological insults,212 but it may also reflect other age-related factors such as co-
morbid disease, functional limitations or social isolation.213 Older age may also 
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contribute to the worse stroke outcomes through reduced access to evidence-based 
stroke care,214 particularly under-investigation and under-treatment of carotid disease 
in the elderly with stroke.215 Limited treatment of elderly people, who are 
predominantly women, may be appropriate given their health profile, potential 
contraindications to some treatments,216 and preferences for end-of-life care. 
However, it is also possible that by building the evidence base for stroke prevention 
and clinical management in the elderly,217 and ensuring access to currently available 
evidence-based care for them, we could improve outcomes for men and women after 
stroke. 
Women’s greater mortality after stroke was attributable to their pre-stroke function, 
which is also closely related to their advanced age. There are sex differences in the 
specific causes of healthy life lost by age.218 In men they are mostly respiratory and 
cardiovascular conditions, whereas in women, they are most often musculoskeletal 
and mental disorders. It is possible that better chronic disease management targeting 
these conditions could improve function219 and prevent frailty220 thereby improving 
the capacity to recover from stroke if it were to occur.  Although we did not find 
evidence that social or economic factors influenced the sex differences in mortality, 
others have highlighted the influence of these factors across the life course on 
women’s health.221  
Atrial fibrillation also contributed to the sex difference in long-term mortality after 
stroke. Women with AF have a greater risk of stroke than men and AF-related stroke 
is more severe.222 Management of AF in respect of proportions treated with anti-
coagulants223 or catheter ablation224 appears suboptimal for women compared to men. 
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This observation is mostly biased by age with the widespread under-treatment of 
older patients with AF.225 This highlights the need of better detection and treatment of 
AF in both elderly men and women prior to stroke. 
We found that stroke severity was an important confounder. Although there were 
statistically significant sex differences in stroke severity in 6/13 studies, the 
magnitude of differences between men and women were quite small. The differences 
in stroke severity between men and women are not well understood but may include 
sex differences in the localisation of brain function,226 and women’s greater 
susceptibility to subarachnoid haemorrhagic or cardioembolic strokes than men.226 
Stroke severity could be modified through better management of risk factors 
associated with stroke severity such as hypertension, AF, diabetes,227 and better acute 
stroke management.228 
Our meta-analysis revealed that the sex differences in mortality were greatest in the 
first 6 months following stroke (Supplemental Table A-8) supporting previous 
research.229 Evidence has shown that women with stroke suffer a disproportionately 
higher risk for death from cerebrovascular diseases while men are more likely to die 
from cardiac disorders and other diseases.230 The causes of death differed by the time 
intervals from the stroke,35 but little is known about differences by sex and age group. 
Examination of causes of death by sex and age group could identify ways to reduce 
disparities between men and women in mortality but such analyses were beyond the 
scope of our study. Further research is warranted to explore these differences after 
stroke and whether they are modifiable. 
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3.6.1 Limitations and strengths 
A number of limitations need to be noted. Some potential confounding factors were 
not measured including hormonal, social and some demographic factors, particularly 
race or ethnicity (only available in Joinville, Melbourne and Matao). Missing data on 
confounding factors for some participants decreased the number of cases in fully 
adjusted analyses. Whilst we cannot discount the possibility of bias, sensitivity 
analyses which replaced missing data using multiple imputation did not markedly 
change the estimates suggesting that the missing data did not greatly influence our 
results. The studies were mostly from high-income countries (HICS), so the results 
might not be generalisable to low- and middle-income countries (LMICs). However, 
the magnitude of the sex differences and the contributing factors, were the same for 
the studies in LMICs as in HICs (Tables 3-3 and 3-4). Among 9 ‘ideal’ stroke cohorts 
for which long-term IPD were not provided, sex-specific findings from 3 studies 
showed similar differences in long-term crude mortality between women and men 
(Chapter 2: Table 2-2), suggesting the results would not be greatly different had they 
been included. There were also limited data on management of stroke, post-stroke 
recurrence and depression. However, among studies with comprehensive data on 
these 3 factors, the sex difference in mortality was not attributable to any of these 
factors. The single exception was the Joinville study, for which carotid investigation 
explained part of the sex difference. In summary, we think that the absence of this 
data is unlikely to have greatly affected our results. The 5-year pooled estimates may 
have lower statistical power because few studies had follow-up into the long term 
resulting in less than the recommended 10 studies for a meta-analysis.231 There is also 
likely to be heterogeneity in the measurement of confounders across studies, 
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particularly vascular risk factors. This may have resulted in measurement error in 
some studies and affected the adjusted estimates.  
Despite these limitations, our study has a number of strengths. This is the first IPD 
meta-analysis to explore the magnitude and causes of sex difference in both short- 
and long-term mortality after stroke. The data came from high-quality and 
generalisable studies free of the limitations of hospital-based or convenience samples. 
We had a very large number of participants, making this study adequately powered to 
test our hypotheses. 
3.6.2 Conclusion 
Our results indicate that women consistently have greater unadjusted long-term 
mortality after stroke than men. These differences were reversed after adjustment for 
confounders indicating that greater mortality in women is explained by their greater 
age, greater stroke severity, worse pre-stroke function and the presence of atrial 
fibrillation. The overwhelming importance of age in explaining the sex difference 
suggests that better stroke prevention and clinical management in the elderly is 
paramount to reduce the overall burden of stroke in men and women.
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Table 3-1. Baseline characteristics of participants with first-ever stroke cases from 13 population-based stroke incidence studies 
Study Study year Region Baseline (N) Women (%) Ischaemic (%) Age, median 1-yr mortality 5-yr mortality 
Oxford, UK 2002-2013 Europe 1374 50.7 80.3 76.8 ✓ ✓ (n=760) § 
Joinville, Brazil  2011-2013 South America 980 48.3 80.5 64.0 ✓  
Melbourne, Australia 1996-1999 Australasia 1316 55.6 70.0 77.2 ✓ ✓ 
Arcadia, Greece  1993-1995 Europe 555 44.3 67.6 77.0 ✓#  
Perth, Australia  2000-2001 Australasia 183 52.5 76.5 77.4 ✓  
Orebro, Sweden  1999-2000 Europe 377† 55.2 72.7 78.0 ✓ ✓ 
Dijon, France  1987-2012 Europe 4621 53.1 82.7 77.7 ✓ ✓ (n=3719) § 
Martinique, FWI*  1998-1999 Caribbean 580 50.9 76.6 73.0 ✓ ✓ 
Porto, Portugal 1998-2000 Europe 688 58.7 76.2 73.0 ✓ ✓ 
Auckland, NZ 2002-2003 Australasia 1423 53.1 72.5 74.0 ✓ ✓ 
L’Aquila, Italia 1994-1998 Europe 4353 52.9 82.6 75.9 ✓ ✓ 
Matão, Brazil 2003-2004 South America 81 37.0 84.0 65.0 ✓  
Tartu, Estonia  2002-2003 Europe 433† 59.1 76.7 73.0 ✓  
Total cases   16,964‡    16,957 13,216 
✓ denotes studies with data 
* FWI, French West Indies 
† Baseline data without including cases of subarachnoid haemorrhage (Orebro 11 cases, Tartu 18 cases) 
‡ Total cases including those with subarachnoid haemorrhage in all studies were 16,993   
§ Follow-up data were available only among cases with year of stroke from’02-’08 for Oxford and ’87-’08 for Dijon  
# There were seven cases who were lost-to-follow-up when comparing to baseline 
Chapter 3. Sex differences in long-term mortality after stroke in the INternational 




Figure 3-1. Kaplan Meier survival curves showing survival for men and women 
after stroke using pooled data among nine cohorts with 1-year follow-up (top 
panel) and among six cohorts with 5-year follow-up (bottom panel) accounting 
for study-specific curves 
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Figure 3-2. Mortality rate ratio (MRR) for women compared to men at 1 year 
after stroke in unadjusted (top panel) and adjusted (bottom panel) models from 
13 studies combined using random effects meta-analysis (n=14,972).  
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Figure 3-3. Mortality rate ratio (MRR) for women compared to men at 5 years 
after stroke in unadjusted (top panel) and adjusted (bottom panel) models from 
eight studies combined using random effects meta-analysis (n=11,368).
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Figure 3-4. Unadjusted mortality rate ratio (MRR) with 95% Confidence 
Interval [CI] at 1 year (top panel) and 5 years (bottom panel) after stroke for 
women and men by age at stroke onset. 
Chapter 3. Sex differences in long-term mortality after stroke in the INternational STRoke oUtComes sTudy (INSTRUCT) 
90 
 
Table 3-2. Factors contributing to sex difference in long-term mortality between women and men after stroke based on the best fit sex-
specific model within studies. Of note, covariates were transformed, as necessary to get the best model fit. 
Study  1-year   5-year  
 N* Actual confounding factors included in the fully 
adjusted model 
N* Actual confounding factors included in the fully 
adjusted model 
Oxford 1290 age3†, NIHSS (2-term)†, pre-stroke mRS, stroke type 732 age3†, NIHSS (2-term)†, pre-stroke mRS 
Joinville 979 age3†, NIHSS, stroke type -  
Melbourne 975 age, log NIHSS†, pre-stroke Barthel (2-term)†, AF, 
stroke type 
975 age, log NIHSS†, pre-stroke Barthel (2-term)†, AF, 
stroke type 
Arcadia 547 age, GCS, AF -  
Perth 183 age, NIHSS, pre-stroke mRS, stroke type -  
Orebro 377 age, log NIHSS†, institutional residence, stroke type 377 age3†, log NIHSS†, institutional residence, stroke type 
Dijon 3994 age3†, LOC, AF, smoking 3094 age3†, LOC, AF, smoking, stroke type 
Martinique  569 age3†, Barthel at onset (2-term)†, history of PVD 569 age3†, Barthel at onset (2-term) † 
Porto 650 age, LOC, smoking, pre-stroke mRS 650 age, LOC, pre-stroke mRS2† 
Auckland 1177 age3†, log GCS†, pre-stroke dependence‡, AF, stroke 
type 
1177 age3†, log GCS†, pre-stroke dependence‡, AF 
L’Aquila 3794 age, LOC§, AF, hospital admission, stroke type, 
smoking 
3794 age, LOC§, AF, hospital admission, stroke type 
Matão 79 age§, NIHSS -  
Tartu 358 age, log NIHSS† -  
Total cases 14972  11368  
AF, Atrial fibrillation; Barthel, Barthel Index; GCS, Glasgow Coma Scale; LOC, loss of consciousness (at onset); mRS, modified Rankin scale; 
NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease. 
* The sample size were the same among the unadjusted model and fully adjusted model; † Transformations were based on the powers (e.g. 3rd 
power, two power terms) suggested by fractional polynomials that produced the best-fitting multivariable model; ‡ Self-reported data regarding 
whether the patient lived independently before stroke; § Not meeting criteria of being a confounder but remain in the fully adjusted multivariable 
model  
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 No of death (n/N)   Unadjusted   Adjusted*  
Men Women I2 (%) PH MRR (95% CI) Psub-
group 





          
Geographic region Australasia 3 380/1339 584/1583 22.6 0.275 1.35 (1.10-1.65) 0.618 0.0 0.794 0.73 (0.57-0.94) 0.479 
 Europe 7 1684/5830 2297/6564 36.2 0.152 1.35 (1.21-1.50)  50.7 0.058 0.80 (0.68-0.94)  
 South America 2 103/558 105/503 39.1 0.200 1.06 (0.60-1.86)  53.7 0.142 0.78 (0.38-1.59)  
 Caribbean 1 76/285 113/295 NA 1.000 1.65 (1.19-2.29)  NA 1.000 1.15 (0.79-1.68)  
Income group HIC 10 2064/7169 2881/8147 26.4 0.201 1.34 (1.23-1.47) 0.948 32.0 0.152 0.79 (0.69-0.89) 0.186 
 LMIC || 3 179/843 218/798 49.8 0.137 1.31 (0.92-1.86)  33.3 0.223 0.98 (0.69-1.39)  
Person-years Actual  9 1394/5450 1940/6060 20.1 0.264 1.35 (1.22-1.49) 0.904 0.0 0.471 0.74 (0.66-0.84) 0.023 
 Estimated  4 849/2562 1159/2885 50.8 0.107 1.37 (1.08-1.73)  24.2 0.266 0.97 (0.80-1.18)  
Death Registries Yes 7 1042/3912 1482/4473 48.4 0.071 1.37 (1.16-1.62) 0.831 0.0 0.452 0.77 (0.68-0.88) 0.594 
 No 6 1201/4100 1617/4472 0.0 0.466 1.31 (1.20-1.43)  56.5 0.043 0.83 (0.68-1.02)  
Age difference§ ≤ 4.5 years 5 934/3002 1149/3143 0.0 0.556 1.21 (1.09-1.34) 0.057 5.8 0.374 0.87 (0.75-1.01) 0.673 
 > 4.5 years 8 1309/5010 1950/5802 20.1 0.270 1.44 (1.30-1.59)  46.0 0.073 0.80 (0.67-0.95)  
Severity 
instrument 
NIHSS 7 687/2561 959/2731 15.5 0.311 1.41 (1.24-1.61) 0.198 0.0 0.639 0.78 (0.66-0.93) 0.345 
 Barthel 1 76/285 113/295 NA 1.000 1.65 (1.19-2.29)  NA 1.000 1.15 (0.79-1.68)  
 Others# 5 1480/5166 2027/5919 14.9 0.319 1.27 (1.15-1.39)  64.3 0.024 0.79 (0.64-0.97)  
SAH data Yes 11 2132/7666 2898/8481 28.5 0.174 1.32 (1.32-1.45) 0.210 38.5 0.093 0.79 (0.69-0.90) 0.166 
 No 2 111/346 201/464 0.0 0.971 1.63 (1.23-2.15)  0.0 0.766 1.08 (0.77-1.52)  
Sample size ≤ 250 2 49/138 39/126 0.0 0.574 0.82 (0.50-1.32) 0.134 0.0 0.745 0.53 (0.29-0.96) 0.321 
 > 250−1000 6 451/1730 643/1876 0.0 0.589 1.44 (1.26-1.65)  58.3 0.035 0.88 (0.67-1.16)  
 > 1000 5 1743/6144 2417/6943 40.9 0.149 1.33 (1.20-1.48)  0.0 0.422 0.82 (0.74-0.90)  







 No of death (n/N)   Unadjusted   Adjusted*  
Men Women I2 (%) PH MRR (95% CI) Psub-
group 




              
Stroke type IS 13 1551/6419 2076/6993 39.0 0.073 1.33 (1.20-1.49) Ref  35.5 0.098 1.01 (0.91-1.12) Ref  
 ICH 13 443/1001 552/1035 26.2 0.179 1.35 (1.09-1.66) 0.894 51.2 0.017 1.22 (0.96-1.55) 0.940 
 SAH 10 87/241 137/358 8.3 0.365 1.11 (0.77-1.60) 0.318 78.0 <0.001 0.85 (0.40-1.80) 0.390 
 Undetermined 12 172/351 364/559 0.0 0.633 1.53 (1.19-1.98) 0.370 80.9 <0.001 0.91 (0.56-1.47) 0.449 
Age group ≤65 13 334/2295 243/1620 0.0 0.504 1.06 (0.89-1.27) Ref -     
 >65-75 13 537/2350 446/1935 0.0 0.489 1.08 (1.00-1.17) 0.337 -     
 >75 13 1372/3367 2410/5390 0.0 0.603 1.12 (0.99-1.28) 0.404 -     
Bold denotes statistically significant results; PH, P-value of heterogeneity; Psub-group, P-value for subgroup analysis; Ref, reference group; NA, not 
applicable; IS, Ischaemic stroke; ICH, Intracerebral haemorrhage; SAH, Subarachnoid haemorrhage; Barthel, Barthel index (at onset), NIHSS, 
National Institutes of Health Stroke Scale; MRR (95% CI), Mortality rate ratio (95% confidence interval) between women and men; HIC, High-
income country; LMIC, Low- and middle-income country. 
* MRR adjusted for actual confounders, but estimates for stroke type adjusted for age only; † Estimates were performed using two-stage method 
analysis; ‡ Estimates were performed using multivariate random-effect meta-analyses from a pooled dataset; § Indicates difference in median age 
at onset between women and men; || Low- and middle-income country (LMIC) group included studies conducted in Martinique, Joinville and 
Mãtao; # Other instruments including Glasgow coma scale and loss of consciousness 
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 No of death (n/N)   Unadjusted   Adjusted*  
Men Women I2 (%) PH MRR (95% CI) Psub-
group 




              
Geographic region Australasia 2 508/1252 758/1487 0.0 0.614 1.39 (1.19-1.61) 0.080 0.0 0.835 0.71 (0.56-0.91) 0.308 
 Europe 5 2306/4596 2832/5301 29.8 0.223 1.13 (1.04-1.24)  77.1 0.002 0.73 (0.59-0.89)  
 Caribbean 1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
Income group HIC 7 2814/5848 3590/6788 51.7 0.053 1.21 (1.09-1.34) 0.239 67.2 0.006 0.73 (0.62-0.85) 0.114 
 LMIC | | 1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
Person-years Actual  6 1230/2334 1476/2599 49.5 0.078 1.25 (1.11-1.41) 0.841 32.2 0.195 0.68 (0.59-0.79) 0.051 
 Estimated  2 1719/3799 2294/4484 81.9 0.019 1.26 (0.91-1.74)  52.0 0.149 0.96 (0.75-1.22)  
Death Registries Yes 4 1367/2848 1760/3324 56.7 0.055 1.29 (1.12-1.48) 0.501 8.9 0.349 0.72 (0.62-0.83) 0.700 
 No 4 1585/3285 2010/3759 64.4 0.060 1.19 (0.98-1.44)  79.9 0.002 0.79 (0.59-1.05)  
Age difference§ ≤ 4.5 years 1 1095/2049 1296/2304 NA 1.000 1.09 (0.98-1.20) 0.261 NA 1.000 0.88 (0.80-0.98) 0.474 
 > 4.5 years 7 1854/4084 2474/4779 52.7 0.048 1.28 (1.14-1.45)  60.4 0.019 0.73 (0.61-0.88)  
Severity 
instrument 
NIHSS 3 539/1118 761/1335 0.0 0.518 1.35 (1.17-1.55) 0.117 39.2 0.193 0.73 (0.56-0.96) 0.307 
 Barthel  1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
 Others# 4 2275/4730 2829/5453 46.6 0.132 1.14 (1.02-1.26)  78.6 0.003 0.72 (0.58-0.89)  
SAH data Yes 7 2863/5964 3637/6875 54.0 0.042 1.21 (1.10-1.34) 0.247 72.2 0.001 0.74 (0.62-0.88) 0.370 
 No 1 86/169 133/208 NA 1.000 1.57 (1.14-2.15)  NA 1.000 1.01 (0.65-1.57)  
Sample size ≤1000 3 358/738 523/907 54.4 0.111 1.36 (1.08-1.72) 0.347 85.2 0.001 0.83 (0.48-1.43) 0.614 
 >1000 5 2591/5395 3247/6176 53.6 0.071 1.19 (1.07-1.33)  56.1 0.058 0.75 (0.65-0.87)  
Participant-level 
characteristics‡ 
              
Stroke type IS 8 226/4949 2782/5546 35.3 0.147 1.21 (1.11-1.32) Ref 48.7 0.058 0.88 (0.82-0.94) Ref 







 No of death (n/N)   Unadjusted   Adjusted*  
Men Women I2 (%) PH MRR (95% CI) Psub-
group 
I2 (%) PH MRR (95% CI) Psub-
group 
 ICH 8 450/770 526/840 61.1 0.012 1.27 (0.94-1.70) 0.529 63.4 0.008 1.01 (0.85-1.19) 0.722 
 SAH 7 77/186 125/279 25.1 0.237 1.14 (0.73-1.76) 0.873 56.3 0.033 1.04 (0.68-1.57) 0.746 
 Undetermined 8 158/228 337/418 35.8 0.143 1.51 (1.05-2.16) 0.397 45.2 0.078 1.02 (0.77-1.35) 0.150 
Age group ≤65 8 394/1605 242/1131 41.9 0.099 0.90 (0.70-1.15) Ref -     
 >65-75 8 1939/3786 2084/4188 33.7 0.159 0.98 (0.89-1.08) 0.917 -     
 >75 8 616/742 1444/1764 36.9 0.134 1.09 (0.90-1.30) 0.055 -     
PH, P-value of heterogeneity; Psub-group, P-value for subgroup analysis; Ref, reference group; NA, not applicable; IS, Ischaemic stroke; ICH, 
Intracerebral haemorrhage; SAH, Subarachnoid haemorrhage; Barthel, Barthel index (at onset), NIHSS, National Institutes of Health Stroke 
Scale; MRR (95% CI), Mortality rate ratio (95% confidence interval) between women and men; HIC, High-income country; LMIC, Low- and 
middle-income country. 
* MRR adjusted for actual confounders, but estimates for stroke type adjusted for age only; † estimates were performed using two-stage method 
analysis; ‡ estimates were performed using multivariate random-effect meta-analyses; § indicates difference in median age at onset between 
women and men; | | low- and middle-income country (LMIC) group included studies conducted in Martinique; # Other instruments including 
Glasgow coma scale and loss of consciousness 
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3.7 Supplemental Methods and Results 
3.7.1 Supplemental Methods 
Statistical analyses 
Potential sources of heterogeneity: Study-level analysis 
In these analyses, we calculated separate pooled effect estimates of sex differences in 
long-term mortality (13 studies at 1 year and 8 studies at 5 years) for models both 
unadjusted and adjusted for actual confounding factors, when appropriate.  
Meta-regression of continuous variables of interest included: geographic latitude, 
proportion of women, proportion of hospital admission, mid-point of study year (e.g. 
a study ranging from 1987 to 2012, the mid-point was 1999), Global Gender Gap 
Index and years of potential life lost. Gender inequality may contribute to sex 
differences in long-term outcome of stroke when women receive less stroke care than 
men. We investigate the role of gender inequality in sex disparities in long-term 
mortality using the Global Gender Gap Index232 (1-135) ranging from 4th in Sweden 
to 82nd in Brazil. It is possible that the magnitude of sex disparities may differ by 
differences in population-based life expectancy.233 We examined whether years of 
potential life lost (YPLL) account for any heterogeneity of sex difference in mortality 
across studies. Ratio of years of potential life lost (YPLL) to life expectancy for 
women-to-men to follow-up (1-year or 5-year) in each study were estimated. The 
country-specific life expectancies were taken from World Bank data.234 YPLL was 
measured by individual data from subtracting the person's age from their life 
expectancy at the year of outcome assessment. 
Meta-regression of categorical variables of interest included: geographic region, mean 
age difference between women and men (≤4.5 years, >4.5 years), severity 
instruments, linkage to National Death Registries, availability of person-years data 
(actual data and imputed data), sample size (small sample size < 25031 may affect the 
results), country income group (low- and middle-income countries (Martinique, 
Joinville and Matão) and high-income country), and availability of subarachnoid 
haemorrhage (SAH) type. Of note, we examined the role of availability of SAH cases 
because of the lack of these data in studies from Orebro and Tartu. 
Patient-level analysis 
To further examine the robustness of our findings we also tested interaction effects 
using the single pooled individual participant data dataset. We used multivariate 
random-effects meta-analysis211 using the pooled IPD to assess the influence of 
participant-level characteristics on the sex differences in long-term mortality of. 
Vaartjes et al. have previously shown that sex difference in long-term mortality of 
stroke may differ by age group and stroke type.97 There was considerable variation in 
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the year when stroke occurred from 1987 to 2013, and so we examined whether year 
of stroke occurrence influenced the sex difference in mortality in 1 year and 5 years 
post-stroke. In this data, we assessed the interaction between sex and participant-level 
covariates (stroke type, age at stroke onset and the year of stroke occurrence) by again 
testing the statistical significance of the sex × covariate product terms. In these 
analyses, we calculated separate pooled effect estimates of sex differences in 1-year 
mortality (13 studies) and in 5-year mortality (8 studies) in both unadjusted and 
adjusted for age, when appropriate.  
Sensitivity analyses 
Sensitivity analyses were used to examine the effect of the multiple imputation (m=50 
imputations), early deaths after stroke and, in a subset of studies, stroke management 
on the results. The effect of imputation was examined by comparing crude and 
adjusted MRR between the complete-case and imputed datasets. The influence of 
death early after stroke on the sex difference in long-term mortality was examined by 
excluding deaths occurring at <1, <3 and <6 months after stroke. In the subset of 
studies with data on in-hospital management, we repeated the analyses among 
hospitalised patients with the addition of treatment or management variables. 
Missing data and multiple imputation 
For studies without person years, sex-specific person-years were estimated based on 
the distribution of available data (i.e. the nine remaining studies) using multiple 
imputation by chained equations206 (m=50 imputations). The influence of imputed 
person-years on the pooled estimates was examined below in ‘Potential sources of 
heterogeneity’.  
Multiple imputation using chained equation206 (m=50 imputation) was also used to 
impute covariates where the fully adjusted model had missing data on confounding 
factors for more than 20% of cases. The effect of imputation was examined by 
comparing crude and adjusted mortality rate ratio (MRR) between the complete-case 
and imputed datasets. The missing values of all covariates such as severity, co-
morbidities were imputed by chained equations with 50 imputations based on all 
remaining completed variables in the dataset.  
We then examined whether the exclusion of those with missing data on confounding 
factors influenced our pooled results by comparing the sex differences in mortality for 
complete-case analyses and imputed analyses.  
Sex difference in mortality rate ratio excluding early deaths  
To investigate the role of timing of death, we repeated Poisson modelling with the 
similar approach in forementioned method (see main text ‘Statistical analysis’) to 
estimate the sex difference in long-term mortality of stroke excluding early deaths 
occurring at <1, <3 and <6 months after stroke. These sensitivity analyses were then 
compared to the main findings.   
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Analyses among hospitalised participants 
In the subset of studies with data on in-hospital management, we repeated the 
analyses among hospitalised patients with the addition of treatment or management 
variables including admission medication and discharge medication, in-hospital 
investigation and surgical interventions.  
Analyses of admission medications including antihypertensives, antiplatelets and 
anticoagulants, neuroimaging and ECG were performed among all hospitalised 
patients irrespective of stroke type. However, analyses of admission thrombolysis, 
discharge antiplatelets, discharge anticoagulants, carotid investigation, holter monitor, 
echocardiography and carotid endarterectomy were examined for ischaemic stroke 
patients only. Analyses of coiling or clipping were performed only for those who 
suffered haemorrhagic strokes. 
The two-stage method of analysis reported in the main text was then repeated among 
hospitalised patients to quantify the magnitude of crude and adjusted differences in 
long-term mortality with confounders not related to treatment. In the relevant 
subgroups specified above, we examined whether any treatment or management 
factors that showed a sex difference were confounders of the association between sex 
and mortality. We then examined whether the exclusion of those with treatment or 
management variables influenced our pooled results. 
3.7.2 Supplemental Results 
Missing data and multiple imputation 
Long-term outcome data were very complete (Appendix A: Supplemental Table A-
7a). Death data of seven studies were linked to National Death Registries. Studies in 
which cases were followed-up by study staff had low losses to follow-up. These 
losses were reported from original papers in L’Aquila, Auckland and Porto. Of note, 7 
cases lost to follow-up in Arcadia were not included in the analyses.   
Missing confounder data reduces the number of cases in the fully adjusted models 
within each study up to 26% (Supplemental Table A-7a). Only the study from 
Melbourne, with the greatest amount of missing data on confounders (>20%) both at 
1 year and 5 years after stroke, was required to have imputation of missing 
confounder information. In Melbourne data, results from imputed models showed the 
same factors contributing to the sex difference in both 1-year and 5-year mortality 
after stroke compared to complete-case analysis. After accounting for these 
confounding factors, compared to complete-case analysis (main Figures 3-2 and 3-3), 
the trend of the sex difference after imputation remained unchanged (supplementary 
table 9b) with the RR being 0.89 at 1 year (vs 0.76, main Figure 3-2) and 0.85 at 5 
years (vs 0.69, main Figure 3-3).  
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In the analysis using multiple imputation, inclusion of imputed data for the 
Melbourne study had no impact on the estimated relative sex differences in mortality 
at 1 or 5 years, in both unadjusted and adjusted estimates (Supplemental Table A-
7b). 
Sex difference in mortality rate ratio excluding early deaths (1 month, 3 months 
and 6 months)  
1-year analysis 
The magnitude of sex difference in crude 1-year mortality after stroke remained the 
same when excluding deaths occurring within the first month (MRR 1.29 95% CI 
1.11, 1.48 vs 1.35 95% CI 1.24, 1.47) but largely attenuated when excluding deaths 
within 6 months after stroke (MRR 1.14 95%CI 0.92-1.40; supplementary table 10). 
After accounting for significant confounders, the sex differences were reversed with 
MRR ranging from 0.81 to 0.84, this being closely similar to the figure of 0.81 in 
main analyses that included all deaths (main Figure 3-2). 
5-year analysis 
The magnitude of sex difference in crude 5-year mortality after stroke attenuated but 
remained significant when excluding deaths occurring within the first month (MRR 
1.15 95% CI 1.02, 1.30 vs 1.24 95% CI 1.12, 1.38) but was no longer significant after 
excluding deaths within 6 months after stroke (MRR 1.07 95% CI 0.92, 1.25; 
Supplemental Table A-8). After accounting for significant confounders, the sex 
differences were reversed with MRR ranging between 0.77 and 0.78, these being 
closely similar to the figure of 0.76 in the main analyses that included all deaths (main 
Figure 3-3). 
Hospitalised analysis 
Sex differences in treatment and management of stroke  
There was little evidence of sex difference in admission medication including 
antihypertensives (1/3 studies), antiplatelet agents (0/4 studies), anticoagulants (2/4 
studies), thrombolysis (0/4 studies) and discharge medication including 
antihypertensives (0/4 studies), antiplatelet agents (0/5 studies), and anticoagulants 
(0/4 studies; Supplemental Table A-9).  
There were no sex differences in the proportion of investigations undertaken 
including ECG ( 9 studies), neuroimaging (12 studies), and holter monitor (3 studies) 
investigations among studies that had these data. In very few studies women 
underwent fewer echocardiography procedures (3/7 studies) and carotid investigations 
(4/9 studies), or carotid endarterectomy (1/2 studies). No difference in surgical 
intervention between men and women was found (Supplemental Table A-9). 
Sex differences in 1-year mortality and 5-year mortality among hospitalised patients 
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The unadjusted difference in mortality between men and women was similar for 
hospitalised patients and all participants. Among the 95·8% (14350/14972) of 
subjects who were admitted at 1 year and 99·3% (11287/11368) at 5 years, women 
were more likely than men to be deceased at 1 year (excessive mortality 33% [95% 
CI 22%, 44%]) and 5 years (excessive mortality 21% [95% CI 10%, 33%]). The 
confounding factors contributing to these differences were similar to the main 
findings (main Table 3-2).  
Subgroup analyses among patients hospitalised with ischaemic stroke  
With the exception of carotid investigations in Joinville, none of the potential 
confounding factors confounded the association between sex and mortality in 
hospitalised patients (Supplemental Table A-10). In Joinville, adjustment for carotid 
investigations reduced the 1-year MRR by 59% among hospitalised cases. The pooled 
estimates of the MRR for women compared to men, including the new estimate for 
Joinville, remained virtually unchanged (Supplemental Table A-11). 
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Chapter 4: Sex differences in long-term functional 
outcome and participation restriction after stroke in the 
INternational STRoke oUtComes sTudy (INSTRUCT) 
4.1 Preface 
This thesis chapter has been published as a paper in the Neurology (see Appendix I). 
Phan HT, Blizzard CL, Thrift AG, Cadilhac D, Sturm J, Heeley E, Konstantinos V, 
Anderson C, Parmar P, Krishnamurthi R, Barker-Collo S, Feigin V, Para V, Bejot Y, 
Cabral N, Carolei A, Sacco S, Chausson N, Olindo S, Rothwell P, Silva C, Correia M, 
Magalhães R, Appelros P, Korv J, Vibo R, Minelli C, Reeves M, Otahal P, Gall S.  
Factors contributing to sex differences in functional outcomes and participation after 
stroke. Neurology. 2018. (Journal IF ~ 8.3; citation: 2). 
https://doi.org/10.1212/WNL.0000000000005602.  
This paper was also accompanied by an editorial noting its novelty, significance and 
implications for improving long-term outcome after stroke (see Editorial by Andrew 
and Srikanth: https://doi.org/10.1212/WNL.0000000000005591).  
This chapter has been removed 
forcopyright or proprietary 
reasons.
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4.7 Supplemental Methods and Results 
4.7.1 Supplemental Methods 
Statistical analysis 
Because covariates were not measured uniformly between studies, we could not 
harmonise and adjust for the same set of covariates. Hence, a two-stage analysis 
method204 for the analysis of pooled data was used. For the first stage of analysis, 
study-specific models for functional outcomes were built using log-binomial 
regression to estimate the relative risk (RR) of poor outcome for women compared to 
men at 1 year (10 studies) and 5 years (7 studies) after stroke. Of note, follow-up data 
on functional outcomes available at 4 years (for Tartu) or 7 years (for Porto) were 
included in 5-year analyses together with outcome data at 5 years of the other four 
studies. Poor outcome was defined as BI <20 (Melbourne and Matão) and mRS >2 
(remaining studies). The 100-point version of BI used in the Matão study was 
rescaled to be the same as the other studies.  
Two of the cohorts (Melbourne and Auckland) included assessment of participation at 
5 years after stroke using the London Handicap Scale (LHS).240 The dimensions of 
the LHS include: orientation, physical independence, mobility, occupation, social 
interaction and economic self-efficiency. The overall LHS score is obtained by 
applying weights to each subdomain score (0 [worst] to 6 [no disadvantage]), 
summing them, and adding a constant; it ranges from 0 (very disadvantaged) to 100 
(not disadvantaged). For analyses of participation restriction (or handicap), study-
specific multivariable linear regression, with Box-Cox transformation of the outcome 
to remove skewness, was used to compare the mean difference of LHS total scores (0-
100) for women and men (2 studies, Melbourne and Auckland). Back-transformed
estimates are presented. Because of causal relationship between LHS and functional
outcome such as BI,260 we did not include long-term functional outcome in analyses
of participation restriction.
Within each study, we then assessed the role of the covariates in the association
between sex and each outcome using purposeful model building.207 Variables were
entered into the model only if they met for all our 4 criteria (being missing <20% of
cases, associated with sex with p<0·1, associated with the outcome with p<0.1, and
the inclusion of the covariate in a model with only sex changed the magnitude of the
sex coefficient by ≥10% [unadjusted β – adjusted β)/ unadjusted β *100]).24
The model-building process started with separate analyses for each variable.
Adjustment was then made for all confounders in multivariable analyses but with age,
stroke severity and pre–stroke function (where available), forced into a final fully
adjusted model. Within each study, the modifying effect of a covariate on the sex
difference was assessed by a test of the statistical significance of the coefficient of a
sex × covariate product term.
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For the second stage of the analysis, both unadjusted and adjusted study-specific 
estimates were pooled in separate meta-analyses, so that the pooled values could be 
compared to determine the effect of adjustment. Heterogeneity was evaluated using I2
statistics with the Mantel-Haenszel approach. 
Sensitivity analyses 
Potential sources of heterogeneity: Study-level characteristics 
Potential sources of heterogeneity were assessed among variables of study-level 
characteristics (e.g. geographic region, income group and instrument of functional 
outcome). Between-study interactions between sex and study-level characteristics 
were assessed by meta-regression. In these analyses, we calculated separate pooled 
effect estimates of sex differences in long-term functional outcome (10 studies at 1 
year and 7 studies at 5 years) for models both unadjusted and adjusted for actual 
confounding factors, when appropriate.  
Meta-regression of continuous variables (n=6 variables) of interest included: 
geographic latitude, proportion of women, proportion of hospital admission, mid-
point of study year (e.g. in the Oxford study, year of stroke ranged from 2002 to 2013, 
and the mid-point was 2008), Global Gender Gap Index and years of potential life 
lost. Gender inequality may contribute to sex differences in long-term outcome of 
stroke when women receive less stroke care than men. We investigated the role of 
gender inequality in sex disparities in long-term functional outcome using the Global 
Gender Gap Index232 (1-135) ranging from 4th in Sweden to 82nd in Brazil. It is 
possible that the magnitude of sex disparities may differ by differences in population-
based life expectancy.233 We examined whether years of potential life lost (YPLL) 
account for any heterogeneity of sex difference in functional outcome across studies. 
Ratio of year of potential life lost (YPLL) to life expectancy for women-to-men to 
follow-up (1-year or 5-year) in each study was estimated. The country-specific life 
expectancies were obtained from World Bank data.234 YPLL was measured 
individually by subtracting the person's age from their life expectancy at the year of 
outcome assessment. 
Other sensitivity analyses 
Analyses in a single IPD dataset 
There were three covariates measured consistently in all studies: year of stroke 
occurrence (ranged from 1993 to 2014), age at stroke onset and stroke type. To 
further test the robustness of our findings, we used a single-stage meta-analysis 
pooling all IPD datasets210 to examine whether these factors modified the sex-effect 
on poor functional outcome at 1 year (10 studies) and 5 years (7 studies) after stroke. 
We chose p ≤ 0.10 as the cut-off for statistical significance of the interaction (sex × 
covariate product term) because this value is commonly accepted in the literature for 
detecting interactions.113  
Missing data and sensitivity analyses 
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We undertook a wide range of sensitivity analyses to assess other potential bias. For 
studies with >20% missing data of long-term functional outcomes, participation or 
covariates, multiple imputation using chained equations (n=50 imputations) combined 
with Inverse-Probability Weighting241 was performed and compared with results from 
complete-case analyses. These sensitivity analyse were based on the assumption that 
the data were missing at random. The missing values of outcomes and all covariates, 
where necessary, such as severity and co-morbidities were imputed based on all 
remaining completed variables in the dataset. We then examined whether the 
exclusion of those with a high rate of missing data on outcomes and confounding 
factors influenced our pooled results by comparing the sex differences in functional 
outcomes for complete-case analysis and imputed analysis with unadjusted and fully-
adjusted models.  
We also performed sensitivity analysis by replacing missing observations on 
functional outcome with extreme values of 0 or 1 and compared with results from 
complete-case analyses.261 These further analyses were based on worst-case scenario 
(all missing cases had poorest possible functional outcome after stroke). To show the 
range of results that might be possible. We had added also a best-case scenario (all 
missing cases had the best possible functional outcome). 
Furthermore, we considered removing studies at risk of bias (high proportion of 
patients lost to follow-up) in sensitivity analysis. We compared the pooled effect size 
estimates between models that included and excluded these studies. 
Analyses among survivors who were hospitalised at stroke onset 
Analyses among hospitalised patients were carried out to determine whether there 
were sex differences in treatment and management, and whether any differences in 
these variables influenced the sex differences in outcome. We used χ2 test or Fisher's 
exact test, as appropriate, to examine whether there were sex differences in admission 
medication and discharge medication, in-hospital investigation and surgical 
interventions. Analyses of admission medications including antihypertensive agents, 
antiplatelet therapies and anticoagulation therapies, neuroimaging and ECG were 
performed among all hospitalised patients irrespective of stroke type. However, 
analyses of admission thrombolysis, antiplatelet agents at discharge, anticoagulation 
therapies at discharge, carotid investigation, holter monitor, echocardiography, carotid 
endarterectomy were examined for patients with ischaemic stroke only. Analyses of 
coiling or clipping were performed only for those who suffered haemorrhagic strokes. 
The two-stage method of analysis reported in the main text was then repeated among 
hospitalised patients to quantify the magnitude of crude and adjusted differences in 
long-term functional outcome with confounders that were not related to treatment. 
Then, in the relevant subgroups specified above, we examined whether any treatment 
or management factors that showed a sex difference were confounders of the 
association between sex and functional outcome. 
Other sensitivity analyses 
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For functional outcomes, due to some evidence proposing an ordinal model approach 
of mRS,262 we also considered sex difference in poor outcomes at full ordinal scale 
among studies that had these data. Ordinal regression with the continuation-ratio 
approach263 was used to calculate the effect size of the sex difference in functional 
outcomes after stroke with mRS data, and was then compared to the dichotomous 
analysis.  
Authors of some previous studies have reported a cut-off of 95 for BI to define poor 
outcome (100-point version).264 Therefore, among studies with BI data, alternative 
cut-off points for poor outcome (BI <95 for Matão or <19 for Melbourne) were 
compared with the main analyses (BI <100 for Matão or <20 for Melbourne). 
Analyses among hospitalised patients were carried out to determine whether there 
were sex differences in treatment and management of stroke, and whether any 
differences influenced the differences in functional outcome. We quantified the 
magnitude of unadjusted and adjusted differences in long-term functional outcomes 
with the addition of treatment or management variables. 
For participation outcome, we compared the level of participation restriction (score 0-
6 with higher categories denoting more severe disadvantage) in each of the six 
dimensions. Because there were some extreme values of higher level of participation 
restriction, we collapsed the LHS sub-domain scores into two levels including less 
disadvantage (categories 1-2) and disadvantage (categories 3-6).   
4.7.2 Supplemental Results 
Sex difference in 5-year functional outcome after stroke 
Analysis of 5-year functional outcome included 2,084 cases (94% of available cases) 
due to missing data of some confounders. At 5 years after stroke, women had a 31% 
higher risk of poor functional outcome in unadjusted analyses (Figure 4-2, top panel). 
There was no evidence of heterogeneity in sex difference in long-term functional 
outcome of stroke at 5 years (I2=0.0, p=0.476). Contributors of the sex difference 
included baseline age (6/7 studies), severity (2/7 studies) and pre-stroke dependency 
(4/5 studies). Separate adjustment by inclusion of individual covariates changed the 
coefficient for sex difference substantially, age alone explained 45% of the sex 
difference (pooled age-adjusted RR 1.16 [95% CI 1.03, 1.30] with I2=0.0, p=0.710; 
Appendix B: Supplemental Table B-4a). The effect was also reduced with separate 
adjustment for stroke severity (17%) and pre-stroke dependency (28%; Supplemental 
Table B-4a). No interaction between sex and any of these factors in the 5-year 
functional outcome after stroke was found with the exception from Oxford study 
(Supplemental Table B-4b; with the excessive risk of worse functional outcome for 
women was stronger in those who were independent before stroke (unadjusted RR 
1.61 [95% CI 1.21, 2.15], adjusted RR 1.37 [1.01, 1.72]) compared to participants 
who were dependent before stroke (unadjusted RR 0.90 [0.77, 1.04], adjusted RR 
0.87 [0.71, 1.06]; for these interactions, p<0.05). There was no evidence that 
socioeconomic status, cardiovascular risk factors, medical comorbidities, post-stroke 
recurrence and depression were confounders of the association between sex and poor 
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functional outcome (Supplemental Table B-10). The pooled adjusted RR was 1.05 
(95% CI 0.94, 1.18) with no evidence of heterogeneity (I2 = 0.0, p = 0.870). Meta-
regression did not identify any sources for the heterogeneity observed in 5-year crude 
or adjusted models (Supplemental Table B-11). 
In further analyses of the IPD data, none of the 3 participant-level characteristics of 
age, stroke type and the year of stroke occurrence were significant sources of 
between-study variation (Supplemental Table B-5b). 
Sensitivity analyses 
Missing data and imputation 
1-year analysis
As shown in Supplemental Table B-7, among who survived to 1 year after stroke, 
information on potential confounding factors were missing in up to 16% of 
participants within studies. However, functional outcome data to 1 year after stroke 
were less complete in three studies (Melbourne, Perth and Tartu) with missing data up 
to 70%. Removing Perth, which had the greatest missing 1-year outcome data did not 
affect the results (Supplemental Table B-6). We found no difference in proportion of 
women and age at stroke onset between those who were assessed in the long-term and 
those lost to follow-up (Supplemental Table B-8a).  
As shown in Supplemental Table B-9, though the relative risks of imputed 1-year 
functional outcome for those studies with >20% lost to follow-up (Barthel Index for 
study from Melbourne and mRS for study from Perth and Tartu) attenuated the sex 
difference, greatest in study from Perth, the pooled estimates remained mostly the 
same compared to complete-case analyses. Pooled crude 1-year RR for poorer 
functional outcome slightly altered from 1.32 to 1.31 in crude analysis and remained 
1.08 after fully adjustment for confounders.  
5-year analysis
As shown in Supplemental Table B-7, among those who survived to 5 years after 
stroke, information on potential confounding factors were missing in up to 20% of 
participants within studies. Functional outcome data to 5 year after stroke were less 
complete in two studies (Melbourne and Auckland) with missing data up to 65.6%. 
Removing Auckland that had the greatest missing 5-year outcome data 
(Supplemental Table B-6) did not affect results. We found no difference in 
proportion of women between those who were assessed in the long-term and those 
lost to follow-up (Supplemental Table B-8b). However, who lost to follow-up were 
younger than those were assessed functional outcome at 5 years after stroke. 
As shown in Supplemental Table B-9, relative risks of imputed 5-year functional 
outcome for those studies with >20% lost to follow-up (Barthel Index for study from 
Melbourne and mRS for study from Auckland) showed a slightly change. The pooled 
estimates were also similar to the complete-case analyses. Pooled crude 5-year RR for 
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poorer functional outcome slightly attenuated from 1.31 to 1.26 in crude analysis and 
from 1.05 to 1.02 after fully adjustment for confounders.  
Other sensitivity analyses 
1-year analysis
Using an alternative cut point for the Barthel Index (Melbourne and Matão) did not 
change the summary estimates of sex difference in functional outcomes at 1 year after 
stroke. An ordinal regression model of mRS categorised into 3 levels (0-1, 2-3 and 4-
5) supported the results with a dichotomous outcome at 1 year (Supplemental Figure
B-1).
5-year analysis
Using an alternative cut point for the Barthel Index (Melbourne) did not change the 
summary estimates of sex difference in functional outcomes at 5 years after stroke. 
An ordinal regression model of mRS categorised into 3 levels (0-1, 2-3 and 4-5) 
supported the results with a dichotomous outcome at 5 years after stroke 
(Supplemental Figure B-2).   
Hospitalised analysis 
There was little evidence of sex differences in acute treatment and management of 
stroke among survivors at 1 year (Supplemental Table B-12) and 5 years (Table B-
13) after stroke. Generally, the unadjusted differences in functional outcome between
men and women in the long term after stroke were the same for hospitalised patients
only as for all participants (hospitalised and non-hospitalised). Among those
hospitalised, women often suffered poorer functional outcomes at 1 year (32%;
Supplemental Figure B-3) and 5 years (34%; Supplemental Figure B-4). In study
specific models, factors contributed to the difference between men and women were
similar to that depicted in Table 4-2 (e.g. age, severity, pre-stroke dependency)
without any additional factors of treatment and management of stroke.
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Chapter 5: Sex differences in long-term health-related 
quality of life after stroke in the INternational STroke 
oUtComes sTudy (INSTRUCT) 
5.1 Preface 
At the time of submission of this thesis, the contents of this chapter have been 
circulated to co-authors in preparation for submission for publication.  
Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac DA, Sturm J, Heeley E, 
Otahal P, Rothwell P, Anderson C, Parmar P, Krishnamurthi R, Barker-Collo S, 
Feigin V, Gall SL. Sex differences in long-term health-related quality of life after 
stroke in the INternational STroke oUtComes sTudy (INSTRUCT).  
5.2 Abstract 
Background: Women are reported to have poorer health-related quality of life 
(HRQoL) after stroke than men, but the reasons why are uncertain. We aimed to 
investigate sex differences in HRQoL up to 5 years after stroke and identify factors 
contributing to these differences.  
Methods: Individual participant data on 9,109 first-ever strokes (1993-2014) were 
obtained from 10 high-quality incidence studies from Australasia, Europe, South 
America, and the Caribbean. Study factors included socio-demographics, pre-stroke 
dependency, stroke-related factors (e.g. stroke severity), comorbidities, post-stroke 
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depression, and functional status. HRQoL utility scores were calculated from the 
EQ5D, SF6D, and AQoL at 1 year (3 studies; n=1,210) and 5 years (3 studies; 
n=1,057) after stroke. EQ5D utility scores were also mapped from the modified 
Rankin Scale (mRS) at 1 year (8 studies; n=4,303) and 5 years (6 studies; n=2,208). 
Quantile regression was used to estimate the median differences (MD) in HRQoL 
utility scores for women compared to men with adjustment for 
covariates/confounding factors. Study-specific unadjusted and adjusted MDs were 
then combined into pooled estimates using random-effect meta-analysis. 
Findings: Women (average age: 73 vs men 70 years) had lower pooled mean utility 
scores than men (1-year MDunadjusted -0.147, 95% CI -0.258, -0.036; 5-year MDunadjusted 
-0.090, 95% CI -0.119, -0.062). These differences were attenuated after adjustment 
for age, stroke severity, pre-stroke dependency, and depression (1-year pooled 
MDadjusted -0.067, 95% CI -0.111, -0.022; 5-year MDadjusted -0.085, 95% CI -0.135, -
0.034). Similar trends were observed for mapped EQ5D utility scores (1 year pooled 
MDunadjusted -0.043, 95% CI -0.064, -0.021; MDadjusted -0.014, 95% CI -0.023, -0.005; 
5-year MDunadjusted -0.040, 95% CI -0.075, -0.005; MDadjusted -0.020, 95% CI -0.044, 
0.004). 
Conclusion: Poorer HRQoL was consistently observed in women after stroke. It was 
mostly attributable to their advanced age, more severe strokes, pre-stroke 
dependency, and post-stroke depression, suggesting targets to reduce the differences. 
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5.3 Introduction  
The greater burden of stroke in women than in men has recently been recognised as a 
major concern worldwide.235,256 Women generally have a poorer health-related quality 
of life (HRQoL) than men, both in the short and long term after stroke.23,24 Despite 
the increased interest in sex differences, the reasons for worse HRQoL in women 
have not been adequately investigated. HRQoL is defined as an assessment of how 
the individual's well-being may be affected over time by a health condition such as 
disease, disability, or disorder.73 HRQOL has become an important component of 
health surveillance and is generally considered a valid indicator of service needs and 
intervention outcomes. 
Existing studies of sex differences in HRQoL after stroke have several limitations.23,24 
The studies were mainly focused on short-term outcomes up to 6 months after 
stroke.24 Many investigators did not report sex-specific findings, or used modelling 
that was not focused on the sex difference. The association between sex and outcomes 
in the studies was usually reported as an incidental finding. Of a small number of 
studies specifically designed to examine sex differences, most were either based in 
the hospitals/convenience samples or restricted to a specific type of stroke or certain 
age groups. This is problematic as selection bias may adversely affect conclusions.26 
By contrast, among several ‘ideal’ population-based stroke incidence studies236 that 
are the most generalisable and ideal to examine sex differences,28,30,94 very few had 
aHRQoL assessment or were analysed to assess for sex differences. There are 
inconsistent findings regarding the factors associated with sex difference in HRQoL 
because of variation in outcome measurement and adjustment for different 
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covariates.24 In the most recent update, only two out of 13 studies on sex differences 
in HRQoL published since 2007 were designed to examine the sex differences, and 
none of these were population-based studies.23  
The aim of this study was to quantify the differences between men and women in 
HRQoL at 1 and 5 years after stroke and identify factors contributing to any observed 
sex differences. We used individual participant data from ‘ideal’ incidence stroke 
studies conducted in different countries.  
5.4 Method 
The INternational STroke OUtComes STudy (INSTRUCT) is an international 
collaboration whereby we have pooled individual patient data after first-ever stroke. 
The INSTRUCT includes 13 studies from Australasia, Europe, South America and 
the Caribbean (1987 and 2014; n=16,964 incident strokes at baseline) that adhered to 
the criteria for ‘ideal’ population-based stroke incidence studies (Chapter 2). This 
project was registered in the PROSPERO (CRD42016036723) and approved by the 
Tasmanian Health and Medical Human Research Ethics Committee (H0014861). All 
the participating studies had approval from their respective local Ethics Committees. 
The 13 studies included in INSTRUCT represented 59% of the 22 potentially eligible 
studies identified through our systematic search. More details of the study selection 
process are provided in Chapter 2. Ten out of the 13 studies were included in the 
analyses of sex differences in long-term HRQoL for this current study (Table 2-7).  
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5.4.1 Outcome measurements 
In the 10 studies, participants of eight studies were followed up with face-to-face 
interviews conducted at 1 and 5 years after stroke, while in the remaining two studies 
(Joinville, Tartu), mail or telephone interviews were used (Chapter 2).265  
Of the 10 studies, four had measures of HRQoL among survivors after stroke (Table 
2-7; Oxford, Perth, Melbourne, and Auckland). However, the measures were 
available for three studies at 1 year (Oxford, Perth, and Melbourne) and for three 
studies at 5 years (Oxford, Auckland, and Melbourne). Three instruments were used 
to assess the HRQoL in the long term after stroke including the European Quality of 
Life–5 Dimensions (EQ5D),194 the Assessment of Quality of Life (AQoL),195 and the 
Short Form–36 questionnaire (SF36)266. In the Oxford study, HRQoL was assessed 
using the EQ5D instrument. For each of the five dimensions of the EQ-5D (including 
mobility, self-care, usual activities, depression/anxiety, and pain), there are three 
response categories: no problem, some/moderate, and extreme problem. In the 
Melbourne (Australia) study, the AQoL was used. The AQoL has five dimensions 
comprising illness, independent living, social relationships, physical senses, and 
psychological wellbeing with four response levels for each domain (from needing no 
help to requiring daily help). The SF36 was used to assess HRQoL among stroke 
survivors in the Perth (Australia) and Auckland (New Zealand) studies. The SF36 
instrument, validated for use among patients with stroke, covers both physical and 
mental health with eight sub-dimensions.267  
In additional analyses data from studies with the modified Rankin scale (mRS; 
measurement of functional outcome) at 1 year (8 studies: Oxford, Joinville, Arcadia, 
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Perth, Orebro, Martinique, Porto, and Tartu) or 5 years after stroke (6 studies: Oxford, 
Joinville, Martinique, Porto, Auckland, and Tartu) was assessed whereby the mRS 
was mapped to European Quality of Life–5 Dimensions (EQ5D) utility scores using 
the published algorithm.268 
 
5.4.2 Study factors 
We included covariates that we hypothesised from our previous studies84,94 that might 
explain differences in outcomes between men and women. These included socio-
demographics (e.g. age, marital status, institutional residence), pre-stroke health (e.g. 
pre-stroke dependence) and comorbidities (e.g. hypertension, atrial fibrillation, 
smoking, alcohol consumption), stroke-related factors (stroke type, severity), 
treatment and management (admission and discharge medication, in-hospital 
investigation and surgical interventions) and post-stroke factors (e.g. depression, 
functional outcome). A summary of the potential confounding factors available in 
each study was described earlier in Chapter 2: section 2.5. 
5.4.3 Statistical analysis 
All the data were analysed in Stata 12.1 (StataCorp Texas, 2011).269 All two-tailed p-
values ≤ 0.05 were considered statistically significant.  
HRQoL utility scores were calculated from the three instruments (EQ5D, AQoL, and 
SF36) among survivors after stroke by summing the component scores and adding 
value sets from relevant general populations to create an overall score. The utility 
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score is a scale on which full health has a value of 1, while 0 indicates death and 
negative values indicate health states worse than death. The SF6D utility scores 
(Perth, Auckland) were estimated from the SF36 using the published algorithm for the 
United Kingdom (UK) population270 given the lack of SF‐6D preference weights for 
Australia or New Zealand (NZ).271 The AQoL utility scores (Melbourne) were 
calculated based on the Australian population-based methods195 while the EQ5D 
utility scores (Oxford) were derived from patient data using the available value sets 
for the UK population.272 Among studies with mRS data, EQ5D utility scores were 
further mapped from the mRS categories (0-5) using the published algorithm.268  
The measured and mapped utilities scores were analysed in separate models. Due to a 
lack of evidence on using mRS-based HRQoL after stroke, the mapped scores were 
only reported in sensitivity analyses to compare with our main analyses of measured 
HRQoL. Quantile regression was used to estimate the median difference for women 
compared to men in utility scores among survivors at 1 and 5 years after stroke. We 
used a two-stage analysis method204 where study-specific models for sex difference in 
HRQoL were built in the first stage. Within each study, the role of the covariates as 
confounders207 of the association between sex and HRQoL outcome were assessed 
(Supplemental Methods: section 5.7). Age, stroke severity, and pre-stroke 
dependency that are common predictors of HRQoL and associated with sex,23,24 
where possible, were forced into the final multivariable models accounting for all 
significant confounding factors. Given a high correlation between HRQoL and 
functional outcome,273 we did not include long-term functional outcome in the final 
models to avoid over-adjustment bias. Further adjustment for this factor is reported in 
separate models. 
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In the second stage of the analysis, the effect estimates from unadjusted and 
multivariable-adjusted models were combined to create pooled estimates in separate 
random-effects meta-analyses. Statistical heterogeneity between studies was 
evaluated using I2 statistics. The potential sources of heterogeneity were assessed 
among several variables of interest (Supplemental Methods: section 5.7) using 
meta-regression.231  
We found substantial disparities in the number of health states (EQ5D-3L: 243, SF-
6D: 18,000, and AQoL: 1.07 billion health states)274,275 across instruments and their 
definitions of the minimum clinically important difference.276,277 The comparability of 
the study populations with measured HRQoL was undertaken to see whether the sex 
differences in utility scores might be clinically meaningful or not. In these analyses, 
the differences between men and women at 0.06 for AQoL,276 0.08-0.12 for EQ5D,277 
and 0.03-0.08 for SF6D277 were considered as clinically relevant. 
For the studies with more than 20% missing data on long-term outcomes, multiple 
imputation using chained equations (n=50 imputations) combined with Inverse-
Probability Weighting241 was performed to compare with results from complete-case 
analyses. 
Subdomain analyses 
Further, subdomain analyses among the included studies (Auckland and Perth: SF36; 
Melbourne: AQoL) were performed to determine the dimensions of HRQoL that 
affected women more often than men in the long-term after stroke.  
Analyses of the comparison with general populations 
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We also examined whether the poorer HRQoL after stroke in women was due to 
stroke or other differences in the comparison between stroke and general populations.  
For each study with measured HRQoL (EQ5D, AQoL, and SF-6D), mean (and 
standard deviation, SD) utility scores for stroke survivors were calculated within sex 
and different age groups (<55, 55-64, 65-74 and ≥75 years old). To examine the 
HRQoL loss caused by stroke when compared with the general population, we 
included those assessed with HRQoL after stroke at 1 or 5 years of follow-up (not 
including death). For each instrument, the corresponding reference scores in the 
general population were obtained from the current literature on UK norms for 
EQ5D,278 and Australian norms for AQoL.276 Due to a lack of published NZ reference 
scores for SF-6D, Australian norms for SF-6D were used as a surrogate.271 We then 
calculated the nect mean difference scores between stroke and general populations 
within each age group, separately for men and women. The Perth study was excluded 
from these analyses due to the small sample size by age and sex strata. 
5.5 Results 
There were with 9,109 first-ever stroke registrants at baseline among the included 10 
studies. HRQoL outcomes were assessed among 1,210 (63%) of 1,914 survivors at 1 
year (3 studies) and 1,057 (58%) of 1,837 survivors at 5 years (3 studies) after stroke 
(Table 5-1). Further, the mapped EQ5D utility scores were available among 4,303 
(78%) of 5,498 survivors at 1 year (8 studies) and 2,208 (70%) of 3,142 survivors at 5 
years (6 studies).  
Differences between women and men at the time of stroke and long-term follow-up 
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In analyses of baseline factors among survivors with 1-year HRQoL assessment, 
women were older (statistically significant difference in 3/3 studies; Appendix C: 
Supplemental Table C-1) and more dependent before stroke than men (3/3 studies; 
evaluated by the mRS or the Barthel Index). They also more often had a higher mean 
score of stroke severity than men although the sex difference was small. Men were 
often ever-smokers (3/3 studies) or alcohol consumers (2/3 studies). There was very 
little difference between men and women in comorbidities, acute stroke therapies and 
management (Supplemental Table C-1). Similar results were found in the 
comparison between sexes of the study factors among those assessed at 5 years within 
each cohort (Supplemental Table C-2).  
Regarding post-stroke factors, women often had poorer functional outcomes assessed 
by the mRS or the Barthel Index (1 year: 3/3 studies; 5-year: 2/3 studies) than men. In 
the Melbourne study, women appeared to have more mood disorders (i.e., anxiety or 
depression) and take antidepressant medications at 5 years after stroke more 
frequently than their male counterparts (Supplemental Tables C-1 and C-2). 
Among studies with HRQoL mapped scores (from the mRS), with the patient 
characteristics by sex being presented in our previous publication on functional 
outcome,265 women were older, had greater pre-stroke dependency, and poorer 
functional outcomes at 1 and 5 years after stroke than men.   
Sex difference in long-term HRQoL among survivors after stroke 
Among three studies with measured HRQoL at 1 year, the sample for complete-case 
analysis was 1,116 (92% of available cases) because of missing data on some 
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confounding factors. In unadjusted analyses, women had significantly poorer median 
utility scores at 1 year after stroke (pooled median difference, MDunadjusted -0.147, 
95% CI -0.258, -0.036). Study-specific unadjusted female:male MD varied from -
0.069 (Oxford), -0.197 (Melbourne) to -0.210 (Perth; Figure 5-1, top). All the sex 
differences were statistically significant but were above only the clinically meaningful 
threshold in the Melbourne and Perth studies.  
However, the differences were substantially attenuated (by 61.4%) after accounting 
for covariates (1-year pooled MDadjusted -0.067, 95% CI -0.111, -0.022; Figure 5-1, 
bottom). In study specific models, the significant confounding factors of the 
association between sex and HRQoL were identified: age (2/3 studies), stroke severity 
(1/3 studies), pre-stroke functional outcome (1/3 studies), and mood disorders 
(Melbourne study; Table 5-2). No factors of treatment and management of stroke 
accounted for the sex differences in 1-year HRQoL. Among the three studies, the 
adjusted female:male MD only remained clinically significant in the Perth study. 
Further adjustment for 1-year functional outcome removed the association between 
sex and HRQoL across the studies (Table 5-2). There were no statistical interactions 
between sex and covariates on the HRQoL scores. 
Similar trends were found among 8 studies with mapped utility scores at 1 year, in 
which the pooled unadjusted female:male MD were -0.043, 95% CI -0.066; -0.021 
and reduced to -0.011 (-0.023; -0.005; Supplemental Figure C-1) after adjustment 
for confounding factors. There was no statistical heterogeneity across the studies (I2 
=25.2%, p=0.228) in adjusted analyses. 
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For the 5-year analyses of measured HRQoL (n=3 studies), the sample for complete-
case analysis was 927 (88% of available cases) because of missing data on some 
confounding factors. In unadjusted analyses, women had significantly poorer utility 
scores (5-year pooled MDunadjusted -0.090, 95% CI -0.119, -0.062). All the study-
specific unadjusted female:male MDs were statistically and clinically significant 
(Figure 5-2, top).  
The sex differences were slightly attenuated (by 5%; 5-year pooled MDadjusted -0.085, 
95% CI -0.135, -0.034; Figure 5-2, bottom) and still significantly different in 2 out of 
3 studies (Melbourne and Auckland) after adjustment. The major confounders were 
age (3/3 studies), stroke severity (2/3 studies), pre-stroke function (2/3 studies) and 
post-stroke mood disorders (1/2 studies; Table 5-3). No statistical interactions were 
observed between sex and covariates on 5-year HRQoL scores. Among the three 
studies, the adjusted female:male MD only remained clinically significant in the 
Melbourne and Auckland studies. Further adjustment for 5-year functional outcome 
removed the association between sex and HRQoL across the studies (Table 5-3).  
Similar trends were observed among 6 studies with mapped utility scores from the 
mRS whereby 5-year unadjusted female:male MD were -0.040, 95% CI -0.075; -
0.005 and reduced by half after adjustment for above-mentioned confounding factors 
(MDadjusted -0.020, 95% CI -0.044, 0.004; Supplemental Figure C-2).  
The greatest loss to follow-up was observed in the study from Perth (1 year) and 
Auckland (5 years), but very few differences between completers and non-completers 
in baseline characteristics were identified (Supplemental Tables C3 and C4). 
Sensitivity analyses using the multiple imputation combined with inverse probability 
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weighting to account for missing data showed that our results were robust 
(Supplemental Table C-5). 
Sex difference in sub-domain HRQoL scores among survivors  
In the Melbourne study, women survivors of stroke had worse scores on three out of 
five AQoL domains, compared to men, including independent living (1 year), social 
relationships (1 and 5 years), and psychological well-being (1 and 5 years; 
Supplemental Table C-6). In the Auckland study, women had lower HRQoL at 5 
years than men in SF-36 domains including physical functioning and mental health 
(Supplemental Table C-7). Generally, compared to men, women’s advanced age, 
more severe strokes, and pre-stroke dependency contributed to their poorer physical 
health while the greater post-stroke mood disorders (Melbourne) in women 
contributed to their poorer mental health (Supplemental Tables C-6 and C-7).  
Comparison between women and men in stroke and general populations 
Generally, HRQoL loss due to stroke, indicated by net differences in utility scores 
between stroke and the relevant general population, was increased with advanced age 
for both sexes (Supplemental Tables C-8a to C-10). Men and women who survived 
after stroke had worse utility scores than those in the general population across age 
groups and the differences were well above clinically relevant thresholds. Statistically 
significant results were achieved more frequently in the analyses of 1-year outcome 
compared to analyses of 5-year outcome (Supplemental Tables C-9b and C-10).  
As compared with the general population, the reduction in HRQoL among stroke 
survivors was generally more extreme in women than in men. However, the 
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magnitude of the sex difference varied among age groups and outcome instruments, 
and often below clinically relevant thresholds. In the analyses of AQoL utility scores 
(Melbourne), compared with the general population, the differences in HRQoL at 1 
and 5 years between women and men survivors of stroke were greater for those aged 
<65 years than for older people (Supplemental Table C-8a and C8-b). The sex 
differences in SF6D utility scores among 5-year survivors (Auckland), compared with 
the general population, were greatest in the youngest age group (<55 years; 
Supplemental Table C-10). By contrast, the sex differences in EQ5D utility scores 
between stroke survivors (Oxford) and the general populations appeared to greater 
among those aged ≥65 years (Supplemental Table C-9a and C-9b) than those aged 
<65 years. 
5.6 Discussion 
Women, in unadjusted analyses, had poorer HRQoL at 1 and 5 years after stroke than 
men across studies. Although the effect estimates varied by outcome measures (i.e. 
EQ5D, SF36 and AQoL), the direction of the association between sex and HRQoL 
was relatively consistent between studies, even in those with mapped HRQoL scores. 
We have examined the contributing factors to the sex differences in HRQoL using the 
pooled individual long-term outcome data from high-quality population-based 
studies, overcoming several current caveats of existing research. 
The greatest contributors to the worse HRQoL in women were advanced age, pre-
stroke functional limitations and stroke severity, but not clinical care. The presence of 
long-term post-stroke mood disorders also accounted for some of the sex difference in 
HRQoL. These same factors also accounted for women’s worse survival, functional 
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outcomes and participation restriction in the long term following stroke.265 The 
contributing factors could form the basis of interventions to reduce the differences in 
these outcomes between men and women after stroke. 
In pooled analyses, the aforementioned covariates accounted for much, but not all, of 
the sex differences in long-term HRQoL after stroke (i.e. explained 54% of the pooled 
MD at 1 year). In study-specific analyses, there was some evidence that women still 
had worse HRQoL following stroke than men based on the fully-adjusted models 
although these differences were clinically relevant in fewer studies (1/3 studies at 1 
year and 2/3 studies at 5 years).  
The important role of age in the association between sex and HRQoL after stroke can 
be explained by the complexity of aging and comorbidities.242 The multimorbidity in 
the elderly should be integrated into management and post-stroke rehabilitation 
strategies to improve HRQoL in the long term after stroke.279 More effective primary 
prevention strategies (e.g. promotion of healthy aging), designed for different levels 
of cardiovascular diseases and stroke risks280 should be a priority to improve health 
for the elderly, many of whom are women.281  
Another main determinant of poorer long-term HRQoL in women survivors was the 
presence of functional limitations before stroke. The poorer pre-stroke function in 
women reflects correlations between sex and age,236 again highlighting the 
importance of improving health for older people from both primary and secondary 
care. 
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Compared to men, women appeared to present with more severe strokes,265 which is 
associated with poor HRQoL after stroke. An implication of this finding is that 
management of modifiable factors of stroke severity such as hypertension,244 
cardiovascular diseases,245 and cardioembolic strokes282 could help mitigate poorer 
outcomes after stroke in women.  
The presence of post-stroke mood disorder (e.g. anxiety, depression) was a 
contributing factor to the sex differences in HRQoL for the Melbourne study, but not 
the Auckland study. These inconsistent findings may be due to the variation in 
assessment scale between studies including the Irritability, Depression and Anxiety 
(IDA)190 Scale (Melbourne) and the sub-score of depression the 28-item General 
Health Questionnaire192 (GHQ-28; Auckland). This is problematic because the IDA 
may be more sensitive than the GHQ for detecting depression.283 It is evident that 
post-stroke depression (PSD) is more common in women than in men,168 and the 
inadequate diagnosis and treatment of PSD may lead to their poorer HRQoL. 
Acknowledging the complexity in the diagnosis of PSD, including the overlapping 
symptoms of stroke and depression (especially in the elderly),284 investigators 
indicated that only one-fifth of people with PSD were taking antidepressant 
medications.191 Also, one-third of patients using antidepressants still reported 
depressive symptoms,285 suggesting an insufficient response to treatment. Sex 
differences in response to PSD treatment and its association with HRQoL are 
unknown, requiring future research. Better detection and appropriate treatment of 
PSD should improve the HRQoL for both men and women after stroke. PSD could be 
prevented by targeting predictive risk factors for PSD such as age, sex, social 
isolation, stroke severity, mental history, poor functional outcome, and participation 
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restriction.284,286 Social and family participation286 in the prevention of PSD in the 
elderly, many of whom are women, may provide opportunities to unravel the sex 
differences in HRQoL after stroke. 
In subdomain analyses, the impacts of stroke on the HRQoL of 1- and 5-year 
survivors were greater in women compared to men in most dimensions of physical 
and mental health which were mainly explained by pre-stroke factors and post-stroke 
mood disorders. A potential limitation of these analyses is that the available 
instruments (EQ5D, AQoL, or SF36) are generic scales. In the few studies of sex 
differences in HRQoL using stroke-specific instruments (e.g. the Stroke Specific 
Quality of Life Scale, Stroke Impact Scale), women appeared to have poorer HRQoL 
in some other domains (i.e., vision, language, thinking, energy, and memory) but sex 
differences still exist after adjustment for the confounding factors.104,287 The residual 
differences between men and women, as mentioned earlier in this paper, may be 
further accounted for by unmeasured or poorly measured factors such as psychosocial 
or mood disorders, requiring further research.  
Authors of previous research in stroke have usually reported a statistically significant 
difference in utility scores between the sexes but less often considered the clinical 
relevance of these findings across HRQoL instruments.276-278 Women in the general 
population may also have poorer HRQoL compared to their male counterparts, 
particularly in older age groups.271,276 However, there is a lack of studies investigating 
the sex difference in comparison with the general population. In our analyses in 
comparison with population reference scores by region, the statistically significant 
differences in utility scores between women and men among stroke and general 
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populations existed in some age groups but varied among studies and HRQoL 
instruments. We found significant sex differences in HRQoL after stroke assessed by 
SF6D (Auckland, NZ) or AQoL (Melbourne, Australia) utility scores, after 
accounting for sex differences in the population, among younger (<65 years) than 
older groups (≥ 65 years); and vice versa for the EQ5D instrument (Oxford, UK). 
Interestingly, the findings of greater sex differences in HRQoL loss caused by stroke 
among those aged ≥ 65 years were consistent with the similar analyses using the 
EQ5D data from the Australian Stroke Clinical Registry – a national stroke registry 
(Chapter 10 of the thesis). It is possibly related to the scale discrepancy whereby 
some social aspects of SF36 or AQoL, e.g. social functioning or family role 
(Supplemental Table C-11; source: Hawthorne et al., 2005)288 that may contribute to 
the greater health loss for younger women than younger men were not captured by the 
EQ5D instrument. Another possibility is the impact of variability in self-reported 
HRQoL due to different demographic, economic, cultural and social factors across 
populations. A previous examination of national culture and HRQoL evaluations 
showed that Australia is closer to NZ on masculinity index (gender role), uncertainty 
avoidance (to prevent anxiety/depression) and long-term orientation (coping skills or 
adaptation) than it is to UK.289 Future studies of sex differences in HRQoL should 
consider the comparison with population norms, contributions of cultural factors, and 
the clinically significant difference. 
We found that stroke caused a substantial HRQoL loss for both men and women in 
the long term following stroke, consistent with previous research by Cadilhac and 
colleagues.21 Our study showed that a considerable proportion of people with strokes 
were not treated with evidence-based therapies such as intravenous thrombolysis for 
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ischaemic stroke. The finding suggests that when stroke happens, ensuring that 
everyone has access to evidence-based processes of care in the hospital that are 
associated with better HRQoL (i.e. stroke unit care, thrombolytic therapy, 
antihypertensive agents, and care plan at discharge)60 should be a priority.  
Our research has several strengths. We used individual long-term outcome data from 
high-quality population-based studies representative of different countries.30 To our 
knowledge, this is the largest study every performed to comprehensively examine the 
contributing factors to the sex difference rather than using a step-wise approach 
overcoming the limitations of previous studies. Our study assessed a broad range of 
potential factors that contribute to the sex difference in HRQoL. Two-stage meta-
analysis was used to compare the sex differences between the populations to 
overcome the variability in HRQoL measures and covariates. We also compared the 
net mean difference in HRQoL utility scores between people with stroke and the 
general population to see how stroke impacts on men and women’s health. Our 
analyses using mapped scores served as a surrogate for the absence of HRQoL 
assessment in many ‘ideal’ population-based studies.   
We have acknowledged a number of limitations in this study. The HRQoL assessment 
was only available in 3 studies at each time point (1 and 5 years after stroke). The 
number of studies forming our pooled estimates, even among those with mapped 
utility scores (n=8 studies), was less than required (≥10) for the exploration of 
heterogeneity between studies using meta-regression.231 The included cohorts were 
mostly conducted in high-income countries so the results might not be generalisable 
to low- and middle-income countries (LMICs). Some previous studies from LMICs 
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presented a lower HRQoL among women than men in the long term after stroke (e.g. 
China 2 years;114 Malawi 1 year290) but they were not based in the population. 
Although we identified some other eligible studies that are ideal for examining the 
sex difference through systematic search during this period, the investigators failed to 
either report sex-specific results or have the HRQoL assessment performed.265 We 
advocate the inclusion of longer-term outcomes in such studies in future research to 
assess sex differences in HRQoL, particularly in LMICs.  
Some potential confounding factors were not measured in all studies including stroke 
care and post-stroke factors. Our analyses of available data on treatment and 
management of stroke suggested that this did not affect the sex difference in HRQoL 
after stroke, but the studies with more comprehensive data (Melbourne, Perth, and 
Auckland) were conducted a long time ago. Further work should confirm whether the 
difference in the contemporary processes of hospital care could have an impact on sex 
differences in HRQoL and associated factors. Among studies with measured HRQoL, 
only two had long-term assessments of mood disorders. Depression accounted for 22-
41% of worse HRQoL in women up to 5 years after stroke for the Melbourne study 
(assessed by the IDA) but not for the Auckland study (the 28-item General Health 
Questionnaire). The variability in measures of outcomes and covariates between 
studies from different populations may bias the adjusted estimates in our analyses. 
Another limitation is the relatively high proportion of loss to follow-up among studies 
(Perth: 1 year; Auckland: 5 years). Sensitivity analyses using multiple imputation and 
inverse probability weighting may somewhat account for the missing data but we 
could not remove the possibility of selection bias.  
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Women generally have poorer long-term HRQoL after stroke in most dimensions of 
physical and mental health. The sex differences were mostly explained by women’s 
advanced age, pre-stroke function, and stroke severity with some evidence that PSD 
was also important. Targeting ‘potentially modifiable’ factors including stroke 
severity and mood disorders will provide more opportunities to reduce the sex 
differences in stroke outcomes. Better prevention and management of PSD, including 
early detection and appropriate treatment, are of importance to improve the HRQoL 
of stroke survivors. Those men and women with stroke, compared to the general 
population, have reasonably similar HRQoL loss. Therefore, strategies should be 
focused on all stroke survivors to improve HRQoL following stroke. 
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Table 5-1. Details of included cohorts, baseline with first-ever stroke cases 
 Study  Study year  Baseline, n Instrument  
 
1-year follow-up   
 
5-year follow-up    
Survivor, n Assessed, n Survivor, n Assessed, n 
Oxford, United Kingdom 2002-2013 1374† EQ5D 988 712 403 269 
EQ5D*  910*  385* 
Joinville, Brazil  2009-2014 2248 EQ5D* 1869 1708* 598 423* 
Melbourne, Australia 1996-1999 1248‡ AQoL 806 465 553 450 
Arcadia, Greece  1993-1995 555 EQ5D* 342 328* - - 
Perth, Australia 2000-2001 183 SF36 120 33 - - 
EQ5D*  36* - - 
Orebro, Sweden  1999-2000 377‡  EQ5D* 253 253* - - 
Martinique, French West 
Indies 
1998-1999 580 EQ5D* 391 391* 265 265* 
Porto, Portugal§ 1998-2000 688 EQ5D* 484 484* 281 259* 
Auckland, New Zealand 2002-2003 1423 SF36 - - 881 338 
EQ5D*  -  745 
Tartu, Estonia§  2002-2003 433‡  EQ5D* 245 194* 161 131* 
Total cases 9,109||   1,914 or 5,498* 1,210 or 4,303* 1,837 or 3,142* 1,057 or 2,208* 
AQoL=Assessment of Quality of Life;195 EQ5D=European Quality of Life–5 Dimensions;194 SF36=Short form–36 questions266 
* denotes EQ5D utility score mapped from the modified Rankin Scale 
† Follow-up data to 5 years after stroke were available only among cases with year of stroke until 2008 (’02-’08) with 760 cases at baseline  
‡ Not including those with a subarachnoid haemorrhagic stroke at baseline 
§ Follow-up data that were available only at 4 years (for Tartu) or 7 years (for Porto) were analysed as an alternative to 5-year outcome   
|| There were 7,295 cases at baseline among studies have 5-year data  
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Figure 5-1. Median difference in utility scores for women compared to men at 1 year after 
stroke in unadjusted (top panel) and adjusted (bottom panel) models from three studies. 
The differences at 0.06 for AQoL, 0.12 for EQ5D, and 0.08 for SF6D were considered as 
clinically relevant (see Methods). 
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Figure 5-2 Median difference in HRQoL utility scores for women compared to men at 5 
years after stroke in unadjusted (top panel) and adjusted (bottom panel) models from 
three studies. The differences at 0.06 for AQoL, 0.12 for EQ5D, and 0.08 for SF6D were 
considered as clinically relevant (see Methods). 
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Table 5-2. Factors contributing to the median difference (MD) in utility scores at 1 year after stroke for women compared to men 
 Oxford (EQ5D; n=700) Melbourne (AQoL; n=385) Perth (SF36; n=31) 
 MD 95% CI ∆* MD 95% CI ∆* MD 95% CI ∆* 
Unadjusted -0.069 -0.089 -0.049  -0.197 -0.334 -0.060  -0.210 -0.308 -0.112  
Adjusted for             
Age -0.060† -0.096 -0.025 13% -0.162† -0.263 -0.061 18% -0.205†‡ -0.341 -0.068 2% 
NIHSS -0.067†‡ -0.107 -0.028 2% -0.173† -0.262 -0.083 12% -0.193†‡ -0.312 -0.074 8% 
Pre-stroke Rankin -0.061† -0.087 -0.034 12% ----    -0.204†‡ -0.380 -0.028 3% 
Pre-stroke Barthel ---    -0.187 †‡ -0.295 -0.080 5% ----    
Marital status -0.052 -0.912 -0.013 25% ----    -0.179 -0.301 -0.058 15% 
Pre-stroke dementia ---    -0.173 -0.278 -0.068 12% ----    
1-y mood disorder (IDA) ---    -0.116† -0.206 -0.026 41% ----    
1-y Barthel  ---    -0.135 -0.211 -0.058 31% ----    
1-y Rankin -0.014 -0.015 0.012 80% ----    -0.072 -0.180 0.036 66% 
Full model -0.049 -0.093 -0.004 29% -0.076 -0.145 -0.007 61% -0.178 -0.340 -0.015 15% 
Further adjustment§ -0.018 -0.058 0.022 73% -0.056 -0.113 0.001 72% -0.064 -0.017 0.041 70% 
AQoL=Assessment of Quality of Life;195 EQ5D=European Quality of Life–5 Dimensions;194 SF36=Short form–36 questions266 
NIHSS=National Institutes of Health Stroke Scale; IDA= the Irritability, Depression and Anxiety Scale (continuous score); 1-y=1-year 
* % change of coefficient of sex difference between unadjusted and adjusted models was calculated by the formula (unadjusted β – adjusted β)/ 
unadjusted β *100  
† denotes covariates which remained in the full models; ‡ not meeting criteria of being a confounder but retaining in the fully adjusted 
multivariable model; § Full model with further adjustment for functional outcome at 1 year (modified Rankin scale or Barthel Index) 
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Table 5-3. Factors contributing to the median difference (MD) in utility scores at 5 years after stroke for women compared to me 
 Oxford (EQ5D; n=263) Melbourne (AQoL; n=363) Auckland (SF6D; n=301) 
 MD 95% CI ∆* MD 95% CI ∆* MD 95% CI ∆* 
Unadjusted -0.086 -0.122 -0.050  -0.165 -0.306 -0.024  -0.089 -0.137 -0.040  
Adjusted for             
Age -0.068† -0.126 -0.010 21% -0.207† -0.327 -0.088 -25% -0.069† -0.120 -0.019 22% 
NIHSS -0.091†‡ -0.146 -0.035 -6% -0.207† -0.317 -0.097 -25% ---    
GCS ---    ---    -0.099† -0.149 -0.049 -11% 
Pre-stroke Rankin -0.048† -0.129 0.033 44% ---    ---    
Pre-stroke Barthel ---    -0.163†‡ -0.307 -0.019 1% ---    
Pre-stroke dependency ---    ---    -0.073† -0.122 0.024 18% 
Marital status -0.036 -0.097 0.025 58% ---    -0.084 -0.136 -0.032 6% 
Pre-stroke dementia ---    -0.149 -0.292 -0.006 10% ---    
5-y mood disorder (IDA)† ---    -0.129 -0.276 0.018 22% ---    
5-y antidepressant medications  ---    -0.187 -0.272 -0.101 -13% ---    
5-y Rankin 0 -0.057 0.057 100% ---    -0.039 -0.069 -0.010 56% 
5-y Barthel ---    -0.075 -0.151 -0.0003 54% ---    
Final model -0.071 -0.142 0.000 17% -0.153 -0.241 -0.064 7% -0.059 -0.110 -0.009 34% 
Further adjustment§ -0.012 -0.068 0.043 86% -0.040 -0.096 0.016 76% -0.033 -0.066 -0.0003 63% 
AQoL=Assessment of Quality of Life;195 EQ5D=European Quality of Life–5 Dimensions;194 SF36=Short form–36 questions266 
GCS, Glasgow Coma Scale; NIHSS, National Institutes of Health Stroke Scale; IDA= the Irritability, Depression and Anxiety Scale (continuous 
score); 5-y=5-year 
* % change of coefficient of sex difference between unadjusted and adjusted models was calculated by the formula (unadjusted β – adjusted β)/ 
unadjusted β *100; † denotes covariates which remained in the full models; ‡ not meeting criteria of being a confounder but remaining in the 
fully adjusted multivariable model; § Full model and further adjustment for functional outcome at 5 years (modified Rankin scale or Bathel 
Index) 
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5.7 Supplemental Methods 
Statistical analysis 
Because covariates were not measured uniformly between studies, we could not harmonise 
and adjust for the same set of covariates. Hence, a two-stage analysis method204 for the 
analysis of pooled data was used. In the first stage, study-specific models for the sex 
difference in health-related quality of life (HRQoL) were built. Within each study, the role of 
the covariates as confounders of the association between sex and HRQoL outcome were 
assessed using purposeful model building techniques.207 The following rules were applied: 1) 
the covariate was associated with HRQoL (p<0.1); 2) the covariate was associated with sex 
(p<0.1), and 3) the inclusion of the covariate in the model with only sex changed the 
magnitude of the sex coefficient at least 10%.207 
Age, stroke severity, and pre-stroke dependency that are common predictors of HRQoL and 
associated with sex,23,24 where possible, were forced into the final multivariable models 
accounting for all significant confounding factors. Given a high correlation between HRQoL 
and functional outcome,273 we did not include long-term functional outcome in the final 
models to avoid over-adjustment bias. Further adjustment for this factor was separately 
reported. 
In the second stage of the analysis, the effect estimates from unadjusted and multivariable 
models were combined to create pooled estimates in separate random-effects meta-analyses. 
Statistical heterogeneity between studies was evaluated using I2 statistics. The potential 
sources of heterogeneity were assessed among variables of interest using meta-regression.231 
Variables of interest in meta-regression included in the supplement xx.  
Potential sources of heterogeneity 
Potential sources of heterogeneity were assessed among variables of study-level 
characteristics (e.g. geographic region, income group) using meta-regression. In these 
analyses, we calculated separate pooled effect estimates of sex differences in long-term 
HRQoL utility scores mapped from the mRS (8 studies at 1 year; 6 studies at 5 years) for 
models both unadjusted and adjusted for actual confounding factors, when appropriate. Meta-
regression of continuous variables (n=3 variables) of interest included: proportion of women, 
proportion of hospital admission, mid-point of study year (e.g. in the Oxford study, year of 
stroke ranged from 2002 to 2013, and the mid-point was 2008). 
There were three covariates measured consistently in all studies: year of stroke occurrence 
(ranged from 1993 to 2014), age at stroke onset and stroke type. To further test the robustness 
of our findings, we used a single-stage meta-analysis pooling all IPD datasets210 to examine 
whether these factors modified the sex-effect HRQoL after stroke. We chose p ≤ 0.10 as the 
cut-off for statistical significance of the interaction (sex × covariate product term) because 
this value is commonly accepted in the literature for detecting interactions.291 
Missing data and sensitivity analyses 
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We undertook a wide range of sensitivity analyses to assess other potential bias. For studies 
with >20% missing data of long-term functional outcomes, participation or covariates, 
multiple imputation using chained equations (n=50 imputations) combined with Inverse-
Probability Weighting241 was performed and compared with results from complete-case 
analyses. These sensitivity analyse were based on the assumption that the data were missing 
at random. The missing values of outcomes and all covariates, where necessary, such as 
severity and co-morbidities were imputed based on all remaining completed variables in the 
dataset. We then examined whether the exclusion of those with a high rate of missing data on 
outcomes and confounding factors influenced our pooled results by comparing the sex 
differences in HRQoL for complete-case analysis and imputed analysis with unadjusted and 
fully-adjusted models. 
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Chapter 6: Sex differences in severity of stroke in the 
INternational STRoke oUtComes sTudy (INSTRUCT): a 
meta-analysis of individual participant data 
6.1 Preface 
At the time of submission of this thesis, the contents of this chapter have been under 
review following request for revisions from the Journal of American Heart 
Association. 
Phan HT, Blizzard CL, Reeves MJ, Thrift AG, Cadilhac DA, Sturm J, Otahal P, 
Rothwell P, Bejot Y, Cabral NL, Appelros P, Kõrv J, Vibo R, Minelli C, Gall SL. Sex 
differences in severity of stroke in the INternational STRoke oUtComes sTudy 
(INSTRUCT): a meta-analysis of individual participant data.  
6.2 Abstract 
Background: Women have worse outcomes after stroke than men, and this may be 
partly explained by stroke severity. We examined factors contributing to sex 
differences in severity of acute stroke assessed by the National Institutes of Health 
Stroke Scale (NIHSS). 
Methods: We pooled individual participant data with NIHSS assessment (n=6,343) 
from eight population-based stroke incidence studies (1996-2014). Information on 
socio-demographics, stroke-related clinical factors, comorbidities and pre-stroke 
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function were obtained. Within each study, log-binominal modeling was used to 
estimate the female:male relative risk (RR) of more severe stroke (NIHSS>7) 
stratified by stroke type (ischaemic stroke―IS and intracerebral haemorrhage―ICH). 
Study-specific unadjusted and adjusted RRs, controlling for confounding variables, 
were pooled using random-effects meta-analysis. 
Results: NIHSS data were recorded in 5326 (96%) of 5570 cases with IS and 773 
(90%) of 855 participants with ICH. The pooled unadjusted female:male RR for 
severe IS was 1.35 (95% CI 1.24–1.46). The sex difference in severity was attenuated 
after adjustment for age, pre-stroke dependency, and atrial fibrillation but remained 
statistically significant (pooled RRadjusted 1.15, 95% CI 1.05–1.27). There was no sex 
difference in severity for ICH (RRcrude 1.08, 95% CI 0.97–1.21; RRadjusted 1.08, 95% 
CI 0.96–1.20). 
Conclusion: Although women presented with more severe IS than men, much 
although not all of the difference was explained by pre-stroke factors. Sex differences 
could potentially be ameliorated by strategies to improve pre-stroke health in the 
elderly, the majority of whom are women. Further research on the potential biological 
origin of sex differences in stroke severity may also be warranted. 
6.3 Introduction  
Women are less likely to survive following stroke because of a higher case fatality 
rate in the acute phase, but long-term sex differences in mortality persist up to 5 years 
after stroke.236 Women also often have poorer functional outcome, increased 
participation restriction, and lower health-related quality of life after stroke than 
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men.236,265 One explanation for these sex differences in outcome is that women have 
more severe strokes than men.84,236 While several studies have reported on sex 
differences in the severity of stroke, most often these studies use severity as a 
covariate rather than as a primary outcome. 110,229 Another challenge is that the 
measurement of severity can differ between studies.208,292,293 Thus the importance of 
and factors associated with sex differences in stroke severity, remain uncertain.84 
Although there are reports on factors that contribute to severity of stroke (e.g. 
hypertension,244 cardiovascular diseases,245 dementia,294 embolic stroke 
mechanism295), the relative importance of these factors to differences in severity 
between women and men has not been investigated thoroughly.  
Among the few studies designed to examine the aetiology of sex differences in stroke 
severity,94,296 there are important differences in the data sources, methods of analysis, 
and adjustment for confounding factors. Renoux et al296 reported a 49% (unadjusted 
OR 1.49, 95% CI 1.23–1.80) increased odds of having a severe stroke (NIHSS ≥5) for 
women compared to men, which was partly explained by age and pre-stroke modified 
Rankin Scale―mRS (adjusted OR 1.19, 95% CI 0.94–1.52 following adjustment for 
these two variables). In contrast, Gall and colleagues reported a 23% (unadjusted RR 
1.23, 95% CI 1.05–1.45) greater risk of severe stroke (NIHSS>7) in women; but the 
difference was almost completely explained by women’s older age, presence of 
dementia, atrial fibrillation, and pre-stroke Barthel Index (adjusted RR 1.05 95% CI 
0.91-1.22).94 Other than age, pre-stroke functional limitations, and comorbidities, 
there has been limited consideration on the influence of other potential confounding 
factors such as pre-stroke medication297, delay in presenting to the hospital,298 and 
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mechanism of ischaemic stroke (i.e. cardioembolic strokes)282 on the sex difference in 
severity.  
Examination of a wider range of potential contributors to any observed sex difference 
in stroke severity is important to help address the gaps in our understanding of factors 
affecting sex-specific difference in stroke outcomes. Using information from an 
individual participant data (IPD) meta-analysis we aimed to (1) quantify the sex 
difference in stroke severity assessed by initial the National Institutes of Health 
Stroke Scale (NIHSS) score among patients with first-ever acute stroke (both 
ischaemic and haemorrhagic), and (2) investigate the factors (i.e. sociodemographics, 
pre-stroke health, comorbidities and clinical factors) that contribute to any observed 
difference. 
6.4 Method 
The INternational STRoke oUtComes sTudy (INSTRUCT) ― an IPD meta-analysis 
of long-term outcomes after stroke ―  is a collaboration of investigators from 13 
‘gold standard’ population-based stroke incidence studies (limited to first-ever acute 
strokes) from Australasia, Europe, South America and the Caribbean. The 
INSTRUCT study was registered in PROSPERO (CRD42016036723)237 and 
performed according to PRISMA-IPD guidelines.203 Further details regarding the 
INSTRUCT study are provided in Chapter 2.  
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6.4.1 Outcome measurement 
Of the 13 studies forming the INSTRUCT, eight studies had data on National 
Institutes of Health Stroke Scale (NIHSS) scores recorded at the acute stage and so 
were included in this analysis. The NIHSS assessment was recorded directly in seven 
studies and responses were mapped from Scandinavian Stroke Scale (SSS) data 
available in one other study (Tartu) using the formula: SSS = 50 – 2 × NIHSS.189   
6.4.2 Predictors of outcome (covariates) 
We obtained data on a range of covariates in each cohort that might explain 
differences in stroke severity between men and women. These factors included: socio-
demographics, pre-stroke health (functional dependence, co-morbidities, health 
behaviours, pre-stroke medications), stroke type; acute management (hospital 
admission, time delay to hospital presentation), and the year of stroke occurrence 
(1996-2014). Details regarding how these data were collected and the definitions used 
for each variable in each specific study are provided in Chapter 2: section 2.5. 
Available sociodemographic data included race/ethnicity (2 studies), marital status (4 
studies), education (4 studies), and socioeconomic status (3 studies). Data on pre-
stroke health status included dependence before stroke (4 studies, mRS >2; 3 studies, 
Barthel Index ≤20; 4 studies, institutional residence); co-morbidities/medical history 
(all studies― atrial fibrillation, hypertension, ischaemic heart disease, transient 
ischaemic attack; 5 studies, peripheral vascular disease; 4 studies, diabetes; 3 studies, 
dementia); medications before stroke (4 studies, antihypertensives; 4 studies, 
antiplatelets; 1 study, anticoagulants); body mass index (5 studies), and health 
behaviours (7 studies, smoking status; 6 studies, alcohol use status). Type of stroke 
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was categorised into 4 groups: ischaemic stroke (IS), intracerebral haemorrhage 
(ICH), subarachnoid haemorrhage (SAH) and undetermined stroke. Ischaemic stroke 
subtypes, available in 4 studies, were categorised by TOAST (Trial of Org 10172 in 
Acute Stroke Treatment) classification299 including large-artery atherosclerosis, 
cardioembolism, small-vessel occlusion, and other determined aetiology.  
6.4.3 Statistical analysis 
All analyses were conducted in Stata 12.1. A two-tailed P-value ≤0.05 was considered 
statistically significant. 
Study-specific analyses of the characteristics of participants (e.g. mean age, % of pre-
stroke functional limitation) were compared between men and women and then 
pooled using random-effects meta-analysis. We only undertook analyses for IS and 
ICH because NIHSS was not routinely collected for SAH and undetermined stroke. 
Stroke severity was dichotomised into severe (NIHSS>7) or not-severe (NIHSS ≤7).94 
Given the uncertainty over the particular cut-point to use to define a severe stroke, we 
also undertook a sensitivity analysis by analysing NIHSS as a continuous outcome. 
Where necessary, transformations of NIHSS data were performed to remove 
skewness. 
Since covariates were not measured uniformly between studies, we could not 
harmonise the data in order to conduct a multivariable analysis of the pooled IPD. 
We, therefore, used the two-stage method of analysis proposed for IPD meta-
analyses.204  
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The first stage involved building study-specific unadjusted and adjusted log-binomial 
regression models to estimate the relative risk of severe stroke (NIHSS>7 vs ≤7) for 
women compared to men. Within each study, we assessed the confounding role207 of 
covariates in the association between sex and severity, separately for IS and ICH. 
Variables were entered into the multivariable models if they met the following 4 
criteria (missing <20% of cases, associated with sex, associated with stroke severity, 
and the inclusion of the covariate changed the magnitude of the sex coefficient by 
≥10%).24 Adjustment was first done for age and then for all identified confounding 
factors but with age forced into a final fully-adjusted model. Within each study, 
statistical interactions were assessed by a test of statistical significance of a sex × 
covariate product term. For the second stage of the analysis, both unadjusted and 
adjusted study-specific estimates were pooled in separate random-effects meta-
analyses. Heterogeneity was evaluated using Q statistics and I2 statistics. Meta-
regression was used to identify the sources of statistically significant heterogeneity 
among study-level characteristics including geographic regions and proportion of 
women.  
We also reported the subgroup analyses of the difference in severity of IS by TOAST 
subtype. Sensitivity analyses using NIHSS as a continuous variable were performed 
to compare with the main results of dichotomous analyses.  
Two covariates were measured consistently in all studies: year of stroke occurrence 
and age. To further test the robustness of our findings, we used a single-stage meta-
analysis pooling all IPD datasets210 to examine whether these factors modified the 
relationship between sex and stroke severity.  
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Sex difference in patient characteristics  
Data on initial NIHSS recorded after acute stroke onset were available among 
5326/5570 (95.6%) IS and 773/855 (92.6%) ICH participants of the eight studies 
(Appendix D: Supplemental Tables D-1a and D−1b). Among those with IS, 
compared to men, women were on average 4.5 years (95% CI 3.8-5.3) older 
(statistically significant difference in 6/8 studies; Table 6-1) and were less likely to be 
living with a spouse (summary estimate 39.4% vs 71.2%, p<0.001; significant 
difference in 3/4 studies). Women also had higher prevalence of functional limitation 
(mRS>2 or Barthel≤20) before stroke (summary estimate 22.6% vs 14.0%, p<0.001; 
significant difference in 2/5 studies) and institutional residence than men (summary 
estimate 12.0% vs 4.6%, p<0.001; significant difference in 3/4 studies). In IS, more 
women were prescribed anti-hypertensive agents (3/5 studies) before stroke than men. 
Men with IS were more often ever-smokers (significant difference in 7/7 studies) and 
consumers of alcohol (significant difference in 4/6 studies). Among ICH participants, 
women were on average 4.7 years (95% CI 2.6-6.7) older than men (significant 
difference in only 3/8 studies), and there was few difference in other baseline 
characteristics between women and men (Supplemental Tables D-1a and D−1b).  
Distribution of the NIHSS by sex among those with either IS or ICH was illustrated in 
Figure D-1 (n=6,099; eight studies). 
Analyses of initial NIHSS scores among eight studies included 5200/5326 
participants with IS (Table 6-2; 2% of cases were excluded due to missing data on 
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covariates). In unadjusted analyses, women with IS were 35% (pooled RR 1.35, 95% 
CI 1.24–1.46) more likely to suffer more severe strokes than men; study-specific 
crude RRs varied from 1.20 (Perth) to 1.71 (Mãtao; Figure 6-2, top). We found no 
statistical evidence of heterogeneity in unadjusted RR estimates (I2=0%; Q=4.4, 
p=0.732) across the studies. In multivariable analysis, adjustment for age alone 
reduced the sex difference in severity by 36% (pooled RRage-adjusted 1.21, 95% CI 1.11–
1.31) without a statistical heterogeneity (I2=0%; Q=4.9, p=0.670). After accounting 
for other confounding variables (e.g., AF, pre-stroke dependency), the pooled 
estimate was substantially attenuated but remained statistically significant (pooled 
RRfully-adjusted 1.15, 95% CI 1.05–1.27). Although study-specific adjusted RRs of the 
association between sex and severity of IS varied from 0.97 (Dijon) to 1.72 (Mãtao) 
there was no statistically significant heterogeneity between studies (I2=19%; Q=8.6, 
p=0.280; Figure 6-2, bottom). Factors that met all the criteria for being a confounder 
were inconsistent between studies (Table 6-2). Among IS, these confounding factors 
were age (6/8 studies, pre-stroke dependency (5/6 studies), atrial fibrillation (2/8 
studies), history of dementia (1/3 studies) and smoking (1/7 studies). None of these 
factors modified the effect of sex on stroke severity (i.e., all sex × covariate 
interactions were non-significant). There was also no evidence that IS subtype 
(TOAST; Supplemental Table D-2), or any of the other covariates (e.g., 
socioeconomic position, education, pre-stroke medications, alcohol use, and other 
comorbidities such as diabetes and hypertension) contributed to the sex difference in 
NIHSS (Supplemental Table D-3).  
Analyses of 855/773 participants with ICH (Table 6-2; 10% of cases were excluded 
due to missing data on confounding factors) found no sex difference in the severity of 
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stroke (pooled RRunadjusted 1.08, 95% CI 0.97–1.21; Figure 6-3, top) without a 
statistical heterogeneity (I2=0%; Q=2.1, p=0.957). There was no effect of adjusting 
for age with the age-adjusted pooled RR being 1.08, 95% CI 0.96–1.20 (Figure 6-3, 
bottom; I2=0%; Q=1.4, p=0.985) or any other covariates.  
Meta-regression did not identify any sources of the heterogeneity between studies. 
Neither study-level factors including geographic region, the availability of pre-stroke 
function (Supplemental Table D-4a) nor proportion of women modified the sex 
differences in both unadjusted (IS: Pmeta-regression=0.559; ICH: Pmeta-regression=0.726) and 
adjusted analyses (Pmeta-regression=0.403; ICH: Pmeta-regression=0.723). Removing two 
studies without data on pre-stroke function (Supplemental Figures 2-3) did not greatly 
influence the pooled estimates in both unadjusted and adjusted analyses (IS: pooled 
RRunadjusted 1.30, 95% CI 1.18-1.44; RRadjusted 1.10, 95% CI 0.98-1.23; ICH: 
RRunadjusted 1.12, 95% CI 0.97-1.30; RRadjusted 1.12, 95% CI 0.97-1.30). Sensitivity 
analyses using NIHSS as a continuous variable showed consistent results to 
dichotomous analyses (Supplemental Table D-5).  
In participant-level analyses of the single pooled IPD dataset, the effect of age as a 
confounding factor was similar (IS: pooled RRunadjusted 1.34, 95% CI 1.22-1.49; RRage-
adjusted 1.21, 95% CI 1.10-1.34; ICH: pooled RRunadjusted 1.08, 95% CI 0.90-1.29; RRage-
adjusted 1.08, 95% CI 0.90-1.29) to the one using the aforementioned two-stage 
approach. The magnitude of the sex differences in severity among those with IS and 
ICH was not modified by age group (Supplemental Table D-4b). Neither did the 
year of stroke occurrence modify the sex differences in stroke severity in both 
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unadjusted (IS: Pinteraction=0.067; ICH: Pinteraction=0.128) and age-adjusted analyses (IS: 
Pinteraction=0.264; ICH: Pinteraction=0.281). 
6.6 Discussion 
We found that women with IS faced a 35% greater risk of severe stroke than men, and 
that much of this difference was explained by women’s older age, the presence of 
functional limitations before stroke and atrial fibrillation. However, adjustment for 
these factors did not fully explain the sex difference and their effects were often 
inconsistent between studies. We also found that there was no sex difference in 
severity of ICH. 
Because of the more advanced age at stroke onset in women than men, age was the 
most important confounding factor of the association between sex and severity of IS, 
accounting for 36% of the sex difference. Older age may be associated with more 
severe strokes due to reduced functional capacity of supporting brain cells, i.e. 
endothelial cells, and astrocytes after neurological insults.212 The physiological 
decrease of cerebral blood flow and its regulation that occurs with increasing age300 
potentially influence neuronal damage after stroke in the elderly. As a consequence, 
impaired brain circulation and subsequent neurological dysfunction might lead to 
more severe strokes and less recovery in older adults with stroke. A better 
understanding of the pathophysiology of both stroke and cognitive function in the 
elderly may have important implications for clinical management and preventative 
strategies. Strategies such as enhancing geriatric care may help to reduce the poor 
outcome of chronic diseases242 including stroke among frail older community-
dwelling adults.301 
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Pre-stroke function was an important confounding factor of the sex differences in 
stroke severity in several (5/6) studies. The association between more severe stroke in 
women and their poorer functional limitation before stroke has been shown to be 
correlated with age and several cardiovascular comorbidities (e.g. AF, hypertension, 
diabetes) at baseline.227,296 Poor physical function and interrelated conditions such as 
frailty, which is more common in women,302 may reflect underlying biologic 
mechanisms, including chronic inflammation, that play an important role in the 
pathogenesis of IS and the severity of the brain tissue damage.303 Better management 
of comorbid diseases and prevention of frailty in the elderly220 could help ameliorate 
the effects of more severe strokes when they occur in women.94 It is also possible that 
poor pre-stroke function and the presence of frailty may affect the accurate 
measurement of items in the NIHSS, as reported by others.304 Combining clinical, 
imaging and biomarker data of the severity of stroke may provide a better assessment 
of severity than a single instrument like the NIHSS.305  
Atrial fibrillation (AF) contributed to the sex difference in severity of IS although 
surprisingly this was only important in two out of eight studies (Oxford and Orebro). 
The inconsistent findings may due to the variations in the data collection and 
definition of AF between studies (Chapter 2: Table 2-4). One reason for more severe 
strokes in women is that women with AF more often have cardioembolic strokes than 
men.222 In addition, previous studies have found that the management of AF, 
specifically, treatment with anti-coagulants223 or catheter ablation224 appears to be 
suboptimal for women compared to men. It is thus possible that our observed 
confounding effect of AF on stroke severity could reflect the widespread under-
treatment of AF in older patients.225 However, we cannot confirm this possibility as 
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treatments for AF were missing from our dataset. This highlights the need for the 
better detection and treatment of AF in both older men and women prior to stroke 
occurrence.306 The data on the presence of AF and management in the incidence 
studies in the INSTRUCT were mostly self-reported and only included a limited 
number of studies. This may have contributed to the inconsistent findings. Data 
linkage may be useful for better examining these associations in men and women but 
could also suffer from issues related to data quality. Thus, more population-based 
stroke studies with diagnosed AF and long-term follow-up as well as qualitative 
research are needed to understand the decision-making for treatment therapies and 
management of AF, particularly among those with stroke. Recent evidence has shown 
that 30-day ECG monitoring improved the AF detection and the rate of 
anticoagulation treatment among those with cryptogenic stroke.307 Cardiac imaging 
could be a fertile ground for improvements in diagnose and effective treatment of AF 
to improve outcomes after stroke. 
Age, AF and pre-stroke function combined only accounted for 53% of the sex 
difference in severity of IS (with RR reduced from 1.35 to 1.15). Other unmeasured 
or poorly measured confounding factors could explain the remaining difference. 
However, it is also possible that a true biological or pathophysiological sex difference 
does exist. Further research is needed to explore potential biological and clinical 
mechanisms that could lead to a greater stroke severity in women. Potential 
dimorphic differences between men and women in severity of stroke include biologic 
(e.g. hormone-dependent) and intrinsic (non-hormonal) factors (e.g. sex 
chromosomes).308 Research on biologic mechanisms has established the 
neuroprotective effect of hormones in women on IS injury during pre-menopause.308 
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Little is known about how the decline of sex steroid hormones in women after 
menopause and ovariectomy influences the sex differences in post-stroke neurologic 
deficits. Further examination of the sex differences in neurologic function, 
specifically injury response and recovery after stroke with regard to different age 
groups, are needed. Infarct size and location of stroke appear to influence the level of 
neurologic deficits and eventual stroke outcomes e.g. left-hemispheric ischaemic 
strokes are more frequent and often have higher admission NIHSS scores as well as 
poorer survival than right-hemispheric counterparts.309 However, few authors have 
attempted to unravel the relative role of these factors in the severity differences across 
the different patient groups including men and women, or young and older people. 
Recent advanced brain imaging undertaken to investigate neurological deficits among 
people with different stroke types may offer better opportunities to understand the sex 
and age differences in brain injury.310,311 Also, female members are often excluded in 
the neuroscience experiments because of the hormonal fluctuations associated with 
the reproductive cycle.312 A recent meta-analysis of neuroscience studies has shown 
that data from female rats are no more variable than data from males.313 This suggests 
a need to include females in animal models to understand the sex difference in 
severity of stroke.314 
The sex differences in stroke severity existed for IS but not ICH. The aetiology of IS 
include hypo-perfusion, embolism, or thrombosis whereas ICH could be caused by 
trauma, ruptured cerebral aneurysm, or arteriovenous malformation. More severe IS 
in women, as discussed above, can reflect a combination of such factors that differ 
between men and women as age, pre-stroke function, and other comorbidities. By 
contrast, the severity of ICH may vary by the size and location of haematoma, and 
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intraventricular extension and be dependent on cardiovascular risk factors.315 
Uncertainty exists over the sex differences in stroke severity among women and men 
with ICH,316 requiring further research. 
Our study has a number of strengths. To our knowledge, we have provided the first 
pooled estimates of sex differences in stroke severity, separately for IS and ICH. We 
compiled the IPD from eight population-based studies from various regions of the 
world. The use of two-stage method for meta-analysis of IPD allowed us to overcome 
some of the limitations that result from not all potential confounding factors being 
measured across all studies.204 The data came from high-quality population-based 
studies free of the limitations of hospital-based or convenience samples and had a 
very large sample, making this study adequately powered to test our hypotheses.  
However, limitations need to be acknowledged. The population-based studies in our 
research networks are mostly from high-income countries (7/8 studies), potentially 
leading to less generalizable results. We were unable to include 5 studies because 
NIHSS data were not available (Table e-1) thereby reducing the statistical power. The 
methods and sources of data collection differed across cohorts, and this may have 
contributed to the differing confounding variables identified between studies. In 
particular, our inability to detect whether IS subtypes confounded the association 
between sex and severity is likely attributable to the scarce data on IS sub-types 
(TOAST classification) which were only collected in 4 studies. Further research is 
needed to explore the role of the mechanism of IS on the sex difference in severity of 
stroke. There was a lack of data on subdomain scores of NIHSS, another potential 
contributor to the sex difference in severity of stroke. Although the rate of missing 
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data on NIHSS and covariates (<10%) was low enough that imputation of missing 
data was not required, we could not eliminate the possibility of some selection bias. 
Finally, the number of studies forming our pooled estimates was less than required 
(≥10) for the exploration of heterogeneity between studies using meta-regression.231 
Conclusion 
Women are more likely to present with severe IS than men and the difference is partly 
explained by their advanced age, greater pre-stroke functional limitation and presence 
of AF. Given these findings, strategies to improve pre-stroke health and access to 
evidence-based care for the elderly could help reduce differences in stroke severity 
between men and women. In addition, understanding the origin of more severe 
strokes in women compared to men should be a priority area for further research, 
more studies that attempt to identify other potential explanatory factors such as IS 
stroke mechanism, treatment of AF, and other comorbidities are needed. 
 









 Among participants with NIHSS data  
N Women  Mean age, years (SD) Median NIHSS (IQR) NIHSS>7, n (%) 
    (%) Men Women Men Women Men Women 
Ischaemic stroke         (n=2,603) (n=2,723) 
Oxford, UK ‘02-‘13 1103 1087 49.4 72.4 (12.0) 77.7 (12.1) 3 (1-6) 3 (1-9) 112 (20.4) 157 (29.2) 
Joinville, Brazil  ‘09-‘14 1494 1494 47.8 63.5 (12.5) 66.8 (15.7) 3 (2-8) 4 (2-11) 198 (25.4) 253 (35.4) 
Melbourne, Australia ‘96-‘99 921 744 52.0 72.4 (12.7) 76.3 (14.3) 4 (2-10) 5 (2-12) 112 (31.4) 150 (38.8) 
Perth, Australia  ‘00-‘01 140 123 50.4 74.0 (12.5) 78.0 (10.1) 5 (3-11) 6 (3-13) 21 (34.4) 26 (41.9) 
Orebro, Sweden  ‘99-‘00 274 274 54.4 73.1 (10.5) 77.1 (10.7) 4 (2-6) 5 (3-10) 28 (22.4) 50 (33.6) 
Dijon, France  ‘06-‘12 1238 1238 54.1 71.7 (15.3) 77.2 (15.8) 4 (2-9) 4 (2-12) 170 (29.9) 248 (37.0) 
Mãtao, Brazil ‘03-‘04 68 67 38.8 65.1 (12.3) 64.5 (12.6) 5 (2-11) 8 (5-10) 12 (29.3) 13 (50.0) 
Tartu, Estonia* ‘02-‘03 332 299 59.5 68.1 (10.9) 75.6 (10.9) 5 (0-14) 9 (2-16) 44 (36.4) 97 (54.5) 
Summary estimate 
(95% CI) 














ICH         (n=400) (n=333) 
Oxford, UK ‘02-‘13 112 94 48.9 69.5 (14.3) 73.5 (16.2) 7 (3-15) 7 (3-16) 22 (45.8) 22 (47.8) 
Joinville, Brazil  ‘09-‘14 223 223 42.2 58.2 (15.4) 62.5 (15.5) 17 (5-27) 17 (5-27) 86 (66.7) 66 (70.2) 
Melbourne, Australia ‘96-‘99 191 136 49.3 70.3 (13.5) 75.2 (15.2) 8 (3-20) 14 (5-27) 39 (53.4) 47 (66.2) 
Perth, Australia  ‘00-‘01 19 13 46.7 68.0 (18.5) 73.5 (12.3) 9 (3-23) 15 (1-21) 4 (50.0) 5 (71.4) 
Orebro, Sweden  ‘99-‘00 44 44 43.2 71.9 (11.5) 75.6 (9.9) 9 (4-12) 10 (4-23) 15 (60.0) 12 (63.2) 
Dijon, France  ‘06-‘12 197 197 53.3 71.0 (15.8) 76.6 (18.3) 9 (4-22) 10 (4-22) 54 (58.7) 67 (63.8) 
Mãtao, Brazil ‘03-‘04 12 11 27.3 62.9 (7.0) 68.7 (7.5) 18 (8-25) 32 (7-32) 6 (75.0) 2 (66.7) 
Tartu, Estonia* ‘02-‘03 57 55 50.9 63.6 (15.9) 68.1 (12.6) 20 (5-25) 14 (7-25) 19 (70.4) 19 (67.9) 
Summary estimate 
(95% CI) 












ICH=Intracerebral haemorrhage; Bold denotes statistically significant results; NIHSS, National Institutes of Health Stroke Scale  
*Stroke severity in Tartu study was mapped from Scandinavian Stroke Scale (SSS) to NIHSS (see Methods)  
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Table 6-2. List of factors contributing to the difference in stroke severity between 
women and men in multivariable models by stroke type (more severe stroke was defined 
as National Institutes of Health Stroke Scale >7) 
Study Ischaemic stroke Intracerebral haemorrhage 
 N* Actual confounders in the fully 
adjusted model 
N* Actual confounders in the 
fully adjusted model 
Oxford 1077 age, pre-stroke mRS, AF 94 age‡ 
Joinville† 1494 age 223 age‡ 
Melbourne 647 age, pre-stroke Barthel, pre-stroke 
dementia  
136 age‡ 
Perth 123 age 13 age‡ 
Orebro 274 age‡, institutional residence, AF 44 age‡ 
Dijon 1238 age, institutional residence, smoking 197 age‡ 
Mãtao† 67 age‡ 11 age‡ 
Tartu 280 age, pre-stroke mRS 55 age‡ 
Pooled 5,200  773  
AF, atrial fibrillation; mRS, modified Rankin Scale 
* the sample size were the same among the unadjusted model and fully-adjusted model  
† data on pre-stroke dependency were unavailable 
‡ age was selected to be forced into all the final fully-adjusted models regardless of meeting  
all 4 criteria (missing <20% of cases; associated with NIHSS; associated with sex, and 
changed the magnitude of the sex coefficient by ≥10%; see Methods)  
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Figure 6-1. Distribution of the National Institutes of Health Stroke Scale (NIHSS) scores 
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Figure 6-2. Difference in stroke severity between women and men with ischaemic 
stroke: unadjusted (top) and adjusted (bottom) random-effects meta-analyses. 
More severe stroke was defined as National Institutes of Health Stroke Scale >7. 
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Figure 6-3. Difference in stroke severity between women and men with intracerebral 
haemorrhage (ICH) in unadjusted (top) and adjusted (bottom) random-effect meta-
analyses. More severe stroke was defined as National Institutes of Health Stroke Scale 
>7. 
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Chapter 7: Methods related to Australian Stroke 
Clinical Registry (AuSCR) data collection and application 
in my research 
7.1 Preface 
In the second part of this thesis, I examined the differences between men and women 
in the receipt of processes of stroke care provided in hospital and associated patient 
outcomes using the data from the Australian Stroke Clinical Registry (AuSCR). This 
Chapter describes the background methods of the AuSCR including the study setting, 
participants, clinical and outcome variables, as well as patient characteristics.  
Detailed information regarding the specific statistical methods for each research 
question are described in relevant chapters (Chapter 8: processes of care and 1-year 
mortality; Chapter 9: cause of death up to 1 year after stroke; Chapter 10: health-
related quality of life at 3-6 months).  
7.2 Ethics 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee (H0015287). My research proposal was also approved by the 
AuSCR Research Task Group and its Management Committee in August 2016 and its 
Management Committee in August 2016 to enable me to examine sex differences in 
acute hospital care and the relationship with patient outcomes up to one year after 
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stroke. Appropriate ethics and/or governance approvals were obtained for all 
participating hospitals in AuSCR and the Australian Institute of Health and Welfare 
(AIHW) to conduct data linkage to the National Death Index. 
7.3 Study population and design 
The AuSCR is a multicentre, prospective, nationwide registry designed to collect 
important patient data on the quality of acute stroke care and patient outcomes.236 The 
AuSCR incorporates standardised methods of data collection using an online webtool 
data entry system with logic checks and data importing and exporting features.317 The 
AuSCR was developed based on national operating standards and technical principals 
for clinical disease registries.318 These principles are used to develop and evaluate the 
structure, governance and operations of Australian Clinical Quality Registries 
including the following categories: attributes of Australian Clinical Quality 
Registries, data collection, data elements, risk adjustment, data security, and ensuring 
data quality. Clinical (process of care) indicators obtained from the AuSCR are those 
prioritised as nationally relevant for stroke care as guided by the National Acute 
Stroke Clinical Guidelines that were prioritised as part of a consensus process.319 All 
the variables available in the AuSCR, their definitions and data specifications are 
compliant with national and international electronic health data dictionaries and 
standards.318 The detailed information on AuCR policies and data dictionary are 
available at the website: www.auscr.com.au. 
Data quality assessments are undertaken regularly by the AuSCR Office staff to 
minimise missing data and to improve the reliability of data. Medical record audits 
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(i.e. 10% random audit at each new site) are conducted and the results of these audits 
are used to improve data quality by indicating areas for additional training or 
amendments to data dictionary items that are ambiguous.317  
The AuSCR includes all consecutive acute stroke or transient ischaemic attack (TIA) 
admissions to participating hospitals that are identified by clinicians. The registry is 
based on an “opt-out” consent model, where patients are provided with information 
on the purpose of the registry and options to withdrawal their data.320 Staff from 
participating hospitals enter patients’ data at the acute stage in the web tool. 
Subsequently, AuSCR trained staff contact eligible patients between 90-180 days 
after the admission date to gather outcome data primarily by postal questionnaire and 
non-responders are followed-up by telephone.321 Survival information is updated each 
year for the AuSCR participants  through linking with national death registrations (the 
National Death Index) provided by the AIHW.320  
Since 2009 when the registry was established, there has been an increasing number of 
patients registered (Figure 1). The AuSCR hospital data scaled up from 4 sites to 13 
sites from mid-2009 to 2010. Now more than 70 hospitals have provided > 60,000 
patient episodes, demonstrating the high level of participation from across Australia. 
The AuSCR was established to be used by a wide range of hospitals (i.e. public and 
private hospitals, children’s hospitals and located in rural or urban areas) to ensure a 
representative sample of Australia’s healthcare system and geography.319  
This observational study included only first-ever cases of stroke registered in the 
AuSCR database between 2010 and 2014 including patients who completed followed-
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up between 3-6 months and had their 1-year survival status determined through the 
data linkage program with AIHW. The dataset included more than 14,000 first-ever 
strokes admitted to 39 hospitals participating in the AuSCR across five states of 
Australia. The patient sample was consistent with other representative stroke 
populations.236 However, patients registered in the AuSCR hospitals during the 2010-
2014 period were mainly admitted to neurology/stroke units and from metropolitan 
areas,236 and the possibility of bias is discussed in the following chapters. It should 
also be noted that cause of death (COD) data from the National Death Index – AIHW 
are updated annually while all other variables e.g. date of death are updated 
monthly.320 The data on COD were only available in a subset of cases registered in 
the 2010-2013 AuSCR dataset, due to the lag times for COD data being available to 
the AIHW. 
The AuSCR data user agreement specifies that data cannot be transferred to the 
University of Tasmania or saved on portable storage devices. In accordance with the 
data access policy, I undertook the data analyses at Monash University, Clayton in 
March and November 2017 under the supervision of Professor Dominique Cadilhac - 
the AuSCR data custodian and coordinating principal investigator. I was provided 
authorised de-identified AuSCR datasets held at Monash University on behalf of the 
Florey - Institute of Neuroscience and Mental Health (data custodial organisation).
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Figure 7-1. Number of registrant in the Australian Stroke Clinical Registry (AuSCR) 
with the data as of September 2015 (Source: the AuSCR report 2016) 
Chapter 7. Methods related to Australian Stroke Clinical Registry (AuSCR) data 
collection and application in my research 
181 
  
7.4 Research questions 
The research questions addressed in the part of thesis using the AuSCR data are 
highlighted below. 
1) Are there differences between women and men in receiving evidence-based care 
and all-cause mortality at 1 year after stroke? What factors contribute to the sex 
differences in mortality? 
2) Are there differences between women and men in causes of death and specific-
cause of excess mortality up to 1 year after stroke? What factors, including the 
evidence-based care, contribute to the sex differences? 
3) Are there differences between women and men in HRQoL up to 6 months after 
stroke? What factors contribute to the sex differences in HRQoL? 
7.5 Study factors  
Factors investigated were patient characteristics and care received in the hospital that 
might explain the sex differences in care or outcomes after stroke. These factors were 
categorised into five groups including (1) socio-demographics, (2) stroke-related 
factors, (3) discharge information, (4) evidence-based processes of care provided in 
the hospital, and (5) post-discharge stroke factors. These groups of factors are 
described in more detail below. 
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Sociodemographic factors included age, country of birth, ethnicity, state of residence 
(New South Wales, Queensland, Western Australia, Victoria, and Tasmania). 
Socioeconomic position was determined using the Index of Relative Socio-Economic 
Advantage and Disadvantage (IRSAD) using patient residential postcodes at time of 
stroke.322 The IRSAD information was presented as predetermined quintiles with a 
higher quintile indicating greater socioeconomic advantage. 
7.5.2 Stroke-related factors 
The ability to walk independently on admission was used as a proxy assessment of 
stroke severity. This simple indicator (one question) has been proven as a reliable 
predictor of stroke severity in the absence of severity scales such as the National 
Institute Health Stroke Scale (11 items).323 Stroke type was categorised into three 
groups including ischaemic stroke, intracerebral haemorrhage and undetermined 
stroke. Information on the time from stroke onset to hospital arrival, and whether 
patients were transferred from another hospital were also collected. 
7.5.3 Discharge information 
The length of stay was counted as the date of discharge minus the date of admission. 
Discharge destination after the acute phase of stroke was categorised into the 
following groups: home (with or without support), residential aged care, inpatient 
rehabilitation, and other places (e.g. transfer to another hospital). 
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7.5.4 Processes of care 
There are four processes of hospital care provided prioritised as nationally relevant 
319,324 and are collected for all patients (n=39 hospitals): access to stroke unit care, 
intravenous thrombolysis, care plan provided at discharge, and being discharged on 
antihypertensive agent(s).  
Four additional processes of care were collected in the state of Queensland (n=21 
hospitals) including: mobilisation during admission, swallow screen, aspirin 
administration ≤48 hours (among those with ischaemic strokes), and being 
discharged on antiplatelets or antithrombotic medications (ischaemic stroke). 
7.5.5 Post-discharge stroke factors 
Between 90 and 180 days after admission eligible AuSCR registrants (i.e. known to 
be alive and not previously followed up) were asked to self-report their current place 
of residence (i.e. high-level residential care, low-level residential care, home with 
supports, home without supports, rehabilitation, transitional care service, hospital, 
and other) and living arrangements (whether the registrant lives alone). The presence 
or absence of a recurrent stroke event (not including TIA) and readmission since 
discharge (i.e. readmission date and reasons) were also self-reported by the registrants 
or their next-of-kin/key contact person.  
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7.6 Study outcomes  
7.6.1 Mortality outcomes 
Survival up to one year after stroke was obtained from patient-level data linkage to 
national death registrations by the AIHW. One-year COD based on ICD-10 
(International Statistical Classification of Diseases and Related Health Problems 10th 
Revision) codes were classified into: stroke, ischaemic heart disease, other 
cardiovascular disease (e.g. hypertensive diseases, atrial fibrillation), cancer, and 
other causes. As mentioned earlier in section 7.3, only a subset of cases registered in 
the AuSCR between 2010 and 2013 were included in my COD analyses. 
7.6.2 Health-related quality of life (HRQoL) 
HRQoL was assessed using the European Quality of Life–5 Dimensions (EQ-5D-3L) 
instrument.194 Participants in the registry were contacted between 90 and 180 days 
after the index event by post or telephone.236 For each of the 5 dimensions of the EQ-
5D including mobility, self-care, usual activities, depression/anxiety, and pain), there 
are three response categories: no problem, some/moderate, and extreme problem.  
EQ-5D information was collected from patients or proxy respondents when patients 
were unable to respond the interviewers. The proxy response to the EQ5D 
questionnaire at 6 months after stroke has an acceptable reliability that can substitute 
for missing of patient assessment.325 Unassessed survivors included those were lost to 
follow-up only after multiple contact attempts (non-responders) and those for which 
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the time from discharge was more than 6 months or the patient/proxy refused (non-
consenters). 
7.6.3 General information regarding my analytical process and AuSCR data 
quality 
I performed the data analyses under the supervision of Prof Cadilhac using the 
prepared dataset from a dedicated folder stored on the Monash University secure 
share drive. The de-identified dataset and relevant coding files were provided in Stata 
programs (version 12.1; StataCorp Texas, 2011)269 with variables derived from 
AuSCR publications and reports to ensure consistency in estimates from these data. 
The only new variable I derived, with the assistance of a staff at Monash, is the COD 
categories. Only data outputs and summary estimates from Stata programs were 
exported for manuscript preparation. 
Data clean was undertaken by Monash staff to ensure data quality. The AuSCR 
dataset has generally very low rate of missing data on covariates (i.e. <10% for almost 
all baseline factors). The linkage of survival status to national death registrations was 
used to minimise the possibility of bias of missing data. Detailed information 
regarding the missing data on covariates and outcomes are described in relevant 
chapters.
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Chapter 8: Sex differences in care and long-term 
mortality after stroke: Australian Stroke Clinical Registry 
(AuSCR) 
8.1 Preface 
At the time of submission of this thesis, the contents of this chapter have been under 
review following request for revisions from the Journal of Women’s Health. 
Phan HT, Gall SL, Blizzard CL, Lannin N, Thrift AG, Anderson CS, Kim J, Grimley 
R, Castley HC, Hand P, Cadilhac D. Differences in stroke care and outcomes after 
stroke for women compared to men: Australian Stroke Clinical Registry (AuSCR). 
Sex differences in care and long-term mortality after stroke: Australian Stroke 
Clinical Registry (AuSCR). 
8.2 Abstract  
Introduction:  There is some evidence that women receive evidence-based care less 
often than men, but how this influences long-term mortality after stroke is unclear. 
We determined this issue using data obtained from a national stroke registry.  
Methods:  Data are first-ever hospitalised strokes (2010-2014) in the Australian 
Stroke Clinical Registry from 39 hospitals linked to the national death registrations. 
Multilevel Poisson regression was used to estimate the female:male mortality rate 
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ratio (MRR), with adjustment for socio-demographics, stroke type, severity, discharge 
disposition, and processes of care (stroke unit care, intravenous thrombolysis, 
antihypertensive agent[s] and discharge care plan).  
Results:  Among 14,118 events (46% females), women were 7 years older and had 
greater baseline severity compared to men (29% vs 37%; p<0.001), but there were no 
sex differences in the four processes of care available across hospitals. Analyses of 
additional processes from Queensland hospitals (n=5,224) revealed that women were 
less often administered aspirin ≤48 hours than men (51% vs 58%, p<0.014). In the 
whole cohort, 1-year mortality was greater in women than men (MRRunadjusted 1.44, 
95% CI 1.34-1.54). However, there were no significant sex differences after adjusting 
for age and stroke severity (MRRadjusted 1.05, 95% CI 0.98-1.14). In Queensland 
hospitals, older age, severity, and under-treatment with aspirin contributed to the sex 
differences in mortality. 
Conclusion:  Greater mortality in women can be explained by differences in age and 
stroke severity. This highlights the importance of better management of risk factors in 
the elderly and, potentially, the need for greater access to early aspirin for women 
with stroke.  
8.3 Introduction 
In many countries, the total burden of disease attributed to stroke is greater in women 
than men.326 Women, in comparison to men, have also been reported to have worse 
outcomes after stroke including greater mortality,236 worse functional outcomes,24 and 
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poorer health-related quality of life.24 Some investigators in the United States and 
Europe have found that women receive evidence-based care less often than men.80,84 
However, whether disparities in stroke care account for differences in outcome 
between men and women has not been fully examined.327 
In our recent meta-analysis of individual participant data obtained from population-
based studies, women received carotid investigations and echocardiography less often 
than men.236 Women had 35% greater mortality at 1 year after stroke compared to 
men. The difference in mortality was largely due to advanced age, more severe stroke, 
functional limitation before stroke and the presence of atrial fibrillation in women, 
rather than differences in care.236 Although these findings were insightful, they were 
limited by the fact that the data on processes of care were scarce and outdated. There 
is a need to explore sex differences in care and outcome in contemporary datasets. 
The purpose of this study was to use contemporary data from the Australian Stroke 
Clinical Registry (AuSCR) to examine (1) sex differences in access to evidence-based 
processes of care and mortality outcome in people admitted to hospital with acute 
stroke in Australia; and (2) identify the factors including evidence-based stroke care 
that may account for any differences in mortality between men and women up to 1 
year after stroke. 
8.4 Methods  
As a nationwide, multicentre, prospective registry, the AuSCR incorporates 
standardised methods of data collection for important processes of stroke care in 
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Australia.236 In this study, we included first-ever cases of stroke admitted to 39 
hospitals participating in the AuSCR between 2010 and 2014. This study was 
approved by the Tasmanian Health and Medical Human Research Ethics Committee 
(H0015287). Our research proposal was also approved by the AuSCR Research Task 
Group and its Management Committee in August 2016. Appropriate ethics and/or 
governance approvals were obtained for all participating hospitals in AuSCR and the 
Australian Institute of Health and Welfare to conduct data linkage to the National 
Death Index. 
8.4.1 Study factors 
Central to the aims of the study was the examination of a wide range of factors 
assessed in the AuSCR registry that might explain the sex differences in mortality 
after stroke, including patient characteristics and care received in hospital. Factors 
investigated included (1) socio-demographics: age, country of birth, state of residence 
(New South Wales, Queensland, Western Australia, Victoria and Tasmania), and 
socioeconomic position determined using the Index of Relative Socio-Economic 
Advantage and Disadvantage;322 (2) stroke-related factors: stroke severity (indicated 
by walking ability on admission),236,328 stroke type (ischaemic, intracerebral 
haemorrhage and undetermined stroke), cause of stroke known, time from stroke onset 
to hospital arrival, and whether patients were transferred from another hospital; (3) 
discharge information: length of stay and discharge destination; and (4) evidence-
based processes of care provided while in hospital. Of note, data on pre-stroke 
function were unavailable in the AuSCR dataset. The ability to walk independently on 
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admission was used as a proxy assessment of stroke severity. AuSCR did not collect 
data on people with subarachnoid haemorrhage (SAH).319 Systemic recording of 
cause of ischemic stroke known was defined according to the Acute Stroke Treatment 
(TOAST) criteria.299 The TOAST classification includes different mechanisms of 
ischemic stroke including large-artery atherosclerosis, cardioembolism, small-vessel 
occlusion, and other determined aetiology (i.e. haemorrhage) that would be applicable 
to all types of stroke. For further details the AuSCR data dictionary is available online 
www.auscr.com.au. 
Data on processes of care obtained from the AuSCR were those prioritised as 
nationally relevant:319,324 stroke unit access, intravenous thrombolysis, care plan 
provided at discharge, and being discharged on antihypertensive agent(s). Four 
additional processes of care were collected in the state of Queensland (n=21 hospitals) 
including: mobilization during admission, swallow screen, aspirin administration ≤48 
hours, and being discharged on antiplatelets or antithrombotic medications 
(ischaemic stroke). 
8.4.2 Outcome measurement 
Survival up to one year after stroke was obtained from patient-level data linkage to 
national death registrations undertaken by the Australian Institute of Health and 
Welfare. 
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8.4.3 Statistical analysis 
Statistical analyses were performed using Stata 12.1 (StataCorp Texas, 2011).269 All 
two-tailed p-values ≤0.05 were considered statistically significant. Multilevel 
random-effects log-binomial regression, accounting for individual hospital clusters, 
was used to generate prevalence ratio (PR) of the sex difference in discharge 
information and processes of care provided while in hospital.  
Multilevel Poisson modelling, accounting for the hospital as a unit of patient clusters, 
with sex-specific person-days of follow-up entered as an offset, was used to estimate 
the mortality rate ratio (MRR) for women compared to men at 7, 30 days, and 1 year 
after stroke. To assess the role of covariates on the association between sex and each 
outcome, we used purposeful model building.207 Variables were entered into the 
model only if they met all three criteria that defined them as potential confounders207 
(Supplemental Methods: section 8.7.1). The model-building process was initially 
undertaken for each variable separately and then adjustment for all significant 
confounding factors were examined in multivariable models. The modifying effect of 
a covariate on the sex difference was assessed by a test of the statistical significance 
of the coefficient of a sex × covariate product term.  
Estimates of the sex differences in processes of care and mortality after stroke were 
performed for all hospitals (4 indicators) and in the Queensland subset that had more 
detailed information on stroke care (4 additional indicators). In the relevant 
subgroups, we examined whether any factors related to processes of care that showed 
a sex difference were confounders of the association between sex and mortality 
(Supplemental Methods: section 8.7.1). Some medication restrictions may be 
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appropriate given contraindication or to meet treatment guidelines.324 We took these 
into account when examining aspirin administration in the subset of Queensland 
patients. For those without aspirin ≤48 hours we examined whether the person: (1) 
died ≤48 hours, (2) received thrombolysis therapy, and (3) received antiplatelet or 
antithrombotic therapy at discharge. 
To investigate the effect of missing data on confounding factors in predictive models, 
multiple imputation using chained equations206 (n=50 imputations) was performed. 
Estimates from imputed results based on valid data on outcome and covariates were 
then compared with complete-case results. Sensitivity analyses were used to examine 
the effect of excluding earlier deaths after stroke where possible (e.g. 7 days), and any 
differences in patient characteristics or quality of care between Queensland and non-
Queensland hospitals on the results. We also considered a further analysis of the sex 
difference in mortality among a subset of those with admission time ≤3.5 hours 
potentially eligible for early thrombolytic therapy. We assumed that those presenting 
at hospital ≤3.5 hours of stroke onset needed about one additional hour for decision 
processes to occur to be eligible for treatment (≤4.5 hours after acute ischaemic 
stroke).   
8.5 Results 
In the whole cohort, there were 14,118 patients experiencing first−ever stroke 
between 2010 and 2014, with 81% being ischaemic and 46.3% female. Median age of 
stroke was 75 years (Interquartile range 64-84). Compared to males, female 
registrants, based on sociodemographic and stroke-related characteristics, were 7 
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years older (median age: 79 vs 72 years; p<0.001), and less able to walk 
independently on admission (indicating more severe strokes; female 28.7% vs male 
37.0%, p<0.001; Table 8-1).  
Sex difference in processes of care and discharge information  
There were no statistically significant differences between men and women in the 
provision of stroke best practice care, with the exception of, in the subset of 
Queensland data, women being less often administered aspirin ≤48 hours than men 
(60.8% vs 68.9%, p=0.015; Table 8-2). Sensitivity analyses (excluding patients who 
died ≤48 hours or received intravenous thrombolysis) did not change this finding 
whereby there was less frequent use of aspirin ≤48 hours in women than men 
(Appendix E: Supplemental Table E-1). The observed difference between men and 
women receiving early aspirin was attenuated after accounting for age and stroke 
severity (female:male prevalence ratio, PRunadjusted 0.91, 95% CI 0.85-0.98; PRadjusted 
0.94, 95% CI 0.87-1.02; Table 8-3).  
Slightly fewer women in the whole cohort appeared to receive thrombolysis therapy 
compared to men, but the difference was only apparent when stroke severity was 
taken into account (PRunadjusted 0.98, 95% CI 0.94-1.02; PRfully-adjusted 0.91, 95% CI 
0.82-1.02). Analyses of a subset of patients (n=4695; 44% being female) potentially 
eligible for thrombolysis (admission time ≤3.5 hours) showed that women and men 
were equally given the therapy (PRunadjusted 1.07, 95% CI 0.96-1.20; PRfully-adjusted 1.03, 
95% CI 0.92-1.14 (Table 8-3).  
When compared to men, women were more often discharged to aged care (6.8% vs 
3.0%; p<0.001), and less often discharged directly home from acute care (34.1% vs 
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42.5%; P<0.001, Table 8-2). Adjustment for age and severity substantially attenuated 
the association between sex and discharge destination (Table 8-3).  
Sex difference in mortality after stroke 
In the whole cohort, the case fatality rate at 7, 30 days and 1 year was greater for 
women compared to men (Figure 8-1). In univariable analyses, significant 
contributing factors to the sex difference in mortality up to 1 year after stroke were 
age, stroke severity, and discharge destination (being discharged home or to aged 
care; Supplemental Table E-2).  
In the best fit multivariable model, data were available for 94% (n=13,304) of 14,114 
cases because of missing data on confounding factors. Women were approximately 
40% more likely to be deceased after acute stroke compared to men in unadjusted 
analysis (MRRunadjusted 7-day 1.42, 95% CI 1.25-1.60; 30-day 1.45, 95% CI 1.33-1.59; 
1-year 1.44, 95% CI 1.34-1.54; Figure 8-2). None of the four processes of care 
available for all hospitals confounded the association between sex and mortality both 
in the short and long term after stroke. Older age at stroke onset in women, compared 
to men, explained about 50-63% of their greater short-term mortality (MRRage-adjusted 
7-day 1.19, 95% CI 1.05-1.35; 30-day 1.15, 95% CI 1.05-1.27; Supplemental Table 
E-2). Separate adjustment for stroke severity reduced the sex difference by 31-39% 
(MRRseverity-adjusted 7-day 1.24, 95% CI 1.09-1.40; 30-day 1.29, 95% CI 1.18-1.41; 
Supplemental Table E-2). In the multivariable final model with adjustment for age 
and severity, there was no longer a significant difference between men and women in 
7-day mortality (MRRfully-adjusted 7-day 1.09, 95% CI 0.96-1.24; 30-day 1.07, 95% CI 
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0.97-1.17; Figure 8-2). There was no evidence ofstatistical interactions between sex 
and covariates on the short-term mortality.  
Importantly, stroke severity modified the sex difference in 1-year mortality after 
stroke (Pinteraction=0.028). Among those able to walk at admission, age explained most 
of the excess deaths after stroke by women (MRRunadjuted 0.99, 95% CI 0.80-1.22; 
MRRage-adjusted 0.81, 95% CI 0.65-1.00; Figure 8-3). For those unable to walk, there 
was an excess of deaths after stroke in men that was only apparent when the generally 
younger age of the men was taken into account (MRRunadjuted 1.36, 95% CI 1.26-1.47; 
MRRage-adjusted 1.05, 95% CI 0.97-1.14; Figure 8-3).  
Analyses of additional processes of care 
Analyses of additional processes of care from Queensland patients (n=5,224) 
provided consistent results with mortality up to 1 year being greater in women than 
men (MRRunadjusted 30-day 1.26, 95% CI 1.26-1.47; 1-year 1.32, 95% CI 1.17-1.49; 
Table 8-4). Age and severity of stroke also contributed to the difference in mortality 
(MRRadjusted 30-day 0.89, 95% CI 0.76-1.03; 1-year 0.90, 95% CI 0.79-1.01; Table 8-
4). There was no evidence of statistical interactions between sex and covariates on 
mortality up to 1 year after stroke. In a subgroup analysis restricted to only patients 
with ischaemic strokes, coupled with age and severity, a lesser proportion of aspirin 
administration in women also contributed to the sex difference in mortality 
(MRRunadjusted 30-day 1.45, 95% CI 1.19-1.76; 1-year 1.50, 95% CI 1.24-1.82; 
MRRfully-adjusted 30-day 0.87, 95% CI 0.72-1.07; 1-year 0.92, 95% CI 0.75-1.12; Table 
8-4). Other sensitivity analyses to examine the effect of the multiple imputation to 
account for missing data, early deaths after stroke (e.g., 7 days) and, in a subset of 
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Queensland hospitals revealed that our findings were robust (Supplemental Results: 
section 8.7.2, and Appendix E: Supplemental Tables E-3 to E-5).  
8.6 Discussion 
We found that women generally had greater mortality up to 1 year after stroke 
compared to men in unadjusted analyses. The sex difference was largely attributable 
to advanced age and more severe strokes in women rather than differences in care 
provided while in hospital, confirming our previous findings in population-based 
studies.236 These findings support the essential need of accounting for age and 
severity in reporting outcomes in stroke research,329 especially sex-specific findings. 
There were no statistically significant sex differences in the provision of care except 
that fewer women received aspirin in hospital relative to men. The contribution of 
undertreatment with early aspirin in women to the sex difference in mortality after 
stroke is concerning and requires further investigation. 
The present study provides additional evidence for the current literature on sex 
differences in stroke care and outcomes. Findings of this study suggest conflicting 
results compared to the US and European studies61,126,145,330 that show no significant 
sex differences in stroke presentation and treatment, in both unadjusted and adjusted 
analyses. The discrepant findings among different studies may reflect differences in 
the study populations or variations in practice among regions.   
Age was the most important factor contributing to the greater mortality after stroke in 
women compared to men. Older age at stroke onset may explain greater mortality for 
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several reasons including that elderly people usually present with more severe strokes 
and more comorbidities (e.g. atrial fibrillation‒AF, hypertension and diabetes) which 
are associated with greater fatality after stroke.15 Older adults may not receive 
evidence-based stroke care,214 which may also be associated with their poorer 
outcome after stroke or may indicate the patient and their family’s preference to avoid 
active treatment as part of end-of-life care. However, the perspectives of end-of-life 
care are rarely recorded in current stroke studies and differences by sex have not been 
explored. Irrespective of age or sex, further investigations are needed to identify the 
needs of palliative and end-of-life care in order to provide adequate care and support 
for stroke patients and their families.331,332 
More severe strokes in women compared to men also contributed to their poorer 
outcome. This suggests that the sex difference could be attenuated by targeting 
modifiable factors contributing to stroke severity e.g. hypertension,244 embolic stroke 
mechanism,295 and AF.245 Walking ability was used as a proxy for stroke 
severity.60,328 The relative importance of these factors to differences in severity 
between women and men remains uncertain84 because stroke severity is less often 
investigated as a separate endpoint. Further research is required to identify potential 
contributors to any observed sex difference in stroke severity. The ability to walk at 
admission, in this study, accounted for up to 39% of the sex difference in mortality. 
These findings are consistent with our meta-analysis of population-based studies 
whereby 51% of the sex difference was explained by stroke severity assessed using 
other instruments (e.g. NIHSS).236 This suggests that although other stroke severity 
scales have more favourable construct validity this simple measure of walking ability 
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is reliably collected and serves as a good marker of stroke severity.329 The study 
results corroborate the findings of previous work suggesting that the sex differences 
in mortality following stroke are mostly accounted by age and stroke severity.236 
However, accounting for age did not fully explain the sex difference in stroke 
severity. Potential reasons for the residual difference could be associated with sex 
differences in comorbid diseases5 or the localization of brain function,226 but further 
investigation is needed.  
Importantly, greater mortality after stroke from women in Queensland could also be 
explained by the sex difference in aspirin administration ≤48 hours, a treatment that 
has strong evidence for reducing poor outcomes after stroke.319 One explanation could 
be the greater presence of AF among women compared to men, with women therefore 
receiving anticoagulants instead of aspirin.333 Aspirin may be withheld for >48 hours 
in cases experiencing haemorrhagic conversion after ischemic stroke, which may be 
either spontaneous or, occasionally a complication of thrombolytic therapy. However, 
this is likely to be a few cases. We were unable to examine these possibilities due to a 
lack of data on comorbidities and prescription of anticoagulant agents. Since 2017, 
the AuSCR recording guidance for aspirin collections has been modified with further 
options on reasons for not given the medication including contraindication and other 
antithrombotic agent provided. These data would be helpful for future studies to 
further examine the lower administration of aspirin in women with stroke compared 
to men. We did find some evidence that women who did not receive aspirin ≤48 hours 
were not receiving antiplatelet/anticoagulants at discharge (Supplemental Table E-
1), which is in line with previous observations reporting the underuse of 
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antiplatelet/anticoagulants in women.334 Another possibility of undertreament in 
women, given their advanced age when having a stroke, is the impact of 
multimorbidity and polypharmacy in older adults335 but this is beyond the scope of 
this paper. The undertreatment with aspirin may also reflect worse health before 
stroke in women or contraindications to treatment such as allergy, bleeding disorder, 
or uncontrolled hypertension.336 Further quantitative and qualitative research must be 
conducted to explore the reasons behind the under-treatment of aspirin in women and 
whether there are potential links between sex, age and medication prescription 
decision-making.  
Although there was no evidence of a statistically significant difference between sexes, 
in the whole cohort, slightly fewer women received thrombolysis therapy than men. 
Patients with more severe stroke symptoms (unable to walk) are more likely to 
receive thrombolysis therapy (16.8% vs 5.3%, p<0.001), consistent with previous 
findings.337 In the whole cohort, slightly fewer women received thrombolysis therapy 
than men and, therefore, adjustment for severity strengthened the association between 
sex and the receipt of thrombolysis (Table 8-3). In the present study, there was no 
detectable sex difference in the time from stroke onset to arrival or the proportion of 
those admitted to the hospital ≤3.5 hours (women 53.4% vs men 52.0%). However, 
due to the high percentage of missing data on admission time (22%, slightly greater 
for women), we suspect that there may be a role of delayed hospitalisation on the 
association between female sex and the lower receipt of intravenous thrombolysis. 
This could explain the findings that removing the delayed hospitalisation reversed the 
direction of sex difference. In the subset of patients with admission time ≤3.5 hours, 
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slightly more women were treated with thrombolysis therapy than men and, thus, the 
association became weaker after accounting for stroke severity (Table 8-3). 
Several strengths should be acknowledged. These analyses are based on a large 
dataset from five states across Australia with a standardised collection to ensure data 
quality and adequate power to test our hypothesis. The possibility of bias of missing 
data could be minimised thanks to the linkage of survival status to national death 
registrations, very low rate of missing data on confounding factors and minor change 
in estimates from sensitivity analyses that replaced missing data using multiple 
imputation.  
A number of limitations need to be considered. Some potential factors contributing to 
the sex difference in stroke care and long-term outcomes of stroke were not available 
in this registry. These include pre-stroke health, depression after stroke, history of 
comorbidities e.g. cardiovascular diseases, lifestyle behaviours and post-stroke 
depression. Our analyses were limited by the lack of information on whether the 
patient was living in institution (i.e. nursing home) or having functional limitations 
before stroke. Except for functional limitation before stroke and the presence of AF, 
we did not find these above factors were important in a previous study using data 
from population-based studies.236 In future research will be able to use liked hospital 
administrative data to obtain comorbidity information (i.e. AF, diabetes, Charlson or 
Elixhauser Comorbidity Index) to enhance the data available from the AuSCR 
cohort.338,339  
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The majority of hospitals participating in AuSCR were those with well-developed 
systems of care for stroke whereby our estimates of in-hospital care processes were 
different from those provided by a wider range of hospitals. This might limit the 
generalizability of the results of the study. For example, according to the National 
Acute Audit Report 2015,340 only 58%-67% patients accessed stroke units (2013-
2015) and 7% of patients with ischemic stroke received intravenous thrombolysis 
(2013). The corresponding figures were 80% and 12%, respectively in the AuSCR. 
Although we found very little difference between men and women in the processes of 
care in the AuSCR, it is possible that there may be sex differences among non-
AuSCR hospitals. Nevertheless, this is unlikely to substantially affect our conclusion 
that the sex differences in mortality were mostly explained by advanced age and 
stroke severity rather than a sex bias in stroke care.  
The hospital-based design might under- or over-estimate the sex difference in 
mortality compared to population-based studies. This is because women tend to be 
older, live alone94 or reside in an institution at time of stroke onset and may be less 
often admitted to hospital than men.29 Among population-based stroke incidence 
studies, the admission rate varied by regions and study year, ranging from 79% in 
Perth (1989-1990),341 91% in Melbourne (1996-1999)236,342 to as high as 96% in 
Adelaide (2009-2010).343 Also, the proportion of neuroimaging performed during 
admission among population-based studies was at 80% for Perth,341 88% for 
Melbourne344 to 95% for Adelaide.343 The latter figure does not greatly differ from 
that of the nationalacute audit data from 2013-2015 whereby up to 96% of 
hospitalized people with stroke were given a brain imaging with only a 2% difference 
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between urban and rural areas.345,346 These above figures suggest the selection bias 
from hospital-based studies is becoming minimal.  
Our findings from the additional information on management of stroke from 
Queensland hospitals may be important to evaluate in the whole registry. Since mid-
2016, all AuSCR hospitals have been able to expand the collection of these processes 
of care. 
Conclusions 
Women, compared to men, were older at stroke onset, less likely to walk on 
admission, less often treated with aspirin, more often discharged to aged care and 
more likely to be deceased up to 1 year after stroke. The greater mortality after stroke 
in women was explained by their advanced age, and more severe stroke. There was 
some evidence that under-treatment with aspirin in women further accounted for the 
sex differences in mortality. These findings highlight the importance of better 
management for high-risk individuals including those with more severe strokes and 
the elderly. This study using a national registry with stroke performance indicators 
aligned with current recommendations provides a greater understanding of the sex 
differences in the quality of care and outcomes to inform future work to address these 
differences.  
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Table 8-1. Characteristic of AuSCR registrants for first−ever stroke during 
2010−2014 by sex 
 Men Women P−value* 
 n (%) n (%)  
Number of cases 7580 (53.7%) 6538 (46.3%) <0.001 
Sociodemographics    
Age, median (IQR)† 71.9 (61.6−80.9) 78.6 (67.2−85.8) <0.001 
State†    
New South Wales 1486 (19.6%) 1166 (18.2%) 0.304 
Queensland 2819 (37.2%) 2405 (36.8%)  
Tasmania 351 (4.6%) 296 (4.5%)  
Victoria 2613 (34.5%) 2432 (36.7%)  
Western Australia 311 (4.1%) 239 (3.6%)  
Born in Australia† 4805 (63.4%) 4419 (67.6%) 0.005 
Aboriginal/Torres Strait 
Islander† 
103 (1.4%) 103 (1.6%) 0.606 
Socioeconomic status†    
IRSAD1 (most disadvantage) 1411 (18.6%) 1154 (17.7%) 0.931 
IRSAD2 1568 (20.7%) 1354 (20.7%)  
IRSAD3 952 (12.6%) 814 (12.5%)  
IRSAD4 1528 (20.2%) 1312 (20.1%)  
IRSAD5 (least disadvantage) 2119 (28.0%) 1904 (29.1%)  
Stroke−related factors    
Transfer from other hospital† 1167 (15.5%) 873 (13.4%) 0.005 
In−hospital stroke† 398 (5.3%) 376 (5.8%) 0.539 
Time (minutes) from onset to 
arrival, median (IQR)§ 
192 (81−710) 184 (81−642) 0.178 
Admission time ≤3.5 hours of 
symptom onset§ 
3083 (52.0%) 2721 (53.4%) 0.268 
Walking independently at 
admission‡ 
2808 (37.0%) 1873 (28.7%) <0.001 
Type of stroke    
Intracerebral haemorrhagic 1185 (15.6%) 1049 (16.0%) 0.434 
Ischaemic stroke (IS) 6174 (81.5%) 5270 (80.6%)  
Undetermined (not including 
subarachnoid haemorrhage) 
218 (2.9%) 219 (3.4%)  
Cause of stroke known (IS 
only)†| | 
3723 (50.5%) 3043 (47.9%) <0.001 
IRSAD: Index of Relative Socio-Economic Advantage and Disadvantage 
* random−effects multilevel model allowing hospital clustering 
† missing data <1% 
‡ missing data <6% 
§ missing data <22% 
| | defined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification 
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Table 8-2. Processes of care and discharge information of AuSCR registrants for 
first−ever stroke during 2010−2014 
 Men Women P−value 
 n (%) n (%)  
Number of cases 7580 (53.7%) 6538 (46.3%) <0.001 
Evidence−based therapies    
Treated in stroke unit  6256 (82.5%) 5257 (80.4%) 0.259 
Intravenous thrombolysis* 767 (12.5%) 632 (12.1%) 0.458 
 767 (29.8%†) 632 (27.4%†) 0.181 
Discharged on antihypertensives 4818 (70.9%) 3945 (70.2%) 0.555 
Care plan on discharge to community 1828 (53.1%) 1368 (51.3%) 0.371 
Discharge information    
Discharge destination    
Died in hospital 658 (8.7%) 780 (11.9%) <0.001 
Aged care 225 (3.0%) 441 (6.8%)  
Home 3220 (42.5%) 2226 (34.1%)  
Rehabilitation 2297 (30.3%) 2023 (31.0%)  
Hospitals/other 1180 (15.6%) 1068 (16.3%)  
Length of stay‡, median (IQR) days 5 (3−9) 6 (3−11) <0.001 
Additional indicators (Queensland data)    
Number of cases 2819 (54.0%) 2405 (46.0%) <0.001 
Mobilisation ≤48 hours§ 857 (53.6%) 764 (49.0%) 0.211 
Received swallow assessment ≤24 hours 1530 (54.3%) 1226 (50.1%) 0.458 
Aspirin administration ≤48 hours* 1639 (68.9%) 1230 (60.8%) 0.015 
Discharged on 
antiplatelets/antithrombotic* 
1678 (81.0%) 1282 (76.7%) 0.442 
Missing data on evidence-based therapy were assumed to be ‘unreceived’ 
* among ischaemic strokes 
† among those with admission time ≤3.5 hours 
‡ among those discharged 
§ if unable to walk on admission 
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Table 8-3. Prevalence ratio (PR)* of having more severe stroke, being discharge 
home or to aged care and receiving acute evidence−based therapies for women 
compared to men 





Characteristics      
Able to walk on 
admission 
13305 0.78 (0.73, 0.82) 0.83 (0.78, 
0.88) 
age 
Discharged home 11646 0.84 (0.79, 0.88) 0.94 (0.88, 
0.99) 
age, severity 
Discharged to aged care 11646 2.40 (2.03, 2.83) 1.48 (1.25, 
1.76) 
age, severity 
Evidence−based care†     
Intravenous thrombolysis 10714 0.96 (0.86, 1.07) 0.88 (0.79, 
0.98) 
severity 




≤48 hours (Queensland 
hospitals) 
4400 0.91 (0.85, 0.98) 0.94 (0.87, 
1.02) 
age, severity 
* using multilevel modelling allowing hospital clustering 
† among eligible patients 
‡ among those with admission time ≤3.5 hours 
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Table 8-4. Mortality rate ratio up to 1 year after stroke for women compared to 
men with unadjusted and multivariable adjusted analyses   




All hospitals    
At 7 days 13304 1.42 (1.25-1.60) 1.09 (0.96-1.24) 
At 30 days 13304 1.45 (1.33, 1.59) 1.07 (0.97, 1.17) 
At 1 year, without interaction with 
severity 
13304 1.44 (1.34, 1.54) 1.03 (0.95, 1.10) 
At 1 year, unable to walk 8624 1.36 (1.26, 1.47) 1.05 (0.97, 1.14) 
At 1 year, able to walk 4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 
Queensland data    
At 7 days 4803 1.22 (0.99, 1.50) 0.93 (0.75, 1.16) 
At 30 days 4803 1.26 (1.09, 1.47) 0.89 (0.76, 1.03) 
At 30 days, ischemic stroke 3536 1.45 (1.19, 1.76) 0.87 (0.72, 1.07)† 
At 1 year 4803 1.32 (1.17, 1.49) 0.90 (0.79, 1.01) 
At 1 year, ischemic stroke 3536 1.50 (1.24, 1.82) 0.92 (0.75, 1.12)† 
MRR: mortality rate ratio; CI: confidence interval 
* adjusted estimates for age and severity of stroke 
† adjusted estimates for age, severity of stroke, and aspirin ≤48 hours 
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Figure 8-1. Case fatality rate up to one year after stroke among women and men 
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Figure 8-2. Mortality rate ratio for women compared to men (39 hospitals, 
n=13,304) at 7, 30 days, and 1 year after stroke. *adjusted for age and stroke 
severity (severe = unable to walk independently at admission; not severe = able 
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Figure 8-3. Mortality rate ratio for women compared to men (39 hospitals, 
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8.7 Supplemental Materials 
8.7.1 Supplemental Methods 
Statistical analyses 
Variables were entered into the model only if they met all three criteria that defined 
them as confounders:207 (1) the covariate was associated with the outcomes, P<0.1; 
(2) the covariate was associated with sex, P<0.1; and (3) the inclusion of the covariate 
changed the magnitude of the coefficient for the sex difference in the outcome 
([unadjusted β-adjusted β]/unadjusted β*100%) by ≥10%. 
Analyses of stroke unit access, receiving comprehensive discharge care plan if 
discharged to the community (i.e. to a home or aged care), being discharged on 
antihypertensive agents, mobilisation during admission (Queensland only) and speech 
pathologist review (Queensland only) were undertaken among all hospitalised 
patients irrespective of stroke type. However, analyses of intravenous thrombolysis, 
aspirin administration (Queensland only) and being discharged on antiplatelets or 
antithrombotics (Queensland) were performed only for those with confirmed 
ischaemic stroke.  
Then, in the relevant subgroups specified above, we examined whether any factors 
related to processes of care that showed a sex difference were confounders of the 
association between sex and mortality. Some medication restrictions may be 
appropriate given patient’s contraindication or to meet treatment guidelines.319 
8.7.2 Supplemental Results 
In sensitivity analysis of multiple imputation to account for missing data of 
confounders, estimates from imputed analysis were similar to the complete-case 
analysis in both at 30 days and 1 year after stroke (Appendix E: Supplemental 
Table E-3). In analyses of the role of early deaths (Supplemental Table E-4), 
excluding deaths ≤7 days produced almost no change in the magnitude of sex 
differences in mortality at 30 days. In 1-year analyses, however, the greater mortality 
was substantially driven by early deaths occurring within the first 6 months after 
stroke and the mortality rate in both sexes became more equal during the period of 6 
months to 1 year after stroke. 
The data from Queensland accounted for 37% of the whole registry. We have 
identified that the magnitudes of sex difference in mortality of stroke after stroke in 
Queensland hospitals, compared to the whole cohort, were smaller (30-day 
MRRunadjusted 1.45 vs 1.26; 1-year MRRunadjusted 1.44 vs 1.32); but, the contributing 
Chapter 8. Sex differences in care and long-term mortality after stroke: Australian 
Stroke Clinical Registry (AuSCR) 
211 
 
factors to the differences were the same across regions including age and stroke 
severity.  
The proportions of females between Queensland and non-Queensland patients with 
stroke were similar (Supplemental Table E-5). Although patients with stroke in 
Queensland, compared to non-Queensland patients, were slightly younger, less able to 
walk on admission, more often in disadvantaged socioeconomic groups and less often 
given evidence-based therapies, these differences were not statistically significant. 
There was a significant difference in intravenous thrombolysis administration in 
Queensland (8.8%) compared to elsewhere (14.4%; Supplemental Table E-5). A 
greater proportion of hospitals in Queensland (36.5%) were in regional areas 
compared to other states (Victoria: 11.7%, New South Wales: 21.6%, Western 
Australia: 0%) 
 
8.7.3 Co-investigators and other contributors 
Co-investigators and other contributors to the Australian Stroke Clinical 
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Mental Health VIC (also on Management Committee); Julie Bernhardt PhD (The 
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Andrew Lee MBBS FRACP (Flinders Medical Centre, South Australia); Richard 
Lindley PhD (The George Institute for Global Health NSW); Mark Mackay MBBS, 
FRACP (Royal Children’s Hospital VIC, site investigator); Sandra Martyn (Health 
Statistics Centre Queensland Health QLD); John McNeil PhD (Monash University 
VIC); Sandy Middleton PhD (Nursing Research Institute, St Vincent’s Health 
Australia NSW, Australian Catholic University NSW); Michael Pollack MBBS, 
FAFRM (RACP), FACRM, FFPM (ANZCA), MMedSci (Clin Epi) (Hunter Stroke 
Service NSW);  
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MSc(Med) (Australasian Rehabilitation Outcomes Centre NSW)  
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Foundation, Australia) 
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Gairdner Hospital WA); Ernie Butler MBBS FRACP (Peninsula Health VIC); Sean 
Butler FIMLS, BM Hons, MRCP(UK), FRACP (Prince Charles Hospital QLD); 
Chris Charnley MBBS (Warrnambool Base Hospital VIC); Douglas Crompton 
MA, PhD, MBBS, FRACP (Northern Hospital VIC); Vanessa Crosby Dip Physio 
(Albury Campus, Albury-Wodonga Health VIC); Carolyn De Wytt MRCP (UK), 
MB BCH DUBL, FRACP (Greenslopes Private Hospital QLD); David Douglas 
MBBS, M Admin, FRACGP, FAFRM (RACP) (Ipswich Hospital QLD); Martin 
Dunlop MBBS, FACRM (Cairns Base Hospital QLD); Paula Easton BPhty (Hons) 
(Mackay Hospital QLD); Sharan Ermel RN (Div1) (Bendigo Health VIC); Nisal 
Gange MBBS, AMC CERT (Toowoomba Hospital QLD); Richard Geraghty 
MBBS, FRACP (Redcliffe Hospital QLD); Melissa Gill BAppSc (SpPath) (Armidale 
Hospital, NSW); Graham Hall MBBS, FRACP (Princess Alexandra Hospital QLD); 
Peter Hand MBBS, MD, FRACP(Royal Melbourne Hospital VIC); Geoffrey 
Herkes MBBS, PhD, FRACP (Royal North Shore Hospital NSW); Karen Hines 
BHIM (Caboolture Hospital QLD); Francis Hishon RN (Redland Hospital QLD); 
James Hughes BMed, FRACP (Tamworth Hospital NSW); Joel Iedema MBBS, 
FRACP (Redland Hospital QLD); Martin Jude MBBS, FRACP (Wagga Wagga 
Hospital NSW); Thomas Kraemer Approbation als Arzt, STATE EXAM MED 
MUNSTER, FRACP (Ballarat Health Services VIC); Paul Laird MBBS, FRACP 
(Rockhampton Hospital QLD); Johanna Madden BPhysio (Goulburn Valley Health 
VIC); Graham Mahaffey RN (Hervey Bay Hospital QLD); Suzana Milosevic MD, 
FRACP, AMC CERT (Logan Hospital QLD); Peter O’Brien MBBS, DIP 
RANZCOG, FRACMA, FACRRM (Warrnambool Hospital VIC); Michaela Plante 
RN (Div 1) (Rockhampton Hospital QLD); Juan Rois-Gnecco Medico Cirujano 
Javeriana, FAFRM (Ipswich Hospital QLD); Stephen Read MBBS, PhD, FRACP 
(Royal Brisbane and Women’s Hospital QLD); Kristen Rowe BNurs, Cert NeuroSci 
Nurs (Austin Health VIC); Fiona Ryan BAppSc (SpPath), MHlthSc (Orange 
Hospital and Bathurst Hospitals NSW);  
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Chapter 9: Sex differences in specific-cause mortality 
and excess death rates after stroke: the Australian Stroke 
Clinical Registry 
9.1 Preface 
At the time of submission of this thesis, the contents of this chapter have been 
circulated to co-authors in preparation for submission for publication.  
Phan HT, Gall SL, Blizzard CL, Lannin N, Thrift AG, Anderson CS, Kim J, Grimley 
R, Castley HC, Hand P, Cadilhac D. Sex differences in specific-cause mortality and 
excess death rates after stroke: the Australian Stroke Clinical Registry. 
9.2 Abstract 
Background: Uncertainty exists over the sex differences in causes of death (COD) 
and specific-cause of excess mortality after stroke. 
Methods: First-ever strokes (2010-2013) admitted to 35 hospitals participating in the 
Australian Stroke Clinical Registry were linked to national death registrations. One-
year COD were categorised as stroke, ischaemic heart disease (IHD), other 
cardiovascular disease (CVD) e.g. hypertension, cancer, and other. Competing risk 
models were used to estimate female:male specific hazard ratios (sHRs) of death with 
adjustment for factors that differed by sex (sociodemographics, stroke severity). Age- 
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and sex-specific death rates by calendar year expected in the general population were 
derived from national data. Female:male standardised mortality ratio (SMR; 
observed/expected deaths) were estimated for COD. 
Results: Among 9,441 admissions (46% women), women were 7 years older than 
men, had more severe strokes, received similar acute care therapies, and had greater 
all-cause mortality (25.4% vs men 19.1%, p<0.001). Women had greater risk of death 
associated with stroke (sHRunadjusted 1.65, 95% CI 1.42-1.91) and other CVD 
(sHRunadjusted 1.65, 95% CI 1.29-2.12), but these differences were explained by age  
and stroke severity (stroke: sHRadjusted 1.19, 95% CI 1.02-1.40; other CVD: sHRadjusted 
1.12, 95% CI 0.85-1.48). Compared to population norms, those surviving to 30-days 
had an >8-fold increased risk of death from stroke/recurrent events ≤1 year 
irrespective of sex (SMR: women 8.8; men 8.3). The excess risk of death from other 
CVD was greater in women than men (SMR 3.6 vs 2.8; p=0.26). Compared to 
population norms, the excess mortality after stroke was greater for IHD (SMR: 
women 3.0; men 3.5,) and cancer (SMR: women 2.6; men 2.6). 
Conclusion: COD after first stroke differ between sexes with women having more 
deaths attributed to stroke or other CVD, which were mostly explained by age and 
stroke severity. Secondary stroke prevention should target vascular risk factors and 
co-morbidity. 
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Women have been reported to have greater all-cause mortality in the long term after 
stroke than men. We have previously reported that women have greater all-cause 
mortality compared to men at 1 and 5 years in unadjusted analyses, but that this is 
mostly associated with deaths in the first 6 months.236 It may be that there are 
discrepancies between men and women in their causes of death (COD) after stroke 
that potentially vary over time. 
In the studies of COD up to 10 years after stroke, the authors have failed to report 
sex-specific findings347 or investigate the factors contributing to differences in COD 
between men and women.230,348,349 The association between sex and COD has mostly 
been reported as an incidental finding in multivariable models (e.g. using step-wise 
regression).348,349 The current research is also limited by the fact that most of the data 
were collected in the 1970s and early 1990s when neuroimaging (e.g. CT scan) was 
irregularly used.348,349 Lack of imaging information may influence the diagnosis and 
determination of underlying COD after stroke. Further, there is some evidence that 
women receive evidence-based care less often than men.80,84 It is uncertain whether 
such differences in stroke care contribute to the sex differences in cause-specific 
mortality after stroke.  
Furthermore, little is known about attributable causes for excess mortality after stroke 
compared to the general population, including any differences by sex. Hansen and 
colleagues (2001)230 reported that the excess 1-year mortality post-stroke due to 
cardiovascular diseases, cancer, or other conditions compared to the general 
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population were greater in women than men. However, this research was conducted 
from 1982-1991 and may not represent the contemporary impact of stroke.  
The aims of this study were to (1) examine whether the COD up to 1 year after stroke 
vary by sex and over time among people admitted to hospital with acute stroke in 
Australia, (2) identify the factors, including access to evidence-based care, that may 
account for any sex differences in COD, and (3) calculate the excess mortality 
atributable to stroke and other causes compared to the general population.   
9.4 Methods 
The data for this study was obtained from the Australian Stroke Clinical Registry 
(AuSCR) which is a national registry on the quality of acute stroke care and patient 
outcomes in Australia.236 As a nationwide, multicentre, prospective registry, the 
AuSCR incorporates standardised methods of data collection using a validated 
system.317 
Our research proposal was approved by the AuSCR Research Task Group and its 
Management Committee in August 2016 to examine sex differences in hospital 
processes of acute care and patient outcomes up to 1 year after stroke using the 2010-
2014 AuSCR dataset. Appropriate ethics and/or governance approvals were obtained 
for all participating hospitals in AuSCR and the Australian Institute of Health and 
Welfare to conduct data linkage to national death registrations, known as the National 
Death Index (NDI). This study was approved by the Tasmanian Health and Medical 
Human Research Ethics Committee (H0015287). 
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Due to the lag times for receiving COD as part of updating the NDI,350 only a subset 
of strokes enrolled in the AuSCR database between 2010 and 2013 (n=35 hospitals) 
were linked with COD for the analysis.  
9.4.1 Study factors 
Factors used on covariates in the analysis included patient characteristics and specific 
care processes received in the hospital that might explain the sex differences in COD 
after stroke. These predictors were categorised into five groups including: (1) socio-
demographics, (2) stroke-related factors (e.g. stroke severity, stroke type, and cause of 
stroke known defined according to the TOAST criteria),351 (3) processes of care 
provided in the hospital such as access to stroke units, (4) discharge information 
(length of hospital stay, discharge destination), and (5) 90-180 day  post-stroke factors 
(e.g. living arrangements, self-reported recurrent stroke event, and readmission since 
discharge).  
Sociodemographic factors included age, country of birth, ethnicity, state of residence 
(New South Wales, Queensland, Western Australia, Victoria, and Tasmania), and 
socioeconomic position determined using the Index of Relative Socio-Economic 
Advantage and Disadvantage (IRSAD) using patient postcodes.322 The IRSAD 
information was presented as predetermined quintiles with a higher quintile indicating 
greater socioeconomic advantage. 
The ability to walk independently on admission was used as a proxy assessment of 
stroke severity.236,328 This indicator has been proven as a reliable predictor of stroke 
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severity in the absence of a neurological scale such as the National Institute Health 
Stroke Scale.323 Stroke type was categorised into three groups including ischaemic 
stroke, intracerebral haemorrhage and undetermined stroke. Information on the time 
from stroke onset to hospital arrival, and whether patients were transferred from 
another hospital were also collected. 
The four processes of care collected for all patients (n=35 hospitals) included access 
to stroke unit care, intravenous thrombolysis if an ischaemic stroke, care plan 
provided at discharge, and being discharged on antihypertensive agent(s).319,324 Four 
additional processes of care were collected in the state of Queensland (n=21 hospitals) 
including: mobilisation during admission, swallow screen, aspirin administration ≤48 
hours (ischaemic stroke), and being discharged on antiplatelets or antithrombotic 
medications (ischaemic stroke). 
The length of stay was counted as the date of discharge minus the date of admission. 
Discharge destination after acute phase of stroke was categorised into home, 
residential aged care, inpatient rehabilitation, and other places.  
Eligible AuSCR participants were surveyed between 90 and 180 days after stroke to 
self-report their current residence (i.e. aged care, home, rehabilitation centres, and 
other) and living arrangements (whether the registrant lives alone). The presence or 
absence of a recurrent stroke event and readmission since discharge from the hospital 
(i.e. readmission date and reasons) were also self-reported by the registrants or their 
next-of-kin/key contact person.  
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9.4.2 Outcome measurements 
Survival and COD up to 1 year after stroke were obtained from patient-level data 
linkage to national death registrations undertaken by the Australian Institute of Health 
and Welfare (AIHW). The records of deaths registered in Australia were certified by a 
medical practitioner on a Medical Certificate of Cause of Death or by a coroner.350 
The accuracy of the COD is ensured by working with providers, quality checks during 
the data process and training of staff.350 The COD were based on ICD-10 
(International Statistical Classification of Diseases and Related Health Problems 10th 
Revision) codes. The primary COD were classified into: stroke, ischaemic heart 
disease − IHD, other cardiovascular disease – CVD (e.g. hypertension, atrial 
fibrillation, heart failure, peripheral vascular diseases, and others), cancer, other 
causes (other diseases, accidents, unclassified conditions), and unknown cause 
(missing ICD-10 codes on death records).  
9.4.3 Statistical analysis 
Statistical analyses were performed using Stata 12.1 (StataCorp Texas, 2011).269 All 
two-tailed p-values ≤0.05 were considered statistically significant.  
Multilevel competing risk modelling, accounting for the hospital as a unit of patient 
clusters, was used to estimate female:male specific hazard ratios (sHRs) of specific 
COD up to 1 year after stroke.  
To assess the role of covariates on the association between sex and each outcome, we 
used purposeful model building.207 Variables were entered into the model only if they 
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met all three criteria that defined them as potential confounders.207 The model-
building process was initially undertaken for each covariate separately and then 
confounding or contributing factors were included in the multivariable models 
(similar to those described earlier in Supplemental Methods: section 8.7.1). The 
modifying effect of time to death and other covariates on the sex difference was 
assessed by a test of the statistical significance of the coefficient of a sex × covariate 
product term.  
Estimates of the sex differences in processes of care and mortality after stroke were 
performed for all hospitals (4 indicators) and in the Queensland subset of patients that 
had more detailed information on stroke care (4 additional indicators). In the relevant 
subgroups, we examined whether any factors related to processes of care that showed 
a sex difference were contributing factors to the association between sex and 
mortality (similar to those described earlier in Supplemental Methods: section 
8.7.1).  
Stroke severity indicated by the walking ability on admission has been proven as a 
predictor of all-cause mortality and contributing factor to the greater mortality in 
women after 1 year after stroke using the same dataset (Chapter 8). We hypothesised 
that stroke severity would also be associated with specific COD following stroke, and 
examined the role of stroke severity on the association between sex and each COD.   
Comparison of patients with stroke and the general population 
For this analysis, 1-year COD due to stroke, ischaemic heart disease (IHD), other 
vascular conditions (e.g. hypertension), and cancer were investigated. Age and sex 
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specific death rates for each COD by calendar year expected in the general population 
were derived from Australian data (Stroke and other CVD: Australian heart disease 
statistics 2016 by the National Heart Foundation;352 cancer: data published by the 
AIHW).353 
Expected deaths were estimated for each sex by multiplying the age-specific person-
years of observation in the study group (stroke registrants) by the death rate of the 
general population, and summing the values for each age group to calculate the 
number of expected deaths. We then estimated the standardised mortality ratio (SMR) 
which was the quotient of the observed to the expected numbers of deaths for each 
COD, separately for women and men. The absolute excess risk (AER) for each COD 
was also estimated to compare the absolute additional mortality between men and 
women at 1 year after stroke (AER= [expected – observed deaths]/age-specific 
person-years at risk ×100). Noting that stroke-specific mortality is largely driven by 
30-day deaths, we reported the 1-year SMR and 1-year AER due to stroke among 
those deceased after 30 days (often called non-fatal strokes230).  
9.5 Results 
There were 9,441 patients experiencing first-ever stroke between 2010 and 2013 with 
81% ischaemic, and 46.4% being female. Median age of stroke was 75 years 
(Interquartile range 64-84).  
Sex differences in patient characteristics 
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Based on socio-demographic and stroke-related characteristics (Table 9-1), women 
were about 7 years older than men (median age 78.8 vs 72.0, p<0.001) and were less 
likely to walk independently at time of admission (indicating more severe strokes; 
38.5% vs 55.6%, p<0.001).  
Women had fewer known causes of stroke and experienced more stroke events while 
in hospital for another condition (in-hospital stroke) compared to men. We found that 
men and women received similar acute care (Table 9-1) except that women were less 
often administered aspirin ≤48 hours than men (49.6% vs 60.2%, p=0.042) based on 
the subset of Queensland data (n=21 hospitals; n=2,972), regardless of whether or not 
early deaths ≤48 hours were excluded. When compared to men, women were more 
often discharged to aged care (7.7% vs men 3.4%; p<0.001), and less often 
discharged directly home from acute care (33.9% vs men 42.5%; p<0.001, Table 9-
2). At 90-180 days after stroke, women were more likely to live alone (25.8% vs men 
16.7%, p<0.001) and less likely to stay at home (87.5% vs men 77.9%). 
Sex difference in specific COD after stroke 
Women had greater all-cause mortality (25.4% vs men 19.1%, p<0.001) at 1 year 
after a first-ever stroke. Stroke and CVD (i.e. IHD and other cardiovascular 
conditions) were the most common COD, accounting for over half of deaths 1 year 
following stroke. However, the distribution of COD differed between the sexes. 
Among those deceased by any cause (n=2,080; Figure 9-1), men had more deaths due 
to cancer (13% vs women 6%) and IHD (8% vs women 6%) while women had more 
deaths attributed to stroke (50% vs men 41%) or other CVD (16% vs men 13%). The 
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proportion of missing ICD codes for COD was relatively equal between sexes 
(women 9%; men 10%). Further details of the distribution of COD for women and 
men by age group and time to death are provided in the Appendix F: Supplemental 
Figures F-1 and F-2. 
For other CVD mortality at 1 year after stroke, women more often died from atrial 
fibrillation (49.2% vs 45.0%) and heart failure (5.5% vs 3.1%) than men. Among 
those who died due to cancer, more men than women died from urinary tract cancer 
(7.5% vs 2.9%) or skin cancer (9.2 vs 5.7%), while more women than men died from 
lung (18.6% vs 11.7%) or digestive system (32.9% vs 25.8%; Supplemental Table 
F-1) cancers. 
Sex difference in specific-cause mortality after stroke  
Data were available for 94% (n=8,889) of the 9,411 patients because of missing data 
on covariates including age and stroke severity. Women were 39% more likely to die 
by 1 year after stroke compared to men in unadjusted analysis (female:male hazard 
ratio, HR 1.39, 95% CI 1.23-1.56). Advanced age and more severe strokes in women, 
compared to men, explained their greater all-cause mortality (HRadjusted 1.01, 95% CI 
0.89-1.15). 
In specific-cause mortality 1 year following stroke, more severe stroke, indicated by 
being unable to walk independently on admission, was associated with increased risk 
of death in all COD groups except cancer (Supplemental Table F-2). Women had a 
65% greater risk of death associated with stroke than men (sHRunadjusted 1.65, 95% CI 
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1.42-1.91; Table 9-2). The sex difference was greatly attenuated after adjusting for 
age and stroke severity (sHRadjusted 1.19, 95% CI 1.02-1.40).  
Women appeared to face a lesser risk of death due to IHD (sHRunadjusted 0.88, 95% CI 
0.65-1.18; sHRadjusted 0.58, 95% CI 0.43-0.77), but they more often died from other 
CVD i.e. atrial fibrillation and heart failure (sHRunadjusted 1.65, 95% CI 1.29-2.12). The 
greater risk of death due to other CVD in women was similarly accounted for by age 
and stroke severity (sHRadjusted 1.12, 95% CI 0.85-1.48).  
The risk of death attributable to cancer was less in women (sHRunadjusted 0.69, 95% CI 
0.50, 0.95) than in men and the sex difference remained significant after accounting 
for age (sHRage-adjusted 0.67, 95% CI 0.50-0.91). None of the factors including stroke 
type (Supplemental Figure F-3), time to death (Supplemental Table F-3), four 
indicators of processes of care available among all hospitals, and other covariates 
confounded or modified the sex difference in cause-specific mortality up to 1 year 
after stroke. 
In the subset of the Queensland patients, women also had greater all-cause 
(HRunadjusted 1.41, 95% CI 1.19-1.66) and stroke-specific mortality (sHRunadjusted 1.79, 
95% CI 1.29-2.12) than men. Age, stroke severity and likelihood of early aspirin 
administration fully accounted for these sex differences (all-cause HRadjusted 0.92, 95% 
CI 0.80-1.05; stroke-specific sHRadjusted 1.04, 95% CI 0.76-1.42). 
Sex difference in excess death rates after stroke 
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Compared to the general Australian population, patients with a first-ever stroke 
surviving to 30-days had an over 8-fold increased risk of death (standardised for age) 
due to the index stroke or a recurrent stroke within 1 year after stroke, irrespective of 
sex (SMR, Women: 8.8; Men: 8.3; p=0.656). The AER for stroke was 35.0/1,000 
person-years in women and 17.4/1,000 person-years for men (Table 9-3; p<0.001). 
People with stroke were also more likely to die from IHD within 1 year than the 
general population, but the excess mortality, standardised for age, was slightly greater 
in men (SMR men 3.5 vs 3.0; p=0.310). By contrast, the excess risk of death from 
other CVDs among those with stroke, compared to the general population, was 
greater among women than men (SMR women 3.6 vs 2.8; p=0.026). Men and women 
with stroke shared an equal 2.6-times greater risk of death caused by cancer than 
expected although the number of cancer deaths was small (Table 9-3).  
9.6 Discussion 
In this paper we provide contemporary data on the sex differences related to COD 
after stroke and the excess risk of death compared with the general population. We 
found that the mortality up to 1 year after stroke was mostly associated with 
cardiovascular diseases and cancer, and the COD differed by sexes. Women had more 
deaths due to stroke and other CVDs (not including IHD) while men had greater risks 
of death by IHD or by cancer. Women’s advanced age and more severe strokes 
(indicated by the inability to walk independently at admission) were attributed to the 
increased risk of death due to stroke and other CVD (i.e. atrial fibrillation, heart 
failure). In a subset of the cohort, women were less often treated with aspirin ≤48 
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hours of an ischaemic stroke and this explained part of the sex difference in stroke-
specific mortality. None of the other evidence-based therapies contributed to the sex 
differences in specific-cause mortality after stroke.  
In the first year following stroke, both men and women surviving to 30 days had at 
least 8 times excess mortality from stroke compared to people of the same age and 
sex in the general population. Patients that had been hospitalised with stroke, 
regardless of sex, were 3 times more likely to die from other CVD and 2.6 times more 
likely to die from cancer than the general population. These findings are in line with 
research by Brønnum-Hansen et al.230  
More deaths due to stroke in women 
Age was the most important factor contributing to 51% of the sex differences in 
stroke-specific mortality. Older age can reflect the multimorbidity15 and underreceipt 
of evidence-based stroke care214 which are associated with lower survival after stroke. 
It is critical to develop clinical recommendations that incorporate age-related 
complexities (e.g. multimorbidities and polypharmacy) as these may optimise the 
outcomes of older patients with stroke.  
Stroke severity accounted for 24% greater stroke mortality in women compared to 
men, supported by the current evidence.236 Targeting modifiable factors contributing 
to stroke severity, e.g. hypertension,244 and AF245, could lessen the sex differences. 
The ability to walk on admission, as a proxy for stroke severity,323 appeared to be a 
reliable predictor of mortality outcome in the study. The collection of NIHSS data in 
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AuSCR was introduced in 2015, and in the future may allow more opportunities to 
explore why women have more severe strokes than men.  
The receipt of aspirin administration contributed to the sex difference in stroke 
mortality but the data were only available in a subset of Queensland hospitals. The 
undertreatment with antiplatelet or anticoagulants in women has been observed 
previously,334 suggesting a need to ensure greater access to early treatment with 
aspirin for women. Although the sex difference in aspirin administration was not fully 
explained by the covariates collected in the AuSCR, other unmeasured factors, such 
as complications and contraindications to treatment (e.g. allergy, bleeding disorder, or 
uncontrolled hypertension),336 may play a role. Since mid-2016, there has been an 
expansion to the whole registry on data collection of additional processes of care 
measures (i.e. aspirin administration) and contraindications are noted for some of 
these. A sex bias in the early treatment of aspirin may warrant further examination to 
inform clinical practice and provide more opportunities to address the sex differences 
in mortality after stroke. 
The role of stroke severity in mortality due to CVD 
We found that the walking ability on admission, as a proxy for stroke severity,323 was 
associated with increased risk of death due to IHD and other CVD, and this covariate 
also contributed to their greater cause-specific mortality in women. The finding is in 
line with evidence that a slow walking speed in older people is strongly linked to 
greater CVD mortality.354 Although uncertainty exists over the causal pathway of the 
association between stroke severity and increased risk of dying from CVD, there are 
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some potential explanations. Inability to walk on admission could reflect the presence 
of functional limitation before stroke that is associated with chronic diseases 
including cardiovascular conditions.236,265 Although early mobilisation is 
recommended in clinical guidelines324,355 to improve walking and functional 
independence,356 only 40% of patients were mobilised ≤48 hours in our study (Table 
9-2). This suggests another possibility that restricted mobility caused by stroke (i.e. 
hemiplegia, paraplegia), indicated by walking ability on admission, may persist into 
the longer term following stroke. Those people with restricted mobility (pre-existing 
or following stroke) may face a high risk of venous thromboembolism and 
cardiovascular events,357 potentially leading to greater CVD mortality.358  
More deaths due to other CVD in women 
Women with stroke, compared to men, were at higher risk of death due to other CVD 
(not including IHD), particularly atrial fibrillation (AF) and heart failure, and the 
difference was accounted for by age and stroke severity. This finding was consistent 
with the sex differences in the comorbidity profile of those with stroke with women 
being older, frailer and with more AF and more hypertension compared to men.236 
The suboptimal management of AF such as undertreatment with anti-coagulants 
among older patients,225 many of whom are women, underpins the need for better 
detection and treatment of AF in older men and women.  
Fewer deaths due to IHD or cancer in women  
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Men with stroke had an increased risk of death from IHD than women and adjustment 
for age and stroke severity underpinned the association. This can be explained 
because men appear to develop IHD and stroke at a younger age and have less severe 
strokes compared to women. Those men with stroke are also presented with worse 
lifestyle risk factors (e.g. smoking, alcohol consumption) or medical histories (i.e. 
more often having a history of coronary heart disease) that may lead to their higher 
IHD mortality.236  
Men with stroke had a greater 1-year risk of death due to cancer than women although 
the number of cancer deaths were small. The finding is consistent with the evidence 
that men are at greater risk of cancer incidence and mortality compared to women.359 
The excess burden of cancer in men is possibly explained by multiple factors 
including their worse lifestyle risk factors, as mentioned above, and less help-seeking 
compared to women.359 
Excess deaths due to stroke, CVD, and cancer for both men and women 
People with stroke had excess deaths due to stroke, other CVD, and cancer when 
compared to the general population. This could be explained by the fact that these 
causes of death share common risk factors, such as hyperlipidemia, diabetes, and 
smoking.360 The excess mortality due to stroke and CVD could also be related to a 
common mechanism (atherosclerosis) of these diseases.361 Prevention strategies 
should be prioritised by targeting vascular risk factors and co-morbidities to improve 
survival following stroke. At the patient level, some potential programs based on 
fitness training alone or in combination with psychosocial or educational 
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interventions may have some benefits on preventing stroke, like the exercise-based 
cardiac rehabilitation has had, particularly on reducing CVD mortality.362,363 
Population-based prevention strategies could offer an excellent option to improve 
outcomes after stroke. For example, the use of ‘polypill’ therapy that combines 
multiple drugs (i.e. statin, antihypertensive agents, aspirin) could reduce stroke and 
other CVDs by 80% among those ≥55 years with existing CVD.364 Moreover, it is 
essential to ensure access to evidence-based care for both men and women who 
experience stroke to promote a better chance of survival.236   
There are two potential mechanisms for the excess death due to cancer among those 
with stroke. Cancer generally has a long development period, suggesting that deaths 
from cancer after stroke were mostly from pre-existing diseases. There is some 
discussion on screening for cancer in the patient with cryptogenic stroke that may 
help to diagnose occult cancer and inform future interventions, but the cost-
effectiveness of this approach warrants more research.365,366 The other potential 
mechanism is related to newly diagnosed cancer patients who have a stroke possibly 
due to hypercoagulation (i.e. causing thromboembolism)367 or side-effects of cancer 
treatment.368 Given the lack of cancer-related data in stroke studies, it may be useful 
to further examine the predictors of long-term outcomes among people with stroke 
and cancer, potentially using data linkage. Because patients with stroke and a history 
of cancer have an increased risk of recurrent stroke and cardiovascular mortality,365 
these outcomes should be considered in future stroke research together with other data 
including cancer treatment (e.g. chemotherapy, radiotherapy). Understanding the 
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interrelationships between cancer and stroke is important given the large burden 
associated with these two diseases.368 
Strengths and limitations 
To our knowledge, this is the first study using a national stroke registry to examine 
sex differences in cause-specific mortality 1 year after stroke. Our research also 
provides the excess death rate according to each COD after stroke (i.e. stroke, IHD, 
other CVD, and cancer) for both men and women compared to the Australian general 
population. The findings were based on a large high-quality dataset, enabling us to 
have enough reliability and power to test our hypotheses. Stroke performance 
indicators in the AuSCR were aligned with high priority national clinical 
recommendations, making our work relevant to current clinical practice. The AuSCR 
data on survival and COD linked to the national registration minimised selection bias 
from missing death records (only 10% of registrants had unknown COD). 
We acknowledge some limitations of the study. Some potential confounding factors 
of the sex differences in mortality after stroke, including living arrangement before 
stroke, behavioural risk factors, pre-stroke function, comorbidities, and other 
processes of care were unavailable. However, in our earlier work using data from 13 
population-based studies,236 there were very few differences between men and women 
in the treatment and management of stroke (i.e. brain imaging, cardiac workup, 
admission and discharge medications). The AuSCR sample was consistent with other 
representative stroke populations.236 For example, the all-cause mortality by 1 year 
(22%) was comparable to other similar studies worldwide.236 However, patients 
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registered in the AuSCR hospitals during the study period were mainly admitted to 
neurology/stroke units and from metropolitan areas.236 The possibility of bias caused 
by this cannot be eliminated, which is another limitation of the study. 
Conclusion 
In this study, we found that women, compared to men, more often died at 1 year after 
stroke and the COD varied by sexes. Women had more deaths attributed to stroke or 
other CVD than men, and the difference was mostly accounted for by their advanced 
age and stroke severity. Women’s lesser receipt of aspirin therapy also contributed to 
their increased risk of stroke-specific mortality. Compared with the general 
population, excess mortality for both men and women was mostly attributed to stroke 
or recurrent events, other cardiovascular conditions, and cancer. Our findings 
reinforce the need for better prevention of stroke and CVD in men and women. It is 
also necessary to deliver high-quality stroke care to all people that suffer stroke as this 
is associated with better survival and other outcomes.  
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Table 9-1. Characteristic of AuSCR registrants for first−ever stroke during 
2010−2013 (n=35 hospitals) by sex 
 Men Women p−value 
 n (%) n (%)  
Number of cases 5059 (53.6%) 4328 (46.4%) <0.001 
Sociodemographics    
Age, median (IQR) 72.0 (61.8−81.0) 78.8 (67.8−85.9) <0.001 
State    
New South Wales 1360 (26.9%) 1067 (24.4%) 0.221 
Queensland 1574 (31.1%) 1398 (31.9%)  
Tasmania 216 (4.3%) 193 (4.4%)  
Victoria 1651 (32.6%) 1535 (35.0%)  
Western Australia 258 (5.1%) 189 (4.3%)  
Born in Australia 3224 (63.7 %) 2939 (67.1%) 0.066 
Aboriginal/Torres Strait Islander 55 (1.1%) 57 (1.3%) 0.168 
Socioeconomic status    
IRSAD1 (most disadvantage) 988 (19.5%) 783 (17.9%) 0.635 
IRSAD2 871 (17.2%) 752 (17.2%)  
IRSAD3 840 (16.6%) 705 (16.1%)  
IRSAD4 936 (18.5%) 840 (19.2%)  
IRSAD5 (least disadvantage) 1424 (28.2%) 1302 (29.7%)  
Stroke−related factors    
Transfer from other hospital 791 (15.6%) 616 (14.1%) 0.100 
In−hospital stroke 264 (5.2%) 278 (6.3%) 0.020 
Time (minutes) from onset to 
arrival, median (IQR) 
181 (78−679) 170 (78−596) 0.983 
Walking independently at 
admission (proxy for less severe 
stroke) 
1949 (38.5%) 2812 (55.6%) <0.001 
Cause of stroke known 2415 (47.7%) 1993 (45.5%) 0.001 
Type of stroke    
Intracerebral haemorrhagic (ICH) 826 (16.3%) 744 (17.0%) 0.724 
Ischaemic stroke 4071 (80.5%) 3490 (79.6%)  
Undetermined 159 (3.1%) 148 (4.4%)  
Processes of care received in 
hospital 
   
Treated in stroke units 4103 (81.1%) 3434 (78.4%) 0.258 
Intravenous thrombolysis*  519 (12.8%) 418 (12.1%) 0.298 
Discharged on antihypertensives† 3133 (69.5%) 2568 (68.9%) 0.634 
Care plan for discharge to the 
community‡ 
1138 (49.0%) 866 (47.5%) 0.487 
Discharge information    
Discharge destination    
Home 2150 (42.5%) 1486 (33.9%) <0.001 
Inpatient rehabilitation 1510 (29.9%) 1339 (30.6%)  
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 Men Women p−value 
 n (%) n (%)  
Residential aged-care facility 174 (3.4%) 337 (7.7%)  
Other hospitals/facilities 764 (15.1%) 668 (15.2%)  
Died in hospital 461 (9.1%) 552 (12.6%)  
Length of stay (LOS), median 
(IQR) days† 
6 (3−10) 6 (3−12) 1.000 
Self-reported 90-180 day 
covariates 
   
Current residence†    
Aged care 201 (7.7%) 353 (17.1%) <0.001 
Home 2240 (85.3%) 1573 (76.1%)  
Rehabilitation 52 (2.0%) 25 (1.2%)   
Hospitals/other 132 (5.0%) 117 (5.7%)  
Recurrent stroke 106 (2.1%) 102 (2.3%) 0.443 
Living alone 408 (8.1%) 538 (12.3%) <0.001 
Readmission  512 (10.1%) 389 (8.9%) 0.366 
Additional processes of care in 
hospital (Queensland; 21 
hospitals) 
   
Number of cases 1574 (53.0%) 1398 (47.0%) <0.001 
Mobilisation§ 515 (59.1%) 454 (52.1%) 0.057 
Mobilisation ≤48 hours§  383 (44.0%) 351 (40.3%) 0.764 
Swallow assessment ≤24 hours 762 (48.4%) 604 (43.2%) 0.389 
Aspirin administration ≤48 
hours* 
788 (60.2%) 570 (49.6%) 0.042 
Discharged on 
antiplatelets/antithrombotics*† 
755 (83.0%) 579 (79.6%) 0.666 
IRSAD= the Index of Relative Socio-Economic Advantage and Disadvantage 
* among ischaemic stroke 
† among those discharged 
‡ among those discharged to community (e, to a home setting or institutional 
residential aged care) 
§ if unable to walk on admission 
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Table 9-2. Specific hazard ratio (sHR) of death up to 1 year after stroke for women compared to men in AuSCR 2010-2013 using 
competing risk models 
Cause of death Unadjusted Adjusted for  
  Age Stroke severity† Age and severity 
 sHR (95% CI) sHR (95% CI) sHR (95% CI) sHR (95% CI) 
Stroke 1.65 (1.42-1.91) 1.28 (1.10-1.49) 1.46 (1.25-1.71) 1.19 (1.02-1.40) 
Ischaemic heart disease 0.88 (0.65-1.18) 0.60 (0.45-0.79) 0.82 (0.60-1.12) 0.58 (0.43-0.77) 
Other cardiovascular disease 1.65 (1.29-2.12) 1.19 (0.91-1.56) 1.49 (1.16-1.93) 1.12 (0.85-1.48) 
Cancer 0.69 (0.50-0.95) 0.67 (0.50-0.91) 0.69 (0.50-0.94) 0.67 (0.49-0.91) 
Other conditions 1.17 (0.87-0.58) 0.99 (0.70-1.36) 1.08 (0.79-1.47) 0.94 (0.68-1.30) 
Unknown 1.12 (0.84-1.49) 0.89 (0.64-1.21) 1.05 (0.78-1.40) 0.86 (0.63-1.17) 
All-cause 1.39 (1.23-1.57) 1.08 (0.95-1.22) 1.26 (1.11-1.44) 1.01 (0.89-1.16) 
Bold denotes statistically significant results 
† Walking ability independently on admission was used as a proxy for stroke severity (unable to walk=more severe; able to walk=less severe) 
‡ the hazard ratio was estimated using Cox model  
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Table 9-3. Standardised mortality ratio (SMR) and absolute excess death rate (AER) among people with stroke compared to general 
population norms after age standardisation 
 Men Women 
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Other CVD=Other cardiovascular disease (e.g. hypertension, atrial fibrillation, heart failure) 
* death rate per 100,000 persons by each COD 
† per 1,000 person-years 
‡ self-reported recurrent event at 3 months after stroke (n=106 cases for men; 102 cases for women) was not included in the analysis 
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Chapter 10: Sex differences in health-related quality of 
life at 3-6 months after stroke: Australian Stroke Clinical 
Registry 
10.1 Preface 
At the time of submission of this thesis, the contents of this chapter have been 
circulated to co-authors in preparation for submission for publication.  
Phan HT, Gall SL, Blizzard CL, Lannin N, Thrift AG, Anderson CS, Kim J, Grimley 
R, Castley HC, Hand P, Cadilhac D. Sex differences in health-related quality of life at 
3-6 months after stroke: Australian Stroke Clinical Registry. 
10.2 Abstract 
Introduction: Women have worse health-related quality of life (HRQoL) after stroke 
than men but the reasons for this difference are uncertain. 
Methods: We included first-ever strokes admitted to 39 hospitals participating in the 
Australian Stroke Clinical Registry (AuSCR; 2010-2014) with HRQoL assessed 
between 3-6 months after stroke using the European Quality of Life–5 Dimensions 
(EQ5D) instrument. Study factors included sociodemographics, stroke type, walking 
ability on admission (proxy for severity) and access to evidence-based care (e.g. 
stroke unit, intravenous thrombolysis, antihypertensive medications and discharge 
plan). EQ5D scores were calculated for each domain, and the results were then 
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transformed into a total utility value. Quantile regression modelling, unadjusted and 
adjusted for confounding factors, was used to calculate the median differences (MD) 
in EQ5D utility scores between women and men. Differences in utility scores within 
the range 0.08-0.12 unit were defined as clinically meaningful.  
Results: About 60% (6852/11418) of survivors completed EQ5D assessment (median 
139 days, interquartile range 123-161); 44% female. Women were older (median age 
77.1 vs 71.2, p<0.001) and less able to walk on admission (37.9% vs 46.1%, 
p<0.001). Women had lower HRQoL compared to men in unadjusted analysis (MD -
0.082 95% CI -0.099, -0.066). Age and stroke severity, but not clinical care, 
explained the sex differences whereby young men (aged <65 years) and older women 
(75+ years) had significantly poorer HRQoL after stroke.  
Conclusion: Poorer HRQoL after stroke among younger men and older women were 
due to stroke severity and health differences in the population. Interventions to reduce 
the severity of stroke (e.g., managing risk factors, increasing access to care) for older 
patients should be prioritised to reduce the sex differences.  
10.3 Introduction 
Women have been reported to have poorer HRQoL after stroke than men; however, 
the factors that may explain sex differences in short- and long-term studies are poorly 
understood.23,24 Many investigators did not report sex-specific outcomes.170,173,369-373 
Others have used prediction models that are not focused on the sex difference (e.g. 
using the step-wise approach) whereby sex was not retained in multivariable 
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models.23,24 Another explanation may be related to the sex differences in stroke 
treatment since women often receive evidence-based care less often than men.80,84 
However, among a few studies specifically designed to examine the sex difference in 
HRQoL, the data on quality of care were lacking.23 Therefore the impact of 
differences in clinical care between women and men on women’s poorer HRQoL is 
inconclusive.  
In our most recent meta-analysis of sex differences in HRQoL using individual 
participant data from four population-based studies conducted in Australasia and UK 
(Chapter 5), the greatest contributors to the worse HRQoL in women were advanced 
age, pre-stroke functional limitations, stroke severity, and the presence of long-term 
post-stroke mood disorders. Differences in stroke care did not account for the sex 
difference in HRQoL but the analyses were limited by the fact that the data on 
management were out of date. In study-specific analyses, there was some evidence 
that women still had worse HRQoL following stroke than men based on the fully-
adjusted models. The sex differences may be further accounted for by unmeasured or 
poorly measured factors. Therefore, further research is required to investigate the 
reasons for the residual differences in HRQoL between men and women.  
Additionally, while women appear to experience worse HRQoL after stroke than 
men, women without stroke also report poorer health status than men of all ages.374 
Therefore, it is uncertain whether the sex difference in HRQoL is caused by stroke or 
is due to other differences between men and women.  
Chapter 10. Sex differences in health-related quality of life at 3-6 months after stroke: 
Australian Stroke Clinical Registry 
242 
 
Our aims were to (1) quantify the sex differences in HRQoL between 3-6 months 
after stroke using contemporary data from the Australian Stroke Clinical Registry 
(AuSCR), (2) identify contributing factors, including processes of stroke care, which 
may contribute to the difference, and (3) compare the sex difference in HRQoL 
between those with and without stroke by using data from the AuSCR and population 
HRQoL norms derived from an Australian general population survey. 
10.4 Methods 
The Australian Stroke Clinical Registry (AuSCR) is a nation-wide prospective 
collection of data on stroke care.236 Currently, more than 65 public hospitals around 
Australia contribute data to the AuSCR. The registry includes information on 
evidence-based therapies while in the hospital, outcomes and some patient 
characteristics. In this study, we included first-ever strokes admitted to 39 hospitals 
participating in the AuSCR database between 2010 and 2014.  
10.4.1 Study factors 
We examined a wide range of factors that might explain the sex differences including 
patient characteristics and in-hospital processes of care. The study factors collected 
from the AuSCR dataset were categorised into five groups. They included the 
following (1) socio-demographics: age, country of birth, state of residential address 
(New South Wales, Queensland, Western Australia, Victoria and Tasmania), and 
socioeconomic position determined using the Index of Relative Socio-Economic 
Advantage and Disadvantage;322 (2) stroke-related factors: stroke severity (ability to 
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walk on admission), stroke type (ischaemic, intracerebral haemorrhage and 
undetermined stroke), time from stroke onset to hospital arrival, and whether patients 
were transferred from another hospital; (3) treatment and management (processes of 
care recommended in Australian clinical guidelines:324,355 stroke unit access, 
intravenous thrombolysis, use of antihypertensive agent(s) at discharge, and receipt 
of a discharge care plan; (4) discharge information: length of stay and discharge 
destination; and (5) post-stroke factors (3-6 month status): survival, recurrent stroke, 
whether the patient was living alone, HRQoL (see below) and proxy assessment by 
caregivers (as required).  
Four additional care processes were only collected in the state of Queensland (n=21 
hospitals) including mobilisation during admission, swallow screen, aspirin 
administration ≤48 hours, and being discharged on antiplatelet or antithrombotic 
medications (ischaemic stroke).  
10.4.2 Outcome measure 
The collection of patient-reported outcomes occurred between 3-6 months after the 
index event using survey methods by post or telephone.236 HRQoL was assessed 
using the European Quality of Life–5 Dimensions (EQ-5D-3L) instrument,194 which 
has been validated for stroke.375 For each of the 5 dimensions of the EQ-5D including 
mobility, self-care, usual activities, depression/anxiety, and pain), there are three 
response categories: no problem, some/moderate, and extreme problem.  
The EQ5D information was collected from patients or proxy respondents when 
patients were unable to respond to the interviewers. Unassessed survivors included 
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those who were lost to follow-up only after multiple contact attempts (non-
responders) and the time from discharge was more than 180 days or the patient/proxy 
refused (non-consenters). 
10.4.3 Statistical analyses 
All these analyses were performed by Stata 12.1 (StataCorp Texas, 2011).269 P values 
≥ 0.05 were considered as statistically significant. 
Utility scores were calculated by summing the component scores of each of the five 
EQ5D domains and adding value sets from relevant general populations to create an 
overall score using Australian population-based methods based on the discrete choice 
experiment (DCE).376 The DCE approach was used instead of Time-Trade-Off 
technique as it was developed with a greater proportion of older people so it was more 
aligned with our stroke cohort. The utility score is a scale on which full health has a 
value of 1, while 0 indicates death and negative values indicate health states worse 
than death. The EQ5D score ranges from a negative score (worse than death) to 1 
(perfect health). Those who died during the follow-up, assigned a score of 0 as per the 
instrument validation, and unassessed patients were excluded in our analyses.   
Among stroke survivors, random-effects quantile regression accounting for individual 
hospital correlations was used to generate median differences in EQ5D utility score 
for women compared to men. Median regression was used as the EQ5D has a bimodal 
distribution or is highly skewed. Multivariable modelling was performed to examine 
the covariates (sociodemographics, stroke-related factors and in-hospital processes of 
care) that would potentially contribute to sex differences in EQ5D at 3-6 months after 
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stroke. Our model-building procedure was based on the purposeful selection of 
covariates.207 The following criteria for being a confounding factor were applied to 
determine the covariates in the multivariable models: (1) the covariate was associated 
with sex; (2) the covariate was associated with outcome (EQ5D scores); and (3) the 
inclusion of the covariate in the model with only sex if it changed the magnitude of 
the sex coefficient by ≥10%.207 Statistical interaction was assessed by a test of 
statistical significance of a sex x covariate product term. In further analyses of sub-
domain scores of EQ5D, female:male relative risk (RR) of having any problem for 
each dimension was performed using log-binomial regression. Factors potentially 
associated with the sex differences in each sub-domain were also examined in 
multivariable models. 
Sensitivity analyses were used to assess the effect of the multiple imputation by 
chained equations (m=50 imputations) and inverse probability weighting377 to account 
for missing data with missing at random assumption on HRQoL and covariates on the 
results. The individual domain scores of EQ5D of missing data were initially imputed 
and subsequently converted into overall utility scores. This approach was justified as 
being more reliable in a large dataset (>500 cases) than directly imputing the overall 
utility score.378  
In analyses comparing the AuSCR with population-level EQ5D, mean utility scores 
for stroke survivors were calculated within sexes and age groups (<55, 55-64, 65-74 
and ≥75 years old). The corresponding utility EQ5D scores of the general population 
were obtained from the data of the South Australian population-based Health 
Omnibus Survey.374 The survey provided mean EQ5D utility scores of the Australian 
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general population that are current and available by age and sex strata. We then 
calculated the weighted mean difference scores between AuSCR stroke registrants 
and the general population within each age group, separately for men and women.  
A minimal clinically important difference represents the minimum benefits in the 
practice (from the treatment or other acute therapies).78 The minimally important 
difference for EQ5D utility scores ranging from 0.08 to 0.12 units are reported in the 
stroke population.277 In this study, therefore, any difference in utility between men 
and women greater than or equal to 0.08 was defined as clinically meaningful.  
10.5 Results 
Over a median follow-up of 139 days (IQR 123-161), there were 2700 deaths out of 
14118 registered cases of stroke. About 60% (6852/11418) of survivors completed 
follow-up surveys with EQ5D assessment; 44% being female (Table 10-1). Among 
those with EQ5D assessment at 3-6 months after stroke (n=6852), compared to men, 
women registrants were 6 years older (median age: 77 years vs men 71; p<0.001), and 
less able to walk independently on admission (37.9% vs men 46.1%, p<0.001; Table 
10-1). Women were more often discharged to aged care (5.1% vs 1.3%; p<0.001), and 
less often discharged directly home from acute care (44.1% vs 51.0%; p<0.001, Table 
10-2). At median 139 days after stroke, women were more likely to live alone (25.8% 
vs 16.7%, p<0.001) and less likely to stay at home (87.5% vs 77.9%) than men. Proxy 
results for the EQ5D were obtained among 44% of available patients with a greater 
proportion for women than for men (46.3% vs 41.7%, p<0.019; Table 10-2).  
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The proportions of women were the same between those with and without assessment 
(44%). However, compared to those unassessed with EQ5D, assessed patients were 
older, had less severe strokes (indicated by the ability to walk independently on 
admission), and fewer intracerebral haemorrhages (Appendix G: Supplemental 
Table G-1). In the entire cohort (n=6,852; 39 hospitals), the assessed patients more 
often received processes of care including being treated in a stroke unit, aspirin 
administered ≤48 hours, and prescription of antihypertensive medication at discharge. 
In a subset of patients from Queensland (n=2,492; 21 hospitals), those with EQ5D 
assessment were more often mobilised and also had more dysphagia screening ≤24 
hours than those without assessment (Supplemental Table G-2). 
Sex difference in EQ5D domain scores among survivors 
Women reported at least one problem in four EQ5D domains including self-care, 
usual activity, pain/discomfort and anxiety/depression more often than men 
(Supplemental Table G-3a). Further examination of the female:male relative risks 
showed that the sex differences were slightly attenuated by stroke severity but 
modified by age group. In all four domains, the effect estimates for sex were 
statistically significant among people aged 75 years and older. Anxiety/depression 
problems were also more prevalent among middle-aged women (65-74 years) than 
their men counterparts (Supplemental Table G-3b).   
Sex difference in overall utility scores among survivors 
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Based on AuSCR data, the DCE utility scores ranged from -0.516 (worse than death) 
to 1 (perfect health). The median overall utility scores among survivors were 0.775 
(IQR 0.576-0.887) and 0.693 (95% CI 0.482-0.887) for men and women, 
respectively. Women had poorer HRQoL compared to men at 3-6 months after stroke 
in unadjusted analysis (median difference; MD -0.082, 95% CI -0.099, -0.066) which 
bordered on the clinically meaningful threshold. Age and stroke severity accounted 
for about 50% of the sex differences and the adjusted MD (-0.039, 95% CI -0.056, -
0.021) was below the clinically significant threshold. Further adjustment for 3-month 
place of residence further attenuated the sex differences (MD -0.029, 95% CI -0.052, 
-0.006). Neither clinical care nor the other factors including length of stay, discharge 
information, living alone status at 3 months, and proxy assessment confounded the 
sex difference in EQ5D utility in the multivariable models.  
Sex difference in EQ5D utility scores between women and men survivors differed by 
age group (pinteraction<0.001) and severity of stroke (pinteraction<0.001). In the younger 
age group (<65 years old), there was no statistically significant difference in utility 
score between sex regardless of stroke severity although women survivors appeared 
to have slightly better scores (Table 10-3). By contrast, the direction of the 
association between sex and HRQoL was reversed in the older age groups. Elderly 
women aged 75+ with a severe stroke had lower utility scores after stroke than elderly 
men and the difference was clinically significant (MD -0.103, 95% CI -0.160, -0.047). 
Among survivors after a less severe stroke, older women also experienced poorer 
HRQoL than their men counterparts and the magnitude of the difference was about 
two times greater in the 65-74 age group than the oldest group (75+ years; Table 10-
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3). Sensitivity analyses to account for missing data on EQ5D using multiple 
imputation with inverse probability weighting technique produced similar results 
when compared with complete-case analysis (Supplemental Table G-4). 
Sex difference in HRQoL between people with and without stroke  
Stroke caused clinically meaningful differences (CMD) in HRQoL across all age 
group but generally increasing with age. The magnitude of the loss was similar for 
men and women. Mean EQ-5D utility scores were significantly lower for people with 
stroke compared to the population norms across all age groups (mean difference 
ranged: 0.25 – 0.51), well above the clinically meaningful threshold (Figure 10-1). 
The magnitude of the sex difference was greatest among those aged 75+ years (utility 
mean difference: 0.44 for men vs 0.51 for women) but generally less than the CMD 
(<0.08). The analysis of the sex difference in utility scores compared between those 
with and without stroke showed that age modified the sex difference. Younger males 
were more like to have greater health loss due to stroke than their female counterparts 
(mean difference, aged <55: 0.31 vs 0.25; aged 55-65: 0.31 vs 0.30; Figure 10-1). On 
the other hand, older men often had lesser health loss caused by stroke than older 
women (mean difference, aged 65-74: 0.40 vs 0.35; aged 75+: 0.44 vs 0.51).  
10.6 Discussion 
The differences between men and women in HRQoL at 3-6 months after stroke were 
explained by age, severity of stroke and 3-month place of residence. Young men and 
older women, particularly those with more severe strokes, had a poorer outcome. No 
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other factors including discharge destination, stroke care, and living alone status at 3-
6 months contributed to the sex differences. Although stroke caused a significant 
health loss for both men and women, generally increasing with age, the magnitude of 
the sex differences in HRQoL between those with and without stroke was small 
across age groups.  
Younger women with stroke had a slightly better self-reported HRQoL score than 
younger men although the difference was not statistically significant. Younger men 
had worse HRQoL compared to younger women which could be because they face a 
greater risk of cardiovascular diseases (e.g. higher prevalence of smoking) that were 
unavailable in our study and develop these diseases at younger ages than women. 
Rather than biological and genetic factors, which have been considered the traditional 
determinants for the sex difference, other covariates based on social context may also 
contribute to the poorer HRQoL among young men after stroke. Previous research 
showed that men who did not return to work at 6 months after stroke had substantially 
worse HRQoL than those men who returned to work while there were no detectable 
differences between women that did and did not return to work.379 This could be 
related to the differences between men and men in self-perceptions of role (i.e. being 
a provider), and ability to work that are associated with HRQoL after stroke.380  
By contrast, elderly women appeared to have poorer HRQoL after stroke than elderly 
men. This difference was statistically and clinically significant, particularly among 
those women with severe strokes. This can be due to the fact that women tend to be 
older, frailer and have more health problems when they develop stroke.236 This means 
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that more women in the older age group experienced severe strokes and poorer 
functional outcome and participation restriction than their male counterparts that are 
associated with reduced HRQoL.60 In our HRQoL sub-domain analyses using the 
AuSCR data, the elderly women generally had more pain/discomfort, 
anxiety/depression, as well as problems with self-care and usual activity after stroke 
than elderly men, consistent with previous research.287,381 Thus, better identification 
and management of anxiety and depression after stroke, particular for women and the 
elderly in general may reduce these sex differences. There are some differences 
between men and women in coping strategies,382 and imperative to life satisfaction,383 
that may differently affect their self-reported HRQoL following stroke. The level of 
self-efficacy that survivors have in their ability to function in daily life has been 
proven to influence well-being after stroke, particularly HRQoL.384  
Walking ability at admission as a proxy for stroke severity was an effect modifier of 
the sex difference in HRQoL after stroke. The finding is somewhat consistent with 
our previous research whereby stroke severity (e.g. indicated by the National Institute 
Health Stroke Scale − NIHSS) contributed to the poor outcomes in women after 
stroke including HRQoL.385 This suggests that although it might not be as sensitive as 
other severity scales (e.g. NIHSS), walking ability is reliably collected and serves as a 
good marker of stroke severity in predicting outcome.236,329  
Our further comparison between stroke with stroke and normal norms revealed 
consistent results whereby stroke caused a greater HRQoL loss for younger men than 
younger women, but the direction of the association with sex was reversed for older 
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people. However, the net differences in utility scores between those elderly women 
and men with and without stroke were below the clinically meaningful threshold. This 
suggests that sex differences in HRQoL after stroke were not only caused by stroke 
but also due to other existing sex differences. Future studies should consider the 
existing differences in HRQoL between men and women when reporting results of 
sex differences in HRQoL after stroke and associated factors. Factors contributing to 
sex differences in the level of HRQoL in people without stroke could include the 
presence of chronic health conditions or depressive symptoms which have a stronger 
negative impact on HRQOL in female patients than male patients in the same age 
group.386 Although we were unable to examine these due to the lack of data on 
comorbidities and mood disorder, our analyses on the EQ5D subcategory of 
depression/anxiety data suggest that women face more problems on mental health 
compared to men.  
These findings have several implications for practice and research in stroke to 
improve HRQoL for both men and women. The large impact of age on the association 
between sex and HRQoL after stroke highlights an imperative of improving health for 
the elderly, who are mostly women. Given the important role of stroke severity in the 
association between sex and HRQoL, better management of the modifiable factors of 
stroke severity should reduce the sex difference. Promotion of active healthy aging to 
increase years lived in healthy life is of utmost importance.281 Strategies to reduce risk 
factors for cardiovascular diseases (CVD), which are more prevalent in men, such as 
smoking need to be addressed to narrow the gender gap in the younger age group. 
Other non-traditional predictors of CVD in young males (e.g. pattern baldness and 
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premature greying)387 are possibly helpful to detect diseases at an early stage but 
further research is required. Developing more effective primary prevention strategies 
to reduce health differences according to age and sex should also be a priority.280 
These programs need to better target people with different levels of CVD and stroke 
risk, particularly providing more supports for those who are more vulnerable to stroke 
including young men and old women. 
When prevention fails and stroke happens, all efforts to reduce the impact of stroke 
should be taken. We found that a number of men and women with strokes were not 
treated with evidence-based therapies such as stroke unit care (>10%) and intravenous 
thrombolysis for ischaemic stroke (88%). It is important to ensure greater access to 
evidence-based processes of care (i.e. stroke unit care, thrombolytic therapy, 
antihypertensive agents, and care plan at discharge) for those with stroke, regardless 
of sex, that are associated with better HRQoL.236 It is also necessary to prevent the 
development of anxiety and depression which can significantly influence the recovery 
after stroke, particular for the elderly. Other individual or social factors (e.g. race, 
ethnicity, and culture), clinical indicators and post-stroke conditions (e.g. living 
alone) that are associated with poorer HRQoL should be taken into account when 
setting up rehabilitation and intervention programs.280 
The magnitude of the sex difference in EQ5D utility overall scores at 3-6 months after 
stroke was small and consistent with previous research with the EQ5D instrument.110 
Although EQ5D has been well-validated for use in stroke, the generic instrument of 
HRQoL may exclude some domains that differ by sex (e.g. family role, social 
Chapter 10. Sex differences in health-related quality of life at 3-6 months after stroke: 
Australian Stroke Clinical Registry 
254 
 
interactions, relationships, self-perception, memory),287,388,389 or are specific to stroke 
(e.g. communication, sexual function). Therefore, the sex difference in HRQoL might 
be underestimated when using EQ5D when compared to other generic instruments 
(e.g. Short-Form 36 questions; SF36) or stroke-specific instruments (e.g. Stroke-
Specific Quality of life; SSQoL). For example, according to the Paul Coverdell 
National Acute Stroke Registry (US), women had significantly lower SSQoL overall 
scores and on various sub-domains, including physical function, thinking, language, 
energy, mood and role function, even after accounting for covariates.104 Further 
comparison of the sensitivity of HRQoL instruments and qualitative studies that focus 
on the sex difference will provide better targets for intervention (e.g. social support) 
to mitigate the sex difference in HRQoL after stroke, particularly for vulnerable 
groups.388 
A number of the study’s strengths need to be acknowledged. The study was based on 
a large dataset obtained from 39 hospitals across five states of Australia with a 
standardised data collection to ensure data quality and adequate power to test our 
hypotheses. Another strength of the AuSCR is the follow up on over 6,500 cases. By 
using a national registry with stroke performance indicators aligned with current 
recommendations (i.e. level-1 evidence of impacting outcome), this study provides a 
value-added contribution to the clinical practice and current literature of whether 
there are sex differences in stroke care in Australia and its association with HRQoL. 
Our results of the sex difference in HRQoL between people with stroke and without 
stroke help fill the gap left because very few studies attempted to examine the loss of 
HRQoL by stroke21,123 and, to our knowledge, none of these specifically aimed to 
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focus on the sex difference. By determining factors that explain sex differences in 
HRQoL, this study provides the evidence basis for future research and intervention 
development to improve outcomes after stroke for both men and women and, in turn, 
reduce the burden of stroke on health systems and communities. 
Several limitations should be acknowledged in this study. The generalisability of the 
study results may be restricted by the fact that patients from the AuSCR hospitals 
appeared to have better care for stroke compared to the current experience of the 
general stroke population according to the national data.345 However, this is less likely 
to substantially affect our conclusion since sex differences in access to care did not 
account for the difference in HRQoL after stroke. The mean score of EQ5D (0.64, SD 
0.33) in the AuSCR dataset was closely similar to those from other developed 
countries (e.g. the United Kingdom, the United States), falling on the lower end of the 
global range (Supplemental Table G-6), suggesting that our results may reflect the 
experience of stroke patients in different settings. The minimal clinically important 
difference (MCID)78 has been performed to determine the benefits of an intervention 
or changes over time rather than designed to assess sex differences. Although the sex 
differences in this study were small, our findings may be biased because the MCID in 
EQ5D utility score for stroke population (0.08-0.12)277 was used to define the 
clinically meaningful difference between sexes. Our findings suggest that poorer 
quality of life in elderly women compared to men was due to stroke and other sex 
differences in the population, but the lack of detailed data (i.e. comorbid diseases, 
pre-stroke function) prevented us from more in-depth analyses of the potential sex 
difference effects of these factors on the HRQoL. Other post-stroke factors such as 
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rehabilitation outcomes and pain, depression and its treatment were not assessed in 
this registry. Gathering the data from multiple sources and linking the data across 
sources (e.g. AuSCR, medical records, and rehabilitation services) would provide 
insight for future work to examine the role of these factors in the sex difference in 
HRQoL. Compared with those unassessed, assessed patients were older, had fewer 
haemorrhages, less severe strokes, and more often received acute stroke therapies. 
However, this was less likely to substantially affect our conclusion since people with 
and without assessment were similar in their gender distribution (44% being female) 
and the other factors (stroke type and evidence-based therapies) did not account for 
the sex difference in HRQoL. Although the results of sensitivity analyses accounting 
for missing data using imputation combined with inverse probability weighting 
technique showed almost no change, we cannot fully preclude the selection bias 
particularly the age difference between those assessed and unassessed.  
Conclusion 
Women generally had worse HRQoL after stroke than men in unadjusted analyses. 
Young men with stroke appeared to have slightly lower HRQoL utility scores at 3-6 
months than their female counterparts. By contrast, elderly women with stroke had 
significantly poorer HRQoL after stroke compared to elderly men but the difference 
was modified by stroke severity. The worse HRQoL after stroke among younger men 
and older women was largely due to stroke, but was also associated with other sex-
related health differences existing in the population. These findings highlight the 
importance of more effective prevention strategies to improve the general health for 
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people across different levels of stroke and CVD risk factors as well as ensuring 
evidence-based acute care and post-stroke management, particularly for women and 
the elderly with more severe strokes more generally.  
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Table 10-1. Characteristic of AuSCR registrants for first−ever stroke during 
2010−2014 having EQ5D assessment at 3-6 months after stroke (n=39 hospitals) 
 Survivors with EQ5D assessment (n=6,852) 
 Men Women p−value 
 N (%) N (%)  
Number of cases 3821 (55.8%) 3031 (44.2%) <0.001 
Sociodemographics    
Age, median (IQR) 71.2 (62.0−79.5) 77.1 (65.7−84.4) <0.001 
State    
New South Wales 618 (16.2%) 436 (14.4%) 0.529 
Queensland 1388 (36.3%) 1104 (36.4%)  
Tasmania 235 (6.2%) 189 (6.2%)  
Victoria 1375 (36.0%) 1150 (37.9%)  
Western Australia 205 (5.4%) 152 (5.0%)  
Socioeconomic position    
IRSAD1 618 (16.2%) 482 (15.9%) 0.529 
IRSAD2 822 (21.5%) 651 (21.4%)  
IRSAD3 522 (13.7%) 393 (13.0%)  
IRSAD4 819 (21.4%) 645 (21.3%)  
IRSAD5 1040 (27.2%) 860 (28.4%)  
Born in Australia 2562 (67.1%) 2153 (71.0%) 0.070 
Aboriginal or Torres Strait Islander 46 (1.2%) 31 (1.0%) 0.594 
Stroke−related factors    
Transfer from other hospital 561 (14.7%) 399 (13.2%) 0.174 
Stroke while in hospital 165 (4.3%) 150 (5.0%) 0.236 
Time (minutes) from onset to arrival, 
median (IQR) 
192 (83−701) 207 (83−742) 0.273 
Walking independently at admission 
(proxy for stroke severity)* 
1653 (46.1%) 1077 (37.9%) <0.001 
Cause of stroke known 1901 (50.5%) 1419 (47.4%) <0.001 
Type of stroke    
Intracerebral haemorrhage 414 (10.8%) 355 (11.7%) 0.505 
Ischaemic stroke 3309 (86.6%) 2587 (85.3%)  
Undetermined 97 (2.5%) 89 (2.9%)  
IRSAD = the Index of Relative Socio-Economic Advantage and Disadvantage 
*stroke severity was defined as unable to walk independently on admission 
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Table 10-2. Processes of care, discharge information and longer term outcomes 
for first−ever stroke in the AuSCR during 2010-2014 
 EQ5D assessed (n=6852) 
 Men Women P−value 
 N (%) N (%)  
Discharged information    
Length of stay if discharged, median 
(IQR) days 
5 (3−8) 5 (3−9) 1.000 
Discharge destination    
Died in hospital − −  
Aged care 61 (1.3%) 155 (5.1%) <0.001 
Home 1950 (51.0%) 1337 (44.1%)  
Rehabilitation 1324 (34.7%) 1142 (37.7%)  
Hospitals/other 486 (12.7%) 397 (13.1%)  
Evidence−based therapies    
Treated in stroke unit  3358 (87.9%) 2647 (87.3%) 0.835 
Intravenous thrombolysis*  436 (13.3%) 315 (12.3%) 0.298 
 436 (33.0%)†  315 (35.6%) 0.175 
Care plan on discharge to community 1100 (54.7%) 782 (52.4%) 0.280 
Discharged on antihypertensives  2834 (74.9%) 2254 (75.1%) 0.986 
Data between 3-6 months (self-
reported) 
   
Current residence    
Aged care 255 (6.7%) 479 (16.0%) <0.001 
Home 3307 (87.4) 2338 (77.9%)  
Rehabilitation 65 (1.7%) 29 (1.0%)  
Hospitals/other 158 (4.2%) 157 (5.2%)  
Living alone‡ 628 (16.4%) 768 (25.3%) <0.001 
Having recurrent stroke‡  155 (4.1%) 138 (4.6%) 0.314 
Proxy EQ5D assessment§ 1109 (41.7%) 968 (46.3%) 0.019 
Readmission  730 (19.1%) 569 (18.8) 0.727 
Additional process of acute care 
indicators (Queensland patients only) 
n = 1388 n = 1104  
Mobilisation ≤48 hours if unable to walk 
on admission 
463 (66.2%) 404 (63.1%) 0.765 
Received swallow assessment ≤24 hours 819 (59.0%) 602 (54.5%) 0.094 
Aspirin administration ≤48 hours* 894 (73.1%) 643 (66.3%) 0.245 
Discharged on antiplatelets or 
antithrombotic* 
960 (82.3%) 715 (77.4%) 0.556 
* among ischaemic stroke 
† among those with admission time ≤3.5 hours 
‡ missing data <10% 
§ missing data: 31% 
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Unable to walk Able to walk 
Men Women Women vs men Men  Women Women vs men 
n Median (IQR) n Median (IQR) MD (95% CI) n Median (IQR) n Median (IQR) MD (95% CI) 
<65 555 0.697 (0.490, 
0.887) 




595 0.800 (0.663, 
0.887) 




65-74 530 0.706 (0.482, 
0.887) 




497 0.887 (0.693, 
0.887) 
246 0.800 (0.689, 
0.887) 
-0.087 (-0.131,  
-0.043) 
>75 847 0.679 (0.459, 
0.887) 




561 0.800 (0.663, 
0.887) 




CI = confidence interval; IQR = interquartile range; MD = median difference 
*more severe stroke = unable to walk without assistance on admission; less severe stroke = able to walk without assistance on admission 




Figure 10-1. Mean difference in EQ5D utility scores between AuSCR survivors and the general population  
* from McCaffrey et al (2016); the score for group <55 was used by weighted estimates from age 15−54 
† AuSCR registrants who survived to 3-6 months after stroke 
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Chapter 11: Summary, implications, and future 
directions 
My thesis examined a series of research questions to comprehensively investigate the 
causes of sex differences in stroke management and outcomes after stroke. This work 
provides an original and significant contribution to the current literature on potential 
targets to mitigate the differences. In the papers produced as a consequence of 
completing this body of work, I substantially contributed to the study concept and 
design; the acquisition, analysis, and interpretation of data; and the preparation of the 
manuscripts for publication in peer-review journals.  
The results are likely to be relevant to people with stroke in many different settings 
given the use of individual participant data (IPD) that I compiled and analysed on 
first-ever strokes from 13 high-quality population-based studies (INSTRUCT; n 
>16,900 cases) conducted in many regions of the world, as well as data from a 
national stroke registry (AuSCR; n >14,000 cases). The two datasets complemented 
each other in addressing potential strengths and weaknesses of their designs (Table 
11-1) while also addressing several limitations of the existing literature.  
There were several novel aspects to the study designs that add to the overall quality of 
my research. The use of the two-stage method for IPD meta-analyses overcame 
inconsistent definitions and measurements of outcomes and covariates between 
different studies in the INSTRUCT. The data came from high-quality and 
generalisable studies with a very large number of participants, making this study 
adequately powered to test our hypotheses. Many investigators did not report sex-
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specific outcomes (section 1.3),170,173,369-373 my study approach could have helped 
address the issue that many investigators did not report sex-specific outcomes173 
which may be due to limited sample size or lack of awareness of the need of reporting 
results stratified by sex.390 I examined the sex differences in a wide range of long-
term outcomes after stroke available in the INSTRUCT including all-cause mortality, 
functional outcome, participation restriction, and HRQoL. The AuSCR analyses 
added substantially to the research through contributions on mortality, including 
COD, and HRQoL outcomes. Further, the data on stroke management in the AuSCR 
were up to date, so that the results are highly relevant to current clinical practice. In 
both datasets, the factors contributing to the poorer outcomes in women after stroke 
were investigated using purposeful model building, rather than traditional step-wise 
methods, providing a more comprehensive understanding of these factors than 
available from most of the previous studies.  
The findings fill important gaps in our understanding of why women have worse 
outcomes after stroke. They are likely to inform clinical practice, the development of 
new interventions and future research. A summary of the major findings is provided 
here, along with the potential implications and future directions for research. 
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Table 11-1. Strengths and limitations of the two datasets: the INternatinal STRoke oUtCome sTudy (INSTRUCT) and Australian Stroke 
Clinical Registry (AuSCR) 
 INSTRUCT AuSCR 
 Strengths  
Study design Population-based 
 
National registry with standardised data collection 
Analytic 
method 
Individual meta-analysis of large dataset (two-stage 
approach) with modelling that specifically focused on sex 
differences 
Multilevel modelling, accounting for hospital clusters, that 
specifically focused on sex differences 
Measures of 
outcomes  
A wide range of patient-reported outcomes were 
assessed. 




A wide range of covariates were assessed. The data on stroke management were up to date, so that the 
results are highly relevant to current clinical practice. 
 Limitations  
Study design Many studies were conducted in high-income countries. The research was based in the acute hospital setting and did not 
include all eligible hospitals across Australia and the number of 
clinical process indicators was minimal (4-8 max) whereby we 
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may over-/under-estimate the sex difference clinical care 
associated with longer term patient outcomes. 
Measures of 
outcomes 
There were fewer eligible studies with data on long-term 
functional outcome and HRQoL with various outcome 
measures. 
There were no data on functional outcome. 
Measures of 
covariates 
Data on stroke management stroke were limited and 
outdated. 
There were no data on history of cardiovascular diseases. 
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Figure 11-1. Summary of contributing factors to the sex differences in outcomes up to 5 years after stroke using the data from 13 population-
based studies (INSTRUCT) and the Australia Stroke Clinical Registry (AUSCR). *denotes carotid investigation or echocardiography 
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11.1 Summary of major findings 
In Chapter 3, I presented that women were 35% more like to be deceased by 1 year 
and 24% by 5 years after stroke compared to men. The poorer survival after stroke in 
women was fully explained by their advanced age, worse pre-stroke function, more 
severe stroke and, to a lesser extent, the presence of atrial fibrillation.  
In Chapter 4, I showed that up to 5 years after stroke, women were 31-32% more 
likely to have poorer functional outcomes and greater participation restriction than 
men. These worse outcomes after stroke among women were mostly explained by 
age, stroke severity, and poorer pre-stroke function.  
In Chapter 5, women, compared to men, were found to have 0.09-0.15 point lower 
mean utility scores up to 5 years after stroke, regardless of the HRQOL instrument 
(i.e. EQ5D, SF6D or AQoL). The poorer HRQoL after stroke in women was mostly 
explained by advanced age, pre-stroke functional limitations, stroke severity, and to a 
lesser extent, the presence of post-stroke depression. The innate differences between 
men and women in the general population were also explored providing potentially 
important context to the sex difference in HRQoL after stroke.  
In findings detailed in Chapters 3-5 (using the INSTRUCT data), women less often 
received in-hospital investigations including echocardiography and carotid 
investigation than men. However, these differences in care did not contribute to the 
sex differences in long-term outcomes after stroke.  
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Stroke severity was presented as a key factor contributing to the sex differences in 
survival, functional outcome, and HRQoL (Chapters 3-5). As such, severity was 
considered as a separate endpoint in Chapter 6. There was a 35% increased risk of 
having severe ischaemic strokes (NIHSS>7) in women than men. The sex differences 
in stroke severity were mostly explained by age, pre-stroke dependency, and atrial 
fibrillation. There was no sex difference in severity for intracerebral haemorrhage, 
even after adjustment for covariates.  
In Chapter 8, using data from the AuSCR, I demonstrated that there were only minor 
differences between men and women in the care received in the hospital. This was 
across several important evidence-based aspects of care including stroke unit access, 
intravenous thrombolysis, care plan provided at discharge, and being discharged on 
antihypertensive agent(s). Results for sex differences in outcomes were very similar 
to those using the INSTRUCT dataset. Women were 45% more like die by 1 year 
after stroke compared to men. The greater mortality in women was fully explained by 
age and stroke severity (indicated by the ability to walk independently on admission) 
but not due to the differences in processes of care  
Additional data from a subset of hospitals in Queensland, did indicate that women 
were 9% less likely to be administered aspirin ≤48 hours than men. In this subset, 
older age, severity, and under-treatment with aspirin, contributed to the sex 
differences in 1-year mortality. 
In Chapter 9, I reported that mortality up to 1 year after stroke was mainly driven by 
stroke and other cardiovascular diseases using the data from the AuSCR. Among 
those with stroke, causes of death (COD) up to 1 year following stroke differed by 
Chapter 11. Summary, implications, and future directions 
269 
 
sex. Women had 65% greater risk of death due to stroke or other cardiovascular 
disease (CVD; not including IHD) than men. These sex differences were mostly 
explained by age and stroke severity, indicated by the ability to walk on admission. In 
contrast, men with stroke were more likely to die by 1 year after their stroke from 
cancer or IHD than women. Both men and women across age groups had excess 
mortality due to stroke (>8 times higher than expected), IHD and other CVD (~3 
times higher) and cancer (2.6 times higher) compared with the general population.  
In Chapter 10, I found that women with stroke had, on average, 0.08 point lower 
HRQOL mean utility EQ5D scores at 3-6 months after stroke than men. Age, stroke 
severity, and living in aged care at 3 months post-stroke explained part of the sex 
differences but the younger men and elderly women still had poorer HRQoL after 
accounting for these factors. None of the differences in processes of care contribute to 
the sex differences in HRQoL. As was found in the comparison with the general 
population in the INSTRUCT data, the innate differences between men and women in 
HRQoL also accounted for some of the sex difference in HRQoL.  
A summary of the main results are illustrated in Figure 11-1. 
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11.2 Implications and future directions 
In the thesis, I have provided a comprehensive examination of the causes of 
differences between men and women in outcomes after stroke. Although most of the 
differences were explained by covariates, this does not mean that there is no sex 
difference. We cannot deny that women present at older ages with more severe 
strokes, and then have poorer outcomes that persist into the long term following 
stroke compared to men. Our research findings show that several factors including 
age, pre-stroke function, atrial fibrillation, stroke severity, and mood come together to 
contribute to a worse outcome for women (Figure 11-1). There were only minor 
variations in stroke care between men and women which reflects the overall advances 
in stroke care in recent times. Indeed the lack of differences across nearly all aspects 
of stroke care are indicative of the success of efforts to systematically monitor and 
improve the quality of stroke care. The findings of this thesis have a number of 
important implications for public health and clinical practice to minimise the gender 
gap in stroke outcomes. 
11.2.1 Factors contributing to sex differences in outcomes after stroke 
11.2.1.1 Age 
The majority of poorer outcomes among women with stroke were explained by their 
advanced age compared to men. In the INSTRUCT data, women with stroke were 
older (mean age of 75.4 years (SD 13.9) compared with men 70.9 years; SD 13.3). 
Over 69% of all participants aged 85 years or older in the dataset were women. These 
figures suggest that reducing the burden of stroke in the elderly will attenuate the sex 
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differences. Older age may reflect the reduced functional capacity of brain cells to 
recover after neurological insults,212 and other age-related factors including frailty, 
comorbidities (e.g. atrial fibrillation, hypertension and diabetes), functional 
limitations, and social isolation,213 which then lead to worse outcomes after stroke. 
Better stroke prevention by targeting modifiable CVD risk factors, prevention of 
frailty,220 and clinical management in the elderly, who are mostly women, are needed 
to improve cardiovascular and general health. This type of prevention will promote 
healthy active ageing and increase the years lived in healthy life.281 In Australia, 
annual health assessments for all people aged ≥75 years and older have been included 
in Medicare Benefits items since 1999.391 However, the uptake of these health checks 
among older Australian (75+) from 1999 until 2010 was general low (approximately 
20%) and slightly higher for women than men.392 In the Australian Longitudinal 
Study on Women’s Health, although there was an increase in assessment uptake in 
older women but many women either did not receive an assessment or did not repeat 
it annually.393,394 In addition, those older women in rural and remote areas were 
particularly disadvantaged.393 This suggests a need for more programs in primary care 
settings for older people, particularly women in rural areas, to closely monitor health 
issues and respond early to their needs. For instance, preventive primary care outreach 
(PPCO) interventions among community-dwelling older people can reduce their 
mortality risk by 17%, according to a meta-analysis of 19 randomised controlled 
trials.395 These outreach interventions are based on proactive, provider-initiated care 
in addition to usual care.395 PPCO can be provided by physicians, nurses, other 
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professionals, or volunteers including home visits, office visits, telephone contacts, or 
a combination of these methods.395  
On the other hand, men face a greater risk of having CVD including stroke at younger 
ages than women. There are therefore opportunities for more effective primary 
prevention aimed at preventing, or delaying, the onset of CVD and stroke in men, 
particularly younger men. This would also help narrow the gender gap in outcomes 
after stroke. Potential methods to achieve this would be better management of 
modifiable CVD risk factors including smoking cessation and promoting healthy 
lifestyle (i.e. healthy diets, physical activity and exercise), so that we can maximise 
stroke-free years of life.396 In Australia, the Medicare 45 Year Old Health Check 
(MBS Item 717) has been available since 2006 for people aged 45-49 years who are 
at risk of developing chronic disease.397 Middle-aged women, compared to their men 
counterparts, are at lower CVD risk and the health check program is less likely to be 
cost-effective.398 However, the rate of services claimed by 2009 per 100 population 
aged 45–49 years did not greatly differ between men than women (6.8 vs 6.6).397 Men 
have been reported to uptake health assessment less often than women, which are 
associated with such factors as the fear of getting the disease, avoidance of 
femininity, and lack of time.399 Clinicians, researchers and policy-makers who are 
developing interventions and policies should be aware of these barriers to increase 
assessment uptake among men particularly those in middle age,399 as well as engage 
them with healthy behaviours.400  
There is evidence that older adults less often receive evidence-based stroke care than 
younger people.214,401 This may contribute, among other factors, to their worse 
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outcomes after stroke compared to younger people.401 Less receipt of some aspects of 
care in the elderly with stroke may be appropriate due to contraindications, side 
effects, or risk of complications of treatment.216 Others have suggested that even older 
persons free of contraindications still receive less care than younger people.402 A 
contributing factor may be that evidence regarding the best care is limited by the 
under-representation of elderly in clinical trials.403 Also, costs of treatment might be 
an issue for the elderly because they may have less disposable income than younger 
people to pay for expensive prevention therapies. For instance, Australian consumers 
face high out-of-pocket costs which accounted for one-fifth of all health care 
spending.404 According to an Australian Bureau of Statistics survey, about one in 20 
people did not see a general practitioner due to cost, and the proportion was higher for 
women compared to men (5.2% vs 2.8%).405 Some researchers have suggested that an 
‘age-bias’ may exist,406 whereby the patients’ age (consciously or subconsciously) 
can influence clinicians’ decision-making.214 There has been an increasing interest in 
unravelling the age differences in management and outcome following stroke, but 
most studies have focused on rehabilitation settings407,408 which may lead to some 
selection bias. More high-quality population-based studies specifically designed to 
examine the age differences in use or underuse of therapeutic interventions and long-
term outcomes after stroke are needed to address these gaps. The data on age 
differences could be then incorporated into clinical guidelines including the safety 
and efficacy of interventions for older patients with stroke.355 Further qualitative 
research to better understand how age-related complexities (e.g. multimorbidities, 
polypharmacy, or health costs) affect clinical decision-making may offer some 
solutions to minimise age and sex differences in care.409 
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When prevention fails and a stroke does happen, it is important to ensure access to 
evidence-based processes of care for all people with stroke, irrespective of their age 
or sex. There has been recent interest in ‘care bundles’, which assess combinations of 
in-hospital care, as they are associated with better survival and HRQoL.60 A care 
bundle includes several evidence-based interventions for a defined patient population 
that is hypothesised to result in significantly better outcomes than when implemented 
individually.410 For instance, receiving acute stroke unit care (ASU) combined with 
antihypertensive medication significantly improved 180-day survival more than ASU 
care alone.60 
Poorer outcomes in elderly people may reflect a lack of intensive treatment due to the 
patient’s and their family’s preference as part of end-of-life care. However, the 
perspectives of end-of-life care are rarely recorded in current stroke studies and 
differences by sex have not been explored. Irrespective of age or sex, further 
investigations are needed to identify the needs of palliative and end-of-life care in 
order to provide adequate care and support for stroke patients and their families.331,332 
There has been recent discussion regarding the need to integrate palliative care within 
stroke services.411 Quality improvement programs and patient outcomes in palliative 
care practices also warrant future stroke research. Increasing our understanding of 
effective treatments and ensuring access to them for the elderly, and indeed in people 
of all ages, should be aligned with patient and family preferences. 
In summary, the overwhelming importance of age in explaining the sex difference 
suggests that better stroke prevention and access to evidence-based care for 
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cardiovascular and general health in the elderly is paramount to reducing the overall 
burden of stroke in men and women.  
11.2.1.2 Functional limitations before stroke  
Worse outcomes in women were also partly explained by their pre-stroke functional 
limitations, regardless of the measure used (i.e. self-reported mRS, Barthel Index and 
residing in a care facility before stroke). People with these type of functional 
limitations before stroke are more often women, older, and those having more 
cardiovascular comorbidities.227,296 Having a functional limitation can impact referral 
to rehabilitation246 and affect functional recovery after stroke.247  
My analysis of the association between pre-stroke function and sex difference in 
outcome after stroke was limited by the use of crude measures of functional 
limitations (i.e. mRS). Future studies using more detailed frailty indices might 
advance our understanding of the impacts of pre-stroke health on outcome and 
management in men and women after stroke.412 There are differences between men 
and women in the specific causes of healthy life lost. In men, they are mostly 
respiratory and cardiovascular conditions, whereas in women, they are most often 
musculoskeletal or related to mental disorders.218 It is possible that better 
management of chronic disease targeting these conditions could improve function219 
and thereby to maximise recovery from stroke for both men and women, if it were to 
occur. 
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11.2.1.3 Stroke severity  
Stroke severity was a prominent contributor to the sex differences in outcomes 
following stroke including mortality, functional outcome and participation restriction 
and HRQoL. Pre-stroke factors including age, pre-stroke functional limitation, and 
atrial fibrillation explained much (36%) of, but not all, the differences in stroke 
severity between men and women. The residual discrepancies may be due to 
unmeasured confounding factors but also underlying mechanisms of the more severe 
stroke in women, which requires further investigation. This should include both 
human and animal models to determine the potential biological reasons for the 
differences. 
Stroke severity contributed to sex differences in outcomes after stroke including 
mortality, functional outcome and participation restriction and HRQoL. Acute 
interventions such as intravenous thrombolysis or endovascular clot retrieval are 
proven to lessen stroke severity, and improve outcomes following stroke.355 Women 
with acute stroke appeared to receive thrombolysis162 and endovascular treatment330 
less often than men although these therapies are equally safe and effective to obtain 
good outcome between the sexes.413,414 Some of the sex differences are potentially 
explained by confounding factors (e.g. age and pre-stroke function), which requires 
further research to understand how these affect treatment and outcome after stroke. It 
is important to ensure equitable access to effective treatments of acute stroke for men 
and women to achieve more equal outcomes after stroke. An alternative way to 
reduce the severity of stroke, and therefore improve outcomes for women, might be to 
better manage the modifiable factors for stroke severity.227 These are reported to 
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include hypertension, diabetes, and particularly atrial fibrillation that are more often 
prevalent in women with stroke than men.236,415,416  
11.2.1.4 Atrial fibrillation 
In my thesis, atrial fibrillation (AF) was found to contribute to the sex difference in 
more severe stroke and greater long-term mortality following stroke. Although 
women have a lower age-adjusted incidence of AF than men; their longer life 
expectancy results in the same lifetime risk of AF.417 This results in a higher absolute 
number of women than men with AF.418 Women with AF face a greater risk of 
stroke.222 It is therefore surprising that they appear to have suboptimal management of 
AF compared to men.419 This includes that women with AF are less often treated with 
anticoagulants223 and receive less rhythm-control treatment (i.e. electrical 
cardioversion and catheter ablation) compared to men.224 Importantly, these 
treatments are equally effective at reducing cardiovascular events including stroke 
among men and women with AF.223,224  
It is important to ensure equitable identification of AF and access to effective 
therapies for men and women, with this likely reducing some of the sex difference in 
outcomes after stroke.256,418 Some of the differences in treatments may be explained 
by women’s greater age and co-morbidities that might lead to contraindications for 
some treatments.420 Those aged ≥75 years with AF have an increased risk of 
haemorrhage than their younger counterparts but there is no clinically justifiable 
reason not to prescribe treatments based on older age alone. The issue of greater 
frailty, fragility, risk of falls, and polymedication in the elderly, many of whom are 
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women, may lead to their underuse of anticoagulant therapy.421 Another possibility is 
the presence of cognitive impairment in elderly people, which is associated with their 
low adherence to AF treatment.422 Identifying potential barriers to effective treatment 
of AF in women, and the elderly in general, and developing interventions to address 
this will help to reduce the burden of stroke.419 For example, doctors might not 
prescribe warfarin in older women with AF if they are at risk of frequent falls but the 
effect of anticoagulation may not exceed the risk of intracranial haemorrhage.419 
Novel direct oral anticoagulants (NOAC) may, therefore, offer a solution given their 
risk of bleeding is much less compared to warfarin.419 The NOACs are also reported 
to have fewer interaction with other drugs which can help increase medication 
adherence among the elderly.419 Some of these new anticoagulants are more cost-
effective than warfarin in preventing stroke and other cardiovascular events among 
those with AF (i.e. apixaban is optimal for those age ≥75 years).423  
11.2.1.5 Processes of care 
One of the greatest opportunities to improve outcome after stroke is to ensure access 
to evidence-based processes of care as recommended in clinical guidelines.60 There is 
some evidence that if hospitals provided care in line with clinical guidelines, the 
health and economic benefits of reducing impacts of stroke would be substantial 
within the Australian context.424 One way to increase the use of evidence-based care 
is through quality improvement programs that aim at changing clinical practice and 
increasing adherence to evidence-based clinical guidelines.425-428 These have been 
shown to reduce variation in stroke care and therefore provide a way to reduce 
differences in outcome for many patient groups including women and the elderly.429  
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There were only minor variations in stroke care between men and women which 
could be interpreted as a success of efforts to systematically monitor and improve the 
quality of stroke care. Even though the differences are small and largely not 
statistically significant, the volume of patients with stroke might mean they may have 
a large impact on the total stroke burden. More importantly, a large number of both 
men and women with strokes were not treated with evidence-based therapies 
including stroke unit access, intravenous thrombolysis for ischaemic stroke, and 
secondary prevention medication. We should continuously strive to provide access to 
evidence-based care irrespective of a person’s sex, age or where they live.430  
11.2.1.6 Receipt of aspirin within 48 hours 
The findings reported in this thesis highlight that early aspirin is important for women 
to access. Age and severity did not fully account for the under-treatment with aspirin 
among women. Further quantitative and qualitative research will be needed to explore 
the reasons for this difference. It is uncertain whether the sex difference in the use of 
this medication is due to unmeasured factors including comorbidities, medications, 
complications, or contraindications to the treatments (i.e. allergy, bleeding disorder, 
or uncontrolled hypertension).336 The greater presence of comorbidities in women 
compared to men, particularly AF, may play a role whereby those women may 
receive anticoagulants instead of antiplatelet agents like aspirin.333 However, in 
previous observational studies the underuse of both anticoagulants and antiplatelets in 
women that have suffered a stroke has been found.334 Further research is required to 
identify the treatment barriers and ways to address these barriers.  
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11.2.1.7 Unmeasured factors  
The association between sex and outcomes may be confounded by sex-specific risk 
factors of stroke, rehabilitation outcomes, and some cultural or social factors. These 
types of data were not collected in the studies included in this thesis. New population-
based, purposely designed studies or re-analysis of existing studies that do gather 
these data are needed to understand how stroke affects women and men’s health in 
relation to these aspects. This approach will allow us to capture a wider perspective of 
the disease including patient characteristics, stroke risk factors, comorbid conditions, 
processes of care, and long-term outcomes after stroke from different settings. 
11.2.2 Broader implications of research findings 
Several findings of the thesis were not related to the sex differences in outcomes, but 
have important implications for both men and women and are discussed below. 
11.2.2.1 Both women and men with stroke had excess mortality and 
significant HRQoL loss compared to the general population 
People with stroke had excess deaths due to stroke, other CVD, and cancer when 
compared to the general population. This could be explained by the fact that these 
causes of death share common risk factors, such as hyperlipidemia, diabetes, and 
smoking. Effective primary and secondary stroke prevention strategies should be 
developed, evaluated and implemented to ameliorate mortality risk due to stroke and 
other CVD. There is a need to implement more effective prevention programs for 
both high-risk individuals and the general population. The high-risk approach 
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includes identification and management of people with increased absolute risk of 
CVD and stroke. Preventive interventions among high-risk individuals such as 
pharmacological treatment have led to a significant reduction in the incidence of 
stroke and CVD.431 For example, evidence has shown that the use of ‘polypill’ 
therapy that combines multiple drugs (i.e. statin, antihypertensive agents, aspirin) 
could reduce stroke and other CVDs by 80% among those ≥55 years with existing 
CVD.364  
On the other hand, promoting prevention strategies at the population level is also 
important. There has been recent interest in population-wide strategies for primary 
stroke prevention that target people at any level of CVD risk using e-health.432 
Government investment in preventive programs is limited.433 This suggests a need to 
advocate for more spending on prevention. There should also be a focus on examining 
the cost-effectiveness of preventive health interventions which are associated with 
better cardiovascular and general health.433 According to the Danish National Patient 
Registry (2015), female patients usually have lower income than their male 
counterparts.434 In this study, there were greater expenses due to hospitalisation and 
medication (direct cost) among younger adults and women with stroke whereas there 
was no sex difference in indirect health cost.434 Little is known about the direct and 
indirect health costs associated with poorer outcomes after stroke in women compared 
to men,434,435 requiring further research. 
In my findings, a large proportion of deaths were attributable to cardiac disease. It is 
recommended in clinical stroke guidelines on ECG monitor for at least 24 hours, 355319  
and 94% patients with received the cardiac functional test while in hospital, according 
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to the National Stroke Audit Report 2013 (Australia).346 However, little is known 
about the effectiveness of routine cardiac imaging or continuous monitoring in the 
longer term, requiring further research.355 More sensitive and specific biomarkers or 
advanced cardiac imaging (i.e. three-dimension echocardiography) may provide 
helpful information for better detection and management of cardiovascular health 
following stroke.  
Cancer generally has a long development period, suggesting that deaths from cancer 
after stroke were mostly from pre-existing diseases. There is some discussion on 
screening for cancer in the patient with cryptogenic stroke that may help to diagnose 
occult cancer and inform future interventions, but the cost-effectiveness of this 
approach warrants more research.365,366 The other potential mechanism is related to 
newly diagnosed cancer patients who have a stroke possibly due to hypercoagulation 
(i.e. causing thromboembolism)367 or side-effects of cancer treatment.368 Given the 
lack of cancer-related data in stroke studies, it may be useful to further examine the 
predictors of long-term outcomes among people with stroke and cancer, potentially 
using data linkage. Because patients with stroke and a history of cancer have an 
increased risk of recurrent stroke and cardiovascular mortality,365 these outcomes 
should be considered in future stroke research together with other data including 
cancer treatment (e.g. chemotherapy, radiotherapy).  Understanding the 
interrelationships between cancer and stroke is important given the large burden 
associated with these two diseases.368 
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11.2.3 More opportunities for rehabilitation programs and interventions to 
increase participation, particularly for women after stroke 
Women have been reported to have worse functional outcome after stroke 
rehabilitation than men, even after matching (i.e. using propensity score matching 
technique) for age, stroke severity, and time to hospital admission.247 One explanation 
is that existing functional limitations, that may be more common in women, can 
influence the choice of discharge destination (i.e. type of rehabilitation setting) and 
subsequent rehabilitation outcomes in women after stroke.246 Women appear to have 
lower response to rehabilitation particularly on mobility than men, which might be 
related to sex-related differences in muscular strength.246 Numerous factors that are 
associated with outcomes including social factors (e.g. sex, age, ethnicity, and 
culture), pre-stroke health, clinical indicators, and post-stroke conditions (e.g. living 
alone, social isolation) should be taken into account in rehabilitation programs.280 
Rehabilitation following stroke is quite individualised and focused. Although in many 
countries (e.g. Australia, New Zealand, and United Kingdom) it is recommended that 
all people with stroke should receive rehabilitation, access to rehabilitation is rarely 
reported.436 The proportion of people with stroke accessing in-hospital rehabilitation 
varied by region (i.e. from 13% in Sweden, 30% in Australia, to 57% in Israel) 
whereas little is known about the access to home- or community-based 
rehabilitation.436 Further work is warranted to identify potential barriers to receiving 
rehabilitation services to understand ways to engage more people into rehabilitation. 
One of the strategies to boost patients' engagement in rehabilitation activities is to use 
advanced technology (e.g. digital game systems), which may keep stroke survivors 
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entertained and motivated during the therapy process.437 The access to rehabilitation 
may be restricted by geographical distances or a lack of allied health professionals in 
rural and remote areas.438 Stroke telerehabilitation may offer more opportunities to 
make rehabilitation services more convenient and accessible, particularly for those 
living in under-resourced areas, to improve outcomes after stroke.438 There is some 
evidence of inequities in access to rehabilitation whereby clinicians tended to 
recommend the patients for rehabilitation based on subjective rehabilitation services 
selection criteria rather than patient’s requirements.439 Improvements in rehabilitation 
service delivery is needed to meet the rehabilitation needs of patients with stroke. 439 
Allied health with a range of services such as physiotherapy, occupational therapy, 
social work and speech-language therapy will help to facilitate participation after 
stroke. More recently, creative art therapies (i.e. music) combined with conventional 
physical therapy program have been suggested to further improve functional 
outcomes and HRQoL as well as reduce depression after stroke.440 Also, fitness 
training in combination with psychosocial or educational interventions may have 
some benefits on improving outcomes following stroke, like the exercise-based 
cardiac rehabilitation has had, particularly on reducing CVD mortality.362,363 
11.2.4 Outcome assessments in research studies 
There has been increasing evidence that several clinical and social needs in survivors 
of stroke remain unmet long after stroke.261,441-443 Common domains of unmet needs 
include activities and participation, environmental factors, body functions, acute care, 
and secondary prevention. However, many of these are not captured in current 
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research (e.g. only two out of 13 studies included in the INSTRUCT had a 
participation outcome).24 More outcome assessments and examination of the reasons 
for unmet needs of stroke survivors in population-based studies would offer specific 
targets for future interventions to address any identified gaps. 
The factors associated with greater unmet needs also varied by countries and study 
settings. Younger persons, the elderly, men, and women express different senses, 
perception, and coping strategies with the consequences of stroke,444 which 
potentially leads to their different needs.261,441,442  Other predictors of unmet needs at 
the time of stroke have been identified such as living alone (many of whom are older 
women),442 ethnic minority groups,443 living in the most deprived areas,443 higher 
education,261 atrial fibrillation,442 diabetes,442 previous stroke,442 stroke severity,442 
and haemorrhages.442 Higher levels of unmet needs were also observed among those 
with greater functional limitations after stroke,261,441,442 pain,442 depression,261,442 the 
receipt of community services,261 the inability to return to work.441 Strategies aimed at 
better supporting stroke survivors and their families should be well-developed 
according to age, gender, and location to meet people’s needs in facilitating 
independent living, participation and increased HRQoL.445 The unmet needs are 
generally most prevalent in secondary stroke prevention,261 meaning that the success 
of secondary prevention management of stroke and CVD is more likely to improve 
the long-term outcomes after stroke for both men and women. In Australia, websites 
such as “EnableMe” (at https://enableme.org.au/),446 developed by the National 
Stroke Foundation, supply trusted resources on impacts of stroke to survivors and 
provide an important advance in meeting their needs. 
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11.2.5 Further work in low- and middle-income countries is needed 
The data used within this thesis mostly focused on high-income countries (HICs) due 
to the lack of eligible studies conducted in low- and middle-income countries 
(LMICs).  
11.2.5.1 More population-based studies  
There are some ‘gold standard’ stroke incidence studies in LMICs that were identified 
in my systematic search. However, very few have data on outcomes following stroke, 
particularly in the long term. This situation is most likely because follow-up can be 
labour intensive and costly. Linkage of stroke incidence studies to the national death 
registrations offers a solution for the lack of long-term survival information in many 
HICs.236 National registration systems for deaths, nevertheless, remain uncommon in 
most LMICs.447 I strongly advocate for other researchers to conduct long term follow-
up within their stroke studies, particularly in LMICs, given the importance of 
understanding the natural history of stroke.  
The burden of stroke is considerable in LMICs accounting for 52% of prevalent 
strokes, 71% stroke-related deaths, and 78% of disability-adjusted life years lost, 
globally.1 Developing countries are experiencing about 23% greater incidence of 
stroke than more developed countries, and the gap continues to widen.1 In HICs, the 
burden of stroke is related to the ageing population while in LMICs, stroke occurs in 
younger age mostly due to the increased CVD risk factors among adults.448 Future 
studies designed to investigate the patient profile and outcomes of early onset strokes, 
as well as any sex differences in developing countries are of utmost importance. This 
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extra information would establish a better understanding of how to reduce the impact 
of stroke in developing countries such as through developing evidence-based models 
of health care and policy frameworks. For instance, several groups/organisations 
working in the stroke field and authorities in Australia work together to tackle agreed 
priorities to improve care based on gaps identified in the national audit and other data 
sources.324,449 
11.2.5.2 More stroke clinical registries 
Although it is essential to ensure access to evidence-based care to reduce the impact 
of stroke, current evidence on the quality of stroke care has mostly been documented 
in HICs. In developed countries, given the use of effective interventions for quality 
improvement and the availability of specialists with extra training in neurology or 
stroke care, the adherence to clinical guidelines for stroke has been increased.425-428 In 
contrast, there is a dearth of evidence for these type of programs, as well as lack of 
stroke care professionals in LMICs, suggesting further researches needed to 
understand and overcome these barriers.450  
According to a recent update on global stroke statistics by Thrift and colleagues, there 
have been eight countries that either lack or provide outdated data on stroke incidence 
but have national clinical registries of hospital-based data.58 On the one hand, 
population-based stroke incidence studies may not be undertaken nor repeated due to 
costs and labour intensity.58 On the other hand, clinical stroke registries allow us to 
capture aspects of the quality of care through measuring current processes of in-
hospital care as well as patient outcomes.25 National stroke registries, therefore, could 
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be serve as a proxy for population-based incidence studies in locations where the 
majority of incidence cases are treated in hospital.58 
It is advocacated that countries unable to afford stroke incidence studies, particularly 
in LMICs, should consider establishing registry program for stroke care, both on the 
national and regional level.451 There is also a pressing need for quality improvement 
efforts452 to monitor and improve the quality of care in both developed and 
developing countries.   
11.2.5.3 More examination of sex differences in stroke outcome 
Of a small number of stroke studies conducted in LMICs, few have been designed to 
investigate the sex- differences in outcomes following stroke or have not reported 
findings by sex categories. There are gender differences in the social determinants of 
health factors, and these gaps appear to be more substantial in LMICs than in 
HICS.453 For example, women in LMICs, compared to men, often sleep shorter hours, 
spend less time on social and cultural activities but more hours on unpaid work, 
housework, and taking care of children and adults,453 which may influence the 
recovery after stroke, community reintegration, survival and HRQoL. Therefore, 
these social and cultural factors need to be investigated when considering the sex 
differences in outcomes after stroke in LMICs.  
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11.2.6 Better evaluation of-pre-stroke function and patient-reported outcomes 
after stroke  
In the previous chapters, the problems related to current measures on functional 
ability before stroke (i.e. using the pre-morbid mRS),454,455 comorbidities, and patient 
outcomes after stroke were outlined. More reliable and sensitive stroke-assessment 
scales that accurately reflect pre-stroke health, stroke outcomes and patients' 
experience of life after stroke will allow greater opportunities for future interventions 
to reduce the burden of stroke for both men and women.  
Because participation restriction is an important person-centred outcome after stroke 
but rarely assessed in stroke research,68 this would be an important outcome to 
advocate for in future studies. Current participation instruments (e.g. London 
Handicap Scale) were designed to evaluate healthcare interventions in a population 
rather than individuals257 and the assessments may reflect what people do, not what 
they can do.258 New instruments to improve measurement of patient-centered 
outcomes particularly participation following stroke may address these problems. 
Some of relevant scales which measures participation include the Nottingham 
extended activities of daily living scale (NEADL) or the Activity Card Sort Test, used 
in more recent studies,259 and international standard sets of patient-centred outcome 
measures (PROMS).68  
A myriad of life perspectives following stroke may differ by sex but receive little 
investigation. In relation to the participation outcome, they include communication, 
general tasks and demands, or performing household tasks259 while in HRQoL 
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outcome, these domains are vision, language, thinking, energy, and memory. In my 
research, post-stroke mood disorder (e.g. anxiety, depression) appeared to contribute 
to women’s poorer HRQoL. However, whether there are differences between men 
and women in the diagnosis and response to post-stroke depression treatment and its 
association with HRQoL are uncertain. Recent international standard sets of PROMS 
after stroke that are valid and reliable may be helpful to further our understanding of 
sex differences in outcome, as well as making the data comparable between countries 
and care settings.68 The PROMS categories recommended for assessment include 
survival, processes of care, acute complications, and patient-reported outcomes.68 
Patient-reported outcomes proposed for assessment at 3-months post-stroke are pain, 
mood, feeding, self-care, mobility, communication, cognitive functioning, social 
participation, ability to return to usual activities, and HRQoL.68 There has been an 
abundance of high-quality research (i.e. randomised clinical trials, population-based 
studies, and clinical stroke registries) with PROMs, which provide numerous 
opportunities to explore the ways to improve patient-relevant outcomes after stroke.23  
11.3 Conclusion 
The differences between men and women in outcomes after stroke are mostly 
explained by age, pre-exisiting functional limitations, and stroke severity. Therefore, 
primary prevention of stroke and other CVD is paramount. There are more 
opportunities for better access to evidence-based care, as well as focused 
rehabilitation programs that provide more support for women, the elderly, and other 
vulnerable individuals. We should reassess all pre-stroke measures and stroke-
assessment scales to ensure the accurate capturing of patient experience after stroke, 
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which would be helpful to target the interventions to reduce or postpone the 
devastating impact of stroke. Overall, this thesis has addressed my primary aims of 
understanding the magnitude of sex differences in outcomes after stroke and the 
causes of these differences. There do, however, remain further avenues for research 
and the development of interventions to mitigate differences between men and 





Appendix A: Sex differences in long-term mortality 
after stroke in the INternational STRoke oUtComes 
sTudy 
Supplemental Table A-1a. Characteristic of included cohort studies from Oxford, 
Joinville, Melbourne, Arcadia and Perth by sex 
  Oxford   Joinville   Melbourne   Arcadia   Perth  
Characteristic Men Women Men Women Men Women Men Women Men Women 
SOCIODEMOGRAPHIC           




















Race (%)           
Caucasian - - 88.0 92.0 92.1 94.4 - - - - 
Non-Caucasian   11.6 7.4 3.3 2.7     
Unknown   0.4 0.6 4.6 2.9     
Marital status (%)           
Single/widowed 23.3 49.5 - - - - - - 33.3 56.3 
Married 62.3 36.0       63.2 38.5 
Unknown 14.3 14.5       3.5 5.2 
Education level (%)           
≤ Grade 12 61.6 62.3 94.5 93.0 43.6 44.7 - - - - 
> Grade 12 14.6 8.9 5.1 6.8 51.5 54.3     
Unknown 23.8 28.8 0.4 0.2 5.0 1.0     
Social class (%)           
Professional 15.2 6.0 - - 36.1 30.0 - - 17.2 6.3 
Non-manual 21.4 28.7   10.6 12.2   6.9 9.4 
Manual 39.6 32.4   44.1 31.7   33.3 20.8 
Unknown 23.8 32.9   9.2 26.1   42.5 63.5 
PRE-STROKE HEALTH           
In an institution (%)           
Yes - - - - 7.9 21.5 - - 8.1 18.8 
No     90.4 77.3   89.7 78.1 
Unknown     1.7 1.2   2.3 3.1 
Modified Rankin Score (%)           
0-2 83.5 70.6 - - - - 99.0 98.0 71.3 56.3 
3-5 13.2 26.0     0.3 0.8 18.4 27.1 
Unknown 3.4 3.4     0.7 1.2 10.3 16.7 
Barthel Index score (%)           
20 - - - - 50.9 36.4 - - 69.0 51.0 
<20     11.6 17.1   20.7 33.3 
Unknown     37.4 46.5   10.3 15.6 




















MEDICAL HISTORY           
Hypertension (%)           
Yes 59.2 63.6 62.7 68.9 50.4 55.8 78.3 84.6 52.9 58.3 
No 40.2 36.4 37.3 31.1 48.0 42.3 21.7 15.5 39.1 39.6 
Unknown 0.5 0.0 0.0 0.0 1.5 1.9 0.0 0.0 8.1 2.1 
Atrial fibrillation (%)           
Yes 20.1 23.0 8.9 10.6 20.7 22.6 30.7 38.2 19.5 24.0 
No 79.6 76.9 91.1 89.4 77.4 74.8 69.3 61.8 73.6 70.8 
Unknown 0.3 0.1 0.0 0.0 1.9 2.6 0.0 0.0 6.9 5.2 
Ischaemic heart disease (%)           
Yes 14.8 8.6 9.7 4.7 16.4 10.7 18.1 15.0 17.2 6.3 
No 84.2 91.0 90.3 95.4 82.9 87.4 81.9 85.0 78.2 88.5 
Unknown 1.0 0.4 0.0 0.0 0.7 1.9 0.0 0.0 4.6 5.2 
Peripheral vascular disease (%)           
Yes 8.7 5.3 - - 11.6 5.5 8.7 6.5 - - 
No 90.7 94.4   87.4 92.3 91.3 93.5   
Unknown 0.6 0.3   1.0 2.2 0.0 0.0   
Transient ischaemic attack (%)           




Supplemental Table A-1a. Characteristic of included cohort studies from Oxford, 
Joinville, Melbourne, Arcadia and Perth by sex 
  Oxford   Joinville   Melbourne   Arcadia   Perth  
Characteristic Men Women Men Women Men Women Men Women Men Women 
No 86.0 87.8 93.7 96.0 90.6 91.0 80.9 86.6 64.4 76.0 
Unknown 0.2 0.1 0.0 0.0 1.0 0.8 0.0 0.0 14.9 11.5 
Diabetes (%)           
Yes 14.9 11.5 - - 20.0 14.1 27.8 32.1 20.7 16.7 
No 84.6 88.5   79.3 84.8 72.2 67.9 77.0 82.3 
Unknown 0.4 0.0   1.0 1.1 0.0 0.0 2.3 1.0 
Dementia (%)           
Yes - - - - 5.3 13.1 - - - - 
No     73.2 65.8     
Unknown     21.5 21.1     
Smoking (%)           
Current 17.3 13.2 28.4 17.6 17.8 11.5 34.0 2.0 4.2 4.2 
Former 51.3 27.1 40.6 18.0 45.1 18.9 - - 14.6 14.6 
Never 28.7 55.5 31.0 64.5 27.7 50.3 66.0 98.0 45.8 45.8 
Unknown 2.8 4.2 0.0 0.0 9.4 19.3 0.0 0.0 24.1 35.4 
Alcohol use (%)           
Non-drinkers 27.0 54.0 51.9 80.6 18.6 40.2 79.3 98.4 24.1 26.0 
Not heavy drinkers 60.4 33.3 38.3 18.0 51.1 35.4 - - 6.9 11.5 
Heavy drinkers 3.6 1.6 9.9 1.5 8.9 1.1 20.7 1.6 34.5 13.5 
Ex-drinkers - - - - 7.7 1.1 - - 4.6 3.1 
Unknown 9.0 11.2 0.0 0.0 13.7 22.2 0.0 0.0 29.9 45.8 












Medication           
Antihypertensives (%)           
Yes - - 59.6 67.0 49.2 56.0 - - 43.7 50.0 
No   40.4 33.0 49.7 42.0   46.0 42.7 
Unknown   0.0 0.0 1.0 2.1   10.3 7.3 
Antiplatelets (%)           
Yes - - 28.8 27.5 30.3 29.4 - - 26.4 40.6 
No   71.2 72.5 68.7 68.7   71.3 54.2 
Unknown   0.0 0.0 1.0 1.9   2.3 5.2 
HOSPITAL ADMISSION           
Hospital admission (%)           
Yes 85.4 86.2 100.0 100.0 93.3 89.7 92.6 92.3 75.9 76.0 
No 14.6 13.8 0.0 0.0 6.7 10.3 7.4 7.7 24.1 24.0 
Time to arrive hospital (%)           
≤ 4.5 hours - - 42.0 45.0 24.5 24.2 - - 16.7 17.8 
> 4.5 – 24 hours   25.4 19.5 9.3 9.5   7.6 9.6 
> 24 hours   29.6 32.4 6.6 4.3   10.6 16.4 
Unknown   2.9 3.2 59.5 62.0   66.2 56.2 
STROKE-RELATED 
FACTORS 
          
Stroke type (%)           
Ischaemic stroke  82.6 78.1 79.1 82.0 74.4 66.5 68.6 66.3 78.2 75.0 
Intracerebral haemorrhage 8.1 8.2 11.4 4.8 16.1 13.3 14.6 8.5 11.5 9.4 
Subarachnoid haemorrhage 2.4 5.7 4.9 6.1 2.7 7.1 1.6 3.3 5.8 6.3 
Undetermined 6.9 8.0 4.5 5.1 6.8 13.1 15.2 22.0 4.6 9.4 
Stroke severity           




7.2 (7.8) 8.0 
(8.5) 
8.1 (8.5) 9.9 (9.5) - - 8.3 (8.3) 9.3 
(8.6) 
Mean (SD) GCS, reversed - - - - - - 4.8 (3.7) 5.5 (3.5) - - 
Loss of consciousness (%)           
Yes - - - - 20.5 27.6 11.7 14.6 - - 
No     57.8 51.4 80.9 77.6   
Unknown     21.7 20.9 7.4 7.7   
Body paralysis (%)           
Yes - - - - 31.1 33.3 33.3 33.7 - - 
No     4.6 59.2 59.2 58.4   
Unknown     21.3 7.4 7.4 7.7   
Incontinence (%)           
Yes - - - - 15.7 21.3 15.9 20.7 - - 
No     78.8 73.9 76.7 71.5   
Unknown     5.5 4.8 7.4 7.7   
POST-STROKE FACTORS           
Depression at 1 year†           




Supplemental Table A-1a. Characteristic of included cohort studies from Oxford, 
Joinville, Melbourne, Arcadia and Perth by sex 
  Oxford   Joinville   Melbourne   Arcadia   Perth  
Characteristic Men Women Men Women Men Women Men Women Men Women 
No     9.6 9.2     
Unknown     47.3 55.4     
Depression at 5 years†           
Yes - - - - 9.5 10.8 - - - - 
No     59.3 56.9     
Unknown     31.2 32.3     
Recurrence at 1 year           
Yes 8.7 10.8 - - 0.5 0.8 4.9 4.5 - - 
No 91.3 89.2   99.5 99.2 92.9 89.8   
Unknown 0.0 0.0   0.0 0.0 2.3 5.7   
Recurrence at 5 years           
Yes 7.1 11.8 - - 7.0 6.8 - - - - 
No 46.7 45.1   93.0 93.2     
Unknown 46.2 43.2   0.0 0.0     
Bold denotes statistically significant results, NIHSS, National Institutes of Health Stroke Scale, GCS, 
Glasgow Coma Scale. 





Supplemental Table A-1b. Characteristic of included cohort studies from Orebro, 
Dijon, Martinique, and Porto by sex 
  Orebro   Dijon   Martinique   Porto  
Characteristic Men Women Men Women Men Women Men Women 
SOCIODEMOGRAPHIC         
















Marital status (%)         
Single/widowed 36.1 66.8 - - - - - - 
Married 63.9 31.7       
Unknown 0.0 1.4       
Education level (%)         
≤ Grade 12 - - - - - - 75.4 63.1 
> Grade 12       3.2 1.5 
Unknown       21.5 35.4 
Social class (%)         
Employed - - - - 29.5 19.3 21.5 10.2 
Retired     62.1 64.1 72.2 72.3 
Unemployed & other     8.4 16.6 1.4 8.7 
Unknown     0.0 0.0 4.9 8.9 
PRE-STROKE HEALTH         
In an institution (%)         
Yes 7.1 17.3 3.6 10.7 - - - - 
No 92.9 82.7 96.5 89.3     
Unknown 0.0 0.0 0.0 0.0     
Modified Rankin score (%)         
0-2 - - - - - - 90.5 77.7 
3-5       7.4 14.4 
Unknown       2.1 7.9 
Barthel Index score (%)         
20 67.5 54.3 - - - - - - 
<20 5.9 7.2       
Unknown 26.6 38.5       








- - - - - - 
MEDICAL HISTORY         
Hypertension (%)         
Yes 29.0 38.5 66.3 65.2 63.9 74.2 56.7 63.9 
No 67.5 57.7 32.7 33.7 34.7 23.4 43.3 36.1 
Unknown 3.6 3.9 1.0 1.1 1.4 2.4 0.0 0.0 
Atrial fibrillation (%)         
Yes 23.1 24.5 19.1 25.0 12.3 14.6 10.9 15.6 
No 79.9 75.5 79.8 73.8 86.3 83.1 89.1 84.4 
Unknown 0.0 0.0 1.1 1.2 1.4 2.4 0.0 0.0 
Ischaemic heart disease (%)         
Yes 16.6 12.0 20.1 16.1 4.6 6.8 7.4 9.9 
No 83.4 88.0 78.7 82.7 94.0 90.9 92.6 90.1 
Unknown 0.0 0.0 0.97 1.3 1.4 2.4 0.0 0.0 
Peripheral vascular disease (%)         
Yes 36.1 24.0 11.8 6.4 9.5 16.6 7.4 3.7 
No 62.7 74.5 87.2 92.4 89.1 81.0 84.2 77.0 
Unknown 1.2 1.4 1.0 1.2 1.4 2.4 8.5 19.3 
Transient ischaemic attack (%)         
Yes 16.0 13.5 11.2 10.4 4.2 6.1 9.9 7.7 
No 84.0 86.5 88.8 89.6 55.1 51.9 90.1 92.3 
Unknown 0.0 0.0 0.0 0.0 40.7 42.0 0.0 0.0 
Diabetes (%)         
Yes 20.1 15.9 - - - - - - 
No 78.1 80.8       
Unknown 1.8 3.4       
Dementia (%)         
Yes 7.1 15.9 - - - - - - 
No 92.9 84.1       
Unknown 0.0 0.0       
Smoking (%)         
Current 26.0 14.9 42.3 9.3 14.0 0.0 28.9 3.5 
Former - - 9.1 1.3 - - 16.9 0.5 
Never 62.7 77.9 36.9 74.5 84.6 97.6 54.2 96.0 




Supplemental Table A-1b. Characteristic of included cohort studies from Orebro, 
Dijon, Martinique, and Porto by sex 
  Orebro   Dijon   Martinique   Porto  
Characteristic Men Women Men Women Men Women Men Women 
Alcohol use (%)         
Non-drinkers - - 88.5 96.5 73.7 93.6 28.5 57.7 
Current drinkers*   10.0 2.0 24.9 4.1 60.6 18.3 
Ex-drinkers   - - - - - - 
Unknown   1.6 1.6 1.4 2.4 10.9 24.0 




HOSPITAL ADMISSION         
Hospital admission (%)         
Yes 92.9 91.4 99.8 99.8 93.7 93.2 95.8 95.1 
No 7.1 8.7 0.2 0.2 6.3 6.8 4.2 5.0 
Time to arrive hospital† (%)         
≤ 4.5 hours - - - -   4.4 39.6 
> 4.5 – 24 hours     86.5 82.6 30.2 35.9 
> 24 hours     13.5 17.1 17.3 12.5 
Unknown     0.0 0.4 9.2 12.0 
STROKE-RELATED FACTORS         
Stroke type (%)         
Ischaemic stroke  74.0 71.6 83.1 82.3 75.1 78.0 77.1 75.5 
Intracerebral haemorrhage 14.8 9.1 11.9 11.3 16.1 9.5 16.6 15.8 
Subarachnoid haemorrhage - - 2.9 3.5 3.5 3.4 1.8 4.5 
Undetermined 11.2 19.2 2.2 2.9 5.3 9.2 4.6 4.2 
Stroke severity         




7.2 (7.1)‡ 8.2 
(7.9)‡ 
- - - - 
Mean (SD) UNSS, reversed - - - - - - 9.3 (9.2) 12.3 (10.5) 
Loss of consciousness (%)         
Yes - - 20.8 25.3 - - 3.9 7.2 
No   79.2 74.8   96.1 92.8 
Unknown   0.0 0.0   0.0 0.0 
Body paralysis (%)         
Yes - - 71.9 73.1 - - 70.4 31.4 
No   27.0 26.5   29.6 68.6 
Unknown   1.1 0.5   0.0 0.0 
Barthel Index score at onset (%)         
> 60 - - - - 45.3 35.9 - - 
≤ 60     24.6 30.9   
Unknown     30.2 33.2   
POST-STROKE FACTORS         
Depression at 5 years§ - - - - 10.7 12.2 - - 
Yes     89.3 87.8   
No     0.0 0.0   
Unknown         
Recurrence at 1 year§         
Yes - - 3.7 8.8 4.9 8.2 9.9  
No   96.3 91.2 95.1 91.8 90.1  
Unknown   0.0 0.0 0.0 0.0 0.0 0.0 
Recurrence at 5 years§         
Yes - - 8.3 8.2 - - 18.7 14.4 
No   91.7 91.9   81.3 85.6 
Unknown   0.0 0.0   0.0 0.0 
Bold denotes statistically significant results, NIHSS, National Institutes of Health Stroke Scale, UNSS, 
Unified Neurological Stroke Scale.  
*current drinker = not heavy drinkers and heavy drinkers; † among hospitalised patients; ‡ NIHSS had 




Supplemental Table A-1c. Characteristic of included cohort studies from Auckland, 
L’Aquila, Matão, and Tartu by sex 
  Auckland   L’Aquila   Matão   Tartu  
Characteristic Men Women Men Women Men Women Men Women 
SOCIODEMOGRAPHIC         
















Race (%)         
Caucasian - - - - 80.4 80.0 - - 
Non-Caucasian     13.7 10.0   
Unknown     5.9 10.0   
Marital status (%)         
Single/widowed 32.5 62.0 - - 25.5 40.0 - - 
Married 65.2 34.1   68.6 56.7   
Unknown 2.3 3.8   5.9 3.3   
Education level (%)         
≤ Grade 12 38.4 49.3 - - 78.4 90.0 - - 
> Grade 12 36.3 23.0   9.8 3.3   
Unknown 25.3 27.7   11.8 6.7   
Social class (%)         
Professional 23.1 11.5 - - - - - - 
Non-manual 15.6 22.4       
Manual 40.8 17.7       
Unknown 20.5 48.4       
PRE-STROKE HEALTH         
Pre-stroke dependence (%)         
Yes 8.9 22.0 - - - - - - 
No 87.6 74.1       
Unknown 3.6 4.0       
Modified Rankin score (%)         
0-2 - - - - - - 90.5 77.7 
3-5       7.4 14.4 
Unknown       2.1 7.9 




MEDICAL HISTORY         
Hypertension (%)          
Yes 50.1 56.9 60.9 69.2 64.7 70.0 54.8 66.0 
No 45.6 39.0 38.3 23.7 29.4 26.7 45.2 34.0 
Unknown 4.4 4.1 0.8 1.1 5.9 3.3 0.0 0.0 
Atrial fibrillation (%)         
Yes 17.5 23.2 18.0 25.1 2.0 0.0 25.4 32.8 
No 80.4 74.5 80.1 71.8 90.2 96.7 74.6 67.2 
Unknown 2.1 2.4 2.0 3.1 7.8 3.3 0.0 0.0 
Ischaemic heart disease (%)         
Yes 23.4 18.1 24.8 24.3 3.9 10.0 33.9 38.7 
No 75.6 80.4 72.9 72.1 88.2 86.7 66.1 61.3 
Unknown 1.1 1.5 2.2 3.6 7.8 3.3 0.0 0.0 
Peripheral vascular disease (%)         
Yes - - 11.4 12.0 2.0 10.0 - - 
No   86.5 83.7 90.2 86.7   
Unknown   2.1 4.3 7.8 3.3   
Transient ischaemic attack (%)         
Yes - - 7.4 7.5 7.8 3.3 5.1 5.9 
No   88.4 87.6 84.3 93.3 94.9 94.1 
Unknown   4.2 4.9 7.8 3.3 0.0 0.0 
Dementia (%)         
Yes 1.7 1.1 - - 2.0 6.7 - - 
No 97.3 97.4   90.2 90.0   
Unknown 1.1 1.6   7.8 3.3   
Smoking (%)         
Current 16.2 11.8 45.3 4.2 43.1 20.0 -   - 
Former 49.9 29.2 -   - -   -   
Never 26.7 47.0 44.7 83.1 51.0 76.7   
Unknown 7.2 12.0 10.1 12.7 5.9 3.3   
Alcohol use (%)         
Non-drinkers 57.7 42.9 -   - 70.6 93.3 -   - 
Current drinkers * 18.3 30.0   21.6 3.3   
Ex-drinkers 24.0 12.3   -   -   




Supplemental Table A-1c. Characteristic of included cohort studies from Auckland, 
L’Aquila, Matão, and Tartu by sex 
  Auckland   L’Aquila   Matão   Tartu  
Characteristic Men Women Men Women Men Women Men Women 




-   - -   - -   - 
Medication          
Antihypertensives (%)         
Yes 39.3 44.3 -   - -   - 34.5 49.2 
No 5.3 6.2     45.8 32.4 
Unknown 55.5 49.5     19.8 18.4 
Antiplatelets (%)         
Yes 35.8 38.4 -   - -   - 17.0 21.5 
No 60.7 57.7     62.7 53.9 
Unknown 3.5 4.0     20.3 24.6 
HOSPITAL ADMISSION         
Hospital admission (%)         
Yes 95.4 90.5 95.6 93.1 100.0 100.0 88.1 87.5 
No 4.7   9.5 4.4 6.9 0.0 0.0 11.9 12.5 
Time to arrive hospital† (%)         
≤ 4.5 hours - - - - - - 34.0 33.9 
> 4.5 – 24 hours 80.7 80.9     5.8 4.0 
> 24 hours 12.0 12.6     2.6 2.2 
Unknown 7.4 6.6     57.7 59.8 
STROKE-RELATED FACTORS         
Stroke type (%)         
Ischaemic stroke  76.2 69.3 83.0 82.2 82.3 86.7 77.4 76.2 
Intracerebral haemorrhage 12.0 12.8 12.1 13.1 15.7 13.3 15.8 11.3 
Subarachnoid haemorrhage 6.2 6.1 2.7 2.7 2.0 0.0 -   - 
Undetermined 5.7 11.8 2.2 2.0 0.0 0.0 6.8 12.5 
Stroke severity         
















-   - 
Loss of consciousness (%)         
Yes 36.7 40.7 31.2 32.7 - - - - 
No 61.5 55.2 66.4 63.9     
Unknown 1.8 4.1 2.4 3.4     
Body paralysis (%)         
Yes 84.7 84.3 79.0 79.1 - - - - 
No 13.5 13.4 17.5 15.8     
Unknown 1.8 2.4 3.5 5.1     
POST-STROKE FACTORS         
Depression at 5 years§         
Yes 12.9 10.7 - - - - - - 
No 19.4 17.4       
Unknown 67.7 72.0       
Recurrence at 1 year§         
Yes - - 7.1 7.1 15.7 10.0 - - 
No   92.9 92.9 80.4 90.0   
Unknown   0.0 0.0 3.9 0.0   
Bold denotes statistically significant results. NIHSS, National Institutes of Health Stroke Scale; GCS, 
Glasgow Coma Scale. 
* current drinker including not heavy drinkers and heavy drinkers; † among hospitalised patients; ‡ 
NIHSS scores were mapped from Scandinavian stroke scale  




Supplemental Table A-2. List of covariates not meeting the criteria for factors confounding 
the difference in 1-year mortality between women and men 
Study Covariates not meeting the criteria for confounding 
factors in univariable model 
Confounding factors in univariable model that were 
not significant in the final multivariable model 
Oxford SEP, education, hypertension, AF, IHD, PVD, TIA, 
diabetes, BMI, smoking, hospital admission, recurrence 
Marital status, alcohol 
Joinville Race, hypertension, AF, PVD, TIA, BMI, smoking, 
hospital admission (100%), pre-stroke medication 
(antihypertensives, antiplatelets, anticoagulants), delay to 
hospital 
IHD, alcohol 
Melbourne Race, SEP, education, hypertension, IHD, PVD, TIA, 
diabetes, smoking, alcohol, hospital admission, recurrence, 
pre-stroke medication (antiplatelets, anticoagulants) 
Dementia, institutional residence, onset hemiplegia, onset 
incontinence, onset LOC, pre-stroke antihypertensives 
Arcadia hypertension, IHD, PVD, TIA, diabetes, BMI, smoking, 
alcohol, stroke type, hospital admission, recurrence  
Onset hemiplegia, onset incontinence, onset LOC 
Perth SEP, hypertension, AF, IHD, TIA, diabetes, smoking, 
alcohol, delay to hospital, pre-stroke medication 
(antihypertensives, antiplatelets) 
Institutional residence, pre-stroke Barthel, hospital 
admission 
Orebro Hypertension, AF, IHD, PVD, TIA, diabetes, pre-stroke 
Barthel 
Marital status, dementia, hospital admission, smoking 
Dijon Hypertension, IHD, PVD, TIA, alcohol, stroke severity 
(NIHSS), stroke type, hospital admission, onset 
hemiplegia, recurrence 
Institutional residence 
Martinique  Hypertension, AF, IHD, TIA, BMI, smoking, alcohol, 
stroke type, hospital admission, delay to hospital 
- 
Porto Education, hypertension, AF, IHD, PVD, TIA, BMI, stroke 
type, stroke severity (UNSS), hospital admission, delay to 
hospital, onset hemiplegia, recurrence 
SEP, alcohol 
Auckland SEP, education, hypertension, IHD, dementia, BMI, 
smoking, alcohol, pre-stroke medication 
(antihypertensives, antiplatelets, anticoagulants), hospital 
admission, delay to hospital, onset hemiplegia 
Marital status, onset LOC 
L’Aquila Hypertension, IHD, PVD, TIA, onset hemiplegia, onset 
LOC*, recurrence 
- 
Matão Race, marital status, education, age†, hypertension, AF, 
IHD, PVD, TIA, smoking, alcohol, hospital admission, 
recurrence 
- 
Tartu Hypertension, AF, IHD, TIA, hospital admission, stroke 
type, delay to hospital, pre-stroke medication 
(antihypertensives, antiplatelets) 
- 
AF, Atrial fibrillation; BMI, body mass index; GCS, Glasgow Coma Scale; IHD, ischaemic heart 
disease; LOC, loss of consciousness (at onset); mRS, modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale; PVD, peripheral vascular disease, TIA, transient ischaemic attack; 
UNSS, Unified Neurological Stroke Scale; SEP, socioeconomic position. 





Supplemental Table A-3. Mortality rate ratio between women and men at 1 year after stroke in crude models and models with adjustment for 
age, severity, atrial fibrillation and pre-stroke dependency  
Study N* Unadjusted Adjusted for age Adjusted for severity Adjusted for AF Adjusted for pre-stroke dependency 
  MRR (95% CI) MRR (95% CI) % change† MRR (95% CI) % change† MRR (95% CI) % change† MRR (95% CI) % change† 
Oxford 1290 1.65 (1.30-2.09) 1.20 (0.93-1.53) 64% 1.26 (0.96-1.66) 53% 1.64 (1.29-2.09) 1% 1.29 (1.00-1.65) 55% 
Joinville 979 1.25 (0.92-1.70) 1.13 (0.82-1.54) 46% 1.27 (0.87-1.83) -10% 1.25 (0.92-1.70) 0% -   
Melbourne 975 1.42 (1.10-1.84) 1.10 (0.84-1.44) 73% 1.14 (0.77-1.68) 64% 1.36 (1.05-1.76) 13% 1.18 (0.90-1.55) 53% 
Arcadia 547 1.21 (0.89-0.63) 1.17 (0.87-1.58) 20% 0.85 (0.58-1.27) 184% 1.17 (0.86-1.57) 18% -   
Perth 183 0.88 (0.51-1.54) 0.77 (0.43-1.36) -115% 0.81 (0.43-1.50) -75% 0.88 (0.50-1.53) -6% 0.75 (0.41-1.37) -132% 
Orebro 377 1.63 (1.09-2.46) 1.26 (0.83-1.94) 52% 1.47 (0.79-2.73) 22% 1.64 (1.09-2.49) -1% 1.23 (0.78-1.94) 58% 
Dijon 3994 1.21 (1.06-1.39) 0.90 (0.78-1.04) 154% 1.12 (0.97-1.30) 41% 1.16 (1.01-1.32) 24% 1.13 (0.99-1.30) 24% 
Martinique  569 1.65 (1.19-2.29) 1.40 (1.00-1.94) 34% 1.53 (1.07-2.18) 16% 1.64 (1.18-2.28) 2% -   
Porto 650 1.41 (1.00-1.98) 1.16 (0.82-1.64) 57% 1.07 (0.73-1.56) 81% 1.41 (1.00-1.98) 1% 1.19 (0.84-1.70) 49% 
Auckland 1177 1.43 (1.12-1.44) 1.12 (0.87-1.44) 69% 1.35 (0.96-1.88) 17% 1.37 (1.08-1.77) 11% 1.16 (0.90-1.50) 59% 
L’Aquila 3794 1.23 (1.09-1.39) 1.02 (0.90-1.39) 92% 1.24 (1.09-1.41) -2% 1.17 (1.04-1.33) 24% -   
Matão 79 0.64 (0.24-1.69) 0.63 (0.24-1.69) 1% 0.43 (0.16-1.19) 32% 0.62 (0.24-1.64) 3% -   
Tartu 358 1.62 (1.11-2.36) 1.16 (0.77-1.75) 69% 1.52 (1.01-2.28) 13% 1.52 (1.04-1.23) 13% -   
Pooled 14,972 1.35 (1.24-1.47) 1.07 (0.98-1.15) 77% 1.19 (1.09-1.31) 42% 1.33 (1.20-1.47) 5% 1.18 (1.06-1.32) 45% 
  I2=26.5% p=0.117 I2=12.7% p=0.317  I2=15.5% p=0.288  I2=57.8% p=0.005  I2=66.1% p<0.001  
Bold denotes statistically significant results; CI indicates confidence interval; MRR, rate ratio; AF, atrial fibrillation. 
* the sample size were the same among the unadjusted model, age-adjusted model, and fully adjusted model 




Supplemental Table A-4. List of covariates not meeting the criteria for factors 
confounding the difference in 5-year mortality between women and men 
Study Covariates not meeting the criteria for 
confounding factors in univariable model 
Confounding factors in univariable model that were not 
significant in the final multivariable model 
Oxford SEP, education, hypertension, IHD, PVD, TIA, 
diabetes, BMI, smoking, hospital admission, 
recurrence 
Marital status, alcohol 
Melbourne Race, SEP, education, hypertension, AF, IHD, PVD, 
TIA, diabetes, smoking, alcohol, hospital admission, 
recurrence, pre-stroke medication (pre-stroke 
antihypertensives, antiplatelets, anticoagulants) 
Dementia, institutional residence, onset hemiplegia, onset 
incontinence, onset LOC  
Orebro Hypertension, AF, IHD, PVD, TIA, diabetes, pre-
stroke Barthel 
Marital status, dementia, hospital admission, smoking 
Dijon Hypertension, IHD, PVD, TIA, alcohol, stroke 
severity (NIHSS), stroke type, hospital admission, 
onset hemiplegia, recurrence 
Institutional residence 
Martinique  Hypertension, AF, IHD, PVD, TIA, BMI, smoking, 
alcohol, stroke type, hospital admission, delay to 
hospital 
- 
Porto SEP, education, hypertension, AF, IHD, PVD, TIA, 
BMI, stroke type, stroke severity (UNSS), hospital 
admission, delay to hospital, onset hemiplegia, 
recurrence 
Alcohol 
Auckland SEP, education, hypertension, IHD, dementia, BMI, 
alcohol, pre-stroke medication (antihypertensives, 
antiplatelets, anticoagulants), hospital admission, 
delay to hospital, onset hemiplegia 
Marital status, onset LOC, smoking 
L’Aquila Hypertension, IHD, PVD, TIA, onset hemiplegia, 
onset LOC*, recurrence 
- 
AF, Atrial fibrillation; BMI, body mass index; GCS, Glasgow Coma Scale; IHD, ischaemic heart 
disease; LOC, loss of consciousness (at onset); mRS, modified Rankin scale; NIHSS, National 
Institutes of Health Stroke Scale; PVD, peripheral vascular disease, TIA, transient ischaemic attack; 
UNSS, Unified Neurological Stroke Scale; SEP, socioeconomic position. 




Supplemental Table A-5. Mortality rate ratio between women and men at 5 years after stroke in crude models and models with adjustment for 
age, severity, atrial fibrillation and pre-stroke dependency 
Study N* Unadjusted Adjusted for age Adjusted for severity Adjusted for AF Adjusted for pre-stroke dependency 
  MRR (95% CI) MRR (95% CI) % change† MRR (95% CI) % change† MRR (95% CI) % change† MRR (95% CI) % change† 
Oxford 732 1.24 (0.98-1.58) 0.96 (0.74-1.23) 121% 1.02 (0.67-1.54) 92% 1.28 (1.00-1.64) -14% 1.03 (0.80-1.34) 85% 
Melbourne 975 1.34 (1.09-1.64) 1.03 (0.82-1.28) 91% 1.09 (0.81-1.47) 70% 1.29 (1.04-1.59) 14% 1.14 (0.91-1.42) 56% 
Orebro 377 1.57 (1.14-2.15) 1.18 (0.84-1.64) 64% 1.45 (0.94-2.24) 17% 1.57 (1.13-2.17) 0% 1.27 (0.91-1.78) 47% 
Dijon 3094 1.09 (0.97-1.22) 0.80 (0.71-0.90) 360% 1.03 (0.91-1.17) 66% 1.04 (0.92-1.17) 54% 1.02 (0.91-1.15) 77% 
Martinique  569 1.52 (1.17-1.97) 1.26 (0.97-1.63) 46% 1.35 (1.04-1.76) 29% 1.51 (1.17-1.97) 1% -   
Porto 650 1.09 (0.85-1.40) 0.87 (0.67-1.14) 253% 0.92 (0.70-1.21) 194% 1.07 (0.83-1.39) 18% 0.96 (0.73-1.25) 152% 
Auckland 1177 1.45 (1.16-1.81) 1.09 (0.86-1.39) 76% 1.39 (1.02-1.91) 10% 1.38 (1.10-1.74) 13% 1.13 (0.89-1.45) 66% 
L’Aquila 3794 1.09 (0.98-1.20) 0.88 (0.80-0.97) 248% 1.09 (0.99-1.20) -5% 1.04 (0.94-1.14) 59% -   
Pooled 11368 1.24 (1.12-1.38) 0.96 (0.86-1.07) 119% 1.11 (1.01-1.20) 51% 1.21 (1.08-1.36) 11% 1.10 (1.02-1.19) 55% 
  I2=57.2% p=0.022 I2=59.7% p=0.015  I2=62.9% p=0.009  I2=20.9% p=0.264  I2=26.8% P=0.215  
Bold denotes statistically significant results; MRR (95% CI), Mortality rate ratio (95% confidence interval); AF, atrial fibrillation.  
* the sample size were the same among the unadjusted model, age-adjusted model, and fully adjusted model 




Supplemental Table A-6. Analyses of heterogeneity in sex difference in mortality at 5 years after stroke among 8 population-based studies 




 No of death (n/N)   Unadjusted   Adjusted*  
Men Women I2 (%) PH MRR (95% CI) Psub-group I2 (%) PH MRR (95% CI) Psub-group 
Study-level 
characteristics† 
              
Geographic region Australasia 2 508/1252 758/1487 0.0 0.614 1.39 (1.19-1.61) 0.080 0.0 0.835 0.71 (0.56-0.91) 0.308 
 Europe 5 2306/4596 2832/5301 29.8 0.223 1.13 (1.04-1.24)  77.1 0.002 0.73 (0.59-0.89)  
 Caribbean 1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
Income group HIC 7 2814/5848 3590/6788 51.7 0.053 1.21 (1.09-1.34) 0.239 67.2 0.006 0.73 (0.62-0.85) 0.114 
 LMIC | | 1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
Person-years Actual  6 1230/2334 1476/2599 49.5 0.078 1.25 (1.11-1.41) 0.841 32.2 0.195 0.68 (0.59-0.79) 0.051 
 Estimated  2 1719/3799 2294/4484 81.9 0.019 1.26 (0.91-1.74)  52.0 0.149 0.96 (0.75-1.22)  
Death Registries Yes 4 1367/2848 1760/3324 56.7 0.055 1.29 (1.12-1.48) 0.501 8.9 0.349 0.72 (0.62-0.83) 0.700 
 No 4 1585/3285 2010/3759 64.4 0.060 1.19 (0.98-1.44)  79.9 0.002 0.79 (0.59-1.05)  
Age difference§ ≤ 4.5 years 1 1095/2049 1296/2304 NA 1.000 1.09 (0.98-1.20) 0.261 NA 1.000 0.88 (0.80-0.98) 0.474 
 > 4.5 years 7 1854/4084 2474/4779 52.7 0.048 1.28 (1.14-1.45)  60.4 0.019 0.73 (0.61-0.88)  
Severity instrument NIHSS 3 539/1118 761/1335 0.0 0.518 1.35 (1.17-1.55) 0.117 39.2 0.193 0.73 (0.56-0.96) 0.307 
 Barthel  1 135/285 180/295 NA 1.000 1.52 (1.17-1.97)  NA 1.000 1.16 (0.82-1.64)  
 Others# 4 2275/4730 2829/5453 46.6 0.132 1.14 (1.02-1.26)  78.6 0.003 0.72 (0.58-0.89)  
SAH data Yes 7 2863/5964 3637/6875 54.0 0.042 1.21 (1.10-1.34) 0.247 72.2 0.001 0.74 (0.62-0.88) 0.370 
 No 1 86/169 133/208 NA 1.000 1.57 (1.14-2.15)  NA 1.000 1.01 (0.65-1.57)  
Sample size ≤1000 3 358/738 523/907 54.4 0.111 1.36 (1.08-1.72) 0.347 85.2 0.001 0.83 (0.48-1.43) 0.614 
 >1000 5 2591/5395 3247/6176 53.6 0.071 1.19 (1.07-1.33)  56.1 0.058 0.75 (0.65-0.87)  
Participant-level 
characteristics‡ 
              
Stroke type IS 8 226/4949 2782/5546 35.3 0.147 1.21 (1.11-1.32) Ref 48.7 0.058 0.88 (0.82-0.94) Ref 
 ICH 8 450/770 526/840 61.1 0.012 1.27 (0.94-1.70) 0.529 63.4 0.008 1.01 (0.85-1.19) 0.722 
 SAH 7 77/186 125/279 25.1 0.237 1.14 (0.73-1.76) 0.873 56.3 0.033 1.04 (0.68-1.57) 0.746 
 Undetermined 8 158/228 337/418 35.8 0.143 1.51 (1.05-2.16) 0.397 45.2 0.078 1.02 (0.77-1.35) 0.150 
Age group ≤65 8 394/1605 242/1131 41.9 0.099 0.90 (0.70-1.15) Ref -     
 >65-75 8 1939/3786 2084/4188 33.7 0.159 0.98 (0.89-1.08) 0.917 -     
 >75 8 616/742 1444/1764 36.9 0.134 1.09 (0.90-1.30) 0.055 -     
PH, P-value of heterogeneity; Psub-group, P-value for subgroup analysis; Ref, reference group; NA, not applicable; IS, Ischaemic stroke; ICH, Intracerebral haemorrhage; SAH, 
Subarachnoid haemorrhage; Barthel, Barthel index (at onset), NIHSS, National Institutes of Health Stroke Scale; MRR (95% CI), Mortality rate ratio (95% confidence 
interval) between women and men; HIC, High-income country; LMIC, Low- and middle-income country. 
* MRR adjusted for actual confounders, but estimates for stroke type adjusted for age only. 
† Estimates were performed using two-stage method analysis 
‡ estimates were performed using multivariate random-effect meta-analyses 
§ indicates difference in median age at onset between women and men 
| | low- and middle-income country (LMIC) group included studies conducted in Martinique 




Supplemental Table A-7a. Loss to follow-up and missing data among the 13 
included studies 























Oxford 1374 0.0* 1290 6.1% 760 0.0* 732 3.7% 
Joinville 980 0.0 979 0.1%     
Melbourne 1316 0.0* 975 26.0% 1316 0.0 975 25.9% 
Arcadia 548 1.3 547 0.2%     
Perth 183 0.0* 183 0.0%     
Orebro 377 0.0* 377 0.0% 377 0.0* 377 0.0% 
Dijon 4621 0.0* 3994 13.5% 3719 0.0* 3094 16.8% 
Martinique  580 0.0 569 1.9% 580 0.0 569 1.9% 
Porto 688 1.3 650 5.5% 688 1.3 650 5.5% 
Auckland 1423 8.2 1177 17.3% 1423 16.7 1177 17.3% 
L’Aquila 4353 1.2 3794 12.8% 4353 1.2 3794 12.8% 
Matão 81 0.0* 79 2.5%     
Tartu 433 0.0* 358 17.3%     
Total 16957  14972  13216  11368  




Supplemental Table A-7b. Comparison of complete-case analysis and imputed 
analysis of mortality rate ratio between women and men at 1 year and 5 years after 
stroke 
Study  Unadjusted   Adjusted for confounders  
 Complete-case Imputed* Complete-case Imputed* 
 MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) 
Melbourne         
1-year 1.42 (1.10-1.84) 1.52 (1.26-1.83) 0.76 (0.50-1.15) 0.89 (0.61-1.28) 
5-year 1.34 (1.09-1.64) 1.42 (1.19-1.70) 0.69 (0.47-1.01) 0.85 (0.65-1.11) 
Pooled data         
1-year (13 studies) 1.35  (1.24-1.47) 1.37 (1.26-1.48) 0.81  (0.72-0.92) 0.82 (0.73-0.93) 
5-year (8 studies) 1.24 (1.12-1.38) 1.28 (1.15-1.42) 0.76  (0.65-0.89) 0.78 (0.67-0.91) 
MRR (95% CI), Mortality rate ratio (95% confidence interval) 




Supplemental Table A-8. Sensitivity analysis of long-term mortality rate ratio between women and men among studies with data on date of 
death at 1 year (n=11 studies) and 5 years (n=6 studies) after stroke excluding early deaths (1 month, 3 months and 6 months) 
Study  Excluding 1-month deaths   Excluding 3-month deaths   Excluding 6-month deaths  
 N* Unadjusted Adjusted N* Unadjusted Adjusted N* Unadjusted Adjusted 
  MRR (95% CI) MRR (95% CI)  MRR (95% CI) MRR (95% CI)  MRR (95% CI) MRR (95% CI) 
1-year outcome                
Oxford 1112 1.62 (1.18-2.24) 0.87 (0.60-1.14) 1054 1.32 (0.89-1.94) 0.69 (0.47-1.02) 1009 1.37 (0.81-2.30) 0.75 (0.45-1.27) 
Joinville 891 0.96 (0.64-1.44) 0.79 (0.52-1.22) 855 1.14 (0.69-1.90) 0.95 (0.57-1.60) 827 1.53 (0.75-3.11) 1.33 (0.68-2.59) 
Melbourne 789 1.45 (1.01-2.08) 0.91 (0.60-1.39) 738 1.44 (0.91-2.27) 0.95 (0.56-1.59) 701 1.20 (0.64-2.25) 0.82 (0.44-1.53) 
Arcadia 428 1.33 (0.86-1.98) 1.10 (0.73-1.65) 412 1.25 (0.81-1.94) 1.05 (0.68-1.63) 400 1.23 (0.76-1.99) 1.05 (0.66-1.70) 
Perth 148 0.59 (0.27-1.28) 0.43 (0.20-0.95) 137 0.50 (0.19-1.33) 0.45 (0.15-1.34) 132 0.31 (0.08-1.11) 0.25 (0.06-1.05) 
Orebro 308 1.52 (0.87-2.64) 1.10 (0.61-1.99) 288 1.59 (0.81-3.15) 1.21 (0.60-2.43) 268 1.42 (0.51-3.95) 1.19 (0.42-3.36) 
Dijon 3477 1.17 (0.98-1.40) 0.78 (0.63-0.97) 3286 1.03 (0.82-1.29) 0.69 (0.54-0.90) 3151 0.93 (0.70-1.25) 0.67 (0.50-0.89) 
Porto 556 1.56 (0.97-2.50) 0.90 (0.54-1.50) 552 1.48 (0.81-2.71) 0.79 (0.41-1.52) 506 0.89 (0.43-1.82) 0.41 (0.20-0.85) 
Auckland 950 1.34 (0.92-1.96) 0.83 (0.56-1.25) 905 1.54 (0.95-2.51) 1.02 (0.60-1.73) 879 1.73 (0.92-3.23) 1.21 (0.62-2.37) 
Pooled 8,659 1.29 (1.11-1.48) 0.84 (0.74-0.95) 8,227 1.19 (1.04-1.37) 0.81 (0.70-0.95) 7,873 1.14 (0.92-1.40) 0.82 (0.64-1.04) 
  I2=23.5% p=0.235 I2=0.0% p=0.663  I2=0.0% p=0.442 I2=0.0% p=0.524  I2=14.5% p=0.313 I2=31.9% p=0.162 
5-year outcome                
Oxford 619 1.11 (0.85-1.45) 0.68 (0.51-0.90) 583 1.00 (0.75-1.32) 0.65 (0.49-0.87) 562 0.98 (0.73-1.32) 0.67 (0.50-0.89) 
Melbourne 789 1.27 (1.01-1.60) 0.86 (0.68-1.10) 738 1.44 (0.91-2.27) 0.95 (0.56-1.59) 701 1.17 (0.90-1.50) 0.83 (0.65-1.06) 
Orebro 308 1.44 (1.03-2.02) 1.02 (0.72-1.45) 288 1.43 (1.01-2.03) 1.02 (0.72-1.45) 268 1.37 (0.94-1.97) 1.00 (0.70-1.44) 
Dijon 2702 1.03 (0.91-1.16) 0.73 (0.63-0.86) 2568 0.94 (0.70-1.25) 0.61 (0.45-0.83) 2468 0.97 (0.84-1.11) 0.71 (0.60-0.83) 
Porto 556 1.03 (0.77-1.34) 0.65 (0.48-0.87) 522 1.48 (0.81-2.71) 0.79 (0.41-1.52) 506 0.83 (0.61-1.12) 0.54 (0.40-0.74) 
Auckland 950 1.36 (1.02-1.83) 0.86 (0.62-1.19) 905 1.44 (1.04-2.00) 0.95 (0.67-1.36) 879 1.46 (1.03-2.08) 1.00 (0.69-1.46) 
Pooled 5,924 1.15 (1.02-1.30) 0.77 (0.69-0.87) 5,604 1.12 (0.97-1.29) 0.77 (0.66-0.89) 5,384 1.07 (0.92-1.25) 0.76 (0.64-0.89) 
  I2=32.5% p=0.192 I2=19.5% p=0.286  I2=49.6% p=0.077 I2=44.8% p=0.107  I2=49.9% p=0.076 I2=53.3% p=0.057 
Bold denotes statistically significant results; MRR (95% CI), Mortality rate ratio (95% confidence interval) 




Supplemental Table A-9. Prevalence of admission and discharge medication, in-hospital investigation on the exposure of female sex in 
13 included studies 
 Oxford Joinville Melbourne Arcadia Perth Orebro Dijon Martinique Porto Auckland L’Aquila Matão Tartu 
 Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women 
Admission medication (%)                           
Antihypertensive - - - - 50.0 57.8 - - 51.5 56.2 - - 46.8 48.5 - - - - - - - - - - - - 
Antiplatelets - - - - 30.8 30.6 24.1 26.0 25.8 32.9 - - 22.8 21.3 - - - - - - - - - - - - 
Anticoagulants - - - - 6.0 5.2 14.3 22.5 13.6 4.1§ - - 7.2 6.8 - - - - - - - - - - - - 
Thrombolysis* - - 9.5 7.2 0.0 0.8 - - - - - - 11.4‡ 9.9‡ - - - - 0.8 0.6 - - - - - - 
Discharge medication (%)                           
Antihypertensive - - - - 37.9 37.7 - - 43.9 31.5 - - - - - - 50.0 47.7 60.6 62.9 - - - - - - 
Antiplatelets* - - - - 48.3 49.2 - - 39.6 47.1 - - 67.5 63.6 - - 71.2 67.6 79.9 81.7 - - - - - - 
Anticoagulants * - - - - 17.9 14.3 - - 22.6 10.2§ - - 14.1 15.8 - - - - 15.9 13.8 - - - - - - 
Investigation (%)                           
Neuroimaging - - 100.0 100.0 94.3 92.8 87.4 81.9 97.0 93.2 89.8 84.2 98.2 97.7 95.9 94.9 99.3 99.5 93.9 92.3 81.5 82.3 100.0 100.0 100.0 96.4 
Electrocardiography-ECG - - 99.0 98.9 89.7 87.3 100.0 100.0 92.4 97.2 - - 98.5 98.5 - - 93.6 91.5 - - 100.0 100.0 100.0 100.0 74.4 76.8 
Carotid investigation* - - 89.8 84.0 50.3 45.4 29.2 25.3 7.6 1.72§ - - 95.5 93.8 - - 46.8 42.4 5.2 3.1 60.0 51.1 - - 24.0 8.5 
Echocardiography* - - - - 43.8 31.7 19.8 12.7 34.6 19.0 - - 79.5 78.9 - - 44.5 38.3 1.4 0.0§ 17.0 14.4 - - - - 
Holter monitor* - - - - 2.2 3.4 - - - - - - - - - - 4.1 2.8 - - 3.0 2.3 - - - - 
Surgery intervention (%)                           
Carotid endarterectomy* 5.9 2.7 - - 1.4 0.6 - - - - - - - - - - - - - - - - - - - - 
Coiling/clipping/other† 9.9 17.0 - - 9.0 7.9 - - - - - - - - - - - - 13.7 18.5 - - - - - - 
Bold numbers denote p-value <0.05; χ2 test or Fisher's exact test, as appropriate, was used to examine if there were sex differences in admission medication and discharge 
medication, in-hospital investigation and surgical interventions. 




Supplemental Table A-10. Factors contributing to sex difference in long-term 
mortality between women and men after stroke based on the best fit sex-specific 
model within studies among hospitalised patients with ischaemic stroke only 
Study  1-year   5-year  
 N* Actual confounding factors used in the fully 
adjusted model 
N* Actual confounding factors used in the fully 
adjusted model 
Oxford 891 age3†, NIHSS (2-term)†, pre-stroke mRS 432 age3†, NIHSS, pre-stroke mRS 
Joinville 789 age3†, log NIHSS†, carotid investigation - - 
Melbourne 733 age, log NIHSS†, pre-stroke Barthel (2-term)† 733 age3†, NIHSS (2-term)†, pre-stroke Barthel (2-
term)†, AF 
Arcadia 356 age, GCS, AF - - 
Perth 112 age, inverse NIHSS†, pre-stroke mRS - - 
Orebro 262 age, log NIHSS†, institutional residence 262 age, NIHSS2†, institutional residence 
Dijon 3341 age3†, LOC, AF, smoking 2608 age3†, LOC, AF, smoking 
Martinique  411 age3†, Barthel at onset (2-term)†, history of PVD 411 age3†, Barthel at onset (2-term)† 
Porto 493 age3†, LOC, smoking, pre-stroke mRS 493 age3†, LOC, smoking, pre-stroke mRS2† 
Auckland 849 age3†, GCS, pre-stroke dependence‡, AF 849 age3†, GCS, pre-stroke dependence‡, AF 
L’Aquila 3076 age, LOC§, AF, smoking 3375 age, LOC§, AF 
Matão 79 age§, NIHSS - - 
Tartu 296 age, log NIHSS - - 
Total cases 11688  9163  
AF, Atrial fibrillation, GCS, Glasgow Coma Scale; LOC, loss of consciousness (at onset); mRS, 
modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale 
* The sample size were the same among the unadjusted model and fully adjusted model 
† Transformations were based on the powers (e.g. 3rd power, two power terms) suggested by fractional 
polynomials that produced the best-fitting multivariable model. 
‡ Self-reported data regarding whether the patient lived independently before stroke 




Supplemental Table A-11. Sensitivity analysis comparing the pooled adjusted 
estimates excluding and including carotid investigations included in the study specific 
model for Joinville 
Study 1-year MRR (95% CI) 
Joinville   
Crude 1.22 (0.84-1.77) 
Adjusted for carotid investigations only 1.08 (0.73-1.60) 
Adjusted for confounders, excluding carotid investigations 0.86 (0.56-1.30) 
Adjusted for confounders, including carotid investigations 0.76 (0.48-1.21) 
Pooled data (13 studies)   
Crude  1.33 (1.18-1.50) 
Adjusted for confounders, excluding carotid investigations for 
Joinville 
0.84 (0.74-0.95) 
Adjusted for confounders, including carotid investigations for Joinville 0.83 (0.73-0.95) 





Figure A-1. Mortality rate ratio (MRR) at 1 year (red lines) and 5 years (black lines) 






















1-year MRR, crude 1-year MRR, age-adjusted




Appendix B: Sex differences in long-term functional outcome and participation restriction 
after stroke in the INternational STRoke oUtComes sTudy 
Supplemental Table B-1. Baseline characteristic of the 10 included cohort studies, by sex, among survivors followed up to 1 year after stroke 
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Race (%)                     
Caucasian - - - - 94.4 97.4 - - - - - - - - - - 78.8 90.5 - - 
Non-Caucasian     2.4 1.6           15.2 9.5   
Unknown     3.2 1.2           6.1 0.0   
Marital status (%)                     
Single/widowed 21.4 49.0 - - - - - - 37.5 45.0 31.5 65.1 - - - - - - - - 
Married 69.9 43.8       62.5 55.0 68.6 34.9         
Unknown 8.7 7.2       0.0 0.0 0.0 0.0         
Education level (%)                     
≤ Grade 12 69.7 73.7 93.3 93.4 66.3 78.0 - - - - - - - - 82.3 75.8 75.8 100.0 - - 
> Grade 12 16.8 12.4 6.6 6.4 26.1 20.0         3.7 2.2 15.2 0.0   
Unknown 13.5 14.0 0.1 0.1 7.6 2.0         14.0 21.9 9.1 0.0   
Social class (%)                     
Professional 18.3 7.7 - - 36.1 35.9 - - 25.0 20.0 - - 30.6 19.8 24.7 13.8 - - - - 
Non-manual 21.6 35.7   13.7 13.9   12.5 25.0   41.7 59.9 69.3 70.3     
Manual 44.5 37.3   47.4 46.5   56.3 35.0   7.7 20.3 1.4 9.7     
Unknown 15.6 19.4   2.8 3.7   6.3 20.0   0.0 0.0 4.7 6.3     
PRE-STROKE HEALTH                     
In an institution (%)                     
Yes - - - - 4.4 8.6 - - 0.0 35.0 1.6 7.8 - - - - - - - - 
No     95.6 91.0   100 65.0 98.4 92.3         
Unknown     0.0 0.4   0.0 0.0 0.0 0.0         
Modified Rankin Score (%)                     
0-2 91.7 84.2 - - - - 99.5 100.0 93.8 50.0 - - - - 96.3 88.5 - - - - 
3-5 8.1 15.6     0.5 0.0 0.0 50.0     3.7 8.9     
Unknown 0.2 0.2     0.0 0.0 6.3 0.0     0.0 2.6     
Barthel Index score (%)                     
20 - - - - 84.3 74.7 - - 93.8 40.0 91.9 11.7 - - - - - - - - 
<20     12.5 21.2   0.0 60.0 8.1 87.6         
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Barthel Index, mean (SD) - - - - 19.6 (1.5) 19.1 
(2.7) 








- - - - - - - - 
MEDICAL HISTORY                     
Hypertension (%)                     
Yes 59.9 61.8 62.0 69.8 51.0 59.6 78.2 84.4 37.5 55.0 30.7 43.4 62.7 74.2 55.8 68.8 69.7 71.4 67.4 75.0 
No 39.9 38.2 38.0 30.2 49.0 40.4 21.8 15.6 62.5 35.0 67.7 55.0 36.4 23.6 44.2 31.2 27.3 28.6 32.6 25.0 
Unknown 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 1.6 1.6 1.0 2.2 0.0 0.0 3.0 0.0 0.0 0.0 
Atrial fibrillation (%)                     
Yes 16.8 16.3 3.3 3.1 15.7 17.1 26.4 32.6 12.5 20.0 15.3 16.3 10.5 11.0 9.8 8.6 3.0 0.0 17.4 28.7 
No 83.2 83.7 96.7 96.9 83.1 82.9 73.6 67.4 87.5 75.0 84.7 83.7 88.5 86.8 90.2 91.4 90.9 100.0 82.6 71.3 
Unknown 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 5.0 0.0 0.0 1.0 2.2 0.0 0.0 6.1 0.0 0.0 0.0 
Ischaemic heart disease (%)                     
Yes 14.1 7.9 5.6 2.5 16.9 9.0 15.0 16.3 25.0 5.0 20.2 15.5 5.3 5.0 7.9 8.9 6.1 0.0 29.1 29.6 
No 85.7 92.1 94.4 97.6 83.1 91.0 85.0 83.7 75.0 95.0 79.8 84.5 93.8 92.9 92.1 91.1 97.9 100.0 70.9 70.4 
Unknown 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 2.2 0.0 0.0 6.1 0.0 0.0 0.0 
Peripheral vascular disease (%)                     
Yes 6.7 4.4 - - 10.0 4.5 8.8 8.2 - - 35.5 21.7 7.7 11.0 7.0 4.5 0.0 4.8 - - 
No 92.9 95.1   90.0 85.5 91.2 91.9   64.5 78.3 91.4 86.8 86.5 80.7 93.9 95.2   
Unknown 0.4 0.5   0.0 0.0 0.0 0.0   0.0 0.0 1.0 2.2 6.5 14.9 6.1 0.0   
Transient ischaemic attack (%)                     
Yes 12.9 12.1 2.4 1.9 10.0 11.0 18.7 14.1 31.3 15.0 15.3 14.0 3.4 7.1 10.7 8.2 6.1 0.0 29.1 26.9 
No 87.1 87.7 97.6 98.1 89.6 89.0 81.4 85.9 62.5 85.0 84.7 86.1 62.7 57.7 89.3 91.8 97.9 100.0 70.9 70.4 
Unknown 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 6.3 0.0 0.0 0.0 34.0 35.2 0.0 0.0 6.1 0.0 0.0 0.0 
Diabetes (%)                     
Yes 14.6 10.3 - - 18.9 15.9 23.8 33.3 18.8 20.0 17.7 18.6 - - - - - - - - 
No 85.5 89.7   80.7 84.1 76.2 66.7 81.3 80.0 81.5 80.6         
Unknown 0.0 0.0   0.4 0.0 0.0 0.0 0.0 0.0 0.8 0.8         
Dementia (%)                     
Yes - - - - 2.0 6.5 - - - - 3.2 7.0 - - - - 0.0 4.8 - - 
No     75.9 72.2     96.8 93.0     93.9 95.2   
Unknown     22.1 21.2     0.0 0.0     6.1 0.0   
Smoking (%)                     
Current 51.4 27.5 30.5 14.5 51.0 21.2 32.6 1.5 68.8 35.0 29.8 18.6 15.8 0.0 21.4 0.7 51.5 14.3 - - 
Former 18.5 16.6 40.5 18.5 16.1 13.5 - - 18.8 5.0 66.1 81.4 - - 32.1 4.5 - -   
Never 29.9 55.0 29.0 66.9 32.1 62.9 67.4 98.5 0.0 55.0 - - 83.3 97.8 46.5 94.8 45.5 85.7   
Unknown 0.2 0.9 0.0 0.0 0.8 2.5 0.0 0.0 12.5 5.0 4.0 0.0 1.0 2.2 0.0 0.0 3.0 0.0   
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Non-drinkers 26.0 55.0 47.9 80.8 18.9 44.1 79.8 98.5 18.8 25.0 - - 74.6 93.4 28.4 66.2 72.7 100.0 - - 
Not heavy drinkers 67.2 38.7 40.9 17.9 65.9 50.0 - - 0.0 25.0   - - - - - -   
Heavy drinkers 3.3 2.3 11.2 1.3 7.6 1.2 20.2 1.5 56.3 30.0   24.4 4.4 67.4 20.5 21.2 0.0   
Ex-drinkers - - - - 6.0 0.4 - - 12.5 10.0   - - - - - -   
Unknown 3.5 4.0 0.0 0.0 1.6 4.1 0.0 0.0 12.5 10.0   1.0 2.2 4.2 13.4 6.1 0.0   
Body mass index, mean (SD) 26.6 
(4.5) 




- -   
Medication                     
Antihypertensives (%)                     
Yes - - 56.1 66.0 51.0 58.0 - - 25.0 45.0 - - - - - - - - - - 
No   43.9 34.1 48.6 42.0   75.0 40.0           
Unknown   0.0 0.0 0.4 0.0   0.0 15.0           
Antiplatelet (%)                     
Yes - - 24.7 28.8 33.3 31.8 - - 25.0 45.0 - - - - - - - - - - 
No   75.3 71.2 66.3 68.2   68.8 50.0           
Unknown   0.0 0.0 0.0 0.0   6.3 5.0           
STROKE-RELATED 
FACTORS 
                    
Hospital admission (%)                     
Yes 81.3 80.7 100.0 100.0 95.2 94.3 91.2 94.8 93.8 70.0 97.6 92.3 91.9 92.3 97.2 96.3 100.0 100.0 96.5 91.7 
No 18.7 19.4 0.0 0.0 4.8 5.7 8.8 5.2 6.3 30.0 2.4 7.8 8.1 7.7 2.8 3.7 0.0 0.0 3.5 8.3 
Time to arrive hospital (%), 
hospitalised 
                    
≤ 4.5 hours - - 41.4 42.2 25.3 21.2 - - 13.3 21.4 - - 82.3 78.6 39.2 35.5 - - 33.7 33.3 
> 4.5 – 24 hours   28.7 25.5 12.1 12.2   6.7 14.3   - - 32.5 38.2   7.2 3.0 
> 24 hours   28.8 29.7 8.4 6.9   6.7 21.4   17.7 21.4 19.1 15.8   4.8 4.0 
Unknown   1.4 2.6 54.2 59.6   73.3 42.9   0.0 0.0 9.1 10.4   54.2 59.6 
Stroke type (%)                     
Ischaemic stroke  90.0 85.3 67.8 69.1 85.9 84.9 74.6 77.8 75.0 80.0 83.1 84.5 80.4 82.4 81.4 80.7 84.9 100.0 86.1 83.3 
Intracerebral haemorrhage 4.6 5.1 8.0 5.9 12.1 8.2 12.4 7.4 6.3 0.0 14.5 7.8 13.4 8.2 13.0 12.6 15.2 0.0 11.6 8.3 
Subarachnoid haemorrhage 1.0 5.4 3.9 6.4 0.0 0.4 0.5 3.0 12.5 5.0 0.0 0.0 2.9 4.4 1.9 4.1 0.0 0.0 0.0 0.0 
Undetermined 4.4 4.2 20.4 18.5 2.0 6.5 12.4 11.9 6.3 15.0 2.4 7.8 3.4 5.0 3.7 2.6 0.0 0.0 2.3 8.3 
Stroke severity                     
NIHSS, mean (SD) 3.5 
(4.4) 
















Glasgow Coma Scale, reversed, 
mean (SD) 








- - - - 
Loss of consciousness (%)                     
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No     70.3 66.9 84.5 89.6       100.0 98.9     
Unknown     22.1 21.6 8.8 5.2       0.0 0.0     
Body paralysis (%)                     
Yes - - - - 16.5 22.0 19.2 19.3 - - - - - - 70.2 70.2 - - - - 
No     61.5 56.7 72.0 75.6       29.8 29.4     
Unknown     22.1 21.2 8.8 5.2       0.0 0.0     
Incontinence (%)                     
Yes - - - - 9.6 12.7 5.7 7.4 - - - - - - - - - - - - 
No     87.2 86.5 85.5 87.4             
Unknown     3.2 0.8 8.8 5.2             
Barthel at onset (%)                     
> 60 - - - - - - - - - - - - 59.3 52.2 - - - - - - 
≤ 60             24.4 31.9       
Unknown             16.3 15.9       
POST-STROKE FACTORS                     
Depression at 1 year                     
Yes - - - - 15.7 16.3 - - - - - - - - - - - - - - 
No     69.1 62.0               
Unknown     15.3 21.6               
Recurrence at 1 year                     
Yes 7.7 10.0 - - 0.8 0.4 7.8 6.7 - -   6.2 10.4 7.9 6.7 18.2 9.5 - - 
No 92.3 90.0   99.2 99.6 92.2 93.3     93.8 89.6 92.1 93.3 75.8 90.5   
Unknown 0.0 0.0   0.0 0.0 0.0 0.0     0.0 0.0 0.0 0.0 0.0 0.0   
Bold denotes statistically significant results between women and men; NIHSS, National Institutes of Health Stroke Scale.  
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Race (%)               
Caucasian - - - - 91.0 96.1 - - - - - - - - 
Non-Caucasian     3.5 2.6         
Unknown     5.6 1.3         
Ethnicity (%)               
New 
Zealand/European 
- - - - - - - - - - 73.7 78.2 - - 
Non-NZ/European           26.3 21.8   
Marital status (%)               
Single/widowed 21.0 49.0 - - - - - - - - - - - - 
Married 68.7 43.7             
Unknown 10.3 7.4             
Education level (%)               
≤ Grade 12 75.4 77.9 93.1 91.0 53.9 62.7 - - 85.6 83.8 35.6 59.3 - - 
> Grade 12 13.3 11.1 6.9 9.0 37.9 35.1   3.6 2.0 54.6 35.7   
Unknown 11.3 11.1 0.0 0.0 8.2 2.2   10.8 14.2 9.8 5.0   
Social class (%)               
Professional 12.8 5.3 - - 37.1 34.7 35.3 25.2 37.0 23.0 28.8 18.6 - - 
Non-manual 17.4 30.5   10.8 11.8 58.7 53.9 54.1 59.5 13.5 28.6   
Manual 51.3 45.3   42.7 38.2 6.0 20.9 1.8 12.2 50.3 14.3   
Unknown 18.5 19.0   9.5 15.4 0.0 0.0 7.2 5.4 7.4 28.6   
PRE-STROKE 
HEALTH 
              
In an institution (%)               
Yes - - - - 2.2 7.5 - - - - - - - - 
No     96.6 91.2         
Unknown     1.3 1.3         
Modified Rankin Score 
(%) 
              
0-2 95.9 89.0 - - - - - - 97.3 93.2 - - 50.0 60.0 
3-5 4.1 11.1       2.7 6.1   0.0 40.0 
Unknown 0.0 0.0       0.0 0.7   0.0 0.0 
Barthel Index score (%)               
20 - - - - 72.8 64.9 - - - - - - - - 
<20     6.9 14.0         
Unknown     20.3 21.1         


















- - - - - - - - 
Pre-stroke dependence 
(%) 
              
Yes - - - - - - - - - - 2.4 9.3 - - 
No           96.9 90.7   
Unknown           0.6 0.0   
MEDICAL HISTORY               
Hypertension (%)               
Yes 55.9 62.6 58.0 65.2 51.7 57.9 59.3 72.2 56.8 73.0 56.4 57.1 80.0 35.0 
No 44.1 37.4 42.0 34.8 47.4 42.1 39.3 27.0 43.2 27.0 42.9 42.1 20.0 65.0 
Unknown 0.0 0.0 0.0 0.0 0.9 0.0 1.3 0.9 0.0 0.0 0.6 0.7 0.0 0.0 
Atrial fibrillation (%)               
Yes 13.9 12.6 0.0 0.0 12.9 15.4 10.7 9.6 7.2 5.4 10.4 20.0 40.0 10.0 
No 86.2 87.4 100.0 100.0 86.2 84.7 88.0 89.6 92.8 94.6 89.6 80.0 60.0 90.0 
Unknown 0.0 0.0 0.0 0.0 0.9 0.0 1.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 
Ischaemic heart disease 
(%) 
              
Yes 12.8 6.3 0.0 0.0 13.4 8.3 4.0 5.2 5.4 6.1 19.6 12.9 30.0 10.0 
No 86.7 93.7 100.0 100.0 85.8 91.7 94.7 93.9 94.6 93.9 80.4 87.1 70.0 90.0 
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Yes 7.2 4.7 - - 6.9 3.5 6.7 9.6 4.5 4.7 - - - - 
No 92.8 95.3   92.2 96.1 92.0 89.6 89.2 83.8     
Unknown 0.0 0.0   0.9 0.4 1.3 0.9 6.3 11.5     
Transient ischaemic 
attack (%) 
              
Yes 13.3 16.3 0.0 0.0 8.2 9.2 4.0 6.1 9.9 8.8 - - 0.0 15.0 
No 86.7 83.7 100.0 100.0 91.4 90.4 64.0 67.0 90.1 91.2   100.0 85.0 
Unknown 0.0 0.0 0.0 0.0 0.4 0.4 32.0 27.0 0.0 0.0   0.0 00.0 
Diabetes (%)               
Yes 11.8 6.8 - - 20.3 15.8 - - - - - - - - 
No 88.2 93.2   78.9 84.2         
Unknown 0.0 0.0   0.9 0.0         
Dementia (%)               
Yes - - - - 0.0 4.0 - - - - 0.6 0.0 - - 
No     78.9 76.3     99.4 100.0   
Unknown     21.1 19.7     0.0 0.0   
Smoking (%)               
Current 50.3 25.8 31.0 15.2 31.5 59.7 18.0 0.0 23.4 1.4 58.9 53.6 - - 
Former 22.6 20.0 36.7 15.7 47.4 21.1 - - - - 11.0 7.9   
Never 27.1 53.7 32.2 69.1 16.4 13.6 80.7 99.1 23.4 93.9 19.5 53.6   
Unknown 0.0 0.5 0.0 0.0 4.7 5.7 1.3 0.9 27.0 4.7 0.6 0.0   
Alcohol use (%)               
Non-drinkers 24.6 51.6 38.0 73.0 17.2 46.9 74.0 94.8 23.4 66.9 16.6 41.4 - - 
Not heavy drinkers 69.2 40.5 47.8 25.3 61.2 43.0 - - - - 71.8 42.9   
Heavy drinkers 4.1 4.7 14.3 1.7 9.1 1.8 24.7 4.4 73.9 24.3 10.4 15.0   
Ex-drinkers - - - - 6.5 0.1 - - - - - -   
Unknown 2.1 3.2 0.0 0.0 6.0 7.9 1.3 0.9 2.7 9.8 1.2 0.7   














- - - - 
Medication               
Antihypertensives (%)               
Yes - - 51.4 61.8 48.3 53.5 - - - - 42.9 42.1 - - 
No   48.6 38.2 51.3 45.6     4.9 7.1   
Unknown   0.0 0.0 0.4 0.9     52.2 50.7   
Antiplatelet (%)               
Yes - - 23.3 24.2 29.3 29.4 - - - - 32.5 28.6 - - 
No   76.7 75.8 70.3 70.2     66.9 70.7   
Unknown   0.0 0.0 0.4 0.4     0.6 0.7   
STROKE-RELATED 
FACTORS 
              
Hospital admission (%)               
Yes 64.1 63.7 100.0 100.0 92.2 94.3 90.7 93.9 97.3 96.0 96.9 95.0 80.0 55.0 
No 35.9 36.3 0.0 0.0 7.8 5.7 9.3 6.1 2.7 4.1 3.1 5.0 20.0 45.0 
Time to arrive hospital* 
(%) 
              
≤ 4.5 hours - - 43.7 46.1 24.3 24.7 83.8 77.8 36.1 37.3 79.8 82.0 25.0 45.5 
> 4.5 – 24 hours   26.5 27.5 14.5 8.4   35.2 36.6 - - 0.0 9.1 
> 24 hours   28.6 23.0 7.9 10.2 16.2 22.2 21.3 16.9 13.9 14.3 12.5 0.0 
Unknown   1.2 3.4 53.3 56.7 0.0 0.0 7.4 9.2 6.3 7.8 62.5 45.5 
Stroke type (%)               
Ischaemic stroke  92.8 84.2 72.7 68.5 82.8 85.1 78.7 87.0 78.4 79.1 82.2 75.7 70.0 45.0 
Intracerebral 
haemorrhage 
3.6 4.7 7.4 9.0 14.7 10.5 16.0 3.5 15.3 13.5 8.6 12.1 10.0 15.0 
Subarachnoid 
haemorrhage 
1.5 7.4 3.3 9.6 0.0 0.0 3.3 4.4 1.8 4.7 5.5 7.1 - - 
Undetermined 2.1 3.7 16.7 12.9 2.6 4.4 2.0 5.2 4.5 2.7 3.7 5.0 20.0 10.0 
Stroke severity               
















UNSS, reversed, mean 
(SD) 
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GCS, reversed, mean 
(SD) 





Loss of consciousness 
(%) 
              
Yes - - - - 7.8 8.3 - - 0.0 1.4 25.8 25.7 - - 
No     71.1 71.5   100.
0 
98.7 73.6 73.6   
Unknown     21.1 20.2 19.1 15.9 0.0 0.0 0.6 0.7   
Body paralysis (%)               
Yes - - - - 64.2 60.5 14.3 18.8 68.5 69.6 82.8 79.3 - - 
No     14.7 19.7 66.7 65.2 31.5 30.4 17.2 20.7   
Unknown     21.1 19.7 19.1 15.9 0.0 0.0 0.0 0.0   
Incontinence (%)               
Yes - - - - 5.6 9.7 - - - - - - - - 
No     91.0 90.4         
Unknown     3.5 0.0         
Barthel at onset (%)               
> 60 - - - - - - 3.2 11.6 - - - - - - 
≤ 60       95.2 84.1       
Unknown       1.6 4.4       
POST-STROKE 
FACTORS 
              
Depression at 5 years               
Yes - - - - 11.6 14.0 11.6 14.0 - - 31.9 31.4 - - 
No     75.4 73.7 75.4 73.7   49.7 47.9   
Unknown     12.9 12.3 12.9 12.3   18.4 207   
Recurrence at 5 years               
Yes 15.4 23.7 - - - - 9.1 9.2 - - - - - - 
No 84.6 76.3     91.0 90.8       
Unknown 0.0 0.0     0.0 0.0       
Bold denotes statistically significant results between women and men. NIHSS, National Institutes of 
Health Stroke Scale. UNSS, Unified Neurology Stroke Scale, Glasgow Coma Scale 




Supplemental Table B-3. List of covariates not meeting the criteria for factors 
confounding the difference in 1-year functional outcome between women and men 
Study  Covariates not meeting the criteria of for confounding 
factors in univariable model 
Confounding factors in univariable model but that 
were not significant in the final multivariable 
model* 
Oxford SEP, education, hypertension, AF, IHD, PVD, TIA, diabetes, 
BMI, smoking, hospital admission, stroke type, recurrence  
Marital status, alcohol 
Joinville Race, hypertension, , AF, IHD, PVD, TIA, BMI, smoking, 
hospital admission, stroke type, pre-stroke medication 
(antihypertensives, antiplatelet, anticoagulant), delay to hospital 
Alcohol 
Melbourne Race, SEP, education, hypertension, IHD, PVD, TIA, diabetes, 
smoking, alcohol, pre-stroke Barthel*, stroke type, hospital 
admission, institutional residence, pre-stroke medication 
(antiplatelet, anticoagulant, antihypertensives), onset LOC, 
onset incontinence, recurrence (1-year), depression (5-year) 
Dementia, onset hemiplegia  
Arcadia hypertension, IHD, PVD, TIA, diabetes, BMI, smoking, 
alcohol, stroke type, hospital admission, recurrence, onset 
hemiplegia, onset incontinence, onset LOC  
- 
Perth SEP, hypertension, AF, IHD, TIA, diabetes, smoking, alcohol, 
delay to hospital, pre-stroke medication (antihypertensives, 
antiplatelet), institutional residence, pre-stroke Barthel, stroke 
type, hospital admission, severity (NIHSS)* 
- 
Orebro Marital status, hypertension, AF, IHD, PVD, TIA, diabetes, 
dementia, smoking, pre-stroke Barthel, stroke type, hospital 
admission 
- 
Martinique  Hypertension, AF, IHD, PVD, TIA, BMI, smoking, alcohol, 
stroke type, hospital admission, delay to hospital 
- 
Porto SEP, education, hypertension, AF, IHD, PVD, TIA, BMI, 
alcohol, stroke type, stroke severity (UNSS), LOC*, hospital 
admission, delay to hospital, onset hemiplegia, recurrence 
- 
Matão Race, marital status, education, age*, hypertension, AF, IHD, 
PVD, TIA, smoking, alcohol, stroke type, hospital admission, 
recurrence 
- 
Tartu Hypertension, AF, IHD, TIA, hospital admission, stroke type, 
delay to hospital, pre-stroke medication (antihypertensives, 
antiplatelet) 
- 
* not a confounder but remaining in the final model 
AF, Atrial fibrillation; Barthel, Barthel Index; BMI, body mass index; GCS, Glasgow Coma Scale; 
IHD, ischaemic heart disease; LOC, loss of consciousness (at onset); mRS, modified Rankin scale; 
NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease, TIA, transient 




 Supplemental Table B-4a. Relative risk of poor functional outcome for women compared to men at 1 year and 5 years after stroke in 
unadjusted models and models with adjustment for age, severity, and pre-stroke dependency  
Study N* Unadjusted Adjusted for age Adjusted for severity Adjusted for pre-stroke dependency 
  RR (95% CI) RR (95% CI) ∆%† RR (95% CI) ∆%† RR (95% CI) ∆%† 
1-year outcome             
Oxford 895 1.45 (1.20, 1.75) 1.26 (1.05, 1.51) 38% 1.34 (1.12, 1.59) 21% 1.21 (1.03, 1.44) 49% 
Joinville 1708 1.42 (1.07, 1.90) 1.24 (1.02, 1.50) 40% 1.36 (1.13, 1.64) 13% -   
Melbourne 415 1.45 (1.18, 1.79) 1.30 (1.06, 1.58) 29% 1.37 (1.13, 1.68) 10% 1.40 (1.13, 1.72) 4% 
Arcadia 327 1.29 (0.93, 1.78) 1.26 (0.91, 1.75) 10% 1.23 (0.89, 1.70) 44% -   
Perth 36 6.80 (1.80, 25.66) 5.18 (1.25, 21.6) 14% 6.39 (1.74, 23.56) 3% 5.03 (1.25, 20.20) 16% 
Orebro 253 0.94 (0.68, 1.30) 0.80 (0.59, 1.10) -260% 0.96 (0.71, 1.29) 34% 0.85 (0.62, 1.18) -162% 
Martinique  328 1.23 (0.91, 1.64) 1.09 (0.82, 1.46) 58% 1.06 (0.82, 1.37) 72% -   
Porto 477 1.27 (1.02, 1.59) 1.18 (0.95,1.46) 31% 1.27 (1.02, 1.58) 0% 1.10 (0.88, 1.36) 60% 
Matão 54 1.05 (0.51, 2.14) 1.06 (0.52,2.17) -19% 0.84 (0.40, 1.76) 457% -   
Tartu 164 1.21 (0.81, 1.83) 0.93 (0.63, 0.37) 138% 1.16 (0.78, 1.73) 22% 1.03 (0.70, 1.52) 84% 
Pooled (10 studies) 4657 1.32 (1.18, 1.48) 1.17 (1.06, 1.30) 43% 1.25 (1.11, 1.41) 20% 1.16 (0.98, 1.38) 45% 
5-year outcome             
Oxford 378 1.61 (1.25, 2.08) 1.39  (1.09, 1.78) 31% 1.54 (1.20, 1.98) 9% 1.40 (1.10, 1.79) 29% 
Joinville 423 1.20 (0.78, 1.83) 1.09 (0.73, 1.62) 9% 1.15 (0.77, 1.72) 4% -   
Melbourne 368 1.22 (0.99, 1.51) 1.14  (0.96, 1.36) 34% 1.16 (0.94, 1.43) 25% 1.13 (0.91, 1.40) 39% 
Martinique 224 1.17 (0.77, 1.78) 1.14  (0.76, 1.71) 17% 1.02 (0.70, 1.50) 87% -   
Porto 258 1.14 (0.84, 1.55) 1.05  (0.79, 1.41) 63% 1.14 (0.84, 1.55) 0% 1.05 (0.77, 1.43) 63% 
Auckland 302 1.25 (0.86, 1.80) 1.04  (0.72,1.51) 82% 1.27 (0.88, 1.83) -7% 1.13 (0.78, 1.63) 45% 
Tartu 131 1.79 (1.06, 3.02) 1.44  (0.84, 2.45) 37% 1.74 (1.03, 2.94) 5% 1.76 (1.04, 2.97) 3% 
Pooled (7 studies) 2,084 1.31 (1.16, 1.47) 1.16  (1.04, 1.30) 45% 1.25 (1.11, 1.41) 17% 1.22 (1.06, 1.41) 28% 
Bold denotes statistically significant results; CI indicates confidence interval; RR, relative risk 
* the sample size was the same among the unadjusted model, age-adjusted model, and fully adjusted model 




Supplemental Table B-4b. Interaction between sex and pre-stroke dependency in 
functional outcomes after stroke at 1 and 5 years after stroke 
















 RR (95% CI) RR (95% CI)  RR (95% CI) RR (95% CI)  
1-year 
outcome   
        
Oxford 0.89 0.78, 1.01 1.48 1.17, 1.87 0.032 0.90 0.78, 1.03 1.20 0.97, 1.49 0.102 
Melbourne 0.89 0.70, 1.11 1.56 1.19, 2.03 0.001 0.92 0.75, 1.13 1.35 0.06, 1.70 0.155 
5-year 
outcome 
          
Oxford 0.90 0.77, 1.04 1.61 1.21, 2.15 0.030 0.87 0.71, 1.06 1.37 1.01, 1.72 0.015 
Melbourne 0.95 0.70, 1.29 1.29 0.98, 1.71 0.063 1.16 0.90, 1.49 0.87 0.63, 1.21 0.089 
Bold denotes statistically significant results between women and men; CI indicates confidence interval; 
RR, relative risk of poorer functional outcomes of stroke (modified Rankin Scale>2 for Oxford or 
Barthel Index for Melbourne <20) 
*denotes RR adjusted for confounding factors 











No of poorer outcome 
(n/N) 
  Unadjusted   Adjusted*  
Men Women I2 (%) PH RR (95% CI) Psub-group I2 (%) PH RR (95% CI) Psub-group 
Study-level characteristics               
Geographic region Australasia 2 100/265 156/265 80.2 0.024 2.72 (0.62-12.0) 0.733 75.6 0.043 2.14 (0.56-8.16) 0.432 
 Europe 5 343/1099 439/1070 24.1 0.261 1.27 (1.10-1.45)  2.2 0.394 1.04 (0.93-1.16)  
 South America 2 159/964 183/798 0.0 0.414 1.40 (1.15-1.69)  0.0 0.415 1.13 (0.94-1.35)  
 Caribbean 1 78/209 82/182 NA 1.000 1.23 (0.91-1.64)  NA 1.000 0.99 (0.76-1.27)  
Income group HIC 7 443/1364 595/1335 50.4 0.060 1.32 (1.12-1.54) 0.970 50.7 0.058 1.08 (0.94-1.26) 0.867 
 LMIC† 3 237/1173 265/980 0.0 0.550 1.34 (1.14-1.58)  0.0 0.512 1.08 (0.93-1.25)  
Loss to follow-up ≤20% 7 549/2186 661/1942 8.1 0.367 1.30 (1.18-1.44) 0.481 0.0 0.559 1.06 (0.97-1.16) 0.295 
 >20% 3 131/351 199/373 66.3 0.052 1.58 (0.99-2.51)  70.8 0.033 1.26 (0.78-2.04)  
Functional outcome measurement Barthel Index 2 110/282 147/266 0.0 0.389 1.42 (1.16-1.73) 0.641 8.2 0.297 1.21 (0.96-1.52) 0.272 
 mRS 8 570/2255 713/2049 42.5 0.095 1.30 (1.14-1.49)  33.1 0.164 1.05 (0.94-1.18)  
Age difference‡ ≤4.5 years 7 513/1954 625/1758 4.9 0.390 1.30 (1.17-1.44) 0.431 20.0 0.277 1.09 (0.97-1.21) 0.975 
 >4.5 years 3 167/583 235/557 66.3 0.052 1.57 (1.00-2.47)  66.9 0.049 1.16 (0.75-1.80)  
Severity instrument NIHSS 7 493/2027 607/1756 51.1 0.056 1.35 (1.14-1.59) 0.766 46.6 0.082 1.12 (0.97-1.29) 0.590 
 Barthel at onset 1 78/209 82/182 NA 1.000 1.23 (0.91-1.64)  NA 1.000 0.99 (0.76-1.27)  
 Others§ 2 109/301 171/377 0.0 0.840 1.26 (1.04-1.53)  0.0 0.509 1.00 (0.82-1.21)  
Pre-stroke function Unavailable 4 290/1076 312/1115 0.0 0.741 1.33 (1.15-1.54) 0.955 0.0 0.625 1.10 (0.96-1.26) 0.908 
 Available 6 390/1171 548/1200 58.4 0.034 1.32 (1.10-1.59)  57.6 0.038 1.07 (0.90-1.26)  
PH, P-value of heterogeneity; NIHSS, National Institutes of Health Stroke Scale; RR (95% CI), relative risk (95% confidence interval) between women and men; HIC, High-
income country; LMIC, Low- and middle-income country 
* RR adjusted for actual confounders 
† low- and middle-income country (LMIC) group included studies conducted in Joinville, Martinique and Mãtao 
‡ indicates difference in median age at onset between women and men 





 Supplemental Table B-5b. Testing the interactions between sex and three 
covariates: time period, age and stroke type using a single pooled IPD dataset in 
functional outcomes after stroke at 1 year and 5 years after stroke 
 
 Unadjusted Adjusted for age 
 
Covariates RR* (95% CI) Pinteraction RR (95% CI) Pinteraction 
1-year outcome        
 Stroke type       
 IS 1.38 (1.24-1.54) Ref 1.19 (1.06-1.35) Ref 
 ICH 1.47 (0.93-2.34) 0.726 1.17 (0.83-1.65) 0.777 
 SAH NA  - NA  - 
 Undetermined 1.03 (0.71-1.50) 0.079 1.04 (0.74-1.45) 0.136 
 Age group       
 ≤65 years 1.11 (0.90-1.36) Ref -   
 >65-75 years 1.22 (1.07-1.39) 0.704 -   
 >75 years 1.10 (0.90-1.35) 0.722 -   
 Year of stroke occurrence       
 1993-2014 (continuous) 1.34 (1.16-1.54) 0.641 1.22 (1.03- 1.44) 0.933 
5-year outcome        
 Stroke type       
 IS 1.35 (1.17-1.57) Ref 1.19 (1.05-1.34) Ref 
 ICH 1.41 (0.75-2.64) 0.999 1.17 (0.60-2.26) 0.884 
 SAH NA  - NA  - 
 Undetermined 1.07 (0.65-1.77) 0.340 0.87 (0.50-1.52) 0.325 
 Age group       
 ≤65 years 1.29 (0.99-1.67) Ref -   
 >65-75 years 1.19 (0.98-1.45) 0.626 -   
 >75 years 1.08 (0.92-1.25) 0.246 -   
 Year of stroke occurrence       
 1996-2011 (continuous) 1.31 (1.19, 1.49) 0.853 1.16 (1.09-1.22) 0.526 
NA, not applicable; IS, Ischaemic stroke; ICH, Intracerebral haemorrhage; SAH, Subarachnoid 
haemorrhage; Ref, Reference group 
*  RR (95% CI), relative risk (95% confidence interval) of poor functional outcome (mRS>2 or 




Supplemental Table B-6. Sensitivity analysis of relative risk of functional outcome 
between women and men at 1 year and 5 years after stroke. Poor outcome was 
defined as Barthel Index <20 for Melbourne (or <100 for Matão) or mRS>2 
(remaining studies)  
Study  Unadjusted   Adjusted for confounders  
 
Poor outcome, Barthel 
<20 (or <100) 
Poor outcome, Barthel 
<19 (or <95) 
Poor outcome, Barthel 
<20 (or <100) 
Poor outcome, Barthel 
<19 (or <95) 
 RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI) 
Melbourne         
1-year 1.45 (1.18, 1.79) 1.64 (1.27, 2.13) 1.25 (1.04, 1.50) 1.38 (1.11, 1.73) 
5-year 1.22 (0.99, 1.51) 1.22 (0.96, 1.56) 1.02 (0.84, 1.45) 1.04 (0.93, 1.17) 
Matão         
1-year 1.05 (0.51, 2.14) 1.14  (0.55, 2.38) 0.84 (0.40, 1.75) 0.92 (0.43, 1.97) 
Pooled data         
1-year, 10 studies 1.32 (1.18, 1.48) 1.34 (1.18, 1.51) 1.08 (0.97, 1.20) 1.09 (0.97, 1.22) 
1-year, 9 studies 
(excluding Perth*) 
1.33 (1.22, 1.45) 1.34 (1.21, 1.47) 1.08 (1.00, 1.18) 1.08 (0.98, 1.20) 
5-year, 7 studies 1.31 (1.16, 1.47) 1.31 (1.16, 1.49) 1.05 (0.94, 1.18) 1.04 (0.93, 1.17) 
5-year, 6 studies 
(excluding Auckland*) 
1.31 (1.15, 1.50) 1.32 (1.15, 1.52) 1.06 (0.94, 1.19) 1.05 (0.93, 1.19) 
Bold denotes statistically significant results between women and men. 
RR (95% CI), Relative risk (95% confidence interval) 




Supplemental Table B-7. Missing data on functional outcome and confounders 
among the 11 included studies 


























Oxford* 910 7.9% 895 1.6% 385 4.5% 378 1.8% 
Joinville 1708 8.6%† 1708 0.0% 423 29.3%† 423 0.0% 
Melbourne* 493 38.8% 415 16.0% 460 16.9% 368 20.0% 
Arcadia 328 4.1%‡ 327 1.8% -    
Perth* 36 70.0% 36 0.0% -    
Orebro* 253 0.0% 253 0.0% -    
Martinique  391 0.0% 328 16.1% 265 0.0% 224 15.4% 
Porto 484 0.0% 477 1.4% 259 7.8% 255 1.5% 
Auckland -    303 65.6%§ 302 0.3% 
Matão* 54 3.6% 54 0.0% -    
Tartu* 194 20.8% 164 15.5% 131 18.6% 131 0.0% 
Total 4,852  4,657  2,226  2,084  
*denotes studies with available data on death matched to National Death Registries 
† n=161 cases with missing data on outcome at 1 year (89 cases were lost to follow up and 72 had new 
stroke events); n=175 cases with missing data on outcome at 5 years (108 were lost to follow up and 67 
had new stroke events)  
‡ n=14 cases with missing data on outcome (7 cases were lost to follow up (not known died/alive); 7 
cases were alive but had no functional outcome assessment) 
§ n=578 with missing data on outcome (13.2% of cases were lost to follow-up (not known died/alive); 





Supplemental Table B-8a. Differences in patient characteristics between those with and without functional outcome assessment at 1 year after 
stroke 





























SOCIODEMOGRAPHIC               
Female (%) 47.1 47.4 45.5 43.1 49.6 54.7 41.2 57.1 55.6 53.6 38.9 50.0 55.7 51.0 
Age, mean (SD) 71.9 (28.1) 69.8 (16.5) 61.8 (14.6) 66.5 (13.2) 72.1 
(13.6) 
69.8 (16.4) 73.2 
(11.9) 
76.3 (6.6) 71.5 
(15.0) 
74.2 (12.4) 62.6 
(10.7) 
64.0 (18.4) 68.7 
(11.7) 
69.5 (13.0) 
Marital status (%)               
Single/widowed 34.4 32.1 - - - - - - 52.8 54.8 - - - - 
Married 5.6 41.0       47.2 41.7     
Unknown 8.0 26.9       0.0 0.0     
Education level (%)               
≤ Grade 12 71.5 47.4 93.4 94.4 72.1 27.9 - - - - 85.2 100.0 - - 
> Grade 12 14.7 9.0 6.5 2.8 13.1 70.4     9.3 0.0   
Unknown 13.7 43.6 0.1 2.8 4.9 1.7     5.6 0.0   
Social class (%)               
Professional 13.3 5.1 - - 36.0 31.3 - - 22.2 10.7 - - - - 
Non-manual 28.2 21.8   13.8 9.1   19.4 7.1     
Manual 41.1 32.1   47.0 28.5   44.4 25.0     
Unknown 17.4 41.0   3.2 31.1   13.9 57.1     
PRE-STROKE HEALTH               
In an institution (%)               
Yes - - - - 6.5 2.9 - - 19.4 3.6 - - - - 
No     93.3 88.6   80.6 94.1     
Unknown     0.2 2.9   0.0 2.4     
Modified Rankin Score (%)               
0-2 88.1 69.2 - - - - 99.7 92.9 69.4 72.6 - - 84.0 56.9 
3-5 11.7 14.1     0.3 7.1 27.8 17.9   3.1 2.0 
Unknown 0.2 16.7     0.0 0.0 2.8 9.5   12.9 41.2 
Barthel Index score (%)               
20 - - - - 79.6 25.9 - - 63.9 71.4 - - - - 
<20     16.8 6.3   33.3 17.9     
Unknown     3.6 67.8   2.8 10.7     
MEDICAL HISTORY               
Hypertension (%)               
Yes 60.8 53.9 65.5 72.2 55.3 52.7 80.8 85.7 47.2 63.1 70.4 0.0 71.7 43.1 
No 39.1 46.2 34.5 27.8 44.7 46.2 19.2 14.3 47.2 34.5 27.8 100.0 28.4 56.9 
Unknown 0.1 0.0 0.0 0.0 0.0 1.1 0.0 0.0 5.6 2.4 2.0 0.0 0.0 0.0 
Atrial fibrillation (%)               
Yes 16.6 11.5 3.2 4.2 16.4 18.2 29.0 28.6 16.7 21.4 1.9 0.0 23.7 23.5 
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Unknown 0.0 0.0 0.0 0.0 0.6 1.1 0.0 0.0 2.8 7.1 3.7 0.0 0.0 0.0 
Ischaemic heart disease (%)               
Yes 11.2 12.8 95.8 8.3 13.0 10.5 15.5 14.3 13.9 8.3 7.4 0.0 29.4 35.3 
No 88.7 85.9 4.2 91.7 87.0 88.3 84.5 85.7 86.1 85.7 88.9 100.0 70.6 64.7 
Unknown 0.1 1.3 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 
Peripheral vascular disease (%)               
Yes 5.6 3.9 - - 7.3 6.8 8.5 0.0 - - 7.4 0.0 - - 
No 94.0 96.2   92.7 92.0 91.5 100.0   89.0 100.0   
Unknown 0.4 0.0   0.0 1.1 0.0 0.0   3.7 0.0   
Transient ischaemic attack (%)               
Yes 12.5 10.3 2.2 5.6 10.5 5.7 16.8 14.3 22.2 10.7 3.7 0.0 8.8 7.8 
No 87.4 89.7 97.8 94.4 89.3 93.7 83.2 85.7 75.0 78.6 92.6 100.0 91.2 92.2 
Unknown 0.1 0.0 0.0 0.0 0.2 0.6 0.0 0.0 2.8 10.7 3.7 0.0 0.0 0.0 
Diabetes (%)               
Yes 12.5 21.8 - - 17.4 16.8 27.7 14.3 19.4 16.7 - - - - 
No 87.5 769   82.4 82.9 72.3 85.7 80.6 82.1     
Unknown 0.0 1.3   0.2 0.3 0.0 0.0 0.0 1.2     
Dementia (%)               
Yes - - - - 4.3 5.1 - - - - 1.9 0.0 - - 
No     74.1 76.4     94.4 100.0   
Unknown     21.7 18.5     3.7 0.0   
Smoking (%)               
Current 40.1 33.3 31.0 26.4 36.2 28.5 19.8 14.3 50.0 27.4 61.1 0.0 - - 
Former 17.6 32.1 23.2 19.4 14.8 19.7 - - 111.1 8.3 - -   
Never 41.8 20.5 46.3 54.2 47.4 35.6 80.2 85.7 30.6 41.7 37.0 100.0   
Unknown 0.6 14.1 0.0 0.0 1.6 16.2 0.0 0.0 8.3 22.6 1.9 0.0   
Alcohol use (%)               
Non-drinkers 39.7 41.0 62.9 58.3 31.4 32.5 87.5 100.0 22.2 28.6 83.3 100.0 - - 
Not heavy drinkers 53.7 32.1 30.4 31.9 58.1 37.6 - - 13.9 11.9 - -   
Heavy drinkers 29 2.6 6.7 9.7 4.5 5.7 12.5 0.0 41.7 20.2 13.0 0.0   
Ex-drinkers - - - - 3.2 4.3 - - 11.1 3.6 - -   
Unknown 3.7 24.4 0.0 0.0 2.8 19.9 0.0 0.0 11.1 35.7 3.7 0.0   
STROKE-RELATED FACTORS               
Hospital admission, yes (%) 81.0 93.6 100.0 100.0 94.7 94.9 92.7 100.0 80.6 86.9 100.0 100.0 93.8 70.6 
Stroke type (%)               
Ischaemic stroke  87.8 56.4 68.4 83.3 85.4 70.7 75.9 71.4 77.8 84.5 90.7 100.0 84.5 60.8 
Intracerebral haemorrhage 4.8 16.7 7.0 5.6 10.1 13.1 10.4 7.1 2.8 8.3 9.3 0.0 9.8 13.7 
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Undetermined 4.3 18.0 19.6 11.1 4.3 5.1 12.2 21.4 11.1 1.2 0.0 0.0 5.7 25.5 
Stroke severity               
NIHSS, mean (SD) 3.7 (4.8) 4.4 (5.5) 5.8 (6.4) 5.6 (6.0) 5.2 (5.4) 5.7 (6.8) - - 5.9 (6.6) 7.6 (7.2) 6.8 (5.6) 9.0 (5.0) 5.7 (6.5) 7.6 (8.6) 
GCS, reversed, mean (SD) - - - - -  3.8 (1.8) 3.7 (1.5) - - - - - - 
POST-STROKE FACTORS               
Depression at 1 year               
Yes - - - - 16.0 0.0 - - - - - - - - 
No     65.6 2.0         
Unknown     18.4 98.0         
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SOCIODEMOGRAPHIC             
Female (%) 49.4 66.7 42.1 34.3 49.6 52.3 57.1 63.6 46.2 50.5 51.9 66.7 
Age, mean (SD) 69.9 (11.5) 70.8 (15.4) 58.1 (14.4) 62.7 (12.1) 69.2 (14.3) 60.7 (16.9) 64.0 (12.6) 67.2 (14.3) 66.0 (12.6) 70.0 (14.2) 64.7 (12.5) 70.4 (9.1) 
Marital status (%)             
Single/widowed 34.8 33.3 - - - - - - - - - - 
Married 56.4 55.6           
Unknown 8.8 11.1           
Education level (%)             
≤ Grade 12 76.6 33.3 92.2 92.5 9.1 35.6 84.6 68.2 46.5 47.2 - - 
> Grade 12 12.2 16.7 7.8 6.0 36.5 64.4 2.7 9.1 45.9 29.6   
Unknown 11.2 50.0 0.0 1.5 5.2 0.0 12.7 22.7 7.6 23.2   
Social class (%)             
Professional 9.1 16.7 - - 35.9 27.3 29.0 13.6 24.1 17.0 - - 
Non-manual 23.9 5.6   11.3 10.6 57.1 72.7 20.5 18.9   
Manual 48.3 27.8   40.4 33.3 7.7 4.6 38.3 33.0   
Unknown 18.7 50.0   12.4 28.8 6.2 9.1 17.2 31.1   
PRE-STROKE HEALTH             
Modified Rankin Score (%)             
0-2 92.5 83.3 - - - - 95.0 95.5 - - 86.3 56.7 
3-5 7.5 5.6     4.6 0.0   0.8 0.0 
Unknown 0.0 11.1     0.4 4.6   13.0 43.3 
Barthel Index score (%)             
20 - - - - 68.9 37.9 - - - - - - 
<20     10.4 4.6       
Unknown     20.7 57.6       
Pre-stroke dependence (%)             
Yes - - - - - - - - 94.1 88.6 - - 
No         5.6 8.1   
Unknown         0.3 3.3   
MEDICAL HISTORY             
Hypertension (%)             
Yes 59.2 38.9 61.0 70.2 54.8 46.2 66.0 45.5 56.8 52.9 70.2 50.0 
No 40.8 61.1 39.0 29.9 44.8 53.0 34.0 54.6 42.6 44.8 29.8 50.0 
Unknown 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.7 2.3 0.0 0.0 
Atrial fibrillation (%)             
Yes 13.3 11.1 0.0 0.0 14.1 9.9 6.2 9.1 14.9 17.1 16.0 20.0 
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Unknown 0.0 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.4 0.0 0.0 
Ischaemic heart disease (%)             
Yes 9.6 5.6 0.0 0.0 10.9 6.1 5.8 4.6 16.5 19.4 28.2 16.7 
No 90.1 94.4 100.0 100.0 88.7 93.2 94.2 95.5 83.5 80.3 71.8 83.3 
Unknown 0.3 0.0 0.0 0.0 0.4 0.8 0.0 0.0 0.0 0.4 0.0 0.0 
Peripheral vascular disease (%)             
Yes 6.0 5.6 - - 5.2 6.1 4.6 4.6 - - - - 
No 94.0 94.4   94.1 93.2 86.1 86.4     
Unknown 0.0 0.0   0.7 0.8 9.3 9.1     
Transient ischaemic attack (%)             
Yes 14.8 16.7 0.0 0.0 8.7 6.1 9.3 22.7 - - 8.4 10.0 
No 85.2 83.3 100.0 100.0 90.9 93.2 90.7 77.3   91.6 90.0 
Unknown 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0   0.0 0.0 
Diabetes (%)             
Yes 9.4 11.1 - - 18.4 12.2 - - - - - - 
No 90.7 83.3   81.5 87.9       
Unknown 0.0 5.6   0.4 0.0       
Dementia (%)             
Yes - - - - 2.0 2.3 - - 0.3 0.4 - - 
No     77.6 80.3   99.7 98.9   
Unknown     20.4 17.4   0.0 0.9   
Smoking (%)             
Current 38.2 38.9 27.9 31.3 34.4 23.5 10.8 13.6 40.6 39.5 - - 
Former 21.3 16.7 24.4 20.9 15.0 31.1 - - 49.5 36.5   
Never 40.3 38.9 47.8 47.8 45.4 35.6 74.9 68.2 9.6 17.3   
Unknown 0.3 5.6 0.0 0.0 5.2 9.9 14.3 18.2 0.3 6.8   
Alcohol use (%)             
Non-drinkers 37.9 50.0 52.7 44.8 32.0 32.6 48.3 50.0 28.1 32.0 - - 
Not heavy drinkers 55.1 33.3 38.3 43.3 52.2 44.7 - - 58.4 43.8   
Heavy drinkers 4.4 0.0 9.0 11.9 5.4 5.3 45.6 40.9 12.5 13.7   
Ex-drinkers - - - - 3.5 3.0 - - - -   
Unknown 2.6 16.7 0.0 0.0 7.0 14.4 6.2 9.1 1.0 10.6   
STROKE-RELATED FACTORS             
Hospital admission, yes (%) 63.9 94.4 100.0 100.0 93.9 97.7 96.5 100.0 96.0 95.3 93.9 63.3 
Stroke type (%)             
Ischaemic stroke  88.6 38.9 70.9 82.1 83.9 59.9 78.8 81.8 79.2 81.5 84.7 53.3 




Supplemental Table B-8b. Differences in patient characteristics between those with and without functional outcome assessment at 5 years after 
stroke 


























Subarachnoid haemorrhage 4.4 27.8 5.9 3.0 0.0 29.6 3.5 9.1 6.3 4.2 - - 
Undetermined 2.9 11.1 15.1 9.0 3.5 1.5 3.5 0.0 4.3 5.0 4.6 33.3 
Stroke severity             
NIHSS, mean (SD) 3.3 (4.5) 3.2 (3.6) 5.8 (6.5) 5.0 (5.0) 4.2 (4.4) 5.2 (6.0) - - - - 5.4 (6.6) 7.4 (8.0) 
UNSS, reversed, mean (SD) - - - - - - 7.3 (7.8) 6.8 (7.3) - - - - 
GCS, reversed, mean (SD) - - - - - - - - 1.7 (1.8) 1.7 (1.9) - - 
POST-STROKE FACTORS             
Depression at 5 years (%)             
Yes - - - - 12.8 0.8 - - 48.8 2.4 - - 
No     74.6 0.8   31.7 1.4   
Unknown     12.6 98.5   19.5 96.2   




Supplemental Table B-9. Comparison of complete-case analysis and sensitivity analyses of missing data on relative risk of functional outcome 





 Adjusted  
 Complete-case Imputed* 
Replace with 
extreme value of 0 
Replace with 
extreme value of 1 
Complete-case Imputed* 
Replace with extreme 
value of 0 
Replace with extreme value 
of 1 
 MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) MRR (95% CI) 
Melbourne                 
1-year 1.45 (1.18-1.79) 1.42 (1.16-1.74) 1.40 (1.10-1.77) 1.21 (1.08-1.35) 1.25 (1.04-1.50) 1.30 (1.07-1.59) 1.22 (0.97-1.53) 1.12 (1.01-1.25) 
5-year 1.22 (0.99-1.51) 1.29 (1.01-1.66)  1.20 (0.94-1.51) 1.15 (0.99-1.34) 1.02 (0.84-1.45) 1.09 (0.86-1.39) 1.00 (0.80-1.24) 1.04 (0.90-1.20) 
Joinville                 
5-year 1.20 (0.78-1.83) 1.14 (0.78-1.66) 1.19 (0.77-1.85) 1.05 (0.87-1.27) 1.06 (0.71-1.57) 1.00 (0.96-1.09) 1.02 (0.67-1.55) 1.00 (0.83-1.20) 
Perth                 
1-year 6.80 (1.80-25.66) 2.14 (0.84-5.46)  7.19 (1.72-29.9) 1.28 (1.09-1.51) 5.10 (1.33-19.58) 1.91 (0.71-5.15)  1.76 (0.29-3.23) 1.21 (1.04-1.41) 
Tartu                 
1-year 1.21 (0.81-1.83) 1.10 (0.80-1.51)  1.14 (0.83-1.55) 1.22 (0.80-1.86) 0.89 (0.60-1.32) 0.89 (0.65-1.21)   0.92 (0.68-1.24) 0.92 (0.61-1.40) 
Auckland                 
5-year 1.25 (0.86-1.80) 1.17 (1.08-1.27)  1.14 (0.76-1.72) 1.07 (0.99-1.16) 0.99 (0.69-1.41) 1.00 (0.93-1.08)  0.99 (0.66-1.50) 1.02 (0.95-1.11) 
Pooled data                 
1-year (10 studies) 1.32 (1.18-1.48) 1.31 (1.20-1.43) 1.29 (1.14-1.46) 1.18 (1.05-1.32) 1.08 (0.97-1.20) 1.08 (0.98-1.18) 1.05 (0.93-1.18) 1.03 (0.97-1.10) 
5-year (7 studies) 1.31 (1.16-1.47) 1.26 (1.13-1.40) 1.31 (1.18, 1.46) 1.27 (1.19-1.35) 1.05 (0.94-1.18) 1.02 (0.96-1.09) 1.07 (0.97-1.19) 1.10 (1.03-1.17) 
Bold denotes statistically significant results between women and men. 
RR (95% CI), relative risk (95% confidence interval) 






Supplemental Table B-10. List of covariates not meeting the criteria for factors 
confounding the difference in 5-year functional outcome between women and men 
Study ID Covariates not meeting the criteria for confounding factors in 
univariable model 
Confounding factors in univariable model 
that were not significant in the final 
multivariable model 
Oxford SEP, education, hypertension, AF, IHD, PVD, TIA, diabetes, BMI, 
smoking, alcohol, hospital admission, stroke type, severity NIHSS*, 
recurrence  
 
Joinville Race, hypertension, age*, stroke severity (NIHSS)*, AF, IHD, PVD, 
TIA, BMI, smoking, alcohol, hospital admission, stroke type, pre-stroke 
medication (antihypertensives, antiplatelet, anticoagulant), delay to 
hospital 
 
Melbourne Race, SEP, education, hypertension, IHD, PVD, TIA, diabetes, 
smoking, alcohol, stroke type, hospital admission, pre-stroke medication 
(antiplatelet, anticoagulant, antihypertensives), onset LOC, onset 
hemiplegia, onset incontinence, depression (1-year), depression (5-
year), IDA score (overall and sub-dimension: anxiety, depression ), 
recurrence (1-year), recurrence (5-year) 
Pre-stroke Barthel*, institutional residence 
Martinique  Hypertension, AF, IHD, PVD, TIA, BMI, smoking, alcohol, stroke type, 
hospital admission, delay to hospital 
 
Porto SEP, education, hypertension, AF, IHD, PVD, TIA, BMI, alcohol, 
stroke type, stroke severity (UNSS), hospital admission, delay to 
hospital, onset hemiplegia, onset LOC*, pre-stroke Rankin*, recurrence 
 
Auckland SEP, education, hypertension, IHD, dementia, BMI, alcohol, smoking, 
pre-stroke medication (antihypertensives, antiplatelet, anticoagulant), 
stroke type, hospital admission, delay to hospital, onset hemiplegia, 
marital status, onset LOC, severity GCS*, depression (5-year), GHQ-28 
scores (overall and sub-dimension: somatic, social, anxiety and 
depression) 
 
Tartu Hypertension, AF, IHD, TIA, hospital admission, stroke type, delay to 
hospital, pre-stroke medication (antihypertensives, antiplatelet), severity 
NIHSS*, pre-stroke mRS* 
 
AF, Atrial fibrillation; BMI, body mass index; GCS, Glasgow Coma Scale; IHD, ischaemic heart 
disease; IDA, Irritability-Depression-Anxiety Scale; GHQ-28, 28-item General Health Questionnaire; 
LOC, loss of consciousness (at onset); mRS, modified Rankin scale; NIH, National Institutes of Health 
Stroke Scale; PVD, peripheral vascular disease, TIA, transient ischaemic attack; UNSS, Unified 
Neurological Stroke Scale; SEP, socioeconomic position 










No of poorer outcome 
(n/N) 
  Unadjusted   Adjusted*  
Men Women I2 (%) PH RR (95% CI) Psub-group I2 (%) PH RR (95% CI) Psub-group 
Study-level characteristics               
Geographic region Australasia 2 140/395 169/368 0.0 0.935 1.23 (1.02-1.48) 0.702 0.0 0.865 1.01 (0.85-1.20) 0.866 
 Europe 3 116/369 186/406 43.9 0.168 1.45 (1.11-1.88)  0.0 0.417 1.11 (0.93-1.34)  
 Caribbean 1 48/150 42/115 NA 1.000 1.17 (0.77-1.78)  NA 1.000 0.98 (0.67-1.42)  
 South America 1 38/245 33/178 NA 1.000 1.20 (0.78-1.83)  NA 1.000 1.06 (0.71-1.57)  
Income group HIC 5 256/764 355/774 20.4 0.285 1.34 (1.15-1.56) 0.516 0.0 0.675 1.06 (0.94-1.20) 0.786 
 LMIC† 2 86/395 75/293 0.0 0.941 1.18 (0.88-1.59)  0.0 0.785 1.01 (0.77-1.33)  
Loss to follow-up ≤20% 6 302/996 386/927 8.6 0.361 1.31 (1.15-1.50) 0.807 0.0 0.799 1.06 (0.94-1.19) 0.727 
 >20% 1 40/163 44/140 NA 1.000 1.25 (0.86-1.80)  NA 1.000 0.99 (0.69-1.41)  
Functional outcome measurement Barthel Index 1 100/232 125/228 NA 1.000 1.22 (0.99-1.51) 0.581 NA 1.000 1.02 (0.84-1.24) 0.734 
 mRS 6 242/927 305/893 0.3 0.414 1.35 (1.16-1.56)  0.0 0.798 1.07 (0.93-1.23)  
Age difference‡ ≤4.5 years 6 327/1096 401/999 0.0 0.540 1.28 (1.14-1.45) 0.282 0.0 0.980 1.03 (0.92-1.16) 0.245 
 >4.5 years 1 15/63 29/68 NA 1.000 1.79 (1.06-3.02)  NA 1.000 1.48 (0.88-2.51)  
Severity instrument NIHSS 3 198/672 252/596 31.9 0.230 1.35 (1.11-1.64) 0.842 0.0 0.823 1.06 (0.92-1.22) 0.926 
 Barthel at onset 1 48/150 42/115 NA 1.000 1.17 (0.77-1.78)  NA 1.000 0.98 (0.67-1.42)  
 Others§ 3 96/337 136/356 6.1 0.345 1.27 (1.02-1.59)  0.0 0.379 1.06 (0.85-1.31)  
Pre-stroke function Unavailable 2 86/395 75/293 0.0 0.941 1.18 (0.88-1.59) 0.516 0.0 0.785 1.01 (0.77-1.33) 0.786 
 Available 5 256/764 355/774 20.4 0.285 1.34 (1.15-1.56)  0.0 0.675 1.06 (0.94-1.20)  
Time to follow-up 5 years 5 286/985 338/851 0.0 0.492 1.31 (1.15-1.50) 0.957 0.0 0.958 1.04 (0.92-1.18) 0.746 
 Not 5 years|| 2 56/174 92/216 52.7 0.146 1.36 (0.88-2.09)  42.0 0.189 1.14 (0.78-1.68)  
PH, P-value of heterogeneity; NA, not applicable; NIHSS, National Institutes of Health Stroke Scale; RR (95% CI), Relative risk (95% confidence interval) between women 
and men; HIC, High-income country; LMIC, Low- and middle-income countries 
* RR adjusted for actual confounders 
† low- and middle-income country group (LMIC) included studies conducted in Martinique 
‡ indicates difference in median age at onset between women and men  
§ other instruments including Glasgow coma scale and loss of consciousness 




Supplemental Table B-12. Prevalence of admission and discharge medication, in-hospital investigation by female sex from 10 studies among 
cases assessed at 1 year 
  Oxford   Joinville   Melbourne   Arcadia   Perth   Orebro   Martinique   Porto  Matão  Tartu 
 
 Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women 
Admission medication 
(%)           
  
        
Antihypertensive - - - - 51.5 58.4 - - 33.3 57.1‡ - - - - - - - - - - 
Antiplatelet - - - - 32.9 32.9 28.4 32.0 20.0 35.7‡ - - - - - - - - - - 
Anticoagulation - - - - 4.6 4.8 11.3 18.8 13.3 0.0‡ - - - - - - - - - - 
Thrombolysis* - - 9.5 8.8 0.0 0.5 - - - - - - - - - - - - - - 
Discharge medication 
(%) 
                    
Antihypertensive - - - - 45.6 48.5 - - 53.3 64.3‡ - - - - 49.3 54.1 - - - - 
Antiplatelet* - - - - 56.8 60.5 - - 45.5 76.9‡ - - - - 70.4 69.8 - - - - 
Anticoagulation* - - - - 21.4 16.1 - - 45·5 0·0‡ - - - - - - - - - - 
Investigation (%)                     
Neuroimaging - - 100.0 100.0 97.1 95.3 90.3 90.6 86.7 100.0‡ 97.5 95.0 98.4 99.4 99.0 99.6 100.0 100.0 100.0 96.6 
Carotid investigation* - - 84.8 85.9 60.0 59.1 35.6 27.5 27.3 0.0‡ - - - - 52.6 52.9 - - 34·1 14·9 
Echocardiography* - - - - 50·6 36·4 24.4 15.7 36.4 7.7‡ - - - - 48.9 45.9 - - - - 
Surgery intervention (%)                     
Carotid endarterectomy* 7.6 4.2 - - 1.9 1.5 - - - - - - - - - - - - - - 
Coiling/clipping/other† 0.0 2.6‡ - - 0.0 0.0 - - - - - - - - - - - - - - 
Bold numbers denote p-value <0.05; χ2 test or Fisher's exact test, as appropriate, was used to examine if there were sex differences in admission medication and discharge 
medication, in-hospital investigation and surgical interventions. 
* among ischaemic stroke only 
† haemorrhagic stroke  




Supplemental Table B-13. Prevalence of admission and discharge medication, in-
hospital investigation by sex from 7 studies among cases assessed at 5 years 
  Oxford   Joinville   Melbourne   Martinique   Porto   Auckland   Tartu  
 Men Women Men Women Men Women Men Women Men Women Men Women Men Women 
Admission medication 
(%)             
  
Antihypertensive - - - - 48.1 53.7 - - - - - - - - 
Antiplatelet - - - - 28.0 30.2 - - - - - - - - 
Anticoagulation - - - - 5.1 6.5 - - - - - - - - 
Thrombolysis* - - 10.1 9.8 0.0 1.6 - - - - 0.8 0.6 - - 
Discharge medication 
(%) 
              
Antihypertensive - - - - 48.6 48.6 - - 46.3 55.6 60.6 62.9 - - 
Antiplatelet* - - - - 60.3 60.5 - - 63.5 69.0 79.9 81.7 - - 
Anticoagulation* - - - - 20.7 19.5 - - - - 15.9 13.8 - - 
Investigation (%)               
Neuroimaging - - 100.0 100.0 96.3 96.3 98.5 100.0 98.2 99.3 93.9 92.3 100.0 96.9 
Carotid investigation* - - 73.0 82.0 62.0 63.0 - - 66.7 59.5 5.2 3.1 54·9 21·4 
Echocardiography* - - - - 52·7 41·4 - - 60.3 61.9 1·4 0·0‡ - - 
Surgery intervention 
(%) 
              
Carotid 
endarterectomy* 
7.1 8.5 - - 3·4 0·5 - - - - - - - - 
Coiling/clipping/other† 0.0 5.3‡ - - 25.0 0.0 - - - - 13.7 18.5 - - 
Bold numbers denote p-value <0.05; χ2 test or Fisher's exact test, as appropriate, was used to examine 
whether there were sex differences in admission medication and discharge medication, in-hospital 
investigation and surgical interventions. 
* among ischaemic stroke only 
† haemorrhagic stroke  




Supplemental Table B-14. List of covariates not meeting the criteria for factors 
confounding the difference in 5-year Participation restriction between women and 
men 





that were not 
significant in the 
final multivariable 
model 
Melbourne Race, SEP, education, hypertension, IHD, PVD, TIA, diabetes, alcohol, 
hospital admission, recurrence, institutional residence, pre-stroke 
medication (antihypertensives, antiplatelet, anticoagulant), onset LOC, 
onset incontinence, onset hemiplegia, depression (1-year), depression 




dimension score of 
anxiety 
Auckland Ethnicity, SEP, education, hypertension, IHD, dementia, BMI, 
smoking, alcohol, pre-stroke medication (antihypertensives, 
antiplatelet, anticoagulant), hospital admission, delay to hospital, 
marital status, onset LOC, onset hemiplegia, GCS*, depression (5-
year), GHQ-28 scores (overall and sub-dimension: somatic, social, 
anxiety and depression) 
 
AF, Atrial fibrillation; BMI, body mass index; GCS, Glasgow Coma Scale; IHD, ischaemic heart 
disease; IDA, Irritability-Depression-Anxiety Scale; GHQ-28, 28-item General Health Questionnaire; 
LOC, loss of consciousness (at onset); mRS, modified Rankin scale; PVD, peripheral vascular disease, 
TIA, transient ischaemic attack; SEP, socioeconomic position 




Supplemental Table B-15. Comparison of complete-case analysis and imputed 
analysis of London handicap scores between women and men at 5 years after stroke 
Study  Unadjusted   Adjusted for confounders  
 Complete-case Imputed* Complete-case Imputed* 

















-1.78 (-6.51, 2.94) 
Pooled (2 












Bold denotes statistically significant results between women and men. 
MD (95% CI), mean difference (95% confidence interval) 




Supplemental Table B-16. Distribution of scores on each sub-dimension of the 
London Handicap Scale at 5 years after stroke, by sex, in Melbourne and Auckland. 
Higher categories (3-6) denotes more severe participation restriction. 
 Melbourne Auckland 
 Men Women p Men Women p 
 n % n %  n % n %  
Mobility           
Less disadvantage (1-2) 116 65.9 90 51.4 0.006 114 79.2 82 67.2 0.027 
Disadvantage (3-6) 60 34.1 85 48.6  30 20.8 40 32.8  
Physical           
Less disadvantage (1-2) 117 66.5 93 53.1 0.011 110 76.4 72 59.0 0.002 
Disadvantage (3-6) 59 33.5 82 46.9  34 23.6 5 41.0  
Occupation           
Less disadvantage (1-2) 102 58.0 78 44.6 0.012 86 59.7 55 45.1 0.017 
Disadvantage (3-6) 74 42.1 97 55.4  58 40.3 67 54.9  
Social           
Less disadvantage (1-2) 156 88.6 138 78.9 0.013 123 85.4 101 82.8 0.558 
Disadvantage (3-6) 20 11.4 37 21.1  21 14.6 21 17.2  
Orientation           
Less disadvantage (1-2) 157 89.2 134 76.6 0.002 120 83.3 96 78.7 0.334 
Disadvantage (3-6) 19 10.8 41 23.4  24 16.7 26 21.3  
Economic           
Less disadvantage (1-2) 131 74.4 124 70.9 0.453 95 66.0 98 80.3 0.009 




Supplemental Figure B-1. Sensitivity analysis of ordinal regression of 
Modified Rankin scale (mRS) which were categorised as ordinal 
outcomes with 3 levels (0-1; 2-3 and 4-5). Relative risk (RR) of poor 
functional outcome at 1 year after stroke for women compared to men 
in unadjusted (top panel) and adjusted (bottom panel) analyses 




Supplemental Figure B-2. Sensitivity analysis of ordinal regression of 
Modified Rankin scale (mRS) which were categorised as ordinal outcomes 
with 3 levels (0-1; 2-3 and 4-5). Relative risk (RR) of poor functional 
outcome at 1 year after stroke for women compared to men in unadjusted 
(top panel) and adjusted (bottom panel) analyses among 6 studies combined 





Supplemental Figure B-3. Hospitalised analysis of relative risk 
(RR) of poor functional outcome at 1 year after stroke for women 
compared to men in unadjusted (top panel) and adjusted (bottom 
panel) models in ten studies. Of note, poor outcome was defined as 




Supplemental Figure B-4: Hospitalised analysis of relative risk (RR) of poor 
functional outcome at 5 years after stroke for women compared to men in 
unadjusted (top panel) and adjusted (bottom panel) models in ten studies. Of 























Melbourne Men Melbourne Women Auckland Men Auckland Women
Supplemental Figure B-5. Proportion of 5-year survivors in 10-point interval 
scores of London Handicap Scale in Melbourne data (blue) and Auckland data 
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Category of disavantage
Economic self sufficiency 
Supplemental Figure B-6. Distribution of scores on each sub-dimension of the 
London Handicap Scale at 5 years after stroke in Melbourne data (blue) and in 





Appendix C: Sex differences in long-term health-
related quality of life after stroke in the INternational 
STroke oUtComes sTudy 
Supplemental Table C-1. Baseline characteristics by sex and outcomes of survivors 
at 1 year after stroke with HRQoL assessment among studies conducted in Oxford, 
Melbourne and Perth 




















SOCIODEMOGRAPHIC          
Age, mean (SD)  70.1 (12.2) 72.7 (12.7) 0.00
6 
70.6 (12.5) 73.4 (14.4) 0.02
6 
64.1 (4.1) 75.5 (2.5) 0.02
4 
Race (%)          
Caucasian - - - 95.3 96.9 0.59
9 
- - - 
Non-Caucasian    2.2 1.8     
Unknown    2.5 1.3     





- - - 37.5 52.9 0.37
3 
Married 74.2 47.9     62.5 47.1  
Unknown 5.5 3.7     0.0 0.0  
Education level (%)          




- - - 
> Grade 12 19.3 14.3  25.9 19.7     
Unknown 7.6 5.5  8.1 2.2     
Social class (%)          






Non-manual 23.7 39.6  14.0 14.4  12.5 23.5  
Manual 45.6 39.6  47.9 47.6  56.3 41.2  
Unknown 10.7 12.5  3.0 3.5  6.3 17.7  
PRE-STROKE HEALTH          
Institutional residence (%)          




No    95.8 92.1  100.0 76.5  
Unknown    0.0 0.4  0.0 0.0  
Modified Rankin Score (%)          
0-2 93.8 86.6 0.00
5 
- - - 93.8 58.8 0.01
1 
3-5 6.0 13.1     0.0 41.2  
Unknown 0.3 0.3     6.3 0.0  
Barthel Index score (%)          
20 - - - 84.3 75.1 0.04
7 
- - - 
<20    12.7 20.1     
Unknown    3.0 4.8     
MEDICAL HISTORY          
Hypertension (%)          






No 40.9 37.2  48.7 41.9  62.5 41.2  
Unknown 0.3 0.0  0.0 0.0     
Atrial fibrillation (%)          






No 84.6 84.5  82.2 83.8  87.5 82.4  
Unknown 0.0 0.0  1.3 0.0  0.0 0.0  
Ischaemic heart disease (%)          






No 85.2 92.1  83.9 90.0  75.0 94.1  




Supplemental Table C-1. Baseline characteristics by sex and outcomes of survivors 
at 1 year after stroke with HRQoL assessment among studies conducted in Oxford, 
Melbourne and Perth 




















Peripheral vascular disease 
(%) 
         




- - - 
No 93.8 96.3  89.8 95.2     
Unknown 0.5 0.0  0.0 0.0     
Transient ischaemic attack 
(%) 
         






No 86.2 87.8  89.8 89.1  62.5 11.8  
Unknown 0.0 0.0  0.4 0.0  6.3 0.0  
Diabetes (%)          






No 85.9 89.3  80.5 83.8  81.3 76.5  
Unknown 0.0 0.0  0.4 0.0  0.0 0.0  
Dementia (%)          




No    76.3 72.1  80.1 80.1  
Unknown    21.6 22.3  0.0 0.0  
Smoking (%)          






Former 18.2 17.4  14.8 14.0  18.8 5.9  
Never 29.7 55.2  33.1 62.9  0.0 52.9  
Unknown 0.3 0.6  0.9 1.8  12.5 5.9  
Alcohol use (%)          






Not heavy drinkers 71.1 42.4  65.3 50.2  0.0 23.5  
Heavy drinkers 3.7 2.1  7.2 1.3  56.3 35.3  
Ex-drinkers - -  5.9 0.4  12.5 0.0  
Unknown 1.6 1.8  1.7 3.5  12.5 11.8  
Pre-stroke medication          
Antihypertensives (%)          




No    47.6 42.9  75.0 47.1  
Unknown    0.0 0.0  0.0 4.8  
Antiplatelet (%)          




No    65.5 66.5  68.8 47.1  
Unknown    0.0 0.0  6.3 4.8  
STROKE-RELATED 
FACTORS 
         






Stroke type (%)          








5.7 5.2  12.7 8.7  6.3 0.0  
Subarachnoid 
haemorrhage 
1.3 6.1  0.0 0.4  12.5 5.9  
Undetermined 4.2 2.4  2.2 6.1  6.3 0.0  
Time to arrive hospital 
(%)* 
         




> 4.5 – 24 hours    12.9 12.8  6.7 14.3  




Supplemental Table C-1. Baseline characteristics by sex and outcomes of survivors 
at 1 year after stroke with HRQoL assessment among studies conducted in Oxford, 
Melbourne and Perth 




















Unknown    51.1 57.1  73.3 42.9  
Stroke severity          
NIHSS, mean (SD) 3.2 (8.4) 3.4 (4.5) 0.385 4.7 (4.8) 5.4 (5.4) 0.16
8 
5.0 (5.7) 5.3 (7.1) 0.916 
TREATMENT AND 
MANAGEMENT* 
         
Admission medication (%)          
Antihypertensives - - - 52.4 57.1 0.32
7 
33.3 57.1 0.198 
Antiplatelet - - - 34.5 33.5 0.83
1 
20.0 35.7 0.427 
Anticoagulant  - - - 4.6 4.7 0.97
3 
13.3 0.0 0.483 
Discharge medication (%)          
Antihypertensives  - - - 47.1 51.1 0.71
3 
53.3 64.3 0.550 
Antiplatelet†  - - - 56.7 59.7 0.55
3 
45.5 76.9 0.113 
Anticoagulant†  - - - 21.1 15.2 0.13
0 
45.5 0.0 0.011 
Investigation (%)          
Neuroimaging - - - 97.3 95.0 0.19
6 
53.3 64.3 0.550 
Carotid investigation† - - - 59.7 59.8 0.98
4 
27.3 0.0 0.082 
Echocardiography† - - - 51.5 37.2 0.00
9 
36.4 7.7 0.112 
POST-STROKE 
FACTORS 
         
Mood disorder           
Depression (IDA 
subscale ≥ 8) 
         
Yes - - - 16.1 17.5 0.17
8 
- - - 
No    72.0 65.1     
Unknown    11.9 17.5     
IDA subscale – 
Depression, median 
(IQR) 






- - - 
IDA subscale – Anxiety, 
median (IQR) 






- - - 
IDA total score, median 
(IQR) 






- - - 
Stroke recurrence ≤ 1 year 
(%) 
- - - 0.9 0.4 0.58
0 
   
Modified Rankin Score (%)          
0-2 23.4 34.5 0.00
1 
- - - 76.2 76.2 0.00
1 
3-5 76.6 65.6     23.8 23.8  
Unknown 0.0 0.0     0.0 0.0  
Barthel Index Score (%)          
20 - - - 61.0 43.7 0.00
1 
- - - 
<20    37.7 54.6     
Unknown    1.3 1.8     
OUTCOME AT 1 YEAR          
EQ5D utility, mean (SD)  0.75 (0.28) 0.67 (0.90) <0.0
01 
- - - - - - 






- - - - - - 
AQoL utility, mean (SD) - - - 0.57 (0.33) 0.45 (0.32) <0.0
01 




Supplemental Table C-1. Baseline characteristics by sex and outcomes of survivors 
at 1 year after stroke with HRQoL assessment among studies conducted in Oxford, 
Melbourne and Perth 


























- - - 
SF6D, mean (SD) - - - - - - 0.75 (0.12) 0.57 (0.11) <0.0
01 






AQoL=Assessment of Quality of Life; EQ5D=European Quality of Life–5 Dimensions; SF36=Short 
form–36 questions 




Supplemental Table C-2. Baseline characteristic of survivors at 5 years after stroke 
with HRQoL assessment among studies conducted in Oxford, Melbourne and 
Auckland 















SOCIODEMOGRAPHIC          






0.132 64.1 (4.1) 75.5 (2.5) 0.024 
Race (%)          
Caucasian - - - 90.8 96.4 0.014 - - - 
Non-Caucasian    3.5 2.7     
Unknown    5.7 0.9     
Marital status (%)          
Single/widowed 18.0 43.9 <0.001 - - - 26.2 47.7 <0.001 
Married 74.0 49.2     73.8 52.3  
Unknown 8.6 6.9     0.0 0.0  
Education level (%)          
≤ Grade 12 79.1 82.3 0.428 37.4 35.9 0.010 37.2 59.4 <0.001 
> Grade 12 16.6 13.1  54.2 61.9  53.6 35.5  
Unknown 4.3 4.6  8.4 2.2  9.3 5.2  
Social class (%)          
Professional 13.7 4.6 0.004 37.9 35.9 0.232 27.9 18.1 <0.001 
Non-manual 20.9 37.7  11.0 12.1  15.3 30.3  
Manual 50.4 43.1  41.9 36.8  49.2 21.9  
Unknown 15.1 14.6  9.3 15.3  7.7 29.7  
PRE-STROKE HEALTH          
Institutional residence (%)          
Yes - - - 2.2 7.2 0.038 - - - 
No    96.9 91.5     
Unknown    0.9 1.4     
Modified Rankin Score 
(%) 
         
0-2 98.6 94.6 0.072 - - - - - - 
3-5 1.4 5.4        
Unknown 0.0 0.0        
Barthel Index score (%)          
20 - - - 6.6 13.5 0.040 - - - 
<20    73.6 65.5     
Unknown    19.8 21.1     
Pre-stroke dependence (%)          
Yes - - - - - - 3.3 8.4 0.085 
No       96.2 91.6  
Unknown       0.6 0.0  
MEDICAL HISTORY          
Hypertension (%)          
Yes 55.4 63.9 0.158 51.1 57.9 0.152 54.1 56.8 0.874 
No 44.6 36.2  48.0 42.2  45.4 42.6  
Unknown 0.3 0.0  0.9 0.0  0.6 0.7  
Atrial fibrillation (%)          
Yes 11.5 9.2 0.541 11.9 14.8 0.255 12.0 19.4 0.063 
No 88.5 90.8  87.2 85.2  88.0 80.7  
Unknown 0.0 0.0  0.9 0.0  0.0 0.0  
Ischaemic heart disease 
(%) 
         
Yes 13.7 5.4 0.043 13.2 9.0 0.127 20.2 12.3 0.050 
No 85.6 94.6  85.9 91.0  79.8 87.7  
Unknown 0.7 0.0  0.9 0.0  0.0 0.0  
Peripheral vascular disease 
(%) 
         
Yes 6.5 3.9 0.332 7.1 3.6 0.220 - - - 
No 93.5 96.2  92.1 96.0     
Unknown 0.0 0.0  0.9 0.5     
Transient ischaemic attack 
(%) 
         
Yes 11.5 11.5 0.994 8.4 9.0 0.975 - - - 
No 88.5 88.5  91.2 90.6     
Unknown 0.0 0.0  0.4 0.5     
Diabetes (%)          
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No 87.1 92.3  78.4 84.8     
Unknown 0.0 0.0  0.9 0.0     
Dementia (%)          
Yes - - - 0.0 3.6 0.004 0.6 0.0 0.357 
No    79.3 76.2  99.5 100.0  
Unknown    20.7 20.2  0.0 0.0  
Smoking (%)          
Current 51.1 26.9 <0.001 48.0 20.2 <0.001 57.9 51.6 <0.001 
Former 21.6 18.5  16.7 14.4  12.0 37.4  
Never 27.3 53.9  31.2 60.1  29.5 10.3  
Unknown 0.0 0.8  4.0 5.4  0.6 0.7  
Alcohol use (%)          
Non-drinkers 23.7 50.8 <0.001 17.6 47.5 <0.001 16.4 40.7 <0.001 
Not heavy drinkers 71.2 41.5  62.1 43.1  71.6 41.9  
Heavy drinkers 4.3 4.6  9.3 1.8  10.4 16.1  
Ex-drinkers - -  6.6 0.5  1.6 1.3  
Unknown 0.7 3.1  4.4 7.2  12.5 11.8  
Pre-stroke medication          
Antihypertensives (%)          
Yes - - - 47.6 53.4 0.369 42.1 42.6 0.527 
No    52.0 45.7  4.4 7.1  
Unknown    0.4 0.9  53.6 50.3  
Antiplatelet (%)          
Yes - - - 29.1 28.7 0.996 32.2 27.7 0.667 
No    70.5 70.9  67.2 71.6  
Unknown    0.4 0.5  0.6 0.7  
STROKE-RELATED 
FACTORS 
         
Hospital admission (%) 59.7 60.0 0.962 92.5 94.6 0.363 97.3 95.5 0.378 
Stroke type (%)          
Ischaemic stroke  92.8 83.1 0.030 83.3 85.7 0.496 84.2 76.1 0.324 
Intracerebral 
haemorrhage 
3.6 4.6  14.1 10.8  91.8 11.6  
Subarachnoid 
haemorrhage 
1.4 9.2  0.0 0.0  4.9 7.7  
Undetermined 2.2 3.1  2.6 3.6  3.3 4.5  
Time to arrive hospital* 
(%) 
         
≤ 4.5 hours - - - 23.8 25.1 0.182 79.2 81.1 0.801 
> 4.5 – 24 hours    14.8 8.1  15.2 14.9  
> 24 hours    8.1 10.0  5.6 4.1  
Unknown    53.3 56.9  73.3 42.9  
Stroke severity          
NIHSS, mean (SD) 3.2 (8.4) 3.4 (4.5) 0.385 4.3 (4.5) 5.2 (5.4) 0.090 - - - 
Reversed GCS, mean 
(SD) 
- - - - - - 1.6 (1.7) 1.7 (2.0) 0.573 
TREATMENT AND 
MANAGEMENT* 
         
Admission medication (%)          
Antihypertensives - - - 47.6 53.4 0.220 - - - 
Antiplatelet - - - 32.3 28.8 0.461 - - - 
Anticoagulant - - - 3.7 6.3 0.249 - - - 
Discharge medication (%)          
Antihypertensives  - - - 46.3 47.5 0.786 66.3 65.3 0.852 
Antiplatelet†  - - - 59.3 59.2 0.985 86.8 85.1 0.698 
Anticoagulant†  - - - 19.6 18.9 0.857 17.2 16.7 0.906 
Investigation (%)          
Neuroimaging - - - 96.2 96.7 0.785 92.7 91.9 0.786 
Carotid investigation† - - - 62.2 62.3 0.985 8.6 5.3 0.296 
Echocardiography† - - - 52.0 41.5 0.065 2.0 0.0 0.130 
POST-STROKE 
FACTORS 
         
Modified Rankin Score 
(%) 
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0-2 20.1 36.9 0.002 - - - 71.0 75.5 0.387 
3-5 79.9 63.1     24.6 22.6  
Unknown 0.0 0.0     4.4 1.9  
Barthel Index Score (%)          
20 - - - 43.2 53.8 0.042 - - - 
<20    56.8 45.7     
Unknown    0.0 0.5     
Mood disorder           
Depression (IDA score 
≥7 or PHQ score ≥8) 
         
Yes - - - 11.9 14.4 0.681 31.2 29.7 0.957 
No    76.8 74.9  47.5 48.4  
Unknown    12.3 10.8  21.3 21.9  
IDA subscale - 
depression, median 
(IQR) 




0.505 - - - 
IDA subscale - anxiety, 
median (IQR) 




0.029 - - - 
IDA total score, median 
(IQR) 




0.337 - - - 
PHQ anxiety, median 
(IQR) 












Use of antidepressant 
medications at 5 years (%) 
         
Yes - - - 15.4 24.7 0.047 - - - 
No    73.1  65.9     
Unknown    11.5 9.4     
Use of antidepressant 
medications among those 
with depression (5-year 
IDA ≥7; %) 
- - - 18.5 21.9 0.175 - - - 
Use of antidepressant 
medications among those 
without depression (5-year 
IDA <7; %) 
   16.3 27.0 0.017    
Of those with 
antidepressant 
medications, % reported no 
depression (5-year IDA 
<7) 
   84.9 86.5 0.827    
Stroke recurrence ≤ 5 years 
(%) 
- - - 8.8 9.0 0.953 15.3 18.1 0.496 
OUTCOME AT 5 YEARS          




0.007 - - - - - - 








0.003 - - - - - - 




<0.001 - - - 
AQoL utility, median 
(IQR) 






<0.001 - - - 
















Supplemental Table C-3. Characteristics of people with and without 1-year 
health-related quality of life assessment after stroke 
 Oxford Melbourne Perth 
 Assessed Unassessed Assessed Unassessed Assessed Unassessed 
Characteristic Men Women Men Women Men Women Men Women Men Women Men Women 

























SOCIODEMOGRAPHIC             
























Marital status (%)             
Single/widowed 20.3 48.5 26.8 46.4 - - - - 37.5 52.9 - - 
Married 74.2 47.9 50.7 31.9     62.5 47.1   
Unknown 5.5 3.7 22.5 21.7     0.0 0.0   
Education level (%)             
≤ Grade 12 73.2 80.2 53.6 50.7 66.1 78.2 29.7 67.3 - - - - 
> Grade 12 19.3 14.3 10.1 4.4 25.9 19.7 66.9 32.7     
Unknown 7.6 5.5 36.2 44.9 8.1 2.2 3.5 0.0     
Social class (%)             
Professional 20.1 8.2 10.9 4.4 35.2 34.5 39.5 27.9 25.0 17.7 15.5 3.8 
Non-manual 23.7 39.6 14.5 23.9 14.0 14.4 5.8 11.5 12.5 23.5 5.6 6.3 
Manual 45.6 39.6 10.6 27.5 47.9 47.6 36.6 22.6 56.3 41.2 28.2 16.5 
Unknown 10.7 12.5 34.1 44.2 3.0 3.5 18.0 38.0 6.3 17.7 50.7 73.4 
PRE-STROKE HEALTH             
In an institution (%)             
Yes - - - - 4.3 7.4 4.7 13.0 0.0 21.4 9.9 17.7 
No     95.8 92.1 91.9 85.1 100.0 78.6 87.3 78.5 
Unknown     0.0 0.4 3.5 1.9 0.0 0.0 1.8 3.8 
Modified Rankin Score 
(%) 
            
0-2 93.8 86.6 79.7 73.9 - - - - 93.8 58.8 66.2 24.1 
3-5 6.0 13.1 14.5 22.5     6.3 41.2 22.5 55.7 
Unknown 0.3 0.3 5.8 3.6     0.0 0.0 11.3 20.3 
Barthel Index score (%)             
20 - - - - 84.3 75.1 33.7 26.4 - - - - 
<20     12.7 20.1 5.2 9.6     
Unknown     3.0 4.8 61.1 63.9     
MEDICAL HISTORY             
Hypertension (%)             
Yes 58.9 62.8 60.9 57.3 51.3 58.1 49.4 57.2 37.5 58.8 66.7 58.3 
No 40.9 37.2 39.1 42.8 48.7 41.9 48.8 42.3 62.5 41.2 28.2 37.5 
Unknown 0.3 0.0 0.0 0.0 0.0 0.0 1.7 0.5 0.0 0.0 5.1 4.2 
Atrial fibrillation (%)             
Yes 15.4 15.6 17.4 18.8 16.5 16.2 14.0 21.6 12.5 17.7 20.6 22.9 
No 84.6 84.5 82.6 81.2 82.2 83.8 84.9 77.4 87.5 82.4 71.8 68.8 
Unknown 0.0 0.0 0.0 0.0 1.3 0.0 1.2 1.0 0.0 0.0 7.7 8.3 
Ischaemic heart disease 
(%) 
            
Yes 14.6 7.9 14.8 8.0 16.1 10.0 12.2 9.1 25.0 5.9 12.8 4.2 
No 85.2 92.1 85.5 92.0 83.9 90.0 86.6 89.9 75.0 94.1 82.1 89.6 
Unknown 0.3 0.0 0.0 0.0 0.0 0.0 1.2 1.0 0.0 0.0 5.1 6.3 
Peripheral vascular 
disease (%) 
            
Yes 5.7 3.7 9.4 5.1 10.2 4.8 9.9 3.9 - - - - 
No 93.8 96.3 90.6 93.5 89.8 95.2 89.0 95.2     
Unknown 0.5 0.0 0.0 1.5 0.0 0.0 1.2 1.0     
Transient ischaemic 
attack (%) 
            
Yes 13.8 12.2 10.9 10.0 9.8 10.9 7.0 5.8 31.3 11.8 18.0 6.3 
No 86.2 87.8 89.1 89.1 89.8 89.1 92.4 93.8 62.5 88.2 69.2 85.4 
Unknown 0.0 0.0 0.0 0.7 0.4 0.0 0.6 0.5 6.3 0.0 12.8 8.3 
Diabetes (%)             
Yes 14.1 10.7 18.8 11.6 19.1 16.2 22.1 12.0 18.8 23.5 15.4 16.7 
No 85.9 89.3 80.4 88.4 80.5 83.8 77.3 88.0 81.3 76.5 82.1 83.3 
Unknown 0.0 0.0 0.7 0.0 0.4 0.0 0.6 0.0 0.0 0.0 2.6 0.0 
Dementia (%)             
Yes - - - - 2.1 5.7 2.3 8.2 - - - - 
No     76.3 72.1 76.2 76.0     
Unknown     21.6 22.3 21.5 15.9     




Supplemental Table C-3. Characteristics of people with and without 1-year 
health-related quality of life assessment after stroke 
 Oxford Melbourne Perth 
 Assessed Unassessed Assessed Unassessed Assessed Unassessed 
Characteristic Men Women Men Women Men Women Men Women Men Women Men Women 
Current 51.8 26.8 46.4 29.0 51.3 21.4 39.0 20.2 68.8 52.9 48.7 10.4 
Former 18.2 17.4 21.7 13.8 14.8 14.0 26.2 14.4 18.8 5.9 10.3 6.3 
Never 29.7 55.2 29.0 50.7 33.1 62.9 22.1 47.6 0.0 35.3 25.6 56.3 
Unknown 0.3 0.6 2.9 6.5 0.9 1.8 12.8 17.8 12.5 5.9 15.4 27.1 
Alcohol use (%)             
Non-drinkers 23.7 53.7 34.1 57.3 19.9 44.5 19.8 41.4 18.8 29.4 30.8 25.0 
Not heavy drinkers 71.1 42.4 49.3 24.6 65.3 50.2 44.8 35.1 0.0 23.5 10.3 14.6 
Heavy drinkers 3.7 2.1 2.9 2.2 7.2 1.3 11.1 1.4 56.3 35.3 25.6 14.6 
Ex-drinkers - - - - 5.9 0.4 8.1 1.0 12.5 0.0 5.1 6.3 
Unknown 1.6 1.8 13.8 15.9 1.7 3.5 16.3 21.2 12.5 11.8 28.2 39.6 
STROKE-RELATED 
FACTORS 
            
Hospital admission (%) 81.3 78.7 84.1 89.9 95.3 95.6 94.2 93.8 93.8 82.4 84.6 83.3 
Stroke type (%)             
Ischaemic stroke  88.8 86.3 83.3 75.4 85.2 84.7 72.7 72.1 75.0 94.1 89.7 75.0 
Intracerebral 
haemorrhage 
5.7 5.2 4.4 8.7 12.7 8.7 15.7 9.1 6.3 0.0 7.7 8.3 
Subarachnoid 
haemorrhage 
1.3 6.1 1.5 5.8 0.0 0.4 6.4 13.5 12.5 5.9 2.6 8.3 
Undetermined 4.2 2.4 10.9 10.1 2.2 6.1 5.2 5.3 6.3 0.0 0.0 8.3 
Stroke severity             



























Supplemental Table C-4. Characteristics of people with and without 5-year 
health-related quality of life assessment after stroke 
 Oxford Melbourne Auckland 
 Assessed Unassessed Assessed Unassessed Assessed Unassessed 
Characteristic Men Women Men Women Men Women Men Women Men Women Men Women 
Number of cases 
139 
(%) 













71 (%) 79 (%) 
SOCIODEMOGRAPHIC             
























Marital status (%)             
Single/widowed 18.0 43.9 29.0 55.6 - - - - 26.2 47.7 34.9 65.7 
Married 74.0 49.2 56.5 36.1     73.8 52.3 62.0 29.5 
Unknown 8.6 6.9 14.5 8.3     0.0 0.0 3.1 4.8 
Education level (%)             
≤ Grade 12 79.1 82.3 61.3 63.9 37.4 35.9 11.5 45.4 37.2 59.4 38.8 46.8 
> Grade 12 16.6 13.1 4.8 9.7 54.2 61.9 49.9 53.6 53.6 35.5 29.8 19.8 
Unknown 4.3 4.6 33.9 26.4 8.4 2.2 5.6 1.1 9.3 5.2 31.4 33.4 
Social class (%)             
Professional 13.7 4.6 11.3 8.3 37.9 35.9 37.5 30.6 27.9 18.1 21.3 9.8 
Non-manual 20.9 37.7 9.7 12.5 11.0 12.1 10.8 12.3 15.3 30.3 15.7 20.3 
Manual 50.4 43.1 50.0 47.2 41.9 36.8 43.3 32.4 49.2 21.9 37.6 16.6 
Unknown 15.1 14.6 29.0 31.9 9.3 15.3 8.3 24.7 7.7 29.7 25.4 53.2 
PRE-STROKE HEALTH             
Pre-stroke dependence 
(%) 
            
Yes - - - - - - - - 3.3 8.4 11.0 25.5 
No         96.2 91.6 84.3 69.4 
Unknown         0.6 0.0 4.8 5.0 
Modified Rankin Score 
(%) 
            
0-2 98.6 94.6 87.1 79.2 - - - - - - - - 
3-5 1.4 5.4 9.7 20.8         
Unknown 0.0 0.0 3.2 0.0         
Barthel Index score (%)             
20 - - - - 6.6 13.5 42.7 33.8 - - - - 
<20     73.6 65.5 5.9 6.8     
Unknown     19.8 21.1 51.5 59.5     
MEDICAL HISTORY             
Hypertension (%)             
Yes 55.4 63.9 58.1 54.2 51.1 57.9 50.0 46.0 54.1 56.8 48.6 56.9 
No 44.6 36.2 41.9 45.8 48.0 42.2 50.0 52.7 45.4 42.6 45.7 38.1 
Unknown 0.3 0.0 0.0 0.0 0.9 0.0 0.0 1.4 0.6 0.7 5.8 5.0 
Atrial fibrillation (%)             
Yes 11.5 9.2 19.4 18.1 11.9 14.8 14.7 10.8 12.0 19.4 19.6 24.1 
No 88.5 90.8 80.7 81.9 87.2 85.2 85.3 87.8 88.0 80.7 77.5 72.9 
Unknown 0.0 0.0 0.0 0.0 0.9 0.0 0.0 1.4 0.0 0.0 2.9 3.0 
Ischaemic heart disease 
(%) 
            
Yes 13.7 5.4 11.3 6.9 13.2 9.0 10.3 1.4 20.2 12.3 24.6 19.6 
No 85.6 94.6 88.7 93.1 85.9 91.0 89.7 97.3 79.8 87.7 74.0 78.6 
Unknown 0.7 0.0 0.0 0.0 0.9 0.0 0.0 1.4 0.0 0.0 1.5 1.8 
Peripheral vascular 
disease (%) 
            
Yes 6.5 3.9 9.7 5.6 7.1 3.6 7.4 4.1 - - - - 
No 93.5 96.2 90.3 94.4 92.1 96.0 82.7 94.6     
Unknown 0.0 0.0 0.0 0.0 0.9 0.5 0.0 1.4     
Transient ischaemic 
attack (%) 
            
Yes 11.5 11.5 17.7 25.0 8.4 9.0 4.4 8.1 - - - - 
No 88.5 88.5 82.3 75.0 91.2 90.6 84.1 91.9     
Unknown 0.0 0.0 0.0 0.0 0.4 0.5 1.5 0.0     
Diabetes (%) 13.0 7.7 9.7 5.6 20.7 15.3 17.7 8.1     
Yes 87.1 92.3 88.7 94.4 78.4 84.8 82.4 81.9 - - - - 
No 0.0 0.0 1.6 0.0 0.9 0.0 0.0 0.0     
Unknown             
Smoking (%)             
Current 51.1 26.9 50.0 23.6 48.0 20.2 36.8 13.5 57.9 51.6 46.9 27.1 
Former 21.6 18.5 22.6 23.6 16.7 14.4 25.3 21.6 12.0 37.4 17.8 45.8 




Supplemental Table C-4. Characteristics of people with and without 5-year 
health-related quality of life assessment after stroke 
 Oxford Melbourne Auckland 
 Assessed Unassessed Assessed Unassessed Assessed Unassessed 
Characteristic Men Women Men Women Men Women Men Women Men Women Men Women 
Unknown 0.0 0.8 1.6 0.0 4.0 5.4 10.3 12.2 0.6 0.7 9.7 15.0 
Alcohol use (%)             
Non-drinkers 23.7 50.8 25.8 55.6 17.6 47.5 23.5 37.8 16.4 40.7 21.7 43.3 
Not heavy drinkers 71.2 41.5 62.9 36.1 62.1 43.1 47.1 10.5 71.6 41.9 47.1 27.0 
Heavy drinkers 4.3 4.6 3.2 4.2 9.3 1.8 8.8 1.4 10.4 16.1 15.3 11.3 
Ex-drinkers - - - - 6.6 0.5 5.9 0.0 1.6 1.3 15.9 18.3 
Unknown 0.7 3.1 8.1 4.2 4.4 7.2 14.7 20.3 0.0 0.0 0.0 0.0 
STROKE-RELATED 
FACTORS 
            
Hospital admission (%) 59.7 60.0 75.8 76.4 92.5 94.6 95.6 97.3 97.3 95.5 94.6 89.2 
Stroke type (%)             
Ischaemic stroke  92.8 83.1 88.7 77.8 83.3 85.7 69.1 51.4 84.2 76.1 73.1 67.6 
Intracerebral 
haemorrhage 
3.6 4.6 6.5 6.9 14.1 10.8 11.8 8.1 91.8 11.6 13.6 13.1 
Subarachnoid 
haemorrhage 
1.4 9.2 1.6 9.7 0.0 0.0 16.2 37.8 4.9 7.7 6.6 5.7 
Undetermined 2.2 3.1 3.2 5.6 2.6 3.6 2.9 2.7 3.3 4.5 6.6 13.6 
Stroke severity             
















- - - - 
Mean (SD) GCS, 
reversed 











Supplemental Table C-5. Comparison of complete-case and imputed analyses of median difference (MD) in utility scores between women and 
men  
 Unadjusted Adjusted 
Study Complete-case IPW Imputation & IPW Complete-case IPW Imputation & IPW 
 MD (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) 
Oxford             
1-year -0.069 (-0.089, -0.049) -0.069 (-0.105, -0.032) -0.086 (-0.123, -0.049) -0.049 (-0.094, -0.003) -0.042 (-0.080, -0.004) -0.048 (-0.092, -0.005) 
5-year -0.086 (0.122, -0.050) -0.086 (-0.135, -0.037) -0.093 (-0.158, -0.028) -0.071 (-0.142, 0.000) -0.063 (-0.116, -0.010)  -0.056 (-0.134, 0.021) 
Melbourne             
1-year -0.197 (-0.334, -0.060) -0.210 (-0.305, -0.115) -0.188 (-0.290, -0.086) -0.076 (-0.145, -0.007) -0.096 (-0.149, -0.044)  -0.069 (-0.128, -0.010) 
5-year -0.165 (-0.306, -0.024) -0.228 (-0.327, -0.129) -0.158 (-0.281, -0.035) -0.153 (-0.241, -0.064) -0.146 (-0.212, -0.080) -0.128 (-0.223, -0.033) 
Perth             
1-year -0.210 (-0.308, -0.112) -0.216 (-0.273, -0.159) -0.163 (-0.302, -0.023)  -0.187 (-0.340, -0.015) -0.182 (-0.268, -0.096) -0.135 (-0.285, 0.016) 
Auckland             
5-year -0.090 (-0.119, -0.062) -0.091 (-0.124, -0.058) -0.067 (-0.111, -0.025) -0.059 (-0.110, -0.008) -0.045 (-0.069, -0.020) -0.049 (-0.092, -0.006) 




Supplemental Table C-6. Median differences (MD) in AQoL domains in the Melbourne 
study 
 Unadjusted Adjusted* 
 MD 95% CI MD 95% CI Covariates† 
1 year     
Illness -0.05 -0.13, 0.03 -0.02 -0.09, 0.05 Age 
Independent living -0.23 -0.37, -0.10 -0.09 -0.14, -0.04 Age, severity, pre-stroke 
Barthel 
Social relationships -0.04 -0.10, 0.02 -0.02 -0.05, 0.002 Severity, pre-stroke Barthel, 
1-year depression 
Physical senses 0 -0.08, 0.08 -0.008 -0.04, 0.02 Age, severity 
Psychological well-being -0.04 -0.05, -0.02 -0.03 -0.06, -0.004 Age  
5 year      
Illness 0.005 -0.07, 0.08 0.01 -0.06, 0.08 Age 
Independent living -0.22 -0.36, -0.09 -0.14 -0.24, -0.05 Age, pre-stroke Barthel 
Social relationships -0.10 -0.19, -0.02 -0.04 -0.08, -0.01 Age, severity 
Physical senses 0 -0.05, 0.05 0.007 -0.02, 0.04 Age, severity 
Psychological well-being -0.04 -0.06, -0.02 -0.06 -0.09, -0.03 5-year depression 
*Age, pre-stroke dependency and stroke severity being forced into the final models with  covariates meeting our 
criteria of being confounding factor 




Supplemental Table C-7. Median differences (MD) in SF36 domains in the studies 
conducted in Perth (1 year) and Auckland (5 years)  
 Unadjusted Adjusted* 
 MD 95% CI MD 95% CI Covariates† 
Perth (1 year)      
Physical functioning -60.0 -83.2, -36.8 -33.0 -64.6, -1.4 Age 
Role physical -50.0 -107.1, 7.1 -12.6 -80.1, 54.9 No confounders 
Bodily pain -30.8 -78.9, 17.3 -7.2 -60.9, 46.5 Severity 
General health -27.0 -74.2, 12.2 -1.7 -35.4, 32.1 Pre-stroke Rankin 
Vitality -30.0 -53.6, -6.4 -27.8 -78.7, 23.1 No confounders 
Social functioning -12.5 -41.1, 16.4 -13.9 -66.0, 38.2 No confounders 
Role emotional 0 -20.3, 20.3 0 -25.6, 25.6 No confounders 
Mental health -16.0 -34.6, 2.6 -10.6 -35.5, 14.4 No confounders 
Overall physical score -15.0 -22.7, -7.3 -11.0 -17.9, -4.1 Age  
Overall mental score -5.7 -16.3, 4.8 -3.8 -21.2, 13.6 No confounders 
Auckland (5 years)      
Physical functioning -25.0 -40.4, -9.6 -0.77 -11.4, 9.8 Age, pre-stroke dependency 
Role physical -25.0 -66.8, 16.8 -5.0 -66.8, 16.8 No confounders 
Bodily pain -10.0 -30.3, 10.4 -25.0 -20.8, 10.9 No confounders 
General health 0 -8.0, 8.0 -5.0 -6.36, 11.9 Pre-stroke dependency 
Vitality -5.0 -15.0, 5.0 2.75 -12.7, 2.8 Age 
Social functioning -12.5 -33.7, 8.7 -12.5 -34.7, 9.7 Pre-stroke dependency 
Role emotional 0 -15.8, 18.8 0 -15.8, 18.8 No confounders 
Mental health -8.0 -16.0, -0.006 -7.29 -12.3, -2.26 No confounders 
Overall physical score -4.45 -8.63, -0.27 -0.89 -4.97, 3.20 Age, pre-stroke dependency 
Overall mental score -2.99 -5.17, -0.81 -2.99 -5.39, -0.58 Pre-stroke dependency 
*Age, pre-stroke dependency and stroke severity, where possible, being forced into the final models with  
significant confounding factors 




Supplemental Table C-8a. Weighted mean difference in AQoL utility scores between Melbourne survivors at 1 year after stroke and general 
population 
  General population* Stroke population Net difference between general and stroke population 


















Net difference  
< 55 950 0.85 0.19 645 0.87 0.17 23 0.74 0.31 26 0.69 0.28 0.11 (0.02, 0.24) 0.18 (0.07, 0.29) 0.07 
55−64 190 0.82 0.20 188 0.79 0.23 44 0.68 0.33 17 0.55 0.26 0.14 (0.04, 0.24) 0.24 (0.11, 0.37) 0.10 
65−74 147 0.80 0.18 154 0.77 0.21 71 0.63 0.30 66 0.54 0.30 0.17 (0.09, 0.25) 0.23 (0.15, 0.31) 0.06 
75+ 146 0.77 0.24 214 0.70 0.27 98 0.45 0.32 121 0.34 0.30 0.32 (0.25, 0.39) 0.36 (0.30, 0.43) 0.04 
Total 1433   1501   236   230      





Supplemental Table C-8b. Weighted mean difference in AQoL utility scores between Melbourne survivors at 5 years after stroke and general 
population 
  General population* Stroke population Net difference between general and stroke population 



















< 55 950 0.85 0.19 645 0.87 0.17 30 0.69 0.35 36 0.69 0.25 0.16 (0.03, 0.29) 0.18 (0.10, 0.26) 0.02 
55−64 190 0.82 0.20 188 0.79 0.23 48 0.73 0.26 21 0.59 0.31 0.09 (0.01, 0.17) 0.20 (0.06, 0.34) 0.11 
65−74 147 0.80 0.18 154 0.77 0.21 75 0.59 0.32 66 0.49 0.30 0.21 (0.13, 0.29) 0.23 (0.15, 0.31) 0.02 
75+ 146 0.77 0.24 214 0.70 0.27 74 0.35 0.33 100 0.28 0.30 0.42 (0.34, 0.51) 0.42 (0.35, 0.49) 0.00 
Total 1433   1501   227   223      





Supplemental Table C-9a. Weighted mean difference in EQ5D utility scores between Oxford survivors at 1 year after stroke and general 
population 
  General population* Stroke population Net difference between general and stroke population 


















Net difference  
<55 935 0.90 0.19 1171 0.91 0.17 50 0.71 0.35 41 0.66 0.34 0.19 (0.09, 0.29) 0.25 (0.15, 0.36) 0.06 
55−64 196 0.78 0.28 288 0.81 0.26 87 0.66 0.40 54 0.65 0.35 0.12 (0.03, 0.21) 0.16 (0.06, 0.26) 0.04 
65−74 228 0.78 0.28 260 0.78 0.25 149 0.67 0.36 105 0.53 0.37 0.11 (0.04, 0.18) 0.25 (0.17, 0.33) 0.14 
75+ 108 0.75 0.27 206 0.71 0.27 253 0.38 0.41 359 0.28 0.38 0.37 (0.30, 0.44) 0.43 (0.38, 0.48) 0.06 
Total 1467   1925   539   559      





Supplemental Table C-9b. Weighted mean difference in EQ5D utility scores between Oxford survivors at 5 years after stroke and general 
population 
  General population* Stroke population Net difference between general and stroke population 


















Net difference  
<55 935 0.90 0.19 1171 0.91 0.17 14 0.78 0.29 17 0.79 0.24 0.12 (-0.03, 0.27) 0.12 (0.10, 0.24) 0.00 
55−64 196 0.78 0.28 288 0.81 0.26 45 0.79 0.26 28 0.79 0.19 -0.01 (-0.10, 0.08) 0.02 (-0.06, 0.10) 0.03 
65−74 228 0.78 0.28 260 0.78 0.25 68 0.77 0.24 43 0.67 0.32 0.01 (-0.06, 0.08) 0.11 (0.01, 0.21) 0.10 
75+ 108 0.75 0.27 206 0.71 0.27 44 0.70 0.26 53 0.57 0.32 0.05 (-0.04, 0.14) 0.14 (0.05, 0.23) 0.09 
Total 1467   1925   171   141      





Supplemental Table C-10. Weighted mean difference in SF6D utility scores between Auckland survivors at 5 years and general population 
  General population* Stroke population Net difference between general and stroke population 



















< 55 2947 0.78† 0.11 3336 0.77† 0.16 38 0.81 0.12 23 0.74 0.15 -0.03 (-0.07, 0.01) 0.03 (-0.03, 0.09) 0.06 
55−64 791 0.76 0.12 915 0.74 0.13 43 0.77 0.14 32 0.72 0.14 -0.01 (-0.05, 0.03) 0.02 (-0.03, 0.07) 0.03 
65−74 599 0.75 0.13 654 0.73 0.13 61 0.77 0.11 42 0.74 0.14 -0.02 (-0.05, 0.01) 0.01 (-0.05, 0.03) 0.03 
75+ 448 0.72 0.13 567 0.69 0.13 41 0.75 0.13 58 0.69 0.12 -0.03 (-0.07, 0.01) 0.00 (-0.03, 0.03) 0.03 
Total 5082   5800   183   155      
MD, mean difference; 





Supplemental Table C-11. Comparison of HRQoL subdomains among the AQoL, 
EQ5D-3L and SF36 (From Hawthorne et al 2001)288 
HRQoL dimension SF36 AQoL EQ5D-3L 
Relative to the body    
Anxiety/depression *** * * 
Bodily care * * * 
General health ******   
Mobility *** * * 
Pain ** * * 
Physical ability/vitality ******   
Rest and fatigue ** *  
Sensory function  **  
Cognition -   
Memorys -   
Social expression    
Activity of daily living  * * 
Communication  *  
Emotional fulfilment **   
Family role  *  
Intimacy/isolation  *  
Medical aid use  *  
Medical treatment  **  
Social function ** *  
Work function **   
Sexual relationship -   
AQoL=Assessment of Quality of Life;195 EQ5D=European Quality of Life–5 
Dimensions;194 SF36=Short form–36 questions266 





   
Supplementary Figure C-1. Median difference in EQ5D utility scores mapped from the 
modified Rankin Scale for women compared to men at 1 year after stroke in unadjusted (top 





Supplementary Figure C-2. Median difference in EQ5D utility scores mapped from 
the modified Rankin Scale for women compared to men at 5 years after stroke in 




Appendix D: Sex differences in severity of stroke in 
the INternational STRoke oUtComes sTudy: a meta-
analysis of individual participant data 
Supplemental Table D-1a. Characteristics of included cohort studies by sex among 
patients with NIHSS data, for studies conducted in Oxford, Joinville, Melbourne and 
Perth 
Characteristic Oxford Joinville Melbourne Perth 

























Number of cases 550 537 48 46 780 714 129 94 357 387 73 71 61 62 8 7 
SOCIODEMOGR
APHIC 
                














































Race (%)                 
Caucasian - - - - - - - - 93.0 94.6 91.8 93.0 - - - - 
Non-Caucasian         3.4 2.8 4.1 5.6     
Unknown         3.6 2.6 4.1 1.4     
Marital status (%)                 
Single/widowed 23.6 54.0 12.5 39.1 - - - - - - - - 64.0 37.1 87.5 57.1 
Married 65.3 34.6 62.5 54.4         32.8 58.1 12.5 42.9 
Unknown 11.1 11.4 25.0 6.5         3.3 4.8 0.0 0.0 
Education level (%)                 
≤ Grade 12 65.1 66.5 47.9 60.9 93.9 93.7 93.8 95.7 51.3 56.1 39.7 47.9 - - - - 
> Grade 12 15.6 9.1 8.3 6.5 5.8 5.6 6.2 3.2 43.4 42.4 53.4 52.1     
Unknown 19.3 24.4 43.8 32.6 0.4 0.7 0.0 1.1 5.3 1.6 6.9 0.0     
Social class (%)                 
Professional 17.1 6.5 6.3 4.4 - - - - 38.7 32.8 38.4 42.3 21.3 3.2 12.5 0.0 
Non-manual 21.8 27.9 20.8 47.8     10.4 14.2 16.4 9.9 6.6 12.9 0.0 0.0 
Manual 41.1 35.9 35.4 19.6     43.7 35.9 38.4 25.4 21.3 15.8 50.0 14.3 
Unknown 20.0 29.6 37.5 28.3     7.3 17.1 6.9 22.5 50.8 58.1 37.5 85.7 
PRE-STROKE 
HEALTH 
                
Modified Rankin 
Score (%) 
                
0-2 85.8 73.6 79.2 69.6 - - - - - - - - 82.0 67.7 12.5 14.3 
3-5 13.6 25.1 10.4 26.1         16.4 24.2 75.0 71.4 
Unknown 0.6 1.3 10.4 4.4         1.6 8.1 12.5 14.3 
Institutional 
residence (%) 
                
Yes - - - - - - - - 6.4 13.2 6.9 15.5 4.9 9.7 62.5 14.3 
No         93.3 86.3 91.8 84.5 95.1 90.3 12.5 42.9 
Unknown         0.3 0.5 1.4 0.0 0.0 0.0 25.0 42.9 
Barthel Index (%)                 
20 - - - - - - - - 60.2 49.6 54.8 36.6 - - - - 
<20         13.5 19.6 6.9 14.1     
Unknown         26.3 30.8 38.4 49.3     
MEDICAL 
HISTORY 
                
Atrial fibrillation 
(%) 
                
Yes 21.1 25.5 16.7 10.9 4.6 6.0 0.0 1.1 22.4 26.6 12.3 11.3 19.7 24.2 0.0 28.6 
No 78.9 74.3 83.3 89.1 95.4 94.0 100.0 98.9 77.0 73.1 84.9 88.7 75.4 74.2 75.0 71.4 
Unknown 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 1.6 0.0 0.0 
Hypertension (%)                 
Yes 61.3 66.7 54.2 47.8 65.8 72.6 69.0 77.7 53.2 58.9 53.4 64.8 54.1 61.3 37.5 42.9 
No 38.7 33.3 41.7 52.2 34.2 27.5 31.0 22.3 45.9 40.6 45.2 35.2 41.0 38.7 37.5 57.1 
Unknown 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.8 0.5 1.4 0.0 4.9 0.0 25.0 0.0 
Ischaemic heart 
disease (%) 
                
Yes 16.2 9.3 8.3 0.0 7.6 3.5 3.1 1.1 16.8 14.0 15.8 2.8 18.0 8.1 12.5 0.0 





Supplemental Table D-1a. Characteristics of included cohort studies by sex among 
patients with NIHSS data, for studies conducted in Oxford, Joinville, Melbourne and 
Perth 
Characteristic Oxford Joinville Melbourne Perth 

























Unknown 0.4 0.0 8.3 2.2 0.0 0.0 0.0 0.0 0.6 0.3 1.4 0.0 3.3 3.2 25.0 0.0 
Peripheral vascular 
disease (%) 
                
Yes 9.1 5.6 2.1 0.0 - - - - 12.6 5.7 6.9 2.8 - - - - 
No 90.7 94.2 97.9 100.0     86.8 94.1 91.8 95.8     
Unknown 0.2 0.2 0.0 0.0     0.6 0.3 1.4 1.4     
Transient ischaemic 
attack (%) 
                
Yes 14.4 11.9 10.4 10.9 2.6 2.4 3.9 0.0 9.8 9.8 8.2 5.6 21.3 11.3 12.5 14.3 
No 85.6 87.9 89.6 89.1 97.4 97.6 96.1 100.0 89.6 89.7 89.0 94.4 67.2 80.7 50.0 85.7 
Unknown 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.5 2.7 0.0 11.5 8.1 37.5 0.0 
Diabetes (%)                 
Yes 15.6 12.1 8.3 8.7 - - - - 19.9 18.4 9.6 4.2 24.6 21.0 0.0 14.3 
No 84.4 87.9 91.7 91.3     79.6 91.7 90.4 95.8 75.4 79.0 75.0 85.7 
Unknown 0.0 0.0 0.0 0.0     0.6 0.0 0.0 0.0 0.0 0.0 25.0 0.0 
Dementia (%)                 
Yes - - - - - - - - 4.5 9.3 4.1 15.5 - - - - 
No         81.8 78.3 84.9 81.7     
Unknown         13.7 124 11.0 2.8     
Smoking (%)                 
Current 17.5 13.8 20.8 4.4 29.6 13.2 34.9 59.6 20.2 13.7 16.4 9.9 11.5 4.8 25.0 0.0 
Former 53.5 28.3 39.6 28.3 41.3 18.6 34.1 25.5 46.2 22.5 53.4 19.7 52.5 14.5 25.0 14.3 
Never 28.4 56.4 27.1 56.5 29.1 68.2 31.0 14.9 29.4 55.0 23.3 52.1 18.0 53.2 25.0 42.9 
Unknown 0.7 1.5 12.5 10.9 0.0 0.0 0.0 0.0 4.2 8.8 6.9 18.3 18.0 27.4 25.0 42.9 
Alcohol use (%)                 
Non-drinkers 28.6 57.0 16.7 41.3 49.0 83.1 19.4 2.1 20.2 46.0 15.1 35.2 27.9 30.7 25.0 28.6 
Not heavy 
drinkers 
63.8 34.6 45.8 32.6 38.7 15.8 34.9 18.1 56.3 41.3 53.4 38.0 9.8 14.5 0.0 0.0 
Heavy drinkers 3.3 1.7 8.3 2.2 13.3 1.1 45.7 79.8 8.2 1.3 12.3 1.4 29.5 17.7 37.5 0.0 
Ex-drinkers - - - - - - - - 8.7 1.3 11.0 2.8 6.6 1.6 0.0 0.0 
Unknown 4.4 6.7 29.2 23.9 0.0 0.0 0.0 0.0 6.7 10.1 8.2 22.5 26.2 35.5 37.5 0.0 
Mean (SD) Body 






















Medication                 
Antihypertensive
s (%) 
                
Yes - - - - 61.2 69.5 55.0 69.2 53.3 61.8 41.1 49.3 45.9 56.5 37.5 42.9 
No     38.9 30.5 45.0 30.9 46.2 38.0 57.5 50.7 47.5 40.3 37.5 57.1 
Unknown     0.0 0.0 0.0 0.0 0.3 0.3 1.4 0.0 6.6 3.2 25.0 0.0 
Antiplatelet (%)                 
Yes - - - - 30.1 33.6 20.9 24.5 30.5 30.5 20.6 28.2 29.5 43.6 25.0 42.9 
No     69.9 66.4 79.1 75.5 69.2 69.5 78.1 71.9 70.5 51.6 62.5 57.1 




                
Hospital admission 
(%) 
82.7 83.1 100.0 97.8 100.0 100.0 100.0 100.0 98.0 99.0 100.0 98.6 77.1 83.9 100.0 57.1 
Ischaemic stroke 
subtype 
                
Atherothromboti
c 
- - - - 27.9 26.0 - - 23.8 18.1 - - - - - - 
Cardioembolic     27.4 28.4   26.3 25.3       
Lacunar     22.4 18.3   19.1 13.2       
Other Causes     22.2 27.3   1.1 1.6       
Undetermined     0.0 0.0   29.7 41.9       
Time to hospital† 
(%) 
                
≤ 4.5 hours - - - - 41.4 45.1 57.4 64.9 - - - - 14.9 19.2 25.0 0.0 
> 4.5 – 24 hours     27.7 24.7 24.8 20.2     8.5 13.5 12.5 0.0 
> 24 hours     28.6 26.9 14.7 11.7     10.6 19.2 0.0 25.0 




Supplemental Table D-1a. Characteristics of included cohort studies by sex among 
patients with NIHSS data, for studies conducted in Oxford, Joinville, Melbourne and 
Perth 
Characteristic Oxford Joinville Melbourne Perth 

























Bold denotes statistically significant differences between men and women; IS, Ischaemic stroke; ICH, 




Supplemental Table D-1b. Characteristics of included cohort studies by sex among patients with NIHSS data, for studies conducted in Orebro, 
Dijon, Mãtao and Tartu 
Characteristic Orebro Dijon Mãtao Tartu 
 IS ICH IS ICH IS ICH IS ICH 
 Men Women Men Women Men Women Men Women Men Women Men Women Men Women Men Women 
Number of cases 125 149 25 19 568 670 92 105 41 26 8 3 121 178 27 28 
SOCIODEMOGRAPHIC                 




















63.6 (15.9) 68.1 (12.6) 
Marital status (%)                 
Single/widowed 32.8 36.9 32.0 63.2 - - - - 26.8 38.5 25.0 66.7 - - - - 
Married 67.2 61.7 68.0 36.8     68.3 61.5 75.0 0.0     
Unknown 0.0 0.0 0.0 0.0     4.8 0.0 0.0 33.3     
Education level (%)                 
≤ Grade 12 - - - - - - - - 80.5 96.2 75.0 33.3 - - - - 
> Grade 12         7.3 3.9 25.0 0.0     
Unknown         12.2 0.0 0.0 66.7     
PRE-STROKE HEALTH                 
Modified Rankin Score (%)                 
0-2 - - - - - - - - - - - - 87.6 87.1 85.2 82.1 
3-5             4.1 7.9 3.7 3.6 
Unknown             8.3 5.1 11.1 14.3 
Institutional residence (%)                 
Yes 2.4 9.4 4.0 21.1 3.5 10.8 4.4 6.7 - - - - - - - - 
No 97.6 90.6 96.0 79.0 96.5 89.3 95.7 93.3         
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0         
Barthel Index (%)                 
20 76.0 65.1 4.0 47.4 - - - - - - - - - - - - 
<20 6.4 7.4 68.0 5.3             
Unknown 17.6 27.5 28.0 47.4             
MEDICAL HISTORY                 
Atrial fibrillation (%)                 
Yes 20.8 26.2 24.0 5.3 14.6 19.0 11.9 20.2 2.4 0.0 0.0 0.0 30.6 41.6 7.4 7.1 
No 79.2 73.8 76.0 94.7 85.3 80.4 88.1 79.8 90.2 100 100 66.7 69.4 58.4 92.6 92.9 
Unknown 0.0 0.0 0.0 0.0 0.2 0.6 0.0 0.0 7.3 0.0 0.0 33.3 0.0 0.0 0.0 0.0 
Hypertension (%)                 
Yes 31.2 42.3 32.0 31.6 66.2 70.6 68.3 64.9 63.4 69.2 87.5 66.7 55.4 71.4 63.0 71.4 
No 67.2 55.7 68.0 68.4 33.6 28.8 31.7 35.1 31.7 30.8 12.5 0.0 44.6 28.7 37.0 28.6 
Unknown 1.6 2.0 0.0 0.0 0.2 0.6 0.0 0.0 4.9 0.0 0.0 33.3 0.0 0.0 0.0 0.0 
Ischaemic heart disease (%)                 
Yes 19.2 14.8 8.0 0.0 16.3 12.7 8.9 7.0 2.4 11.5 12.5 0.0 38.0 43.8 22.2 32.1 
No 80.8 85.2 92.0 100.0 93.5 86.7 91.1 93.0 90.2 88.5 87.5 66.7 62.0 56.2 77.8 67.9 




Supplemental Table D-1b. Characteristics of included cohort studies by sex among patients with NIHSS data, for studies conducted in Orebro, 
Dijon, Mãtao and Tartu 
Characteristic Orebro Dijon Mãtao Tartu 
 IS ICH IS ICH IS ICH IS ICH 
Peripheral vascular disease (%)                 
Yes 37.6 26.9 28.0 21.1 7.7 4.5 5.9 5.3 - - - - - - - - 
No 62.4 72.5 78.0 79.0 92.1 94.9 94.1 94.7         
Unknown 0.0 0.7 0.0 0.0 0.2 0.6 0.0 0.0         
Transient ischaemic attack (%)                 
Yes 20.0 13.4 4.0 10.5 6.6 8.8 5.9 3.5 9.8 3.9 0.0 0.0 7.4 8.4 0.0 0.0 
No 80.0 86.6 96.0 89.5 93.3 91.2 94.1 96.5 82.9 93.2 100.0 33.3 92.6 91.6 100.0 100.0 
Unknown 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.3 0.0 0.0 33.3 0.0 0.0 0.0 0.0 
Diabetes (%)                 
Yes 20.8 16.1 8.0 10.5 - - - - - - - - - - - - 
No 78.4 81.9 92.0 89.5             
Unknown 0.8 2.0 0.0 0.0             
Dementia (%)                 
Yes 4.8 10.1 8.0 10.5 - - - - - - - - - - - - 
No 85.2 89.9 92.0 89.5             
Unknown 0.0 0.0 0.0 0.0             
Smoking (%)                 
Current 29.6 18.1 24.0 10.5 47.0 81.7 59.4 82.5 43.9 19.2 50.0 33.3 - - - - 
Former - - - - 23.2 2.5 15.8 2.6 - - - -     
Never 63.2 79.2 64.0 79.0 27.3 12.3 21.8 9.7 51.2 80.8 50.0 33.3     
Unknown 7.2 2.7 12.0 10.5 2.6 3.5 3.0 2.3 4.9 0.0 0.0 33.3     
Alcohol use (%)                 
Non-drinkers - - - - 86.6 95.6 77.1 95.6 70.7 100.0 75.0 33.3 - - - - 
Current drinkers*     11.5 2.3 20.8 3.5 22.0 0.0 25.0 33.3     
Ex-drinkers     - - - - - - - -     
Unknown     1.9 2.1 2.0 0.9 7.3 0.0 0.0 33.3     
STROKE-RELATED FACTORS                 
Hospital admission (%) 95.2 96.0 92.0 94.7 99.7 100.0 100.0 99.1 100.0 100.0 100.0 100.0 98.4 99.4 100.0 100.0 
Ischaemic stroke subtype                 
Atherothrombotic 54.4 55.7 - - - - - - - - - - 28.9 25.8 - - 
Cardioembolic 12.8 14.1           28.1 39.3   
Lacunar 30.4 26.9           30.6 23.0   
Other Causes 1.6 1.3           12.4 10.7   
Undetermined 0.8 2.0           0.0 1.1   
Time to arrive hospital† (%)                 
≤ 4.5 hours - - - - - - - - - - - - 30.3 32.2 59.3 57.1 
> 4.5 – 24 hours             6.7 5.1 3.7 0.0 
> 24 hours             2.5 2.8 0.0 0.0 




Supplemental Table D-1b. Characteristics of included cohort studies by sex among patients with NIHSS data, for studies conducted in Orebro, 
Dijon, Mãtao and Tartu 
Characteristic Orebro Dijon Mãtao Tartu 
 IS ICH IS ICH IS ICH IS ICH 




Supplemental Table D-2. Severity of ischaemic stroke by subtype among women 
and men 
Study Number of cases (%) NIHSS, mean (IQR) NIHSS>7, n (%) More severe 
stroke 
 Men Women Men Women Men Women RR (95% CI) 
Large-artery 
atherosclerosis 
       
Joinville 247 
(56.0%) 
194 (44.0%) 4.0 (2.0-9.0) 5.0 (2.0-12.0) 74/247 (30.0%) 73/194 (37.6%) 1.26 (0.97-1.63) 
Melbourne 85 (23.8%) 70 (45.2%) 4.0 (1.0-8.0) 4.0 (2.0-14.0) 22/85 (25.9%) 29/70 (41.4%) 1.60 (1.01-2.53) 
Orebro 68 (45.0%) 83 (55.0%) 3.0 (2.0-10.5) 6.0 (3.0-10.0) 20/68 (29.4%) 34/83 (41.0%) 1.39 (0.89-2.19) 




22/35 (62.9%) 33/46 (71.7%) 1.14 (0.93-1.56) 
Pooled 435 
(52.5%) 
393 (47.5%) 4.0 (2.0-10.0) 6.0 (3.0-13.0) 138/435 (31.7%) 169/393 (43.0%) 1.32 (1.05-1.66)* 
Cardioembolis
m 
       
Joinville 259 
(47.3%) 
289 (52.7%) 5.0 (2.0-12.0) 8.0 (3.0-16.0) 100/259 (38.6%) 150/289 (51.9%) 1.34 (1.11-1.63) 
Melbourne 94 (49.0%) 98 (51.0%) 7.5 (4.0-14.0) 9.5 (5.0-17.0) 47/94 (50%) 58/98 (59.2%) 1.18 (0.91-1.54) 
Orebro 16 (43.2%) 21 (56.8%) 4.0 (2.0-7.0) 12.0 (4.0-
20.0) 
4/16 (25.0%) 13/21 (61.9%) 2.48 (0.98-6.25) 
Tartu 34 (32.7%) 70 (67.3%) 8.5 (4.0-20.0) 12.5 (4.0-
20.0) 
18/34 (52.9%) 43/70 (61.4%) 1.16 (0.80-1.68) 
Pooled 403 
(45.7%) 
478 (54.3%) 6.0 (3.0-13.0) 9.0 (3.0-17.0) 169/403 (41.9%) 264/478 (55.2%) 1.32 (1.08-1.60)* 
Small-vessel 
occlusion 
       
Joinville 247 
(56.5%) 
190 (43.5%) 3.0 (2.0-4.0) 2.0 (1.0-5.0) 17/247 (6.9%) 20/190 (10.5%) 1.53 (0.82-2.84) 
Melbourne 68 (57.1%) 51 (42.9%) 3.0 (2.0-4.0) 2.0 (1.0-5.0) 3/68 (4.4%) 6/51 (11.8%) 2.67 (0.70-10.2) 
Orebro 38 (48.7%) 40 (51.3%) 4.0 (3.0-5.0) 3.0 (2.0-4.0) 2/38 (5.3%) 2/40 (5.0%) 0.95 (0.14-6.49) 
Tartu 37 (47.4%) 41 (52.6%) 0.0 (0.0-3.0) 2.0 (0.0-8.0) 1/37 (2.7%) 11/41 (26.8%) 9.93 (1.33-74.2) 
Pooled 390 
(54.8%) 
322 (45.2%) 3.0 (2.0-4.0) 3.0 (1.0-5.0) 23 (5.9%) 39 (12.1%) 2.05 (1.23, 3.44)* 
Other aetiology        
Joinville 27 (39.7%) 41 (60.3%) 2.0 (1.0-8.0) 2.0 (1.0-6.0) 7/27 (25.9%) 10/41 (24.4%) 0.94 (0.41-2.18) 
Melbourne 4 (40.0%) 6 (60.0%) 4.0 (1.5-8.5) 5.0 (1.0-10.0) 1/4 (25%) 2/6 (33.3%) 1.33 (0.16-11.5) 
Orebro 2 (50.0%) 2 (50.0%) 7.5 (6.0-9.0) 14.5 (5.0-
24.0) 
1/2 (50.0%) 1/2 (50.0%) 1.00 (0.10-9.61) 
Tartu 15 (44.1%) 19 (55.9%) 5.0 (0.0-7.0) 5.0 (1.0-15.0) 3/15 (20.0%)  9/19 (47.4%)  2.37 (0.76-7.36) 
Pooled 48 (41.4%) 68 (58.6%) 3.0 (1.0-7.5) 3.0 (1.0-10.0) 12/48 (25.0%) 22/68 (32.4%) 1.29 (0.64-2.61)* 
Undetermined        
Joinville - - - - - - - 
Melbourne 106 
(39.6%) 
162 (60.5%) 5.0 (2.0-11.0) 4.0 (2.0-10.0) 39/106 (36.8%) 55/162 (34.0%) 0.92 (0.66-1.28) 
Orebro 1 (25.0%) 3 (75.0%) 28.0 (NA) 3.0 (0.0-6.0) 1/1 (100%) 0/3 (0%) NA 
Tartu 0 (0.0%) 1 (100%) - 7.5 (3.0-12.0) 0/0 (0%) 1/2 (50.0%) NA 
Pooled 107 
(39.1%) 
167 (61.0%) 5.0 (2.0-11.0) 4.0 (2.0-10.0) 40/107 (37.4%) 56 (33.5%) 0.90 (0.60-1.35)* 
National Institutes of Health Stroke Scale=NIHSS; Bold denotes statistically significant differences 
between men and women 




Supplemental Table D-3. List of covariates not meeting the criteria for confounding 
factors of sex difference in severity (NIHSS) of ischaemic stroke 
Study Covariates  
Oxford SEP, education, hypertension, AF, IHD, PVD, TIA, diabetes, BMI, smoking, marital status, alcohol, hospital 
admission,  
Joinville Stroke subtype, race, hypertension, AF, PVD, TIA, BMI, smoking, hospital admission (100%), pre-stroke 
medication (antihypertensives, antiplatelets, anticoagulants), delay to hospital, IHD, alcohol 
Melbourne Stroke subtype, race, SEP, education, hypertension, IHD, PVD, TIA, diabetes, smoking, alcohol, hospital 
admission, pre-stroke medication (antiplatelets, anticoagulants, antihypertensives), institutional residence 
Perth SEP, hypertension, AF, IHD, TIA, diabetes, smoking, alcohol, delay to hospital, pre-stroke medication 
(antihypertensives, antiplatelets), institutional residence, pre-stroke Barthel, hospital admission 
Orebro Stroke subtype, age†, marital status, hypertension, AF, IHD, PVD, TIA, diabetes, dementia, pre-stroke Barthel, 
hospital admission, smoking 
Dijon Hypertension, IHD, PVD, TIA, alcohol, hospital admission, institutional residence 
Matão Race, marital status, education, age†, hypertension, AF, IHD, PVD, TIA, smoking, alcohol, hospital admission 
Tartu Stroke subtype, hypertension, AF, IHD, TIA, hospital admission, delay to hospital, pre-stroke medication 
(antihypertensives, antiplatelets) 
AF, Atrial fibrillation; BMI, body mass index; IHD, ischaemic heart disease; mRS, modified Rankin 
scale; NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease, TIA, 
transient ischaemic attack; SEP, socioeconomic position. 
* Not meeting all 4 criteria (missing <20% of cases, associated with sex, associated with stroke 
severity, and the inclusion of the covariate changed the magnitude of the sex coefficient by ≥10%) but 




Supplemental Table D-4a. Analyses of heterogeneity in the sex differences in stroke 




Unadjusted Adjusted for covariates* 
I2 (%) PH RR (95% CI) Psub-group I2 (%) PH RR (95% CI) Psub-group 
Ischaemic stroke            
Geographic region            
Australasia 2 0.0 0.444 1.23 (1.02-1.48) 0.565 0.0 0.203 1.07 (0.89-1.29) 0.465 
Europe 4 0.0 0.533 1.36 (1.21-1.52)  0.0 0.327 1.13 (0.97-1.32)  
South America 2 0.0 0.925 1.41 (1.22-1.64)  0.0 0.902 1.28 (1.10-1.50)  
Pre-stroke function            
Unavailable 2 0.0 0.515 1.43 (1.24-1.64) 0.334 12.4 0.336 1.10 (0.98-1.23) 0.139 
Available 6 0.0 0.718 1.30 (1.18-1.44)  0.0 0.885 1.27 (1.10-1.46)  
Intracerebral 
haemorrhagic stroke 
   
  
      
Geographic region            
Australasia 2 0.0 0.958 1.26 (0.97-1.63) 0.515 0.0 0.948 1.21 (0.97-1.20) 0.503 
Europe 4 0.0 0.728 1.05 (0.89-1.24)  0.0 0.832 1.07 (0.91-1.26)  
South America 2 0.0 0.759 1.05 (0.88-1.25)  0.0 0.778 1.03 (0.87-1.24)  
Pre-stroke function            
Unavailable 2 0.0 0.665 1.12 (0.97-1.30) 0.483 0.0 0.779 1.12 (0.97-1.30) 0.549 
Available 6 0.0 0.935 1.04 (0.88-1.22)  0.0 0.983 1.03 (0.87-1.21)  
Bold denotes statistically significant differences between men and women; NIHSS, National Institutes 
of Health Stroke Scale; PH, P-value of heterogeneity; RR (95% CI), relative risk (95% confidence 





Supplemental Table D-4b. Testing the interactions between sex and two covariates: 
age and time period using a single pooled individual participant dataset in stroke 
severity 
 Unadjusted Adjusted for age 
Covariates RR* (95% CI) Pinteraction RR (95% CI) Pinteraction 
Ischaemic stroke       
Age (continuous) 1.35 (0.69-2.64) 0.793    
Age group       
≤65 years 1.19 (0.92-1.53) Ref -   
>65-75 years 1.23 (1.00-1.52) 0.855 -   
>75 years 1.25 (1.11-1.41) 0.705 -   
Year of stroke occurrence       
1996-2011 (continuous) 1.26 (1.15-1.41) 0.067 1.15 (1.03- 1.29) 0.128 
Intracerebral haemorrhagic stroke       
Age (continuous) 0.85 (0.52-1.39) 0.324    
Age group       
≤65 years 1.00 (0.86-1.16) Ref -   
>65-75 years 1.14 (0.97-1.33) 0.360 -   
>75 years 1.13 (1.03-1.24) 0.136 -   
Year of stroke occurrence       
1996-2011 (continuous) 1.16 (0.99, 1.36) 0.264 1.16 (1.09-1.22) 0.281 
Ref, Reference group 




Supplemental Table D-5. Sensitivity analyses of difference in National Institutes of 
Health Stroke Scale (NIHSS) continuous scores between women and men  
Study N* Unadjusted Adjusted for 




  MD (95% CI) MD (95% CI) MD (95% CI) MD (95% CI) 
Ischaemic stroke      
Oxford 1077 0.834 (0.265, 1.404) 0.391 (-0.177, 0.959) 0.478 (-0.089, 
1.045) 
0.247 (-0.228, 0.722) 
Joinville 1494 0.856 (0.278, 
1.434) 
0.607 (0.038, 1.176) --- 0.607 (0.038, 1.176) 
Melbourne 647 1.171 (0.190, 
2.152) 
0.697 (-0.260, 1.654) 1.141 (0.190, 2.091) 0.645 (-0.334, 1.625) 
Perth 123 -0.466 (-2.893, 
1.960) 
-1.162 (-3.596, 1.215) -0.681 (-3.240, 
1.876) 
-1.162 (-3.596, 1.215) 
Orebro 274 1.220 (-0.029, 
2.469) 
1.102 (-0.196, 2.373) 1.021 (-0.210, 
2.252) 
0.853 (-0.278, 1.984) 
Dijon 1238 1.130 (0.467, 
1.794) 
0.640 (-0.017, 1.297) 0.086 (0.213, 1.500) 0.018 (-0.703, 
0.7381) 
Mãtao 67 3.330 (0.095, 
6.564) 
3.337 (0.078, 6.595) --- 3.337 (0.078, 6.595) 
Tartu 280 2.477 (0.742, 
4.213) 
1.182 (-0.619, 2.983) 1.729 (0.078, 3.380) 1.122 (-0.911, 2.900) 
Pooled 5,200 1.011 (0.700, 
1.323) 
0.601 (0.296, 0.905) 0.802 (0.440, 1.164) 0.426 (0.095, 0.757) 
Intracerebral 
haemorrhage 
     
Oxford 223 1.996 (-1.661, 
5.654) 
1.96 (-1.748, 5.671) --- --- 
Joinville 94 0.207 (-2.380, 
2.793) 
-0.118 (-2.718, 2.482) --- --- 
Melbourne 114 4.139 (0.598, 
7.680) 
3.572 (0.014, 7.129) --- --- 





Orebro 44 2.912 (-2.450, 
8.276) 
3.751 (-1.649, 9.150) --- --- 
Dijon 197 0.914 (-1.579, 
3.406) 
0.460 (-2.044, 2.964) --- --- 





Tartu 55 -0.828 (-5.104, 
3.449) 
-0.706 (-5.074, 3.662) --- --- 
Pooled 753 1.654 (0.188, 
3.120) 
1.452 (-0.027, 2.931)   






Appendix E: Sex differences in care and long-term 
mortality after stroke: Australian Stroke Clinical 
Registry 
Supplemental Table E-1. Sensitivity analyses of receiving medications among those 
without aspirin within 48 hours in the subset of Queensland data 
Medication Men Women  
 n (%) n % P-value 
Died within 48 hours      
No  711 (96.2%) 755 (95.3%) 0.392 
Yes 28 (3.8%) 37 (4.7%)  
Antiplatelets or antithrombotics at discharge      
No  293 (51.4%) 311 (54.4%) 0.315 
Yes 277 (48.6%) 261 (45.6%)  
Thrombolysis therapy       
No  592 (85.3%) 643 (88.6%) 0.068 





Supplemental Table E-2. Sex differences in mortality up to 1 year after stroke in 
univariate (unadjusted) and bivariate models (adjusting for single covariates that 
differ by sex) 
 7 days 30 days 1 year 
 MRR 95% CI ∆ 
(%)* 
MRR 95% CI ∆ 
(%)* 
MRR 95% CI ∆ 
(%)* 
Unadjusted 1.42 1.25 1.60  1.45 1.33 1.59  1.44 1.34 1.54  
Adjusted for             
Age 1.19 1.05 1.35 50% 1.15 1.05 1.27 63% 1.09 1.01 1.17 76% 
Born in Australia 1.43 1.26 1.62 -2% 1.46 1.33 1.60 -1% 1.44 1.34 1.55 0% 
Transfer from other 
hospital 
1.41 1.25 1.60 2% 1.46 1.33 1.60 -1% 1.44 1.34 1.54 0% 
Stroke severity (unable to 
walk on admission) 
1.24 1.09 1.40 39% 1.29 1.18 1.41 42% 1.31 1.22 1.41 26% 
Cause of stroke known 
(IS) 
1.58 1.34 1.87 0%§ 1.57 1.40 1.76 0%§ 1.55 1.42 1.69 0%§ 
Discharge to aged care† 1.47 0.92 2.34 16%§ 1.39 1.15 1.69 29%§ 1.31 1.18 1.45 23%§ 
Length of stay† 1.56 0.99 2.46 -30%§ 1.63 1.34 1.97 -4%§ 1.40 1.26 1.54 5%§ 
Aspirin administration 
≤48 hours (IS)‡ 
1.38 1.02 1.85 30%§ 1.31 1.07 1.59 26%§ 1.42 1.22 1.65 16%§ 
MRR, mortality rate ratio; CI, confidence interval; IS, ischaemic stroke 
* % change of coefficient of sex difference between unadjusted and adjusted models was calculated by 
the formula (unadjusted β – adjusted β)/ unadjusted β *100 
† among those discharged only 
‡ among Queensland hospitals only 




Supplemental Table E-3. Sensitivity analyses of the role of missing data of confounders (age and severity) on mortality rate ratio at 30 days and 
1 year after stroke for women compared to men with unadjusted and (n=50 imputations) 
 Complete−case analysis Imputed analysis 
 N Unadjusted MRR (95% 
CI) 
Adjusted MRR* (95% CI) N Unadjusted MRR (95% 
CI) 
Adjusted MRR* (95% CI) 
All hospitals       
At 7 days 13304 1.42 (1.25-1.60) 1.09 (0.96-1.24) 14118 1.42 (1.25-1.60) 1.09 (0.96-1.24) 
At 30 days 13304 1.45 (1.33, 1.59) 1.07 (0.97, 1.17) 14118 1.45 (1.33, 1.59) 1.07 (0.97, 1.17) 
At 1 year, without interaction with 
severity 
13304 1.44 (1.34, 1.54) 1.03 (0.95, 1.10) 14118 1.45 (1.35, 1.57) 1.03 (0.95, 1.11) 
At 1 year, unable to walk 8624 1.36 (1.26, 1.47) 1.05 (0.97, 1.14) 8626 1.36 (1.26, 1.47) 1.05 (0.97, 1.14) 
At 1 year, able to walk 4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 4681 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 
Queensland data       
At 7 days 4803 1.22 (0.99, 1.50) 0.93 (0.75, 1.16) 5224 1.20 (0.98, 1.47) 0.93 (0.75, 1.16) 
At 30 days 4803 1.26 (1.09, 1.47) 0.89 (0.76, 1.03) 5224 1.26 (1.10, 1.47) 0.89 (0.76, 1.03) 
At 1 year 4803 1.32 (1.17, 1.49) 0.90 (0.79, 1.01) 5224 1.34 (1.19, 1.50) 0.92 (0.82, 1.04) 
MRR: mortality rate ratio; CI: confidence interval 





Supplemental Table E-4. Sensitivity analyses of mortality rate ratio at 30 days and 1 year after stroke for women compared to men with 
excluding early deaths i.e. ≤7 days, ≤30 days, ≤90 days, or ≤180 days) 
 Not excluding early deaths Excluding early deaths Confounders in 
adjusted models   Unadjusted Adjusted  Unadjusted Adjusted Excl. deaths 
 N MRR (95% CI) MRR (95% CI) N MRR (95% CI) MRR (95% CI)   
At 30 days 13304 1.45 (1.33, 1.59) 1.07 (0.97, 1.17) 12285 1.48 (1.29, 1.69) 1.02 (0.89, 1.17) ≤7 days Age, severity 
At 1 year, unable 
to walk 
8624 1.36 (1.26, 1.47) 1.05 
 
(0.97, 1.14) 7632 1.37 (1.25, 1.51) 1.01 (0.91, 1.12) ≤30 days Age 
At 1 year, able to 
walk 
4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 4653 0.98 (0.78, 1.22) 0.80 (0.64, 1.00) ≤30 days Age 
At 1 year, unable 
to walk  
8624 1.36 (1.26, 1.47) 1.05 
 
(0.97, 1.14) 6848 1.37 (1.19, 1.56) 0.99 (0.86, 1.14) ≤30 days age 
At 1 year, able to 
walk  
4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 4575 0.91 (0.70, 1.17) 0.75 (0.58, 0.98) ≤30 days age 
At 1 year, unable 
to walk  
8624 1.36 (1.26, 1.47) 1.05 
 
(0.97, 1.14) 10967 1.22 (1.02, 1.46) 0.87 (0.73, 1.05) ≤90 days age 
At 1 year, able to 
walk  
4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 4497 0.91 (0.67, 1.24) 0.75 (0.55, 1.02) ≤90 days age 
At 1 year, unable 
to walk  
8624 1.36 (1.26, 1.47) 1.05 
 
(0.97, 1.14) 6237 1.13 (0.89, 0.45) 0.81 (0.64, 1.05) ≤180 days age 
At 1 year, able to 
walk  
4680 0.99 (0.80, 1.22) 0.81 (0.65, 1.00) 4408 0.80 (0.51, 1.28) 0.66 (0.42, 1.06) ≤180 days age 




Supplemental Table E-5: Characteristic of AuSCR registrants among all hospitals, 
Queensland (21 hospitals) and non-Queensland (18 hospitals) 
 All hospitals Queensland  Non-
Queensland 
P−value* 
 n (%) n (%) n (%)  
Number of cases 14118 5224 8894  
Sociodemographics     
Women 7580 (46.3%) 2405 (46.0%) 4133 (46.5%) 0.897 





Born in Australia† 9224 (65.3%) 3675 (70.4%) 5549 (62.4%) 0.311 
Aboriginal or Torres Strait Islander† 206 (1.5%) 126 (2.4%) 80 (0.9%) 0.065 
Socioeconomic status†     
IRSAD1 (most disadvantage) 2565 (18.2%) 1418 (27.1%) 1147 (12.9%) 0.610 
IRSAD2 2922 (20.7%) 1033 (19.8%) 1889 (21.2%)  
IRSAD3 1766 (12.5%) 653 (12.5%) 1113 (12.5%)  
IRSAD4 2840 (20.1%) 1090 (20.9%) 1750 (19.7%)  
IRSAD5 (least disadvantage) 4023 (28.5%) 1030 (19.7%) 2993 (33.7%)  
Stroke−related factors     
Transfer from other hospital† 2040 (14.5%) 929 (17.9%) 1111 (12.5%) 0.910 
In−hospital stroke† 774 (5.5%) 329 (6.3%) 445 (5.0%) 0.958 
Time (minutes) from onset to arrival, 
median (IQR)§ 
186 (81−677) 181 (81−614) 190 (81−706) 0.762 
Walking independently at admission‡ 4681 (35.2%) 1645 (34.3%) 3036 (35.7%) 0.735 
Cause of stroke known† 6964 (50.7%) 2727 (52.2%) 4272 (50.2%) 0.547 
Type of stroke     
Intracerebral haemorrhagic 2234 (15.8%) 828 (15.9%) 1406 (15.8%) 0.958 
Ischaemic stroke 11444 (81.1%) 4232 (81.0%) 7212 (81.1%)  
Undetermined 437 (3.1%) 164 (3.1%) 273 (3.1%)  
Discharge destination     
Died in hospital 1438 (10.2%) 500 (9.6%) 938 (10.6%) 0.999 
Aged care 666 (4.7%) 233 (4.5%) 433 (4.9%)  
Home 5446 (38.6%) 1998 (38.3%) 3448 (38.8%)  
Rehabilitation 4320 (30.6%) 1274 (24.4%) 3046 (34.3%)  
Hospitals/other 2248 (15.9%) 1219 (23.3%) 1029 (11.6%)  
Length of stay†     
LOS if discharged, median (IQR) days 5 (3−10) 6 (3−10) 5 (3−10) 0.285 
LOS if died in hospital, median (IQR) 6 (3−12) 6 (3−13) 6 (3−12) 1.000 
LOS including death, median (IQR) 5 (3−10) 6 (3−10) 5 (3−10) 0.244 
Evidence−based therapies     
Treated in stroke unit  11513 (81.6%) 4192 (80.3%) 7321 (82.3%) 0.694 
Intravenous thrombolysis (ischaemic) 1339 (12.3%) 368 (8.8%) 1031 (14.4%) 0.018 
Intravenous thrombolysis (ischaemic)| |   1339 (28.3%) 368 (20.4%) 1031 (32.8%) 0.181 
Discharged on antihypertensives# 8763 (70.6%) 3189 (69.5%) 5574 (71.2%) 0.452 
Care plan on discharge to community** 3196 (52.3%) 1008 (45.2%) 2188 (56.4%) 0.185 
*compared the difference between Queensland and non-Queensland patients  
† missing data <2%; ‡ missing data 6-8%; § missing data 22%; | | among those aged ≤85 with 




Appendix F: Sex difference in specific-cause 
mortality and excess death rates after stroke: the 
Australian Stroke Clinical Registry 
Supplemental Table F-1. Primary causes of death up to 1 year after stroke in 
AuSCR 2010-2013 (n=9,441) by sex 
Cause of death (COD) † Men (967 deaths) Women (1113 
deaths) 
p-value 
 n % N %  
Stroke 398 41.2* 560 50.3* 0.016 
Ischaemic stroke 87 21.9 114 20.4  
Intracerebral haemorrhagic stroke 123 30.9 168 30.0  
Subarachnoid haemorrhage 10 2.5 15 2.7  
Undetermined 178 3.5 263 6.0  
Ischaemic heart diseases (IHD) 81 8.4* 62 5.6* 0.016 
Acute myocardial infarction 33 40.7 31 50.0  
Other acute ischaemic heart diseases 3 3.7 0 0  
Chronic ischaemic heart disease 45 55.6 31 50.0  
Other cardiovascular diseases (CVD) 129 13.3* 181 16.3* 0.083 
Hypertensive diseases 5 3.9 6 3.3  
Atrial fibrillation 58 45.0 89 49.2  
Heart failure 4 3.1 10 5.5  
Peripheral vascular diseases 9 7.0 9 5.0  
Other cerebrovascular diseases (not 
stroke) 
30 23.3 42 23.2  
Other diseases 23 17.8 25 13.8  
Cancer 120 12.4* 70 6.3* <0.001 
Lung 14 11.7 13 18.6  
Brain 12 10.0 6 8.6  
Digestive system 31 25.8 23 32.9  
Breast 0 0 2 2.9  
Female genital organs - - 4 5.7  
Male genital organs 15 12.5 - -  
Skin 11 9.2 4 5.7  
Unknown site 10 8.3 3 4.3  
Lymphoid, hematopoietic and related 
tissue 
15 12.5 10 14.3  
Urinary tract 9 7.5 2 2.9  
Other causes 3 2.5 3 4.3  
Other conditions 141 14.6* 147 13.2* 0.434 
Digestive system 16 11.4 23 15.7  
Respiratory system 10 7.1 13 8.8  
Skin and subcutaneous tissue 1 0.7 2 1.4  
Musculoskeletal system 4 2.8 2 1.4  
Genitourinary system 9 6.4 9 6.1  
Congenital malformations 2 1.4 1 0.7  
Infection 6 4.3 7 4.8  
Unclassified conditions 73 51.8 74 50.3  
Accidents 20 14.1 16 10.9  
Unknown (missing on COD) 98 10.1* 93 8.4* 0.218 
*Percentages of six major groups of COD (stroke, IHD, CVD, cancer, other conditions and 
unknown cause) add up to 100%; the subcategories, if available, under each major group also add up 





Supplemental Table F-2. Specific hazard ratio (sHR) of death up to 1 year for those with more 
severe stroke* compared to those with less severe stroke men in AuSCR 2010-2013 (n=9,441) 
Cause of death (COD) sHR (95% CI) 
Stroke 8.50 (6.14-11.76) 
Ischaemic heart diseases 2.24 (1.58-3.19) 
Other cardiovascular diseases 4.90 (3.71-6.46) 
Cancer 1.04 (0.78-1.38) 
Other conditions 2.99 (2.00-4.46) 
Unknown (missing on COD) 2.30 (1.48-3.57) 
Bold denotes statistically significant results 




Supplemental Table F-3. Specific hazard ratio (sHR) of death up to 1 year after stroke for women compared to men in AuSCR 2010-2013 
using competing risk models by time to death 
Cause of death Unadjusted Adjusted for 
  Age Stroke severity† Age and severity 
 sHR (95% CI) sHR (95% CI) sHR (95% CI) sHR (95% CI) 
Stroke 1.65 (1.42-1.91) 1.28 (1.10-1.49) 1.46 (1.25-1.71) 1.19 (1.02-1.40) 
≤1m (n=8889) 1.56 (1.33-1.83) 1.26 (1.07-1.49) 1.38 (1.17-1.63) 1.18 (1.01-1.39) 
>1‒3ms (n=7637) 2.05 (1.40-3.00) 1.40 (0.99-1.99) 1.85 (1.25-2.72) 1.30 (0.91-1.87) 
>3‒6ms (n=7324) 1.78 (1.22-2.59) 1.14 (0.73-1.76) 1.64  (1.13-2.38) 1.05 (0.68-1.62) 
>6‒12ms (n=7098) 2.23 (1.32-3.79) 1.43 (0.88-2.35) 2.04 (1.18-3.54) 1.36 (0.81-2.27) 
Ischaemic heart disease 0.88 (0.65-1.18) 0.60 (0.45-0.79) 0.82 (0.60-1.12) 0.58 (0.43-0.77) 
≤1m (n=8889) 1.01 (0.68-1.51) 0.69 (0.49-0.97) 0.91 (0.61-1.38) 0.66 (0.47-0.92) 
>1‒3ms (n=7637) 0.81 (0.43-1.52) 0.54 (0.29-0.99) 0.81 (0.43-1.52) 0.55 (0.29-1.01) 
>3‒6ms (n=7324) 0.74 (0.26-2.12) 0.41 (0.14-1.25) 0.69 (0.23-2.03) 0.40 (0.13-1.23) 
>6‒12ms (n=7098) 0.79 (0.30-2.13) 0.51 (0.19-1.38) 0.76 (0.29-2.00) 0.50 (0.19-1.34) 
Other cardiovascular disease 1.65 (1.29-2.12) 1.19 (0.91-1.56) 1.49 (1.16-1.93) 1.12 (0.85-1.48) 
≤1m (n=8889) 1.65 (1.22-2.22) 1.21 (0.89-1.64) 1.47 (1.08-1.99) 1.12 (0.82-1.55) 
>1‒3ms (n=7637) 1.93 (1.03-3.62) 1.28 (0.68-1.42) 1.78 (0.93-3.41) 1.21 (0.63-2.35) 
>3‒6ms (n=7324) 1.49 (0.82-2.71) 1.00 (0.51-1.98) 1.37 (0.75-2.49) 0.95 (0.48-1.85) 
>6‒12ms (n=7098) 1.82 (0.82-4.02) 1.23 (0.51-2.95) 1.71 (0.80-3.66) 1.18 (0.50-2.78) 
Cancer 0.69 (0.50-0.95) 0.67 (0.50-0.91) 0.69 (0.50-0.94) 0.67 (0.49-0.91) 
≤1m (n=8889) 0.95 (0.59-1.51) 0.94 (0.62-1.44) 0.88 (0.54-1.42) 0.89 (0.58-1.38) 
>1‒3ms (n=7637) 1.12 (0.59-2.11) 1.13 (0.60-2.15) 1.08  (0.58-2.04) 1.10 (0.58-2.09) 
>3‒6ms (n=7324) 0.46 (0.26-0.82) 0.40 (0.22-0.73) 0.48 (0.28-0.87) 0.42 (0.23-0.77) 
>6‒12ms (n=7098) 0.38 (0.18-0.78) 0.33 (0.15-0.74) 0.37 (0.18-0.76) 0.33 (0.15-0.72) 
Other conditions 1.17 (0.87-0.58) 0.99 (0.70-1.36) 1.08 (0.79-1.47) 0.94 (0.68-1.30) 
≤1m (n=8889) 1.19 (0.85-1.65) 1.04 (0.72-1.50) 1.05 (0.75-1.47) 0.96 (0.67-1.38) 
>1‒3ms (n=7637) 1.11 (0.60-2.06) 0.84 (0.41-1.72) 1.05 (0.56-1.96) 0.82 (0.40-1.67) 
>3‒6ms (n=7324) 1.24 (0.70-2.17) 0.95 (0.57-1.60) 1.20 (0.68-2.13) 0.93 (0.55-1.60) 
>6‒12ms (n=7098) 1.36 (0.82-2.27) 1.08 (0.67-1.74) 1.31 (0.79-2.16) 1.05 (0.66-1.69) 
Unknown cause 1.12 (0.84-1.49) 0.89 (0.64-1.21) 1.05 (0.78-1.40) 0.86 (0.63-1.17) 
≤1m (n=8889) 1.04 (0.57-1.91) 0.87 (0.45-1.69) 0.91 (0.50-1.70) 0.80 (0.41-1.57) 
>1‒3ms (n=7637) 1.33 (0.99-1.76) 0.99 (0.73-1.34) 1.26 (0.95-1.69) 0.97 (0.71-1.31) 
>3‒6ms (n=7324) 2.32 (1.44-3.74) 1.74 (1.01-2.90) 2.19 (1.34-3.57) 1.68 (0.97-2.91) 




Supplemental Table F-3. Specific hazard ratio (sHR) of death up to 1 year after stroke for women compared to men in AuSCR 2010-2013 
using competing risk models by time to death 
Cause of death Unadjusted Adjusted for 
  Age Stroke severity† Age and severity 
 sHR (95% CI) sHR (95% CI) sHR (95% CI) sHR (95% CI) 
Bold results denotes statistical significance; m=month 





























































































Stroke IHD Other CVD Cancer Other conditions Unknown
Supplemental Figure F-1. Distribution of causes of death up to 1 year after stroke by sex 
and age. IHD= Ischaemic heart disease; Other CVD= Other cardiovascular disease (e.g. 
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Stroke IHD Other CVD Cancer Other conditions Unknown
Supplemental Figure F-2. Distribution of causes of death up to 1 year after stroke by sex 
and time. IHD= Ischaemic heart disease; Other CVD= Other cardiovascular disease (e.g. 























































Supplemental Figure F-3. Cumulative incidence of death up to 1 year due to stroke by 
stroke type. IS=Ischaemic stroke; ICH=Intracerebral haemorrhagic stroke; 




Appendix G: Sex differences in health-related quality 
of life at 3-6 months after stroke: Australian Stroke 
Clinical Registry 
Supplemental Table G-1. Baseline characteristics of stroke survivors assessed and 
those not assessed with EQ5D at 3-6 months after stroke 
 Non-assessed 
survivors 
Assessed survivors P−value 
 N (%) N (%)  
Female, % 2023 (44.4%) 3031 (44.2%) 0.663 
Age, median (IQR) 71.4 (59.5, 81.5) 83.0 (75.0, 88.2) <0.001 
Age group    
<45 360 (7.8%) 353 (5.2%) <0.001 
45-54 452 (9.9%) 527 (7.7%)  
55-64 777 (17.0%) 1065 (15.5%)  
65-74 1068 (23.4%) 1715 (25.0%)  
75-84 1206 (26.5%) 2113 (30.8%)  
85+ 697 (15.3%) 1079 (15.8%)  
Stroke−related factors    
Type of stroke    
Haemorrhagic stroke (ICH) 721 (15.8%) 769 (11.2%) <0.001 
Ischaemic stroke 3675 (80.5%) 5896 (86.1%)  
Undetermined 168 (3.7%) 186 (2.7%)  
Able to walk at admission (proxy for stroke 
severity‡) 
1692 (39.6%) 2730 (42.5%) <0.001 
Evidence−based therapies (%)    
Treated in stroke unit  3656 (80.1%) 6005 (87.6%) 0.001 
Intravenous thrombolysis* 387 (10.6%) 751 (12.8%) 0.001 
 387 (30.2%)† 261 (45.2%)† 0.105 
Care plan on discharge to community 1113 (51.7%) 1882 (53.7%) 0.103 
Discharged on antihypertensives  3037 (67.8%) 5088 (75.0%) 0.009 
Additional indicators (Queensland data only)    
Mobilisation ≤48 hours if unable to walk on 
admission 
554 (73.5%) 867 (81.1%) <0.001 
Aspirin administration ≤ 48 hours* 1014 (68.3%) 1537 (70.1%) 0.024 
Discharged on antiplatelets or antithrombotic* 1090 (78.9%) 1675 (80.1%) 0.156 
Received dysphagia assessment ≤24 hours 902 (51.8%) 1421 (57.0%) <0.001 
* among ischaemic strokes; † among those with admission time ≤3.5 hours; ‡ severe = unable to walk 




Supplemental Table G-2. Characteristics, processes of care and discharge information of AuSCR registrants for first−ever stroke during 
2010−2014 having EQ5D assessment at 3 months after stroke in Queensland data only 
 Assessed (n=2492) All registrants (n=5224) 
 Men Women P−value* Men Women P−value* 
 N (%) N (%)  N (%) N (%)  
Number of cases 1388 (55.7%) 1104 (44.3%) <0.001 2819 (54.0%) 2405 (46.0%) <0.001 
Sociodemographics       
Age, median (IQR) 69.7 (61.1−78.4) 75.4 (63.6−83.7) <0.001 70.9 (61.1−80.1) 77.6 (64.9−85.7) <0.001 
Age group       
<45 69 (5.0%) 71 (6.4%) <0.001 153 (5.4%) 143 (6.0%) <0.001 
45-54 127 (9.2%) 86 (7.8%)  225 (9.1%) 172 (7.2%)  
55-64 278 (20.0%) 154 (14.0%)  532 (18.9%) 289 (12.0%)  
65-74 424 (30.6%) 230 (20.8%)  777 (27.6%) 433 (18.0%)  
75-84 354 (25.5%) 336 (30.4%)  735 (26.1%) 708 (29.4%)  
85+ 136 (9.8%) 227 (20.6%)  366 (13.0%) 660 (27.4%)  
Socioeconomic status       
IRSAD1 316 (22.8%) 253 (22.9%) 0.872 760 (27.0%) 658 (27.4%) 0.994 
IRSAD2 281 (20.2%) 215 (19.5%)  557 (18.8%) 476 (19.8%)  
IRSAD3 190 (13.7%) 138 (12.5%)  347 (12.3%) 306 (12.7%)  
IRSAD4 301 (21.7%) 235 (21.3%)  607 (21.5%) 483 (20.1)  
IRSAD5 300 (21.6%) 263 (23.8%)  548 (19.4%) 482 (20.0%)  
Born in Australia 988 (71.2%) 829 (75.1%) 0.277 1925 (68.3%) 1750 (72.8%) 0.075 
Aboriginal or Torres Strait Islander 25 (1.8%) 17 (1.6%) 0.924 62 (2.2%) 27 (2.7%) 0.522 
Stroke−related factors    546 (19.4%) 383 (15.9%) 0.010 
Transfer from hospital 264 (19.0%) 186 (16.7%) 0.283    
Stroke while in hospital 64 (4.6%) 69 (6.3%) 0.128 168 (6.0%) 161 (6.7%) 0.394 
Time (minutes) from onset to arrival, median (IQR) 190 (83−672) 211 (87−690) 0.261 186 (81−673) 177 (81−553) 0.479 
Walking independently at admission (proxy for stroke severity‡) 579 (42.0%) 373 (33.8%) 0.002 992 (35.2%) 653 (27.2%) <0.001 
Cause of stroke known 705 (50.8%) 518 (47.0%) <0.001 1390 (49.3%) 1104 (45.9%) 0.055 
Type of stroke       
Intracerebral haemorrhagic (ICH) 165 (11.9%) 135 (12.2%) 0.541 2302 (81.7%) 1930 (80.3%) 0.415 
Ischaemic stroke 1190 (85.7%) 932 (84.4%)  441 (15.6%) 387 (16.1%)  
Undetermined 33 (2.4%) 37 (3.4%)  76 (2.7%) 88 (3.7%)  
Discharge information       




Supplemental Table G-2. Characteristics, processes of care and discharge information of AuSCR registrants for first−ever stroke during 
2010−2014 having EQ5D assessment at 3 months after stroke in Queensland data only 
 Assessed (n=2492) All registrants (n=5224) 
 Men Women P−value* Men Women P−value* 
 N (%) N (%)  N (%) N (%)  
Discharge destination       
Died in hospital − −  246 (8.7%) 254 (10.6%) <0.001 
Aged care 24 (1.7%) 61 (5.5%) <0.001 75 (2.7%) 158 (6.6%)  
Home 716 (51.6%) 496 (44.9%)  1171 (41.5%) 827 (34.4%)  
Rehabilitation 391 (28.2%) 320 (29.0%)  708 (25.1%) 566 (23.5%)  
Hospitals/other 257 (18.5%) 227 (20.6%)  619 (22.0%) 600 (25.0%)  
Evidence−based therapies       
Treated in stroke unit  1229 (88.5%) 948 (85.9%) 0.507 2312 (82.0%) 1880 (78.2%) 0.215 
Intravenous thrombolysis*  122 (10.4%) 89 (9.7%) 0.730 767 (12.5%) 632 (12.1%) 0.458 
 122 (25.9%)† 89 (28.7%)† 0.400 767 (33.1%)† 632 (36.1%)† 0.175 
Discharged on antihypertensives  1003 (73.6%) 769 (70.6%) 0.348 1776 (70.8%) 1413 (68.0%) 0.114 
Care plan on discharge to community 339 (45.8%) 240 (43.1%) 0.372 578 (46.4%) 430 (43.7%) 0.582 
IRSAD; Index of Relative Socioeconomic Advantage and Disadvantage 
* among ischaemic strokes 
† among those with admission time ≤3.5 hours 




Supplemental Table G-3a. Difference in EQ5D domain scores (1-3) between 
women and men at 3-6 months after stroke, among those were assessed (n=6852) 
 Men (n=3821) Women (n=3031) P value 
Dimension n % n %  
Mobility      
1 (no problem) 1752  45.9% 1402 46.3% 0.264 
2 1888 49.4% 1369 45.2%  
3 (severe problem) 181 4.7% 260 8.6%  
Self-care      
1 2739 71.7% 1905 62.9% <0.001 
2 786 20.6% 711 23.5%  
3 296 7.8% 415 13.7%  
Usual activity      
1 1721 45.0% 1085 35.8% <0.001 
2 1453 38.0% 1283 42.3%  
3 647 16.9% 663 21.9%  
Pain/discomfort      
1 2058 53.9% 1410 46.5% 0.002 
2 1603 42.0% 1432 47.3%  
3 160 4.2% 189 6.2%  
Anxiety/depression      
1 2152 56.3% 1475 48.7% 0.007 
2 1460 38.2% 1377 45.4%  






Supplemental Table G-3b. Relative risk (RR) of having any problem in each 
dimension of EQ5D for women compared to men, using log-binomial regression 
Any problem in Age (years) Unadjusted Adjusted for stroke 
severity* 
  RR  95% CI RR  95% CI 
Mobility <65 1.02 0.90, 1.16 1.02 0.90, 1.16 
 65-74 0.96 0.83, 1.10 0.96 0.84, 1.11 
 >75 1.02 0.92, 1.12 1.02  0.92, 1.12 
Self-care <65 0.81 0.65, 1.01 0.80 0.64, 1.00 
 65-74 1.08 0.88, 1.31 1.02 0.84, 1.24 
 >75 1.32 1.18, 1.47 1.25 1.12, 1.40 
Usual activity <65 0.94 0.82, 1.08 0.93 0.82, 1.07 
 65-74 1.16 1.01, 1.33 1.13 0.98, 1.30 
 >75 1.18 1.08, 1.29 1.16 1.06, 1.26 
Pain/discomfort <65 0.90 0.77, 1.04 0.89 0.77, 1.03 
 65-74 1.10 0.95, 1.28 1.08 0.93, 1.25 
 >75 1.20 1.09, 1.33 1.18 1.08, 1.31 
Anxiety/depression <65 1.02 0.89, 1.17 1.02 0.89, 1.16 
 65-74 1.29 1.11, 1.52 1.27  1.09, 1.49 
 >75 1.19 1.09, 1.33 1.18  1.06, 1.30 




Supplemental Table G-4. Sensitivity analyses accounting for missing data of EQ5D data among survivors at 3-6 months after stroke  
 Complete−case analysis Inverse probability weighting 
(IPW) 
Multiple imputation (MI) MI combined with IPW 
Age Unable to walk* Able to walk* Unable to walk Able to walk Unable to walk Able to walk Unable to walk Able to walk 
(years) n MD  
(95% CI) 






n MD  
(95% CI) 






             


























































MD = median difference in EQ5D scores for women compared to men; CI = confidence interval 




Supplemental Table G-5. Net mean difference in EQ5D utility scores between AuSCR stroke survivors and the general population norms  
  Population norms* AuSCR utility EQ5D scores (DCE)† Net difference between normal norms and AuSCR 














MD (95% CI) MD (95% CI) Net difference  
< 55 948 0.93† 0.12† 944 0.88 0.12 520 0.70 0.27 360 0.73 0.24 0.23 (0.21, 0.25) 0.15 (0.12, 0.18) -0.08 
55−64 217 0.90 0.14 226 0.88 0.15 709 0.68 0.28 356 0.69 0.28 0.22 (0.19, 0.25) 0.19 (0.16, 0.23) -0.03 
65−74 153 0.87 0.16 193 0.87 0.16 1098 0.71 0.29 617 0.66 0.33 0.16 (0.13, 0.19) 0.21 (0.18, 0.24) 0.05 
75+ 104 0.85 0.16 122 0.82 0.15 1494 0.64 0.34 1698 0.53 0.38 0.21 (0.18, 0.25) 0.27 (0.24, 0.30) 0.06 
Total 1422   1483   3821    3031     
MD (95% CI), mean difference (95% Confidence Interval) 




Supplemental Table G-6. EQ5D utility scores among people with stroke in different 
populations 
Study Year Stroke survivors People without stroke 
  Mean  SD Mean  SD 
AuSCR registry, (3-6 
months; current study) 
2009-2014 0.64 0.33 0.83* 0.16 
Oxford study, UK (6 
months)456 
2002-2007 0.70 0.29 0.85 0.23 
AVAIL study, US (3 
months; ischaemic only)110 
2006-2008 Median 0.83  IQR 0.76-1 - - 
Vietnam (3 months)457 2012 0.67 0.30 0.91† 0.15 
KOSCO study, Korea (6 
months)117  
2012-2014 0.82 0.19 0.95‡ 0.001 
IQR: Interquartile range 
* from McCaffrey et al (2016)374 
† from Nguyen et al (2017)458 
‡ from Kwon et al (2018)459 
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